




**World Health
Organization**

REGIONAL OFFICE FOR **Europe**



Tuberculosis surveillance and monitoring in Europe

2018

2016 data

**Tuberculosis surveillance
and monitoring in Europe**

2018

2016 data

This report has been published jointly by the WHO Regional Office for Europe (WHO/Europe) and the European Centre for Disease Prevention and Control (ECDC). WHO/Europe developed the overview of the European Region as a whole and validated the figures for the non-EU/EEA countries and ECDC developed the overview of the EU/EEA countries and validated the EU/EEA figures.

The report was coordinated by Vahur Hollo (ECDC) and Andrei Dadu (WHO Regional Office for Europe).

Contributing authors: Phillip Zucs¹, Masoud Dara², Pierpaolo de Colombani², Soudeh Ehsani², Ogtay Gozalov², Arax Hovanesyan², Csaba Ködmön¹, Brigita Molnarova¹, Martin van den Boom², Marieke J. van der Werf¹.

¹ European Centre for Disease Prevention and Control

² WHO Regional Office for Europe

This report was sent for consultation and review to the operational contact point for epidemiology or national focal point for tuberculosis in the EU/EEA Member States and TB surveillance country correspondents in the non-EU/EEA member states.

Trend tables and country profiles are included in the online report at Trend tables and country profiles are included in the online report at www.ecdc.europa.eu/en/publications/ and www.euro.who.int/tb.

Suggested citation for full report:

European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2018 – 2016 data.

Stockholm: European Centre for Disease Prevention and Control, 2018.

Tables and figures should be referenced:

European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2018 – 2016 data.

This publication follows the ECDC terminological practice, which reflects the European Union Inter-institutional Style Guide with regard to names and designations of countries. The names and designations of countries used in this publication should not be understood as an endorsement by WHO of the terminology used in this publication.

ECDC has amended the maps supplied by the WHO Regional Office for Europe for this publication. The designations employed and the presentation of this material do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries.

The WHO Regional Office for Europe is responsible for the accuracy of the translation of the Russian summary.

© World Health Organization

© European Centre for Disease Prevention and Control, 2018

Reproduction is authorised, provided the source is acknowledged.

ECDC and the WHO Regional Office for Europe would like to thank the nominated national operational contact points for tuberculosis (TB) surveillance from EU/EEA Member States and the national TB surveillance focal points from other

countries of the WHO European Region for providing data and valuable comments on this report:

Albania: Donika Mema; Andorra: Clara Palma Jordana; Armenia: Hayk Davtyan; Austria: Bernhard Benka; Azerbaijan: Natavan Alikhanova; Belarus: Andrei Astravko; Belgium: Maryse Wanlin, Patrick de Smet; Bosnia and Herzegovina: Snježana Brčkalo; Bulgaria: Tonka Varleva; Croatia: Aleksandar Simunovic; Cyprus: Maria Koliou; Czech Republic: Jiří Wallenfels; Denmark: Peter Henrik Andersen, Troels Lillebæk; Estonia: Piret Viiklepp; Finland: Hanna Soini; the former Yugoslav Republic of Macedonia: Maja Zakoska; France: Jean-Paul Guthmann; Georgia: Ucha Nanava; Germany: Nita Perumal; Greece: Ourania Kalkouni; Hungary: Gabor Kovács; Iceland: Thorsteinn Blondal; Ireland: Joan O'Donnell, Sarah Jackson; Israel: Yana Levin; Italy: Stefania D'Amato; Kazakhstan: Yana Bestrashnova; Kyrgyzstan: Jekaterina Maljukova; Latvia: Dace Mihalovska; Liechtenstein: Marina Jamnicki Abegg; Lithuania: Edita Davidavičienė; Luxembourg: Irene Demuth; Malta: Analita Pace Ascjak; Moldova: Ana Ciobanu; Monaco: Jean Lorenzi; Montenegro: Biljana Grbavčević; Netherlands: Erika Slump; Norway: Trude Margrete Arnesen; Poland: Maria Korzeniewska-Kosela; Portugal: Raquel Duarte; Romania: Domnica Ioana Chiotan; Russia: Sergey Sterlikov; Serbia: Radmila Curcic; Kosovo¹: Majlinda Gjocaj; Slovakia: Ivan Solovič; Slovenia: Petra Svetina; Spain: Laura Sanchez-Cambronero Cejudo; Sweden: Jerker Jonsson; Switzerland: Ekkehardt Altpeter; Tajikistan: Firusa Sharipova; Turkey: Aysegul Yildirim; Ukraine: Liliia Masiuk; Turkmenistan: Aisoltan Charyeva; United Kingdom: Maeve Lalor; Uzbekistan: Salihdjan Alimov.

ECDC

ISBN 978-92-9498-174-5; ISSN 2443-5538; DOI 10.2900/1940

WHO

ISBN 978-92-89053037

¹ This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo Declaration of Independence

Contents

| | |
|--|-----|
| Abbreviations | v |
| Summary | 1 |
| Executive summary | 3 |
| The WHO European Region | 3 |
| European Union and European Economic Area countries | 3 |
| Monitoring progress towards TB elimination..... | 4 |
| Резюме | 5 |
| Европейский регион ВОЗ | 5 |
| Страны Европейского союза и Европейской экономической зоны | 5 |
| Мониторинг прогресса в направлении ликвидации туберкулеза | 6 |
| 1. Main facts about TB | 7 |
| 2. Technical note | 11 |
| 2.1 Data reporting and analysis | 13 |
| 2.2 Definitions | 14 |
| 3. Commentary | 17 |
| 3.1 The WHO European Region | 19 |
| 3.2 European Union and European Economic Area countries | 27 |
| 4. Commentary – Monitoring | 31 |
| 4.1 WHO European Region | 33 |
| 4.2 European Union and European Economic Area countries | 39 |
| 5. Annexes | 69 |
| Annex 1: Tuberculosis surveillance system overview, 2016 | 70 |
| Annex 2: List of variables for 2017 TB data collection | 71 |
| Annex 3: Reporting completeness of main variables used for the report | 72 |
| Annex 4: Reporting completeness into Global TB database, 2016 | 73 |
| Annex 5: Laboratory network capacity, European Region, 2016 | 74 |
| Annex 6: Monitoring framework for follow up of the TB Action Plan for the WHO European Region, 2016 – 2020 | 75 |
| 6. Tables | 79 |
| 7. Trend tables | 119 |
| 8. Country profiles | 141 |

| | |
|--|-----|
| 6. Tables | 79 |
| Summary table Tuberculosis surveillance data by region, European Region, 2016 | 81 |
| Table 1 Estimates of the TB disease burden, European Region 2016 | 82 |
| Table 2 Estimates for TB/HIV co-infection and MDR TB, European Region, 2016 | 84 |
| Table 3 Tuberculosis cases, notification rates per 100 000 population and mean annual change in rates, European Region, 2012–2016 | 86 |
| Table 4 New TB cases and relapses, notification rates per 100 000 population and mean annual change in rates, European Region, 2012–2016 | 87 |
| Table 5 Tuberculosis cases by history of previous TB treatment, European Region, 2016 | 88 |
| Table 6 Tuberculosis cases by site of disease, European Region, 2016 | 89 |
| Table 7 New and relapse pulmonary tuberculosis cases by diagnostic method, European Region, 2016 | 90 |
| Table 7a New and relapse tuberculosis cases by diagnostic method, European Region, 2016 | 91 |
| Table 8 Tuberculosis cases according to EU case definition, EU/EEA, 2016 | 92 |
| Table 9 New TB cases and relapses by age group and male-to-female ratio, European Region, 2016 | 95 |
| Table 10 Tuberculosis cases by origin, European Region, 2016 | 96 |
| Table 11 Drug resistance surveillance of pulmonary bacteriologically-confirmed tuberculosis cases, European Region, 2016 | 97 |
| Table 12 Drug resistance surveillance of bacteriologically-confirmed pulmonary tuberculosis cases by previous TB treatment history, European Region, 2016 | 98 |
| Table 13 Drug resistance in all laboratory-confirmed tuberculosis cases, EU/EEA, 2016 | 100 |
| Table 14 XDR TB cases among all laboratory-confirmed MDR TB cases, European Region, 2016 | 101 |
| Table 15 MDR and XDR TB cases enrolled in treatment, European Region, 2016 | 102 |
| Table 16 New and relapse tuberculosis cases with HIV infection, European Region, 2016 | 103 |
| Table 16a All tuberculosis cases with HIV infection, EU/EEA, 2016 | 104 |
| Table 17 Tuberculosis in prisons, European Region, 2016 | 105 |
| Table 18 Treatment outcome for all TB cases notified in 2014, European Region, 2016 | 106 |
| Table 19 Treatment outcome of new tuberculosis cases and relapses notified in 2014, European Region, 2016 | 107 |
| Table 20 Treatment outcome of new and relapse tuberculosis cases in children (0–14 years) notified in 2015, European Region, 2016 | 108 |
| Table 21 Treatment outcome of HIV positive new and relapse tuberculosis cases notified in 2015, European Region, 2016 | 109 |
| Table 22 Treatment outcome after 24 months of RR TB/MDR TB cases started on second-line treatment in 2014, European Region, 2016 | 110 |
| Table 23 Treatment outcome after 24 months of laboratory-confirmed MDR TB cases notified in 2014, EU/EEA, 2016 | 111 |
| Table 24 Treatment outcome after 24 months of XDR TB cases started on second-line treatment in 2014, European Region, 2016 | 112 |
| Table 25 Treatment outcome after 36 months of XDR TB notified in 2013, EU/EEA, 2016 | 113 |
| Table 26 Monitoring the WHO Europe Roadmap to Implement the Tuberculosis Action Plan for the WHO European Region, 2016–2020 | 115 |
| 7. Trend tables | 119 |
| Table I Estimated TB mortality per 100 000 population, European Region, 2007–2016 | 120 |
| Table II Estimated TB incidence per 100 000 population, European Region, 2007–2016 | 122 |
| Table III Tuberculosis cases in children under 15 years, European Region, 2012–2016 | 124 |
| Table IV Tuberculosis cases by origin, European Region, 2012–2016 | 126 |
| Table V MDR TB notification among new bacteriologically-confirmed pulmonary TB cases with available DST results, European Region, 2012–2016 | 128 |
| Table VI MDR TB notification among previously treated bacteriologically-confirmed pulmonary TB cases with available DST results, European Region, 2012–2016 | 129 |
| Table VII MDR TB notification among all bacteriologically confirmed TB cases with available DST results, European Region, 2012–2016 | 130 |
| Table VIII XDR TB notification among pulmonary MDR TB cases with second-line drug sensitivity test results, European Region, 2012–2016 | 131 |
| Table IX Tuberculosis cases with HIV infection, European Region, 2012–2016 | 132 |
| Table X: Treatment success after 12 months of new TB cases and relapses, European Region, 2011–2015 | 134 |
| Table XI Treatment success after 12 months of all TB cases, European Region, 2011–2015 | 135 |
| Table XII Treatment success after 24 months of RR/MDR TB cases started on treatment, European Region, 2010–2014 | 136 |
| Table XIII Treatment success after 24 months of XDR TB cases started on treatment, European Region, 2010–2014 | 137 |
| Table XIV Treatment success after 36 months of XDR TB cases notified in European Region, 2009–2013 | 138 |

Abbreviations

| | |
|---------------|---|
| ADR | Adverse drug reactions |
| AFB | Acid-fast bacilli |
| AIDS | Acquired immunodeficiency syndrome |
| ART | Antiretroviral therapy |
| CI | Confidence interval |
| CISID | Centralized Information System for Infectious Diseases |
| DRS | Drug resistance surveillance |
| DST | Drug susceptibility testing |
| ECDC | European Centre for Disease Prevention and Control |
| EEA | European Economic Area |
| EPTB | Extrapulmonary tuberculosis |
| EQA | External quality assessment |
| EU | European Union |
| HIV | Human immunodeficiency virus |
| HPC | High-priority countries (Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan) |
| LTBI | Latent tuberculosis infection |
| MDR | Multidrug resistance |
| MDR TB | Multidrug-resistant tuberculosis |
| MSM | Men who have sex with men |
| PTB | Pulmonary tuberculosis |
| PLHIV | People living with HIV/AIDS |
| RR TB | Rifampicin-resistant tuberculosis |
| SLD | Second-line drugs |
| TB | Tuberculosis |
| TESSy | The European Surveillance System |
| TME | WHO Tuberculosis Monitoring and Evaluation platform |
| TOM | Treatment outcome monitoring |
| UN | United Nations |
| WHO | World Health Organization |
| WRD | WHO-approved rapid diagnostics |
| XDR | Extensive drug resistance |
| XDR TB | Extensively drug-resistant tuberculosis |



Summary

Executive summary

The WHO European Region

Tuberculosis incidence in the WHO European Region increased sharply from 1990 onwards, reaching a peak in 1999. Since 2000, the number of TB cases emerging in the Region has consistently decreased. The average annual decline in the TB incidence rate was 4.3% during the period 2007–2016, and 4.4% between 2015 and 2016. Over the last 10 years TB incidence in the Region has decreased from 47 to 32 cases per 100 000 population; the equivalent of 410 000 in 2007 and 290 000 in 2016. This represents a decrease of the TB burden in the Region by a third, as well as a decline from 4% to 3% in the Region's proportion of the Global TB burden during the period 2007–2016. Yet, despite this being the fastest decline in the world compared to other regions, it will still need to be accelerated to achieve the milestone of reducing TB incidence as part of the End TB strategy.

In 2016, the TB mortality rate had fallen more than two-fold compared with the rate for 2007, 2.8 and 6.5 TB deaths per 100 000 population respectively, which on average represents a decline of 8.9% per year. Over the last five years, this decline has accelerated to 10.5% per year, which is notably higher than the global rate of decline for TB mortality (3.2% between 2012 and 2016). Yet in 2016, 26 000 TB deaths occurred in the European Region.

Nine out of 30 countries with the highest multidrug-resistant (MDR) TB burden in the world are in the WHO European Region. In 2016, an estimated 71 000 incident cases of rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR TB) emerged in the WHO European Region. This represents about 20% of the global RR/MDR-TB burden which is 350 000. The proportion of RR/MDR-TB among new and previously treated TB cases in the Region is also significantly above the global average, with 19% in new and 55% in previously treated cases compared to 4.1% and 19% respectively. Since 2011, and with the introduction and scale up of the WHO-recommended rapid diagnostics, the detection rate of MDR-TB has increased significantly, from 33% in 2011 to 73% in 2016.

During the period 2007–2016, the WHO European Region faced an unprecedented increase in HIV prevalence in incident TB cases from 3% to 12%. This is higher than both the global average and the dynamic, which declined from 13% in 2007 to 10% in 2016. The number of TB/HIV co-infections emerging in the WHO European Region has increased from 13 000 to 34 000, representing a 260% increase during the period from 2007 to 2016. This situation is driven by the spread and dynamic of the HIV epidemic in the Region.

Despite universal treatment coverage for TB and RR/MDR-TB patients, the treatment success rate in the Region is still below the 85% and 75% Regional targets respectively. Nevertheless, when data for 2012 and 2016 are compared,

a slow but sustainable increase can be seen in both cohorts for all new and relapse TB and RR/MDR-TB cases, from 72% to 75% and from 49% to 55% respectively. Nonetheless, several high countries with high MDR-TB burdens have shown remarkable success in the treatment of MDR-TB patients (Kazakhstan 76.5% and Latvia 73.2%).

To commemorate the tenth anniversary of the Berlin Declaration 'All against Tuberculosis' and the fact that we are now half way through implementation of the Tuberculosis Action Plan for the WHO European Region 2016–2020, this report also provides an overview of the progress made and the challenges faced in addressing TB in the Region.

European Union and European Economic Area countries

Epidemiology

In 2016, 58 994 cases of TB were reported in 30 EU/EEA countries (Liechtenstein did not report). The decreasing notification rates observed in most countries are reassuring, but annual rates of decline are still insufficient to achieve the WHO target of TB elimination by 2050 in European low-incidence countries.

Of all notified TB cases, 70.4% were newly diagnosed and 71.0% were confirmed by culture, smear or nucleic acid amplification test. Thirty-three per cent of all TB cases were of foreign origin, mostly residing in low-incidence countries. Overall, adult age groups were equally affected by TB. Children under 15 years of age accounted for 4.1% of all TB cases, corresponding to a notification rate of 3.0 per 100 000 population. Higher-incidence countries also had the highest age-specific notification rates in children. Males were over-represented in all EU/EEA Member States.

Multidrug-resistant (MDR) TB was reported for 3.7% of 36 071 cases with drug susceptibility testing (DST) results and continues to be highest (more than 10%) in the three Baltic countries. Extensively drug-resistant (XDR) TB was reported for 20.1% of 984 MDR TB cases tested for second-line drug susceptibility. The drug resistance for the second line anti-TB drugs has slightly increased compared to recent years.

Data on HIV co-infection remained very incomplete, and the number of countries reporting HIV status was similar to 2015. Of all TB cases with known HIV status, 4.5% were co-infected with the virus.

TB in prisons remains poorly reported. For the 18 EU/EEA countries reporting data, the notification rate amounted to 163.8 per 100 000 inmates - i.e. an incidence ratio of 11.1 compared to the general population in the same countries.

Monitoring progress towards TB elimination

In 2016, 19 of 26 WHO targets could be effectively monitored based on the data available from EU/EEA Member States. Almost all EU/EEA Member States met the four targets regarding estimated TB case detection (at least 84%), TB notification (below 24.6 per 100 000), treatment enrolment of RR/MDR TB cases (100%) and estimated TB mortality (below 2.7 per 100 000).

A majority of reporting countries met or were close to the targets on first-line DST coverage among bacteriologically confirmed cases (100%) and the percentage of RR/MDR TB among previously treated TB patients (decrease compared with 2014). However, only a minority of reporting Member States met the targets regarding use of WHO-recommended rapid tests for diagnosis (40% of new cases and relapses), the percentage of RR/MDR TB among new TB patients (decrease compared with 2014) and the percentage of TB/HIV co-infection (decrease compared with 2014).

Finally, a small minority, sometimes only a single Member State, met the targets regarding estimated RR/MDR TB case detection (at least 85%), TB and MDR TB treatment success (at least 85% and 75%, respectively), HIV testing coverage (100%) and the detection of TB/HIV co-infection (100%).

Резюме

Европейский регион ВОЗ

Начиная с 1990 г. в Европейском регионе ВОЗ отмечался резкий рост заболеваемости туберкулезом, которая достигла максимального значения в 1999 г. С 2000 г. число возникающих в Регионе случаев ТБ неуклонно снижается. В период с 2007 по 2016 г. показатель заболеваемости ТБ снижался в среднем на 4,3% в год и на 4,4% в год в период с 2015 по 2016 г. За последние 10 лет абсолютное число случаев ТБ, возникающих в Регионе ежегодно, сократилось с 47 до 32 на 100 000 населения, что эквивалентно снижению с 410 000 случаев в 2007 г. до 290 000 случаев в 2016 г. Это означает, что в период с 2007 по 2016 гг. бремя ТБ в Регионе сократилось на треть, а процентный вклад Региона в глобальное бремя ТБ снизился с 4% до 3%. При этом несмотря на то, что Региону удалось обеспечить самые высокие в мире темпы снижения показателей ТБ, их недостаточно, чтобы достичь целевого показателя снижения заболеваемости ТБ, предусмотренного стратегией «Ликвидировать ТБ».

В 2016 г. показатель смертности от ТБ сократился более чем вдвое по сравнению с 2007 г., до 2,8 с 6,5 случаев на 100 000 населения, что соответствует снижению этого показателя в среднем на 8,9% в год. За последние пять лет темпы снижения ускорились до 10,5% в год, что существенно выше глобальных темпов снижения смертности от ТБ (3,2% в период с 2012 по 2016 г.). Тем не менее, в 2016 г. в Европейском регионе от ТБ умерло 26 000 человек.

Девять из 30 стран мира с самым высоким бременем МЛУ-ТБ находятся в Европейском регионе ВОЗ. В 2016 г. расчетное число новых случаев и рецидивов ТБ с устойчивостью к рифампицину и множественной лекарственной устойчивостью (РУ/МЛУ-ТБ) в Европейском регионе ВОЗ составляло 71 000. Это соответствовало приблизительно 20% от 350 000 случаев, составляющих глобальное бремя РУ/МЛУ-ТБ. Доля РУ/МЛУ-ТБ среди впервые выявленных и ранее леченных больных ТБ в Регионе также значительно превышает среднемировой показатель и достигает 19% среди впервые выявленных и 55% среди ранее леченных больных, по сравнению с 4,1% и 19% соответственно. С 2011 г. и с внедрением и расширением масштабов применения рекомендованных ВОЗ методов ускоренной диагностики существенно вырос уровень выявления МЛУ-ТБ, с 33% в 2011 г. до 73% в 2016 г.

В период с 2007 по 2016 г. Европейский регион ВОЗ столкнулся с беспрецедентным ростом распространенности ВИЧ-инфекции у впервые выявленных больных и больных с рецидивом ТБ - с 3% до 12%, что превышало среднемировой показатель и шло в разрез с глобальной тенденцией к снижению с 13% в 2007 г. до 10% в 2016 г. Число случаев сочетанной инфекции ТБ/ВИЧ в Европейском регионе ВОЗ выросло с 13 000 до

34 000, что соответствует росту этого показателя к 2016 г. на 260% по сравнению с 2007 г. Сложившаяся ситуация обусловлена распространением и динамикой развития эпидемии ВИЧ-инфекции в Регионе.

Несмотря на всеобщий охват лечением больных ТБ и РУ/МЛУ-ТБ, показатель успешности лечения в Регионе по-прежнему остается ниже целевых показателей 85% и 75% соответственно. Тем не менее, сравнивая данные за 2012 и 2016 гг., отмечается медленный, но устойчивый рост успешности лечения в обеих когортах как среди всех впервые выявленных больных ТБ, так и среди больных РУ/МЛУ-ТБ, с 72% до 75% и с 49% до 55% соответственно. При этом, нескольким странам с высоким бременем МЛУ-ТБ удалось достичь значительных успехов в лечении больных МЛУ-ТБ (Казахстан 76,5% и Латвия 73,2%).

По случаю 10-й годовщины принятия Берлинской декларации «Все против туберкулеза» и в ознаменование половины срока реализации Плана действий по борьбе с туберкулезом для Европейского региона ВОЗ на 2016-2020 гг. в настоящем докладе также представлен обзор достигнутого прогресса и проблем в борьбе с ТБ в Регионе.

Страны Европейского союза и Европейской экономической зоны

Эпидемиология

В 2016 г. в 30 странах ЕС/ЕЭЗ (Лихтенштейн не предоставил отчетных данных) было зарегистрировано 58 994 случая ТБ. Наблюдаемое в большинстве стран снижение показателей регистрации случаев ТБ обнадеживает, но ежегодных темпов снижения по-прежнему недостаточно для достижения целевого ориентира ВОЗ в отношении ликвидации ТБ к 2050 году в европейских странах с низким уровнем заболеваемости.

В структуре всех зарегистрированных случаев ТБ 70,4% составили впервые выявленные случаи, 71,0% случаев был подтвержден культурально, с помощью микроскопии мазка мокроты или метода амплификации нуклеиновых кислот. Тридцать три процента всех случаев ТБ были зарегистрированы у лиц иностранного происхождения, в основном проживавших в странах с низкой заболеваемостью ТБ. В целом, взрослые возрастные группы были в равной степени затронуты ТБ. Дети в возрасте до 15 лет составляли 4,1% всех больных ТБ, что соответствовало показателю регистрации случаев 3,0 на 100 000 населения. В странах с более высоким уровнем заболеваемости также отмечались самые высокие возрастные показатели регистрации случаев ТБ у детей. Во всех государствах членах ЕС/ЕЭЗ в структуре больных преобладают мужчины.

Туберкулез с множественной лекарственной устойчивостью (МЛУ) был зарегистрирован в 3,7% от 36 071 случая ТБ с результатами тестирования на лекарственную чувствительность (ТЛЧ), и его показатели остаются самыми высокими (свыше 10%) в трех странах Балтии. Туберкулез с широкой лекарственной устойчивостью (ШЛУ) был зарегистрирован в 20,1% от 984 случаев МЛУ-ТБ, протестированных на лекарственную чувствительность к препаратам второго ряда. По сравнению с прошедшими годами отмечался незначительный рост лекарственной устойчивости к противотуберкулезным препаратам второго ряда.

Данные о сочетанной ВИЧ-инфекции оставались весьма неполными, и число стран, предоставивших данные о ВИЧ-статусе, осталось неизменным с 2015 г. Сочетанная ВИЧ-инфекция была зафиксирована у 4,5% всех больных ТБ с известным ВИЧ-статусом.

По-прежнему сохраняются проблема качества отчетности о случаях ТБ в местах лишения свободы. Для 18 стран ЕС/ЕЭЗ, предоставивших данные, показатель регистрации равнялся 163,8 на 100 000 заключенных, т. е. коэффициент заболеваемости составил 11,1 по сравнению с населением в целом в тех же странах.

Мониторинг прогресса в направлении ликвидации туберкулеза

В 2016 году на основе данных, полученный от государств-членов ЕС/ЕЭЗ было возможным проведения

мониторинга по 19 из 26 показателям ВОЗ. Почти все государства-члены ЕС/ЕЭП достигли все четыре цели, касающиеся выявления случаев ТБ (не менее 84%), заболеваемости туберкулезом (ниже 24,6 на 100 000), покрытию лечением РУ/МЛУ-ТБ случаев (100%) и смертности от туберкулеза (ниже 2,7 на 100 000).

Большинство стран, подающие отчет о ТБ, достигли или были близки к достижению намеченных целевых уровня показателей в отношении охвата тестами на лекарственную чувствительность к препаратам первого ряда (ТЛЧ ПТП) среди бактериологически подтвержденных случаями (100%) и распространенности РУ/МЛУ ТБ среди ранее леченного больного туберкулеза (снижение по сравнению с 2014 годом). Однако, лишь немногие страны достигли целевых показателей в отношении использования рекомендованных ВОЗ экспресс-тестов для диагностики (40% новых случаев и рецидивов), процентное соотношение РР/МЛУ ТБ среди новых больных туберкулезом (снижение по сравнению с 2014 годом) и доля коинфекции ТБ/ВИЧ (снижение по сравнению с 2014 годом).

Наконец, несколько стран, а иногда и только одно государство-член, достигло целевых показателей по выявлению случаев РУ/МЛУ-ТБ (не менее 85%), успеха лечения ТБ и МЛУ-ТБ (по меньшей мере, 85% и 75% соответственно), охватом тестирования на ВИЧ (100%) и выявлению коинфекции ТБ/ВИЧ (100%).



1. Main facts about TB

1. Main facts about TB

Tuberculosis (TB) is an infectious disease caused by a group of *Mycobacterium* species called the *Mycobacterium tuberculosis* complex [1]. Although TB typically affects the lungs (pulmonary TB), it can cause disease in any organ (extrapulmonary TB). TB is transmitted from person to person, for example when people with pulmonary TB expel bacteria by coughing.

Only a small proportion of people ($\approx 10\%$) infected with *Mycobacterium tuberculosis* will develop TB disease during their lifetime, but this probability is much higher among immunocompromised individuals (e.g. people infected with HIV).

Sputum smear microscopy is the most common TB diagnostic method worldwide. However, culture remains the gold standard and the use of rapid molecular testing is increasing.


Standard treatment of non-resistant TB consists of a six-month regimen of four first-line drugs (isoniazid, rifampicin, ethambutol and pyrazinamide), with success rates usually above 85% [2]. Multidrug-resistant (MDR)

and extensively-drug-resistant (XDR) TB require longer treatments with more drugs and are associated with lower success rates.

In 2016, the World Health Organization (WHO) estimated that 10.4 million people fell ill with TB, 62% of them in South-East Asia and the Western Pacific Region. The African Region accounted for 25% of all TB cases. Smaller proportions of cases were estimated for the Eastern Mediterranean Region (7%), and the Region of the Americas (3%). The European Region accounted for 3% of all cases [3].

Overall, in the European Union and European Economic Area (EU/EEA), TB remains a common infection [4]. However, most EU/EEA countries are low-incidence countries (i.e. with a notification rate below 10 per 100 000) where TB predominantly affects vulnerable populations, such as migrants, prison inmates or people co-infected with HIV.

The overall aim of TB surveillance is to help inform public health action. The Annual TB Surveillance and Monitoring report presents the key figures and trends and provides an overview of the TB situation in the EU/EEA and the WHO European Region.



2. Technical note

2. Technical note

Between 1996 and 2007, TB surveillance data from the European Region were collected and analysed annually under the 'EuroTB' project.

Since 1 January 2008, ECDC and the WHO Regional Office for Europe have jointly coordinated the collection and analysis of TB surveillance data in Europe, aiming to ensure data standardisation and high quality across the countries of the WHO European Region. The underlying standards and definitions have been agreed by leading European experts. The definitions used in this report are in line with the latest WHO revised definitions [5].

This report covers the 53 countries of the WHO European Region plus Liechtenstein. These are collectively referred to as the 'European Region'.

The data published in this report may differ from figures in national reports due to variation in reporting periods. The deadline for updating the data used in this report was 1 October 2017.

2.1 Data reporting and analysis

Designated experts within the national surveillance institutes submitted their TB surveillance and control programme management data for 2016 electronically to the ECDC–WHO Regional Office for Europe Joint TB Information System via a common portal¹. Designated experts within the national surveillance institutes submitted their TB surveillance and control programme management data for 2016 electronically to the ECDC–WHO Regional Office for Europe Joint TB Information System via a common portal. The TB surveillance data from the EU/EEA countries were redirected to The European Surveillance System (TESSy) platform, hosted by ECDC (Annex 1). The surveillance data from the non-EU/EEA countries, from France for 2016, and the programme management data from the entire European Region were processed through WHO's Tuberculosis Monitoring and Evaluation (TME) platform in aggregated format. A total of 29 EU/EEA Member States reported case-based data². All countries in the European Region were also asked to provide updates for 2013, 2014 and 2015 to allow for the exclusion of duplicate cases, or those later found not to have TB, and for the reporting of treatment outcomes in previously-notified cases.

The TESSy variable list for collection of the 2016 data (Annex 2) has not undergone any changes compared to the previous year.

Reporting completeness (Annex 3 and 4) varied among countries due to differences in legislation, specifics of

national surveillance systems and TB case ascertainment. Although the quality and comparability of reported data have improved in recent years, the reader should be cautious when making comparisons across countries. Data for the year 2016 from France have been noted as provisional and reported only in aggregated format to the WHO Global TB database. For the calculation of notification rates, country total population denominators by age group and gender were obtained from Eurostat³ (22 September 2017) for the EU and EEA countries and from United Nations Population Division statistics⁴ for all others.

Reported data were analysed using the main epidemiological (time, place, gender, age, patient origin) and case management variables (history of previous anti-TB treatment, localisation of disease, laboratory results, HIV serostatus and treatment outcome). Associations between variables were quantified as prevalence ratios and their 95% confidence intervals, and results were considered significant if the confidence interval did not include 1.

TB/HIV co-infection

Case-based HIV serostatus was reported by Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia and Spain. The non-EU/EEA countries, Latvia (for years 2004–2014), the Netherlands (2004–2012) and United Kingdom (2011–2013) submitted this information in aggregate format via WHO's TME platform. Finland and Poland reported the number of HIV-infected TB cases for most of the years, but not the denominator of known HIV test results. United Kingdom reported the number of HIV-tested TB cases but not the test results and were therefore excluded from the analysis. The proportion of HIV-TB co-infection was expressed as a percentage of reported TB cases with known HIV status. HIV status had to be available for >50% of all TB cases to be considered complete in the country profiles. Antiretroviral therapy was reported by eight EU/EEA Member States.

Laboratory network performance and drug resistance

Since the reporting year 1998, the results of drug susceptibility testing (DST) from initial isolates of *Mycobacterium tuberculosis* have been collected for isoniazid and rifampicin, and most EU/EEA countries have also reported susceptibility to ethambutol and streptomycin. Data on second-line drug resistance to amikacin, kanamycin, capreomycin, ciprofloxacin and ofloxacin have been reported via TESSy since 2008 and via CISID/TME since 2009. Data on resistance to gatifloxacin, levofloxacin and moxifloxacin

¹ ECDC/WHO Europe Joint Surveillance: <http://www.ecdcwhosurveillance.org>

² As Liechtenstein has not provided any TB data, except for five cases in 2007, it is not included in the commentary.

³ Available from: <http://ec.europa.eu/eurostat/data/database>

⁴ Population by UN Population Division, World Population Prospects: The 2015 Revision, medium variant (2016).

were added in 2013 and bedaquiline and delamanid in 2016. In countries where DST results are linked to TB case notifications, case-based information on DST is collected (27 countries in 2016). When individual DST data are not available, data are collected in aggregate format in TME based on previous anti-TB treatment history. Information on the organisation and laboratory practices for anti-TB DST in the country is collected using the TME module of the joint TB surveillance system. Drug resistance surveillance (DRS) methods vary across countries. Initial DST results may be collected routinely for all culture-positive TB cases notified, or only for cases included in specific surveys or diagnosed in/referred to selected laboratories. DRS data were considered complete if:

- they were collected nationwide and linked to TB case notifications in countries routinely using culture (> 50% culture confirmation);
- DST results for isoniazid and rifampicin were available for ≥75% of culture-positive cases;
- at least 95% of external quality assessment (EQA) results were confirmed by a supranational reference laboratory.

DRS data are considered incomplete for Albania, Andorra, Azerbaijan, Greece, Italy, Kazakhstan, Kyrgyzstan, Moldova, Portugal, San Marino, Spain, Turkmenistan and Uzbekistan.

External quality assurance (EQA) systems are essential for ensuring accurate diagnosis of TB and drug-resistant TB. The implementation of EQA by organising regular EQA rounds and identifying training needs is one of the key activities of the European TB reference laboratory network (ERLTB-Net)[6]. The EQA test results for 2016 are published in Annex 5.

Percentages of laboratory-confirmed drug-resistant cases were calculated using cases with known DST results (for at least isoniazid and rifampicin) as the denominator. If the cases had DST results for ethambutol and streptomycin, these were shown under resistance to any TB drugs. The results of DST for second-line drugs were analysed for MDR TB cases only.

Treatment outcome monitoring (TOM)

Since the reporting year 2002, treatment outcome data have been provided by EU/EEA countries through the submission of an updated dataset for cases notified one year prior to the year of reporting. The same applies to MDR TB treatment outcome for cases reported two years earlier and XDR TB treatment outcome for cases reported three years earlier. Thus, as part of the 2017 data call, for 2016 data, outcome data were collected for TB cases reported in 2015, MDR TB cases reported in 2014 and XDR TB cases reported in 2013. Non-EU/EEA countries have reported aggregated treatment outcome data following the same principle since 2013.

For the purpose of TOM analysis, two types of MDR TB cases were considered: cases with a known treatment start and cases with no indication of treatment. For countries reporting case-based data, the most recently updated information was used. This may result in denominators

differing from the number of notified cases reported in the previous year's report. For countries reporting aggregate outcome data, completeness of cohorts is assessed by comparing the total number of cases included in TOM cohorts with those initially notified as pulmonary and culture or smear-positive, depending on the type of cohort.

Geographical areas

The following 31 EU/EEA countries are presented separately in tables and in Chapter 3.2: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom.

The 23 remaining (non-EU/EEA) countries in the WHO European Region are: Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Israel, Kazakhstan, Kyrgyzstan, the former Yugoslav Republic of Macedonia, Moldova, Monaco, Montenegro, Russia, San Marino, Serbia, Switzerland, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

Data from Serbia include TB cases reported from Kosovo⁵, and these are also stratified in tables to reflect UN Security Council Resolution No. 1244 (1999).

In order to highlight the 18 high-priority countries (HPC) identified by WHO Regional Office for Europe's Stop TB Strategy in the European Region, their data are presented in italics and as subtotals alongside the subtotals for the EU/EEA and non-EU/EEA Member States. The 18 high-priority countries in the WHO European Region are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

TB notifications from France include overseas territories. TB notifications from Greenland are not included in the report.

2.2 Definitions

TB case definition for surveillance

Information from EU/EEA countries was collected to enable the classification of cases according to the case definition approved by the EU Member States and published by the European Commission⁶. This classifies cases as 'possible', 'probable' or 'confirmed'. Possible cases meet clinical criteria only. Probable cases are defined by the additional detection of acid-fast bacilli (AFB), *M. tuberculosis* nucleic acid or granulomata. Confirmed cases require a

5 This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo Declaration of Independence

6 European Union Commission. 2008/426/EC: Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document number C(2008) 1589). OJ L 159, 18.06.2008, p. 46

positive culture or detection of both AFB by microscopy and *M. tuberculosis* by nucleic acid amplification testing.

Data from all countries in the European Region also follow the WHO-recommended definitions – 2013 revision⁷. They define a ‘case of tuberculosis’ as a patient in whom TB has been confirmed by bacteriology or diagnosed by a clinician. A ‘bacteriologically confirmed TB case’ is one from whom a biological specimen is positive by smear microscopy, culture or WHO-approved rapid diagnostics (WRD) such as Xpert MTB/RIF. A ‘clinically diagnosed TB case’ is one that does not fulfil the criteria for bacteriological confirmation, but has been diagnosed with active TB by a clinician or other medical practitioner who has decided to give the patient a full course of TB treatment.

Cases discovered post-mortem, whereby gross pathological findings are consistent with active TB that would have indicated anti-TB treatment, had the patient been diagnosed before dying, also fit the clinical criteria and are included.

Previous anti-TB treatment status

New patients have never been treated for TB or have taken anti-TB drugs for less than one month.

Previously-treated patients have received one month or more of anti-TB drugs in the past. They are further classified by the outcome of their most recent course of treatment as follows:

- **Relapse:** patients have previously been treated for TB, were declared cured or to have completed their treatment at the end of their most recent course of treatment, and are now diagnosed with a recurrent episode of TB (either a true relapse or a new episode of TB caused by reinfection).
- **Treatment after failure:** patients who have previously been treated for TB and whose treatment failed at the end of their most recent course of treatment.
- **Treatment after loss to follow-up:** patients have previously been treated for TB and were declared lost to follow-up at the end of their most recent course of treatment. (These were previously classified as ‘treatment after default’.)
- **Other previous treatment:** patients who have previously been treated for TB but whose outcome after their most recent course of treatment is unknown or undocumented.

Patients with unknown previous TB treatment history do not fit any of the categories listed above.

New cases and relapses of TB are **incident TB cases**.

Site of disease

Pulmonary tuberculosis (PTB) refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or the tracheobronchial tree (laryngeal TB is classified as pulmonary). A patient with both

pulmonary and extrapulmonary TB should be classified as a case of PTB.

Extrapulmonary tuberculosis (EPTB) refers to any bacteriologically confirmed or clinically diagnosed case of TB involving organs or anatomical sites other than the lungs (e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, or meninges).

Notes on the definition

- The above definitions are in accordance with the European Commission’s approved definitions for TB surveillance.
- All possible, probable and confirmed cases are reported to the joint European surveillance database. For countries with laboratory-based reporting where no clinical information is available, laboratory-confirmed cases should be reported.
- Cases should be notified only once in a given 12-month period. However, a case should be reported again if the diagnosis of confirmed tuberculosis is made following completion of anti-TB treatment (relapse), even if this occurs within 12 months of reporting the initial episode of disease.
- Cases that have never been treated are commonly referred to as new cases, although this term should not be considered to indicate incidence in the strict epidemiological sense.
- Among re-treated cases, relapses are included in notifications from all countries, whereas cases re-treated after failure or loss to follow-up and chronic cases are not included or further defined by Belgium, Cyprus, Denmark, Ireland, France, Luxembourg, Malta, Norway, Spain and United Kingdom.
- DST data were analysed for laboratory-confirmed cases.

Origin of cases

The geographic origin of a TB case is classified according to place of birth of a person with TB disease (born in the country/born outside of the country) for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Iceland, Ireland, Israel, Italy, Kyrgyzstan, Latvia, Lithuania, Luxembourg, the former Yugoslav Republic of Macedonia, Malta, the Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Tajikistan, Turkey, the United Kingdom and Uzbekistan. Albania, Andorra, Armenia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Georgia, Greece, Hungary, Kazakhstan, Moldova, Montenegro, Poland, Russia, Serbia, Turkmenistan and Ukraine used citizenship (citizen/non-citizen) for classification. Azerbaijan and Turkmenistan did not report information on origin. In Denmark, the birthplace of the parents is also used to classify origin (similarly, in the Netherlands, the birthplace of parents is notified for case management purposes). The country of origin is included in case-based data. The term ‘native’ as used in this report refers to cases born in, or having the citizenship (nationality) of the reporting country. ‘Foreign origin’ refers to cases born in (or citizens of) a country different to the reporting country.

⁷ WHO. Definitions and reporting framework for tuberculosis 2013 revision, updated December 2014. Geneva: WHO; 2015. Available from: <http://www.who.int/tb/publications/definitions/en/>

Drug resistance

Resistance among cases never treated (new TB cases): indicates primary drug resistance due to infection with resistant bacilli.

Resistance among cases previously treated: usually indicates acquired drug resistance emerging during treatment following selection of drug-resistant mutant bacilli. It can also result from exogenous re-infection with resistant bacilli.

Multidrug resistance (MDR): resistance to at least isoniazid and rifampicin.

Extensive drug resistance (XDR): resistance to (i) isoniazid and rifampicin (i.e. MDR), (ii) resistance to a fluoroquinolone, and (iii) resistance to one or more of the following injectable drugs: amikacin, capreomycin, or kanamycin [7].

Rifampicin resistance: resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. This includes any resistance to rifampicin, whether mono-resistance, multi-drug resistance, polydrug resistance or extensive drug resistance.

Treatment outcome

Cohorts

All TB cases notified in the calendar year of interest, after exclusion of cases with a final diagnosis other than TB, or cases found to have been reported more than once.

In accordance with the new WHO treatment outcome definitions⁸ two types of cases were considered:

- patients treated for drug-susceptible TB;
- patients treated for drug-resistant TB using second-line treatment (defined as combination chemotherapy for drug-resistant tuberculosis).

The two groups are mutually exclusive. Any patient found to have drug-resistant TB and placed on second-line treatment is removed from the drug-susceptible TB outcome cohort.

Period of observation

Cases are observed until the first outcome up to a maximum of 12 months after the start of treatment. For MDR TB cases in EU/EEA countries, treatment outcome after 24 months should be reported if treatment lasts longer than 12 months and the reported 12-month outcome is coded as 'still on treatment'⁹. For XDR TB cases in EU/EEA countries, treatment outcome after 36 months should be reported if treatment lasts longer than 24 months and the reported 12-month and 24-month outcomes are coded as 'still on treatment'¹⁰. Non-EU/EEA countries evaluate treatment outcomes according to the WHO definition.

⁸ WHO. Definitions and reporting framework for tuberculosis 2013 revision, updated December 2014. Geneva, Switzerland: World Health Organization; 2015. Available from: <http://www.who.int/tb/publications/definitions/en>

⁹ The degree of adherence to the 12-month limit is unknown, and a number of countries are known to exceed it.

¹⁰ The degree of adherence to the 24-month limit is unknown.

Treatment outcome categories

All outcome categories but one apply to the entire region and follow the recommendations in 'Definitions and reporting framework for tuberculosis – 2013 revision'. The additional category: 'still on treatment' only applies to the EU/EEA Member States. The categories are as follows:

Cured: A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who was smear- or culture-negative in the last month of treatment and on at least one previous occasion.

Cured of MDR TB: Treatment completed as recommended under national policy without evidence of failure AND three or more consecutive cultures taken at least 30 days apart are negative after the intensive phase.

Treatment completed: Treatment completed, but does not meet the criteria to be classified as cure or treatment failure.

Treatment failed: A TB patient whose sputum smear or culture is positive at month 5 or later during treatment.

Treatment failed for MDR TB case:

Treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of: lack of conversion by the end of the intensive phase, or

- bacteriological reversion in the continuation phase after conversion to negative, or
- evidence of additional acquired resistance to fluoroquinolones or second-line injectable drugs, or
- adverse drug reactions (ADRs).

Died: A TB patient who dies for any reason before starting or during the course of treatment.

Lost to follow-up: A TB patient who did not start treatment or whose treatment was interrupted for two consecutive months or more.

Still on treatment¹¹:

- patient still on treatment at 12 months without any other outcome during treatment;

or


- patient reported as still on treatment at 12 months and still on treatment at 24 months without any other outcome.

Not evaluated: a TB patient for whom no treatment outcome is assigned. This includes cases 'transferred out' to another treatment unit as well as cases for whom the treatment outcome is unknown to the reporting unit.

In this report:

Success: The sum of 'cured' and 'treatment completed'.

¹¹ Definition applicable to EU/EEA countries only.



3. Commentary

3. Commentary

3.1 The WHO European Region

Tuberculosis burden estimates

In 2016, an estimated 290 000 new and relapse TB cases (range 251 000–333 000) occurred in countries of the WHO European Region, equivalent to an average incidence of 31.6 cases (27.3–36.3) per 100 000 population. This represents about 3% of the total burden of tuberculosis in the world. During 2016, the absolute number of incident TB cases in the WHO European Region fell by 13 000 compared to the previous year. About 83% of the estimated TB cases in the Region occur in the 18 high-priority countries, where estimated TB incidence was 60.4 cases per 100 000 population¹², which is about five times higher than the EU/EEA average. The five countries with the largest absolute number of incident TB cases were Russia (94 000), Ukraine (39 000), Uzbekistan (24 000), Romania (15 000) and Kazakhstan (12 000). The number relative to population (incidence rate) was highest in Kyrgyzstan (145 per 100 000 population), followed by Moldova (101 per 100 000 population) Georgia (92 per 100 000 population), Ukraine (87 per 100 000 population) and Tajikistan (85 per 100 000 population) (Table 1).

Since 2000, the estimated number of TB cases in the Region has been consistently decreasing. The average annual decline in the TB incidence rate was 4.3% during the period 2007–2016, with 4.6% between 2015 and 2016, which is notably higher than the global rate of decline for TB incidence (1.9%). Yet, despite this being the fastest decline in the world compared to other regions¹³, it will still need to be accelerated to achieve the milestone of reducing TB incidence as part of the End TB strategy. It should, nevertheless, be pointed out that all the high-priority countries in the Region have experienced a decline in the TB incidence rate. Those countries with the highest annual rate of decline during the period 2007–2016 were Kazakhstan (-9.4%), Estonia (-8.6%) and Tajikistan (-7.4%) (Table 1).

In 2016, there were an estimated 26 000 TB deaths among HIV-negative people in the European Region, which is equivalent to 2.8 deaths per 100 000 population (range 2.8–2.9). There was considerable variation across the Region, ranging from less than one TB death per 100 000 population in western European countries to more than nine deaths per 100 000 in high-priority countries. The TB mortality rate was highest in Ukraine (9.5 deaths per 100 000), followed by Russia (8.2 deaths per 100 000), Turkmenistan (7.6 per 100 000) and Kyrgyzstan (7.2 deaths

per 100 000 in each). Together, the 18 high-priority countries account for over 90% of TB deaths in the Region (Table 1).

At Regional level, the TB mortality rate fell by 57%, from 6.5 to 2.8 deaths per 100 000 population between 2007 and 2016 (Table 1), which on average is a decline of 8.9% per year. Over the last five years, this decline has accelerated to 10.5% annually, which is notably higher than the global rate of decline for TB mortality (3.4% between 2015 and 2016).

In 2016, 12.0% (range 8.6–15.0%) of incident TB cases were estimated to be co-infected with HIV, 5.9% (5.4–6.3) in the EU/EEA group of countries and 13.1% (11.7–13.8) in the non-EU/EEA group of countries (Table 2). The proportion of TB cases co-infected with HIV was highest in Ukraine (21%) and Russia (19%), followed by Portugal and France (14% each). Although Malta and Luxemburg also showed high prevalence of HIV among TB cases (26% and 15% respectively), this represented only a few cases in absolute numbers. The top five countries with the highest number of TB/HIV co-infections were Russia (18 000), Ukraine (8 100), Uzbekistan (1 200), France (670), Kazakhstan (580) and the UK (560).

Nine out of 30 countries with the highest MDR TB burden in the world are in the WHO European Region¹⁴. In 2016, there were an estimated 122 000 (range, 110 000–134 000) incident cases of rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR TB) in the WHO European Region, with MDR TB accounting for 95% of the total. An estimated 19% (95% CI: 12–26%) of new cases and 55% (95% CI: 43–67%) of previously treated cases had RR/MDR TB. If all notified pulmonary tuberculosis patients were tested for drug resistance to rifampicin and isoniazid, it is estimated that around 71 000 (range 71 000–72 000) would be detected (Table 2).

TB notification and trends

In 2016, a total of 297 132 TB cases were reported from 52 countries¹⁵ in the WHO European Region, 253 096 of which were new, relapses or had an unknown previous treatment history (Table 5). This represents 85.2% of all TB cases notified in 2016.

The notification rate of new and relapse cases varies widely among countries, from none (San-Marino) to 118 (Kyrgyzstan) per 100 000 population (Map 1 and Table 4).

In 2016, there were 34 countries with low notification of new and relapse cases (less than 20 cases per 100 000), all located in the western and central part of the Region and the majority of them were high-income countries. Seven


¹² The 18 high-priority countries are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan.

¹³ World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Available from: <http://apps.who.int/iris/bitstream/10665/259366/1/9789241565516-eng.pdf>


¹⁴ Top 10 countries with the highest global MDR TB burden (in alphabetical order): Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Somalia, Tajikistan, Ukraine, Uzbekistan according to WHO Global tuberculosis report, 2017.

¹⁵ Monaco was the only non-reporting country in 2017.

Map 1: TB notification rates of new TB cases and relapses per 100 000 population, European Region, 2016



Map 2: Percentage of notified TB cases with multidrug resistance among new pulmonary laboratory confirmed TB cases, European Region, 2016



countries reported new or relapse case rates of between 20 and 50 per 100 000 population. Nine reported between 50 and 100 cases per 100 000 population: Moldova (88), Georgia (76), Kazakhstan (69), Tajikistan (68), Romania (65), Ukraine (65), Russia (64), Azerbaijan (53) and Uzbekistan (51). The 18 high-priority countries with new and relapse case notifications account for about 83% of the Regional burden. Around 36% of new and relapse cases come from Russia, even though Russia only accounts for 16% of the Region's population.

During the period 2012–2016, an overall downward trend of 16.6% was observed in the notification of incident TB cases, from 33.5 to 28.0 cases per 100 000 population (Table 4). This trend reflects a genuine reduction in the spread of the disease, significantly influenced by the decrease in notification rates throughout the Region's 18 high-priority countries from 64.7 to 53.5 per 100 000 population. The notification rate of new and relapse cases in the 18 high-priority countries is almost twice as high as for the Region overall (53.5 cases per 100 000 compared to 28.0 for the Region) and about five times higher than the rate in the EU/EEA (10.9 cases per 100 000 population).

Previous treatment history

In 2016, previously treated cases represented 10.5% and 30.3% in the EU/EEA and non-EU/EEA respectively. The average in the 18 high-priority countries was 30.0%, impacting the pan-European average of 26.4%. There were 16 countries in which previously treated cases accounted for 15% or more of all TB cases: Azerbaijan (43.4%), Russia (35.5%), Ukraine (31.6%), Moldova (31.2%), Kyrgyzstan (28.7%), Belarus (26.3%), Georgia (26.0%), Kazakhstan (25.9%), Armenia (24.3%), Uzbekistan (21.7%), Romania (21.1%), Lithuania (20.2%), Turkmenistan (17.8%), Montenegro (16.1%), Tajikistan (16.0%) and Latvia (15.2%) (Table 5). Reasons for the high percentage of previously-treated cases include clinical failure or poor treatment adherence and mismanagement in previous treatment episodes and possible re-infection during the current treatment episode.

Disease localisation

In 2016, pulmonary localisation was notified in about 72% of the overall TB cases in the Region (Table 6). The proportion of patients with pulmonary localisation in the EU/EEA was higher than in non-EU/EEA countries. Extra-pulmonary TB was notified on average for 14.2% of all TB cases in the Region. Eight countries reported more than 30% of their tuberculosis cases having extra-pulmonary localisation: Belgium, Ireland, Italy, Netherlands, Norway, Sweden, Turkey and United Kingdom.

Bacteriological confirmation

Bacteriological confirmation of TB diagnosis was reported for 135 472 (64.2%) of all 211 018 new and relapse pulmonary cases in the Region (Table 7). Confirmation of TB diagnosis among pulmonary TB cases by culture, smear and/or nucleic acid amplification tests (such as WHO-recommended rapid diagnostics Xpert MTB/RIF) was much lower in non-EU/EEA countries (60.1%) than in EU/EEA countries

(80.3%). Confirmation also varied considerably among countries - from 45% in Uzbekistan to 93% in Slovenia. In five countries bacteriological confirmation of new and relapse pulmonary cases was below 60%, underlining the need to strengthen diagnostics: Uzbekistan (45.3%), Armenia (52.8%), Hungary (54.4%), Russia (50.8%) and Kyrgyzstan (57.7%). In 34 countries bacteriological confirmation of new and relapse pulmonary cases was 75% and above.

Age and sex

There is a wide variation in the distribution of age- and sex-specific notification rates across countries. Notification rates in eastern European countries are highest in young adults (25–44 years) and subsequently decrease, while in the countries of Central Asia and in Turkey the notification rates either increase with age, or are relatively constant across adult age groups.

In the group of 18 high-priority countries, the rate of TB in children under five years was lower than the notification rate among children aged 5–14 years, indicating that detection of TB remains especially challenging in young children.


In countries with at least 100 new and relapse TB cases the proportion of TB cases notified in children (0–14 years) varied at country level from below one percent (Turkmenistan, Belarus, Hungary) to 21.4% (Slovakia) of all new cases and relapses. The difference in proportions of childhood TB cases across the countries may reflect differences in case-finding practice (e.g. contact tracing), population age-structure and under-/over-diagnosis or reporting of childhood TB. The average percentage of new and relapse TB patients under 15 years in the Region is around 4.0% (Table 9).

There were twice as many males as females reported among all TB cases (Table 9), however a large variation was observed for male predominance in the sex distribution of TB cases, ranging from almost even distribution to over three times greater in Armenia and Luxembourg. In most countries, gender differences in notification rates appear to be more significant among middle-aged and older adults. TB rates in males and females appear to be more similar in children and younger adults (0–14 and 15–24 years). This gender difference in TB case notification most likely reflects the overrepresentation of males in the various TB risk groups, notably the homeless, prisoners, seasonal migrant workers, people living with HIV (PLHIV), men who have sex with men (MSM) and people who inject drugs (PWID).

Drug resistance

In 2016, 50 countries in the Region reported on first-line anti-TB drug susceptibility test (DST) results. The percentage of confirmed MDR TB cases among 86 797 new pulmonary TB cases tested for first-line DST in the Region was 17.7%, which is slightly lower than the rate observed in 2015 (18.3%) (Fig 3.1.2). One possible reason for the low percentage of MDR TB at Regional level is the unusually low number of MDR TB cases reported from Kazakhstan and Uzbekistan compared to previous years. While 13 countries reported no MDR TB or less than 1%

Figure 3.1.1. Trend in TB notification rate per 100 000 between 2012 and 2016 in countries with under 20 cases per 100 000 (upper panel) and 20 cases and over per 100 000 (lower panel) in the WHO European Region



among new TB cases, eight countries reported a rate over 20% (Table 12). With the exception of the Baltic States, where MDR TB among new cases varied from 7.6% in Latvia to 13.3% in Lithuania, the prevalence was 4.1% or lower in all EU/EEA countries, with an average of 2.4% (Fig 3.1.3). In the non-EU/EEA area, three countries had an MDR TB prevalence ranging from 10–19% among new cases tested for first-line DST: Armenia (15.4%), Azerbaijan (15.4%) and Georgia (10.2%). Six countries had 20–29% MDR TB among new cases: Kazakhstan (25.5%), Kyrgyzstan (21.9%), Moldova (25.6%), Russia (27.3%), Tajikistan (20.8%) and Ukraine (22.0%). Belarus and Uzbekistan reported MDR prevalence above 30% (38.6%).

The percentage of confirmed MDR TB cases among 46 272 previously-treated TB cases whose isolates were tested for first-line DST was 51.9%, which is higher than the 2015 rate (46.3%) (Fig 3.1.2). The reason for such an increase at Regional level is the notable increase in the absolute number of previously treated cases with DST results in the Russian Federation as a result of the introduction of a country-wide electronic surveillance system. In 2016, the Russian Federation reported twice as many MDR TB cases as in previous years. The new surveillance system in Russia facilitated an accurate estimate of the number of previously treated MDR TB patients. This had not been possible before and consequently regional data had been under-estimated.

Eighteen countries had between 15% and 49% MDR TB among previously-treated TB cases tested for first line DST. In six countries this rate was even higher: Albania (50.0%), Kyrgyzstan (56.3%), Moldova (57.4%), Armenia (57.7%), Belarus (71.6%) and Russia (65.2%) (Table 12). However, it should be noted that in Albania this involved only four cases in absolute numbers.

In 2016, the per capita rate of MDR TB notification among new TB cases at Regional level was 1.7 per 100 000. This represents an average annual increase of 0.8% between 2012 and 2016 (Table V).

Trends in the MDR percentage among new TB cases and trends in the per capita notification rate of MDR TB among new cases have differed significantly by country in recent years (Table V). The proportion of MDR among new pulmonary TB cases tested for drug resistance decreased slightly in the EU/EEA sub-region over the last five years, from 2.7 to 2.4%, and the per capita rate of notified MDR TB cases remained stable at around 0.1 per 100 000 population. Meanwhile, in the non-EU/EEA countries the MDR percentages among new cases increased from 18.4% in 2012 to 22.8% in 2016. At the same time, despite an impressive decline in incident TB cases per capita, the notification rate for MDR TB increased from 3.4 to 3.7 per 100 000 population, suggesting that the replacement of susceptible TB strains with resistant strains is becoming more common in the non-EU/EEA subregion. The Regional trend is influenced by an increase in the MDR notification rate experienced mainly by Russia and Ukraine, as well as by Azerbaijan and Tajikistan. In a few settings (Armenia, Belarus, Georgia, Lithuania, Moldova) the MDR rate has levelled off, while Estonia and Latvia serve as clear examples of countries that

have reversed the trend in rising epidemics of MDR TB. In central Asian countries the prevalence and rate of MDR TB fluctuates widely from year to year, indicating weaknesses in routine drug-resistance surveillance.

In 2016, a total of 50 countries reported on second-line DST data. Data on second-line DST was available from about 96% of all notified MDR TB cases (compared to 29% in 2015), which is an exceptional achievement for data coverage in the history of drug resistance surveillance for the European Region. Of the 37 663 MDR TB cases subjected to second-line DST, 4 917 (13.1%) were XDR TB (Table 14). This is notably lower than the previous year's result (21.9%). Such rapid change at Regional level is related to the fact that Russia, which accounts for around 67% of MDR TB cases in the Region, began reporting second-line drug (SLD) data to the global TB database for the first time. In EU/EEA countries, where 74.4% of MDR TB cases were tested for second-line drugs, the prevalence of XDR among MDR cases was 20.1%, which is comparable to the result for 2015. Among the countries reporting at least 30 MDR cases with second-line DST results, five countries reported over 20% XDR prevalence among MDR TB cases: Belarus (45.9%), Latvia (37.5%), Lithuania (23.8%), Romania (30.0%) and Poland (20.5%).

There is no clear trend in the XDR TB percentage for countries with a long history of SLD DST surveillance. Thus, in Belarus the alarming rate of increase for XDR continued in 2016, reaching a prevalence of 45.6%. An increasing trend in XDR-TB was also observed in Estonia, Latvia and Romania, while in Lithuania, Armenia, Azerbaijan, Georgia and Tajikistan XDR prevalence among MDR TB cases has levelled off (Table VIII).

Of the 51 752 RR/MDR TB patients notified, 49 446 (95.5%) were enrolled into MDR TB treatment programmes. Five high-priority countries reported a gap of over 5% between the number of patients enrolled and the number diagnosed: Turkey (82.4%), Azerbaijan (86.3%), Belarus (87.2%), Georgia (87.5%), and Russia (94.0%) (Table 15).

Access to XDR TB treatment at regional level was only 76.6% in 2016, which is notably lower than the 98.6% treatment coverage reported for the previous year. This trend is influenced by Russia where XDR TB treatment coverage is only 52%, whereas in the rest of the high-priority countries, except for Tajikistan, XDR-TB treatment coverage is above 90%.

TB/HIV co-infection

A total of 40 countries provided surveillance data on TB/HIV co-infection (Table 16). In the reporting countries, of the 224 282 new and relapse TB patients notified, 193 128 were screened for HIV (86.1%). Nine high-priority countries achieved a testing level above 90%: Armenia, Azerbaijan, Belarus, Georgia, Estonia, Moldova, Tajikistan and Ukraine and Uzbekistan. A total of 25 844 TB cases were detected with HIV-positive status, 13.4 % of those tested versus 9.0% recorded in 2015. The sudden change in TB/HIV cases is related to improvement of the TB/HIV surveillance system in Russia following the introduction of a

Figure 3.1.2. Percentages of MDR among laboratory-confirmed pulmonary TB cases, European Region, 2012 – 2016




Figure 3.1.3. Percentages of MDR among laboratory-confirmed pulmonary TB cases, EU/EEA, 2012 – 2016





Figure 3.1.4. Percentages of MDR among laboratory-confirmed pulmonary TB cases, 18 high-priority countries, 2012 – 2016



case-based, country-wide electronic surveillance system. Until 2016 Russia only reported TB/HIV data from among the TB cases newly diagnosed with HIV in the civilian population. Improvement of electronic surveillance has indicated that the burden of TB/HIV infection is much higher than was estimated. This has also resulted in a substantial revision of regional estimates.

Among those countries reporting representative HIV testing (above 50% HIV testing coverage), six have documented a significant overlap of the HIV and TB epidemics by exceeding 10% HIV prevalence among new and relapse TB cases (Table 16): Russia, Ukraine (20.7% each), Malta (17.4%), Portugal (13.9%), Estonia (11.7%) and Latvia (11.0%). Six countries with representative routine surveillance had 5–10% HIV prevalence among TB patients: Belarus, Moldova (8.7% each), Spain (7.3%), Israel (7.2%), Armenia (5.6%) and Kazakhstan (5.4%). In 2016, 32 countries in the Region provided information on anti-retroviral therapy (ART) enrolment among TB cases with HIV-positive status. Of 25 844 HIV-positive tuberculosis cases, 16 829 (65.1%) had received ART. This is somewhat higher than in 2015 (62.4%), but far below the WHO target of universal ART coverage. Among the high-priority countries there were only eight that achieved coverage of over 75%: Armenia, Belarus, Estonia, Georgia, Kazakhstan, Romania, Tajikistan and Turkey.

Origin of cases

TB cases of foreign origin represent 8.2% of all TB cases notified Region-wide, 32.7% in EU/EEA countries and only 2.0% in non-EU/EEA countries (Table 10). In many countries TB cases of foreign-origin represent a large majority: Malta (96.0%), Sweden (89.8%), Norway (88.6%), Israel (80.8%), Cyprus (93.3%), Switzerland (79.8%), Netherlands (75.3%) and Luxemburg (75.9%).

TB in prisons

During 2016, 36 countries in the Region provided information on TB case detection and treatment in prisons (Table 17). Overall, 12 298 (6.0%) of the new and relapse TB cases in the Region were reported from prisons, 11 863 (97%) of which were in the high-priority countries. In EU/EEA countries the proportion of TB cases in prisons represented only 1.7% of the country total; in non-EU countries the proportion was 7.1%. In the non-EU/EEA countries, the notification rate in prisons was 1144 new TB cases per 100 000 detainees, which is about seven times higher than in the EU/EEA sub-region (164 per 100 000). The overall notification rate for new TB cases in prisons in the WHO European Region was 862 per 100 000 detainees. In five countries the TB notification rate exceeded 1000 cases per 100 000 detainees: Azerbaijan, Kyrgyzstan, Moldova, Russia and Ukraine. The highest TB risks in prison relative to the risk in the general population are calculated to be in Slovakia (41), Moldova (25), Azerbaijan, Latvia and Russia (23 each). Six countries (Andorra, Ireland, Luxemburg, Malta, and San-Marino and Slovenia) did not report any cases of TB from their penitentiary systems.

Treatment outcome

The treatment success rate among 218 028 new TB cases and relapses having started treatment in 2015 was 77.2% (Table 19). This is slightly higher than the 76.2% treatment success rate reported in the previous year (Table X). The average rate for the 18 high-priority countries was 78.5% cured and treatment completed. The treatment success rate was slightly lower in the EU/EEA countries than in non-EU/EEA countries (74.1% versus 78.0%). Only 17 countries achieved an 85% treatment success rate in this treatment cohort. Another eight countries were close to the target, with success rates of 80–85%. Six countries had treatment success rates below 60%, where no treatment follow-up data were inversely correlated (Croatia (10.4%), Cyprus (55.6%), Poland (53.1%), Ireland (57.0%), Finland (36.2%) and Denmark (50.0%).

In the 2015 cohort of all clinically-diagnosed and bacteriologically-confirmed new TB and relapse cases, a total of 17 403 (8.0%) cases were reported to have died, 4.6% to have been lost to follow-up and 4.2% to have had treatment that failed. These unfavourable outcomes were lower in the EU/EEA countries than in the rest of the Region, exemplified by the proportion of patients with failed treatment – 0.7% in the EU/EEA versus 5.1% in non-EU/EEA countries (Table 19). Countries reporting fatal outcomes in excess of 10% were Czech Republic (19.0%), Slovenia (16.3%), Estonia (14.5%), Hungary (11.9%), Moldova (11.3%), Lithuania (11.1%), Russia and Ukraine (10.0% each). Countries reporting the highest failure rates were Ukraine (8.2%) and Russia (7.0%).

For 2015, the treatment success rate among the 7 215 child TB cases was 91.9% (Table 20). The treatment success rate in EU/EEA countries was somewhat lower than that for the non-EU/EEA countries (86.7% vs. 93.5%). Among child TB cases in the Region 1.0% died, another 0.8% failed and 1.4% were lost to follow-up.

Of 7 177 TB/HIV co-infected patients who started treatment throughout the Region in 2015, only 4 461 (62.2%) had a successful treatment outcome (Table 21). This is notably higher than the 41.4% treatment success rate reported in the previous year. The reason for such a sharp change year to year was most probably the weakness of data quality and coverage. Treatment outcome data is available for only 30% of notified TB/HIV cases. Given that within recent years there has been no indication of a sharp increase in ART and CPT coverage, the observed improvement in the TB/HIV co-infection treatment success rate would appear to be the result of selection bias.

In 2016, the treatment outcome was notified for 44 703 laboratory-confirmed RR/MDR TB cases reported by 41 countries (Table 22). For the whole Region the treatment success rate was 54.7%, which is somewhat higher than the 51.5% treatment success rate reported for the 2013 RR/MDR TB treatment cohort (Table XII). The treatment success rate for RR/MDR TB patients was higher in the non-EU/EEA countries than in the EU/EEA countries (55.2% versus 39.4%). The countries that performed best were the Hungary (100%), Sweden (88.2%) and Netherlands (85.7%). In the Region

as a whole 15.3% of RR/MDR TB cases died, 12.4% failed and 10.9% were lost to follow-up.

Conclusion

The year 2016 was the first year in which the Roadmap to implement the TB Action Plan for the WHO European Region 2016–2020 was activated. The TB Action Plan incorporates the lessons learned in implementing Regional Committee resolution EUR/RC61/15 on The Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015, and is in-line with WHO's new European health policy framework, Health 2020. The new TB Action Plan sets a Regional goal of ending the spread of drug-susceptible and drug-resistant TB by achieving universal access to prevention, diagnosis and treatment in all Member States of the Region. This, in turn, will contribute to ending the TB epidemic, which is the main aim of the End TB Strategy. Under the TB Action Plan, targets to be achieved by 2020 are: a 35% reduction in TB deaths, a 25% reduction in TB incidence rates and a 75% treatment success rate among MDR TB patients.

TB continues to be a major public health challenge in the WHO European Region. According to the latest estimates, about 290 000 incident TB cases and 26 000 deaths were reported in the Region in 2016, mostly from eastern and central European countries. In the last 10 years, new cases of TB have been falling at an average rate of 4.3% per year. The rate of decline has been accelerated in recent years. If this trend continues then the Regional target of a 25% reduction in the incidence rate compared to 2015 will be achieved.


The WHO European Region is the most affected area for MDR TB in the entire world. Of the 30 countries in the world with the highest MDR TB burden, nine are in the Region (Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Ukraine and Uzbekistan). In 2016, estimated percentages of MDR among new and previously treated TB cases in the Region were 19% and 55% respectively, while reported percentages were 17.7% and 51.9%.

Around 122 000 people in the Region are estimated to become infected with RR/MDR TB every year. It is important to note that over the last six years (2011–2016) the capacity of countries' health systems for early detection of RR/MDR TB has increased substantially. In 2016, 73% of RR/MDR TB were detected out of an estimated 71 000 of all notified TB cases. Progress in detections could be attributed to the early-detection diagnosis coverage of the WHO-recommended rapid diagnostics and countries' efficient diagnostic algorithms.

TB is a major cause of death among people living with HIV, and this deadly combination is increasing in the Region. Rapid detection and appropriate treatment are therefore vital. In 2016, only 25 844 (76.0%) of an estimated 34 000 HIV patients co-infected with TB were detected and only 65% of them were offered antiretroviral treatment. The percentage of HIV among TB cases increased from 3.4% in 2008 to 13.4% in 2016.

TB cases of foreign origin represent 8.2% of all TB cases notified Region wide, 32.7% in EU/EEA countries and only 2.0% in non-EU/EEA countries.

Figure 3.2.1. TB notification rates per 100 000 population by year of reporting, EU/EEA, 1995–2016^a



^a Missing data from Liechtenstein (except 2007)

Data source: ECDC Surveillance Atlas of Infectious Diseases. <http://www.ecdc.europa.eu/en/data-tools/atlas/Pages/atlas.aspx>

A total of 6.0% (12 298 cases) of the new and relapse TB cases in the Region were reported from prisons, 11 863 (96.5%) of which were in the 18 high-priority countries. The overall notification rate for new TB cases in prisons in the WHO European Region was 862 per 100 000 detainees. A Regional average of related risks for emerging TB in prisons was 25 times higher than in society as a whole.

In 2016, treatment success rates increased to 77.2% in the new and relapse cohort and 54.7% in the RR/MDR TB cohort respectively. It is reassuring that the trend towards a decline in treatment success rates, seen in the Region since the beginning of the new millennium, has reversed. This is the fourth consecutive year in which the treatment success rate has been improving, both among the new and relapse and the RR/MDR TB cohorts. A possible contributing factor to the improvement of treatment efficiency is the increase in diagnostic capacity in countries (reflected by improved DST coverage, including SLD). This means that countries are able to detect and treat more rapidly with the right regimen, in line with the individual resistance pattern. However, Regional progress is not rapid enough to meet the 2020 target of a 75% treatment success rate for MDR TB cases and additional efforts are required to improve the treatment success rate by introducing and expanding access to short treatment regimens, new TB drugs and patient-centred care.

On 16–17 November 2017, the WHO Global Ministerial Conference ‘Ending TB in the Sustainable Development Era: A Multisectoral Response’ was held in Moscow, Russia. The Conference aimed to accelerate the implementation of the WHO End TB Strategy – with immediate action to address gaps in access to care and the MDR TB crisis – in order to reach the End TB targets set by the World Health Assembly and the United Nations (UN) Sustainable Development Goals (SDGs) through national and global commitments, deliverables and accountability.

At the Conference a Ministerial Declaration was signed, containing bold commitments by countries to accelerate action to end TB and meet the milestones on the path towards the 2030 SDGs. The Moscow Declaration to End TB is a promise to increase multi-sectoral action as well as track progress, and build accountability. It will also inform the first UN General Assembly High-Level Meeting on TB in 2018, which will seek further commitments from heads of state.

3.2 European Union and European Economic Area countries

Data completeness

For 2016, TB notification data were reported by 30 countries (none from Liechtenstein). As with TB cases notified from 2011 to 2015, the reporting of non-mandatory variables in 2016 was complete or near-complete for age, gender, TB site and variables defining the origin of a case (Annex 3). Previous treatment history was available for 76.8% of cases, which was lower than in previous years (84.3% and

87.7% for 2015 and 2014 data, respectively) and masked substantial differences across countries. For example, previous treatment history was only available for 3.4% from Luxembourg and 5.7% of cases from France.

Reporting completeness for the results of culture (82.2%) in 2016 was similar to 2015 (82.5%), with only five countries remaining below 75% (Croatia, France, Greece, Portugal and the United Kingdom). Reporting completeness for microscopy (72.5%) was lower than in 2015 data (76.9%), continuing the declining trend observed in recent years. In 2016, drug susceptibility reporting completeness for first-line TB drugs was 87.4%, which was less than in 2015 (91.3%), continuing the decrease observed since 2014. Second-line DST reporting completeness decreased from 76.7% of MDR TB cases in 2015 to 74.4% in 2016, after having increased from 64.9% in 2013. Of particular note was the fact that four countries (Croatia, Iceland, Malta, and Slovenia) reported no MDR TB cases, and two countries (Greece and Luxembourg) did not report any results for second-line DST.

HIV status was available for 33.9% of all reported cases in 2016, which was lower than in 2015 (34.4%). As for 2015 data, HIV status is still missing for TB cases from Austria, Croatia, Finland, France, Germany, Italy, Poland, Sweden and the United Kingdom. Greece reported HIV status too late for these data to be included in the report. Denmark reported HIV status for the first time.

In 2016, treatment outcome at 12 months, 24 months and 36 months was available for 70.6% of all reported cases, 78.5% of MDR TB and 80.1% of XDR TB cases, respectively. Compared to the 2012–2015 period, completeness was lower for all cases in 2016. Treatment outcome was not reported by France, Greece, Italy, Luxembourg, Malta or Spain. Treatment outcome for MDR TB cases was missing from Finland.

Time and place

In 2016, 58 994 cases of TB were reported in 30 EU/EEA countries (Table 3). As in previous years, three countries (Poland, Romania and the United Kingdom) accounted for nearly 45% of all reported cases, with Romania alone accounting for 23.1% of all cases.

The EU/EEA notification rate in 2016 was 11.4 per 100 000 population, continuing the downward trend observed since the launch of European enhanced TB surveillance in 1996 (Figure 3.2.1). During the period 2012–2016, the average annual decline in the notification rate was 4.5%.

As in 2015, country-specific notification rates differed considerably in 2016, ranging from 1.8 in Iceland to 68.9 per 100 000 in Romania. Rates were below 10 per 100 000 in 20 countries and below 20 per 100 000 in 26 countries. In the majority of countries, the notification rates have fallen steadily during the period 2012–2016 (Table 3). The downward trend was particularly pronounced in Hungary, Iceland and Luxembourg where the average annual rate of decrease exceeded 10%. Among the five WHO high priority countries which are Member States of

the EU/EEA, Latvia and Estonia saw substantial decreases, with rates declining by more than 8% per year. The decline was more moderate in several low-incidence countries, and increasing rates were observed in four countries (Belgium, Germany, Malta and Sweden) during the period 2012–2016. Between 2015 and 2016, notification rates in Malta and Ireland increased by 54.4% and 10.1%, respectively.

Previous treatment, laboratory confirmation and TB site

In 2016, the distribution of cases by previous treatment history was similar to that in recent years: 41 531 (70.4%) of 58 994 TB cases reported in 2016 were newly diagnosed; 6 207 (10.5%) had been previously treated for TB and 11 256 (19.1%) had an unknown previous treatment status (Table 5). The Member States with the lowest proportions of new cases had the highest proportions of cases with unknown previous treatment status. Of 11 256 TB cases with unknown previous treatment status, 5 249 (46.6%) were reported by Germany, representing 88.7% of all German cases reported in 2016. The proportion of previously treated cases was above 20% in two countries (Lithuania and Romania) and more than 10% in another seven countries (Bulgaria, Denmark, Estonia, Hungary, Latvia, Poland and Slovakia).

Laboratory confirmation was reported for 41 868 (71.0%) of 58 994 cases overall (Table 8). Country-specific proportions of laboratory-confirmed cases ranged from 39.5% in Slovakia to 92.4% in Slovenia. Of the five high-priority countries, the three Baltic States (Estonia, Latvia, and Lithuania) had proportions of confirmed cases above 80%. Overall, the proportion of laboratory-confirmed cases has almost doubled since 1996 and reached its highest level in 2016¹⁶.

Of all 58 994 TB cases reported in 2016, 38 102 (64.6%) were diagnosed with pulmonary TB, 13 450 (22.8%) with extrapulmonary TB, 6 922 (11.7%) with a combination of both and 520 (0.9%) with no TB site reported (Table 6). The proportion of extrapulmonary TB was highest in the Netherlands (46.0%), the United Kingdom (45.3%), and Norway (37.1%) and lowest in Iceland (0%) and Hungary (3.7%).

Of 42 720 new and relapse pulmonary TB cases reported in 2016, 34 304 (80.3%) were confirmed by culture, smear and/or nucleic acid amplification test (Table 7). Hungary reported the lowest proportion of new, culture-confirmed pulmonary cases (54.4%).

According to the EU case definition, 41 867 (71.0%) of 58 994 TB cases reported in 2016 would be classified as confirmed, 3 890 (6.6%) as probable and 13 237 (22.4%) as possible (Table 8). The percentage of clinically diagnosed cases was highest in Hungary (45.8%) and Bulgaria (44.7%). It is unclear if the low proportion of laboratory-confirmed cases and the reliance on clinical diagnosis reflects a potential risk that TB is being over-diagnosed in these countries,

or if it is related to under-reporting of laboratory results to the national surveillance systems.

Age and sex

Of 55 718 new TB cases and relapses with known age, 36 049 (64.7%) were aged between 25 and 64 years (Table 9). The highest notification rate was observed in the age group 25–44 years (13.8 per 100 000). On average, adults over 64 years accounted for less than 20% of all cases, but more than one third of all cases reported by Croatia, Finland and Slovenia were in this age group.

In 2016, children under 15 years accounted for 2 424 (4.4%) of 55 718 new TB cases and relapses reported with information on age (Table 9). The notification rate for all TB cases in children under 15 years was 3.0 per 100 000 (Table III). Three countries (Bulgaria, Lithuania, and Romania) reported age-specific notification rates per 100 000 in children over 10 years.

In 2016, the male-to-female ratio in new TB cases and relapses was 1.5, similar to 2016 (Table 9). Males were over-represented in all EU/EEA Member States. There was no sex imbalance in children under 15 years.

Origin of cases

Of the 58 994 TB cases notified in 2016, 3 909 (6.4%) were born in or citizens of the reporting country (referred to as 'native'), 19 312 (32.7%) were of foreign origin and 1 773 (3.0%) were of unknown origin (Table 10). Over the past five years, the annual number and proportion of native TB cases declined whereas the annual number and proportion of TB cases of foreign origin decreased only between 2012 and 2014, before increasing again thereafter (Table IV). Of the 19 312 cases of foreign origin in 2016, 8 494 (44.0%) were reported by Germany and the United Kingdom. Country-specific proportions of foreign-origin TB cases ranged from below 1% in Bulgaria, Croatia, Lithuania and Romania to above 90% in Cyprus and Malta.

Drug resistance

Annex 5 displays participation and performance in an external quality assessment (EQA) scheme for drug susceptibility testing (DST) by Member State.

Of 41 273 laboratory-confirmed TB cases notified in 2016, 36 071 (87.4%) underwent isoniazid and rifampicin susceptibility testing (Table 13). Resistance to at least one anti-TB drug was reported for 3 216 (9.9%) of the cases tested overall and for 26–32% of cases tested in Estonia, Latvia, and Lithuania. MDR TB was reported for 1 322 (3.7%) of 36 071 cases with DST results overall and for 10–20% of the cases tested in Estonia, Latvia and Lithuania. The rate of notified MDR TB cases has remained unchanged over the past four years at 0.3 per 100 000 population (Table VII). Overall, XDR TB was reported for 198 (20.1%) of 984 MDR TB cases that underwent second-line DST (Table 14). The proportion of XDR TB cases among MDR TB cases that underwent second-line DST increased from 13.9% in 2012 to 20.6% in 2016 (Table VIII).

¹⁶ European Centre for Disease Prevention and Control. ECDC Surveillance Atlas of Infectious Diseases. Available at: <http://www.ecdc.europa.eu/en/data-tools/atlas/Pages/atlas.aspx>

Of 21 915 new confirmed pulmonary TB cases with DST results, 524 (2.4%) were resistant to isoniazid and rifampicin (Table 12). Of 4 022 previously treated confirmed pulmonary TB cases with DST results, 602 (15.0%) were resistant to isoniazid and rifampicin. Compared to new cases, previously treated confirmed pulmonary TB cases were over seven times more likely to be resistant to isoniazid and rifampicin (odds ratio [OR] 7.2, 95% confidence interval [CI] 6.3–8.1).

HIV co-infection

HIV status was reported for 19 988 (69.0%) of 28 971 TB cases from 20 countries (Table 16a). Of these 19 988 cases with known HIV status, 895 (4.5%) were reported as HIV-positive. Among countries with at least 50% reporting completeness for HIV status, the proportion of co-infected cases was highest in Malta, Portugal and Estonia at 17.4%, 13.9%, and 12.0%, respectively. Since 2012, the proportion of HIV-co-infected TB cases has been decreasing (Table IX).

TB in prisons

For 2016, 18 EU/EEA countries reported 671 new and relapse TB cases in prisons, resulting in a notification rate of 163.8 per 100 000 inmates and a relative risk of 11.1 compared to the general population (Table 17). TB cases in prisons accounted for 1.7% of all new and relapse cases notified; however, this proportion was above 4% in Estonia, Latvia, and Slovakia.

Treatment outcome

Of the 46 870 TB cases notified in 2015 with a treatment outcome reported in 2016, 33 519 (71.5%) were treated successfully, 3 709 (7.9%) died, 583 (1.2%) experienced treatment failure, 2 442 (5.2%) were lost to follow-up, 2 011 (4.3%) were still on treatment in 2016 and 4 606 (9.8%) had not been evaluated (Table 18). France, Greece, Italy, Luxembourg, Malta and Spain did not report treatment outcome. Among 43 695 new TB cases and relapses notified in 2015, 32 376 (74.1%) were treated successfully (Table 19). In countries where at least 75% of new confirmed TB cases and relapses had a known outcome, treatment success ranged from 64.9% in Germany to 100.0% in Iceland. The proportion of successfully treated cases among new TB cases and relapses decreased from an average of 77% in cases notified during the period 2011–2013, to an average of 74% in cases notified during 2014 and 2015 (Table X). More than 16% of TB cases notified by the Czech Republic and Slovenia died, a remarkably high proportion for these countries where it is rare for cases not to be evaluated.

Of 1 214 MDR TB cases notified in 2014 with a treatment outcome reported in 2016, 455 (37.5%) were treated successfully, 202 (16.6%) died, 168 (13.8%) experienced treatment failure, 154 (12.7%) were lost to follow-up, 167 (13.8%) were still on treatment in 2016 and 68 (5.6%) were not evaluated (Table 23). In addition to the countries that did not report treatment outcome data, Cyprus, Iceland and Slovenia did not report any MDR TB cases for 2014, and Finland and Spain did not report treatment outcome after 24 months. Overall, the 24-month MDR TB treatment success rate remains low, although it has improved over the past five

years: from an average of 34% for cases initially reported in 2010–2012, to an average of 41% for cases reported in 2013–2014 (Table XII).

Of 151 XDR TB cases notified by 14 countries in 2013 with a treatment outcome reported in 2016, 51 (33.8%) were treated successfully, 33 (21.9%) died, 37 (24.5%) experienced treatment failure, 27 (17.9%) were lost to follow-up, and three (2.0%) were not evaluated (Table 25). Overall, the 36-month XDR TB treatment success rate remains low and trends over time are unreliable due to the small number of cases (Table XIV).

Of 664 HIV-positive TB cases notified in 2015 with a treatment outcome reported in 2016, 413 (62.2%) were treated successfully, 95 (14.3%) died, five (0.8%) experienced treatment failure, 66 (9.9%) were lost to follow-up, 64 (9.6%) were still on treatment in 2016 and 21 (3.2%) were not evaluated (Table 21).

Conclusions for the EU/EEA

In 2016, the overall TB notification rate in the EU/EEA continued the decline observed since 2002. As in previous years, a few countries reported large numbers of cases, including Romania, which still accounts for 23% of all reported cases. The decreasing notification rates observed in most countries are reassuring, but annual rates of decline are still insufficient to achieve the WHO target of TB elimination by 2050 in European low-incidence countries [5]. To achieve annual decreases of over 10% in notification rates, further efforts would be required to address the most vulnerable and hard-to-reach groups, such as migrants or prison inmates.

In contrast to native TB cases, the number and proportion of TB cases of foreign origin has increased since 2014. TB incidence rates among foreign-born patients remain several times higher than those among natives and may reflect the incidence in their country of origin, as suggested by a study looking at pre-entry screening [8]. Foreign-born patients may have been exposed to TB prior to their immigration to the EU/EEA or when travelling back to their country of origin. Thus, the most frequently reported foreign countries of origin were in regions known for high TB incidence [8]. Asylum seekers are probably at greater risk of TB infection due to the disruption of screening and control programmes in their countries of origin after years of conflict or due to exposure to infection during their journey or in crowded migrant centres. As with any other vulnerable group, it is essential to ensure good access to healthcare services for migrants and TB cases of foreign origin.

In 2016, overall notification rates of MDR TB remained stable at a relatively low level and showed markedly decreasing trends in two of the three Baltic countries where MDR TB is particularly prevalent.

Data on HIV co-infection remained very incomplete, and the number of countries reporting HIV status was similar to 2015. Since 2012, the proportion of HIV co-infected TB cases has been decreasing slightly. HIV co-infection has been found to be more likely in TB cases originating

from Africa [9]. Since HIV co-infection is associated with low TB treatment success, special attention should be given to these cases, with strict adherence to international guidelines for prevention and treatment of TB in HIV-infected adults [9].

Data on TB in prisons remain scarce for the EU/EEA and only 18 countries provided such data for 2016. This situation has not changed over the past few years, and the information available remains insufficient to accurately monitor TB in prisons at EU/EEA level. TB prevalence is substantially higher in the prison population, with higher proportions of drug-resistant TB than in the general population [10]. To efficiently control TB in prisons, it is important that all countries collect and report these data.

Finally, treatment success rates have decreased slightly over the past 10 years and are now at approximately 75%. The surveillance data also show that treatment success rates for both MDR and XDR TB are far below the targets set. Countries with a persistently high proportion of fatal cases (>10%) should further investigate the reasons for this and increase efforts to reduce case fatality.



4. Commentary – Monitoring

4. Commentary – Monitoring

4.1 WHO European Region

To address the challenges to tuberculosis and M/XDR TB prevention and care, the WHO Regional Office for Europe, working in close consultation with representatives from the countries, experts and communities, has developed the Tuberculosis Action Plan for the WHO European Region 2016–2020. The Action Plan is based on lessons learned implementing the seven areas of intervention in the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015, and is in line with the global End TB Strategy and other health policy guidance, such as Health 2020: the European policy for health and wellbeing.

The Tuberculosis Action Plan for the WHO European Region 2016–2020 is supported by a monitoring and evaluation (M&E) framework that to monitor progress towards targets. The framework consists of 26 indicators that enable performance monitoring in the Action Plan's areas of intervention, as well as follow on from the Berlin Declaration on Tuberculosis 2007 'All Against Tuberculosis'. Nine are core indicators for monitoring and reporting to the WHO Regional Committee for Europe. In addition, the selection of indicators was harmonised with the End TB Strategy's recommended top 10 global indicators. The status of the core indicators, which is analysed on an annual basis, appears below.

Indicator 1.B.1 Percentage of newly notified TB patients diagnosed using WHO-recommended rapid tests (G9)

Given the large burden caused by MDR TB in the Region, the early detection and diagnosis of drug-resistant tuberculosis using rapid molecular tests is a priority. The Action Plan acknowledged that the uptake of new rapid diagnostic technologies is slow in many settings. The long duration of the diagnostic process for TB (lasting several days) may discourage many vulnerable patients from returning for results and possible treatment.

In the Action Plan, introduction and roll-out of rapid tests followed by the adoption of a diagnostic algorithm for difficult-to-diagnose paediatric TB and extrapulmonary TB, particularly among hard-to-reach and vulnerable populations, was also seen as an opportunity to rapidly identify and control drug-resistant TB. Faster detection of drug-resistant strains means that patients can be initiated onto appropriate treatment regimens more quickly, thereby minimising the window of transmission.

A total of 44 countries reported data on the proportion of newly-notified patients diagnosed using WHO-recommended rapid tests in 2016. There was no data available as a baseline for this indicator and the Action

Plan target was set at 40%. As shown in Figure 4.1.2, the target was over-achieved at regional level, with 57% of new and relapse cases diagnosed using rapid tests. For the 18 high-priority countries this figure was even higher, reaching 63%. Nine of the high-priority countries met the target, seven did not meet it and two (Ukraine and Turkey) did not provide information. In the EU/EEA region, only 25% of cases were diagnosed using rapid tests.

Indicator 1.B.2. First-line DST coverage (%) among all bacteriologically confirmed TB cases (G1)

The Action Plan aims to ensure provision of DST for all bacteriologically confirmed tuberculosis cases. In 2016, a total of 49 countries reported on DST routine surveillance data. Coverage of DST among all notified TB cases confirmed by culture was 87%, which is lower than the 91% level recorded at the baseline. In all, eight of 16 high-priority countries had DST coverage above 90% (Figure 4.1.2). Turkmenistan did not report complete routine drug-resistance surveillance data.

Indicator 1.B.3. MDR TB case detection rate (%) (G3)

From 2016, WHO began generating RR TB estimates instead of MDR TB as, due to the intensive roll-out of WHO recommended rapid diagnostic testing, a considerable number of drug-resistant TB cases are being diagnosed based on GeneXpert MTB/RIF results only. In addition RR TB is a good proxy for MDR TB. Therefore, the MDR TB detection rate has been slightly modified: This indicator is now calculated by dividing the total number of notified RR/MDR TB cases by the total number of estimated RR/MDR TB cases among notified pulmonary TB patients (Figure 4.1.3).

If all notified TB patients with pulmonary TB in the Region had been tested in 2016 for drug resistance to rifampicin and isoniazid, an estimated 71 000 cases of RR/MDR TB would have been found by national tuberculosis control programmes. In 2016, a total of 51 752 RR/MDR TB cases were detected among notified tuberculosis patients in the WHO European Region. This is 73% of all estimated cases, indicating notable progress in RR/MDR case detection compared to the baseline (62%) documented in 2014. Six of 16 high-priority countries achieved targeted 85% RR/MDR case-detection rate (Figure 4.1.3).

Indicator 1.B.4 TB notification rate per 100 000 population (E1)

The Regional Action Plan aims to reduce the TB incidence rate by 25% against 2015 before 2020. To enhance this the countries should have annual reduction of at least 5.5% in notification of new and relapse TB cases.

Figure 4.1.1. Percentage of new and relapse TB patients notified in 2016 that were diagnosed using WHO recommended rapid tests in 18 high-priority countries and WHO European Region, 2016





Figure 4.1.2. First-line DST coverage (%) among all bacteriologically confirmed TB cases (G1) by 18 high-priority countries and WHO European Region, 2016



The total average annual decline of TB notification in 2016 compared to 2015 was 5.2%, which is quite close to the targeted annual decline of 5.5%. If this trend continues, the Regional target of a 25% decline in notification by 2020 compared to 2015 will be achieved. Of 51 Member States, 43 have seen a decline in the TB notification rate in the last five years. Kyrgyzstan was the only one of the high-priority countries not on track to reduce TB notification. It should also be noted that notification data reported by Turkmenistan and Kazakhstan vary significantly from year to year, indicating weakness of surveillance data (Figure 4.1.4).

Indicator 1.B.5 TB case detection rate (%)

In 2016, a total of 253 096 incident TB cases were notified in 52 countries across the WHO European Region compared to an estimate of 290 000 cases. This represents a case detection rate of 87.2%, which is slightly higher than the 84.1% baseline measured in 2014. In all, 15 of the 18 high-priority countries have case detection rates above 75% (Figure 4.1.5). Detection of TB cases in the Region is therefore improving and most countries are on track in their efforts to increase TB case detection.

Indicator 1.B.6 Percentage of RR/MDR TB among new TB patients (E₂)

Percentage of MDR TB among new TB patients (E₂)

The Regional Action Plan aims to reduce MDR prevalence among new TB cases. At Regional level MDR TB prevalence among 85 851 new pulmonary TB cases tested for first-line DST was 17.7%, which is slightly lower than the rate observed in 2015 (18.3%). In seven of the 18 high-priority countries reporting routine DST data, the MDR prevalence among new pulmonary TB cases was higher than or comparable to 2015 data. In contrast, the MDR percentage in Bulgaria, Estonia, Latvia, Romania and Turkey has been declining over the past five years. Meanwhile in Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan significant variation from year to year and missing data indicate that routine drug-resistance surveillance in these countries is challenging and additional efforts are required to produce quality data (Figure 4.1.6).

Indicator 1.B.7 Percentage of RR/MDR TB among previously treated TB patients

A number of studies have demonstrated that acquired drug-resistance can be prevented by appropriate infection control measures, application of home-based care and efficient treatment of drug-sensitive tuberculosis cases. Nevertheless, high prevalence of MDR TB is still a challenge for many countries in the WHO European Region. In 2016, the percentage of confirmed MDR TB cases among previously-treated TB cases tested for first-line DST was 51.9%, which is higher than the 2015 rate (46.3%). The reason for such a rapid change at Regional level is the significant increase in the absolute number of previously treated cases with DST results in the Russian Federation, as a result of the introduction of a country-wide, case-based electronic surveillance system. In 2016, the Russian Federation reported twice as many MDR TB cases as in

previous years. A new surveillance system in Russia facilitated the accurate estimation of previously treated MDR TB patients. In the past, these patients had not been accounted for, which meant that MDR TB cases in the Region were under-estimated. In the rest of the high-priority countries there is no clear trend in MDR: in nine countries the MDR percentage among previously treated cases declined in 2016 against 2015, and in another six countries it increased or remained comparable with the previous year. The very significant variation in data from year to year in Kazakhstan and Uzbekistan and the lack of data from Turkmenistan raise concerns about the capacity of these countries to accurately measure routine data.

(Indicator?) 1.C.1. Percentage of hospitalisation of new TB patients (E₃)

The practice in some countries of hospitalising patients unnecessarily has been shown to contribute to the spread of drug-resistant forms of TB. Ambulatory services and home-based treatment were not fully functional in many countries. In the absence of adequate airborne infection control, hospitalisation can lead to nosocomial transmission and superinfection with M/XDR TB strains among patients and healthcare workers. On the other hand, studies showed no difference in treatment outcomes between patients treated in ambulatory and hospital settings. Therefore, WHO recommends minimising unnecessary hospitalisation and using ambulatory rather than hospital-based models of care for TB treatment.

In 2016, a total of 31 countries provided information on the hospitalization percentage for TB patients enrolled in first and second-line treatment. Hospitalisation rates for first-line TB treatment ranged from 25 (Georgia) to 100% (Belarus), with an average of 74%. The proportion of patients hospitalised for second-line treatment was even higher, ranging from 68 (Tajikistan) to 100%. This data suggests that hospitalisation rates remain very high in most of the countries in the Region and additional efforts are required to change the model of care.

Indicator 1.C.2. Percentage of detected RR/MDR TB patients enrolled in treatment (G₃)

Achieving universal second-line treatment coverage for all detected RR/MDR TB patients is a fundamental requirement for reducing TB transmission in the community and TB mortality.

The number of cases starting MDR TB treatment in 2016 was equivalent to 95.5% of the 51 752 RR/MDR TB patients notified in 2016 across the European Region. Access to MDR treatment in the Region increased significantly from 2010 onwards. Over the past five years many of the high-priority countries have consistently reported higher numbers of cases enrolled than cases detected. There are numerous reasons for such discrepancies, including incomplete reporting; backlogs of RR/MDR TB patients; frequent treatment failures and treatment interruptions (leading to re-enrolment of the same patients in the same yearly cohort), and weakness of surveillance. It is noteworthy that in 2016 the gap between the number of RR/MDR TB

Figure 4.1.3. RR TB case detection rate (%) (G3) for 18 high-priority countries and WHO European Region, 2016





Figure 4.1.5. TB case detection rate (%) (G3) for 18 high-priority countries and WHO European Region, 2016



cases detected and enrolled narrowed considerably in most of the countries, suggesting improvement in the surveillance system. In five of the 18 high-priority countries the shortfall between the number of cases detected and the number enrolled into second-line TB treatment was over 5%, indicating an urgent need to improve second-line treatment coverage. Countries with an enrolment rate below 95% were Azerbaijan (86.3%), Belarus (87.2%), Bulgaria (86.4%) Georgia (87.5%), Russia (94.0%) and Turkey (82.4%).

Indicator 1.C.3. Treatment success rate (%) among all new and relapse TB patients (G4)

Effective TB treatment is essential to prevent death and cut transmission. Therefore, the treatment success rate serves as a key indicator for monitoring progress on the Sustainable Development Goals. According to the TB Action Plan, WHO European Region aims to increase the treatment success rate for new and relapse TB cases to at least 85%.

In 2015, the treatment success rate for new and relapse patients enrolled in treatment at Regional level was 78.5% against a baseline of 75.2%. Only seven of the 18 high-priority countries achieved the target level of an 85% treatment success rate. Eight of the 18 high-priority countries showed a trend towards improvement of treatment success, but for most countries the pace of improvement is very slow if the 85% treatment success rate target is to be achieved.

Indicator 1.C.4. Treatment success rate (%) among the MDR TB treatment cohort (G4) (E4)

Treatment success rate is an indicator of high quality TB care. Despite the treatment success rate having continuously improved from 46.1 to 54.8% in recent years, it remains far below the 75% target set by the TB Action Plan. Only two of the 18 high-priority countries (Estonia and Kazakhstan) have achieved the benchmark of at least 75% treatment success rate for RR/MDR TB patients (Figure 4.1.11). Overall, ten of the 18 high-priority countries are on track to increase their RR/MDR TB treatment success rate, however progress is not rapid enough to meet the 2020 target of 75% treatment success rate for MDR TB cases.

Indicator 1.C.5. TB mortality rate (ICD A15-19) (G10) (E6)

The TB Action Plan aims to reduce the number of TB deaths in 2020 by 35% against 2015. As seen in Figure 4.1.12, all high-priority countries except Azerbaijan have shown a rapid decline in TB mortality over the last six years. If the current trend continues, the Regional target will most probably be surpassed. Although decline is comparatively slow in Georgia and Uzbekistan, in three countries (Armenia, Belarus and Kazakhstan) the decline was so fast that the 2020 target of reducing the TB mortality rate by 35% has already been achieved.

Indicator 1.D.1 Percentage of detected out of estimated incident TB/HIV co-infected cases

In 2016, the number of TB/HIV co-infections detected was 83% of the estimated number of TB/HIV incident cases in the Region, which is comparable with the baseline data. It

should be noted that following the epidemiological review in February 2017 and the improvement of reporting completeness for this indicator – after introduction of case-based surveillance system in Russia – the Regional estimate was revised considerably. However, since both estimates and the reported number of TB/HIV cases increased proportionally, the overall Regional detection rate did not change significantly. Only three of the 18 high-priority countries achieved a detection rate of over 90%. In eight high-priority countries the detection rate was below 70%, indicating the need to invest more effort into improving detection.

Indicator 1.D.2 HIV testing coverage (G9) (E7)

The TB Action Plan sets a target of achieving close to 100% HIV testing coverage. In 2016, HIV testing coverage at Regional level was 86.1%, which is a notable improvement on the 67.6% testing coverage at baseline. Nine of the 18 high-priority countries reported over 90% HIV testing coverage.


Indicator 1.D.3 Percentage of HIV co-infection among all TB (new and relapse TB cases)

In 2016, 13.4% of new TB patients with known HIV status were HIV positive, compared to 9.0% in 2015. This rapid change is partially due to an improvement in the surveillance system in the Russian Federation, however, TB/HIV co-infections are increasing in the Region, on average by about 20% annually. An increase in TB/HIV co-infection has been recorded in eleven of the 18 high-priority countries. In 2016, Armenia, Georgia and Uzbekistan reported fewer TB/HIV cases than in 2015, however, there is no clear trend of reversion. Only Bulgaria and Latvia have seen a noticeable decline in the TB/HIV co-infection rate over the last five years. This rapid increase is an indication that HIV transmission continues apace in most eastern European and Central Asian countries and that efforts towards the early identification of people living with HIV (PLHIV) and preventive TB treatment are inadequate.

Indicator 1.D.4 Percentage of TB/HIV co-infected patients enrolled in antiretroviral therapy

The TB Action Plan aims to achieve full coverage with antiretroviral therapy (ART) for all patients detected with TB/HIV co-infection, as per WHO recommendations. In 2016, 25 countries in the Region provided information on ART enrolment among TB cases with positive HIV status. All the reporting countries together accounted for 45% of notified TB cases. Among the reporting countries ART coverage was 65.1%. This represents some improvement against the baseline 53.8%. Six of the high-priority countries attained coverage of above 90% and eleven of the 18 high-priority countries demonstrated a trend towards increasing ART coverage over the last five years. However, for most countries the trends have been quite slow and are not stable – consequently more efforts are needed to further strengthen TB/HIV collaborative activities in the Region.

Figure 4.1.4. Trend in new and relapse TB notification rate per 100 000 population for 18 high-priority countries and WHO European Region, 2012–2016.



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

Indicator 1.D.5 Latent TB infection treatment coverage among people living with HIV/AIDS (G5a)

Detection of latent TB infection (LTBI) offers an opportunity to treat and prevent reactivation of the latent infection that leads to active disease, especially in people with compromised immune systems. WHO recommends that people living with HIV (PLHIV) should be treated, even if they are infected but do not have active TB, due to the very high risk of progression to TB. The proportion of the population with latent TB infections varies from country to country, depending on the TB burden, but it is estimated that about 30% of the adult population in eastern Europe have LTBI. It is therefore probable that about 30% of PLHIV who are newly enrolled in HIV care might have LTBI and should be offered TB preventive treatment. In 2016, a total 12 countries in the Region provided information on LTBI treatment to the UNAIDS reporting system. Overall, of 36 086 PLHIV newly enrolled in HIV care 70% received LTBI treatment. In Russia and Uzbekistan over 90% of PLHIV received LTBI treatment, which is much higher than expected. Belarus and Moldova reported no access to LTBI treatment, while in Armenia and Georgia the coverage was below the target of 30%. Such large variation from country to country indicates a lack of standardised approach and a gap in adherence to WHO recommendations in countries.

Indicator 1.E.1 Contact investigation coverage (G2) (E7)

Contact tracing is a key component of TB prevention, especially in children. Contact investigation may result in earlier identification of cases, possibly decreasing disease severity and reducing transmission of *Mycobacterium tuberculosis*. WHO recommends that all contacts of bacteriologically confirmed TB patients be followed up and screened for TB.

This indicator is calculated as the number of contacts of people with bacteriologically confirmed TB evaluated for TB, divided by the number eligible. Only 17 countries in the Region reported contact-tracing data to the WHO Global TB Database, and 99.3% of all contacts with TB cases were investigated for TB/LTBI in 2016. The target of 90% was achieved by all seven reporting high-priority countries (Figure 4.1.18).

Indicator 1.E.2 LTBI treatment coverage of childhood TB contacts aged under five years (G5b) (E8)

WHO recommends that children <5 years of age who are household or close contacts of people with TB and who, after an appropriate clinical evaluation, are found not to have active TB should be treated for presumed LTBI as per WHO guidelines. The Regional Action Plan aims to achieve at least 90% presumptive LTBI treatment coverage of childhood TB contacts aged under five years. This indicator is calculated as the number of children aged <5 years who are household contacts of cases started on LTBI treatment, divided by the number of all child contacts <5 years. In 2016, a total of 12 countries provided information on childhood contact investigations for the Global TB database. At Regional level LTBI treatment coverage of childhood TB contacts aged under 5 years was 75.3%. Azerbaijan was

the only country among the 18 high-priority countries that achieved the 90% target (Figure 4.1.19).

Indicator 2.E.1 Treatment success (%) of new and relapse TB cases among prisoners

In 2016, 36 countries in the Region provided data on treatment outcome of prison TB cases. The overall treatment success rate at Regional level was 59.9%, which is much lower than the 78.5% treatment success rate in the general population, or the 63.2% baseline. The Regional indicator is influenced by the outcome for Russia, which accounts for over 75% of prison TB cases notified in the Region. However, it should be noted that seven of the 18 high-priority countries achieved the target 85% treatment success rate (Figure 4.1.20).

4.2 European Union and European Economic Area countries

In 2016, WHO's Regional Office for Europe, working closely with representatives from the countries, experts and communities, developed the 'Roadmap to implement the tuberculosis action plan for the WHO European Region 2016–2020'. This roadmap is based on lessons learnt implementing the Regional Committee Resolution on The Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011–2015. It is applicable to all Member States in the WHO European Region, including high-priority countries and those with a low incidence of TB.

The Roadmap to implement the TB Action Plan for the WHO European Region 2016–2020 was published in 2016, establishing three areas of intervention with 26 indicators to assess the performance of the countries in tackling TB.

This is the first monitoring report applying these WHO indicators. A summary of findings by EU/EEA Member State and indicator is provided in Table 26, while indicator definitions and targets can be found in Annex 6.


1. Integrated patient-centred care and prevention

1.A. Systematic screening of contacts and high-risk groups

Indicator 1.A.1 Coverage of population at risk with systematic screening for active TB and LTBI

Contact investigation (and potentially source-case investigation) should be promoted to contribute to the detection of active and latent cases of TB. The less generalised the epidemic becomes, the more emphasis needs to be placed on this activity. This indicator is a direct measure of the level of contact investigations in the community. Strategies for contact investigation, including source-case investigation among recently infected cases (young children) and outbreak management, should be developed and/or revised. Of the 30 countries reporting data, five also reported the TB contact investigation coverage for

Figure 4.1.6. Trend of MDR percentage among new pulmonary TB cases for 18 high-priority countries and WHO European Region, 2012–2016.



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

2016 and four countries (Bulgaria, Lithuania, Norway and Slovakia) reported a screening coverage of over 80% for all TB contacts (Figure 4.2.1).

1.B. Early diagnosis of all forms of tuberculosis and universal access to drug susceptibility testing, including the use of rapid tests

Indicator 1.B.1 Percentage of newly notified TB patients diagnosed using WHO-recommended rapid tests (G9)

Twenty-five EU/EEA Member States reported on the proportion of patients newly notified in 2016 who were diagnosed using WHO-recommended rapid tests. There were no baseline data available and the target was first set to 30% and later updated to 40%. Overall, almost 25% of cases reported in the EU/EEA are diagnosed using WHO-recommended rapid tests. The target (40% of all new cases and relapses) has been met by nine Member States (Figure 4.2.2).

Indicator 1.B.2 First-line DST coverage among bacteriologically confirmed new and relapse pulmonary TB cases (G1)

In 2016, 33 383 incident TB cases were laboratory-confirmed in 30 EU/EEA Member States, and for 29 426 (88.1%) of them, DST results for rifampicin and isoniazid were provided. The target (100%) was achieved by seven countries (Figure 4.2.3).

Indicator 1.B.3 RR/MDR TB case detection rate (%) (G3)

In 2016, WHO started replacing MDR TB estimates with RR TB estimates, since the latter is a good proxy of the former and the recommended management is identical for both. The MDR TB detection rate is therefore calculated by dividing the number of notified cases with RR/MDR TB by the estimated number of such cases. In 2016, seven EU/EEA countries achieved an RR detection rate of 85% or more (Figure 4.2.4). Six countries (Croatia, Cyprus, Iceland, Luxembourg, Malta and Slovenia) did not report any RR cases for 2016, and their detection rate could not be calculated.

Indicator 1.B.4 TB notification rate per 100 000 population (E1)

In 2016, country-specific notification rates in EU/EEA Member States differed considerably, ranging from 1.8 per 100 000 in Iceland to 68.9 in Romania. Rates were below the Regional target (24.6 per 100 000) in 27 countries. Only Latvia, Lithuania and Romania reported rates above the Regional target (Figure 4.2.5).

Indicator 1.B.5 TB case detection rate (%)

The case detection rate is calculated by dividing the number of notified new and relapse TB cases by the total number of TB cases estimated by WHO. The target was set to a minimum of 84% which, in 2016, was reached by all EU/EEA countries except Denmark, Greece and Bulgaria (Figure 4.2.6).

Indicator 1.B.6 Percentage of RR/MDR TB among new TB patients (E2)

In 2016, 30 EU/EEA countries reported on first-line anti-TB DST results. The prevalence of rifampicin-resistant (RR) TB among 21 915 new pulmonary TB cases with first-line DST results was 2.4%, which was slightly higher than in 2014 (2.2%). Croatia, Cyprus, Iceland Luxembourg, Malta and Slovenia did not report any new RR TB cases in 2016. The target of a decreasing percentage was met by 11 of the remaining 24 Member States. Twelve countries reported an increase in RR cases of up to 4%, and Sweden reported the same proportion of RR cases in 2016 and 2014 (Figure 4.2.7).

Indicator 1.B.7 Percentage of RR/MDR TB among previously treated TB patients

In 2016, the prevalence of RR/MDR TB among 4 022 previously treated pulmonary TB cases tested for first-line DST was 15%, which is slightly less than in 2014 (16.6%). Six EU/EEA Member States did not report any previously treated RR TB cases in 2016 and 2014 and were considered as having achieved the target. Among the remaining 24 countries, the target of a decreasing percentage was met by 14 countries, whereas 10 countries reported an increase of up to 27% compared with 2014. (Figure 4.2.8).

1.C. Equitable access to quality treatment and continuum of care for all people with tuberculosis, including drug-resistant tuberculosis; and patient support to facilitate treatment adherence

Indicator 1.C.1 Percentage of hospitalisation of new TB patients (E3)

In the EU/EEA, 18 Member States reported on hospitalisation of new TB patients in 2016. There were no baseline data available for 2014, so this target was not defined. In the 18 reporting EU/EEA Member States, 60.7% of new TB cases were hospitalised at the beginning of treatment (Figure 4.2.9).


Indicator 1.C.2 Percentage of detected RR/MDR TB enrolled in treatment (G3) (E4)

Eighteen Member States reported on treatment enrolment of MDR TB patients in 2016. For other Member States 100% treatment enrolment for MDR TB cases was used as a proxy. Croatia, Iceland, Malta and Slovenia did not diagnose any MDR TB cases in 2016. The global target of 100% treatment enrolment was met by 22 Member States. Altogether, 99.5% of MDR TB cases reported in the EU/EEA started treatment with second-line anti-TB drugs in accordance with WHO guidelines, and all countries except the Czech Republic reported treatment of more than 95% of their MDR TB cases (Figure 4.2.10).

Indicator 1.C.3 TB treatment success rate (G2)

Of the 43 695 new and relapse TB cases notified in 2015 with a treatment outcome reported in 2016, 32 376 (74.1%) were treated successfully. France, Greece, Italy, Luxembourg, Malta and Spain did not report treatment outcome. In countries where at least 75% of new confirmed TB cases and relapses had a known outcome, treatment success ranged from 64.9% in Germany to 100% in Iceland. Only

Figure 4.1.7. Trend in MDR percentage among previously treated pulmonary TB cases for 18 high-priority countries and WHO European Region, 2012–2016.



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

six countries (Iceland, the Netherlands, Norway, Romania, Slovakia and Sweden) met the treatment success target of 85% (Figure 4.2.11).

Indicator 1.C.4 TB treatment success rate among the MDR TB cohort (G4), (E4)

Of the 1367 RR TB cases notified in 2014 with a treatment outcome reported in 2016, 539 (39.4%) were treated successfully. France, Greece, Italy, Luxembourg, Malta and Spain did not report treatment outcome, Cyprus, Iceland and Slovenia did not diagnose any RR TB cases in 2014. Among the remaining 20 Member States, treatment success ranged from 12.5% in Lithuania to 100% in Hungary. Only four countries (Hungary, the Netherlands, Norway and Sweden) met the treatment success target of 75% for RR TB cases (Figure 4.2.12).

Indicator 1.C.5 TB mortality rate (ICD A15-19) (G10) (E6)

For 2016, WHO estimated 4 270 TB deaths among HIV-negative people in the European Region. Estimated mortality in the EU/EEA was 0.8 deaths per 100 000 population, ranging from 0.2 in Denmark, Malta, Netherlands and Norway to more than five in Lithuania and Romania. The regional target of below 2.7 cases per 100 000 was met by all EU/EEA Member States except Lithuania and Romania (Figure 4.2.13).

1.D. Collaborative TB/HIV activities, and management of relevant co-morbidities

Indicator 1.D.1 Percentage of detected cases of estimated incident TB/HIV co-infected cases

In 2016, 16 EU/EEA Member States reported TB patients with HIV infection. The detection rate of TB/HIV co-infected cases is based on reporting data (numerator) and WHO estimates (denominator). The HIV detection rate was estimated as 70.9% and the target of 100% was reached only by Slovenia (Figure 4.2.14).

Indicator 1.D.2 HIV testing coverage (G9) (E7)

Twenty EU/EEA countries provided information on the HIV status of their TB cases and 69% of cases had a known HIV status. The target testing coverage of 100% was achieved by Iceland (Figure 4.2.15).

Indicator 1.D.3 Percentage of HIV co-infection among all TB (new and relapse TB cases)

In 2016, twenty EU/EEA Member States reported 826 new and relapse TB cases with HIV infection with an overall percentage of 4.4% TB/HIV co-infection. Country-specific proportions ranged from 0% in Bulgaria, Cyprus, Iceland and Slovakia to above 15% in Luxembourg and Malta. The target – a decrease compared to 2014 – was met by 10 Member States. In Iceland and Slovakia, there were no co-infected cases diagnosed in 2014 or 2016 (Figure 4.2.16).

Indicator 1.D.4 Percentage of TB/HIV co-infected patients enrolled in ART

Eight EU/EEA Member States reported ART enrolment to the WHO Global TB Database. Four countries did not report any HIV-positive TB cases among those tested. In 2016, 94.2% of HIV-coinfected TB cases had started ART. The target for enrolment coverage (close to 100%) was achieved by four Member States (Figure 4.2.17).

Indicator 1.D.5 Latent TB infection (LTBI) treatment coverage among people living with HIV/AIDS (PLHIV)(G5a)

No relevant data were available in the UNAIDS database for any EU/EEA Member State in 2016, therefore this indicator could not be monitored.

1.E. Management of latent tuberculosis infection and preventive treatment of persons at high risk, and vaccination against tuberculosis


Indicator 1.E.1 Contact investigation coverage (G2)(E7)

Only four EU/EEA Member States reported contact-tracing data to the WHO Global TB Database, with 95.8% of all contacts with TB cases investigated for TB/LTBI in 2016. The target of 90% was achieved by all reporting Member States (Figure 4.2.18).

Indicator 1.E.2 LTBI treatment coverage of childhood TB contacts aged under five years (G5b) (E8)

Only three EU/EEA Member States reported LTBI treatment data for TB contacts among children under five years to the WHO Global TB Database, with 47.9% of these contacts reported to have started LTBI treatment in 2016. The target of 90% was achieved by Slovakia but not by Slovenia or Norway (Figure 4.2.19).

Figure 4.1.8. Proportion of TB patients hospitalised for first-line and second-line TB treatment (%) (E3) for 18 high-priority countries and WHO European Region, 2016



2. Bold policies and supportive system

2A Political commitment with adequate resources, including universal health coverage policy

Indicator 2.A.1 Number of Member States that have a regular TB control/elimination performance publication every five years (E8)

Target: TB control/elimination performance publication published.

Data are not available for 2016.

2B Health systems strengthening in all functions, including well-aligned financing mechanisms for tuberculosis and human resources

Indicator 2.B.1 Percentage of TB patients and their households that experience catastrophic financial consequences due to TB (G8) (E9)

Target: Close to 0

Data are not available for 2016.

2C Regulatory frameworks for case-based surveillance, strengthening vital registration, quality and rational use of medicines, and pharmacovigilance

Indicator 2.C.1 Treatment coverage with new TB drugs (%)

Target: 20%.

Data are not available for 2016.

2D Community systems and civil society engagement

Indicator 2.D.1 Number of Member States with functioning multi-stakeholder coalitions advocating for TB care and resources.

Target: Not defined


Data are not available for 2016.

2E Social protection, poverty alleviation and actions on other determinants of tuberculosis, such as migration and prisons

Indicator 2.E.1 Treatment success (%) of new and relapse TB cases among prisoners

Of the 544 TB cases notified in prisons across 13 EU/EEA Member States in 2015 for whom treatment outcome data are available, 372 (68.4%) were treated successfully. Ireland, Luxembourg, Malta and Slovenia reported no TB cases among prisoners. France, Greece, Italy, Luxembourg and Spain did not report treatment outcome. Among the 13 Member States reporting, treatment success ranged from 44.4% in Poland to 100% in Slovakia. Four countries (Bulgaria, Estonia, Romania and Slovakia) met the treatment success target of 85% for TB cases diagnosed in prisons (Figure 4.2.20).

Figure 4.1.9. Absolute number of RR/MDR TB cases detected (orange lines) compared with those reported to have been enrolled on second line treatment (blue lines) 2010–2016 in each of the 18 high-priority countries, and as a total for the 18 high-priority countries and WHO European Region, 2010–2016.



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

3. Intensified research and innovation

3A Discovery, development and rapid uptake of new tools, interventions and strategies

Indicator 3.A.1 European Tuberculosis Research Initiative established by mid-2016

Target: Established

The country-specific indicators are not defined for 2016.

Conclusions and monitoring recommendations

In 2016, only 14 of 26 WHO targets could be effectively monitored based on the data available from EU/EEA Member States. Almost all EU/EEA Member States met the four targets regarding estimated TB case detection (at least 84%), TB notification (below 24.6 per 100 000), treatment enrolment of RR/MDR TB cases (100%) and estimated TB mortality (below 2.7 per 100 000). A majority of reporting countries also met or were close to the targets on first-line DST coverage among bacteriologically confirmed cases (100%) and the percentage of RR/MDR TB among previously treated TB patients (decrease against 2014). However, only a minority of the Member States reporting met the targets regarding use of WHO-recommended rapid tests for diagnosis (40% of new cases and relapses), the percentage of RR/MDR TB among new TB patients (decrease against 2014) and the percentage of HIV co-infection (decrease against 2014). Finally, a small minority, in some instances only a single Member State, met the targets regarding estimated RR/MDR TB case detection (at least 85%), TB and MDR TB treatment success (at least 85% and 75%, respectively), HIV testing coverage (100%) and the estimated detection of TB/HIV co-infection (100%).

Although, TB seems well under control in the vast majority of EU/EEA Member States, certain aspects – especially the trends in detection and prevalence of MDR TB, treatment success of TB and MDR TB, and HIV testing coverage and detection - leave much to be desired. Special efforts should also be made to improve the reporting of LTBI, HIV status and treatment outcome results.

References

1. Lawn SD, Zumla AI. Tuberculosis. *Lancet*. 2011 Jul 2;378 (9785):57-72.
2. D'Ambrosio L, Dara M, Tadolini M, Centis R, Sotgiu G, van der Werf MJ, et al. Tuberculosis elimination: theory and practice in Europe. *Eur Respir J*. 2014 May;43(5):1410-20.
3. World Health Organization. Global tuberculosis report 2016. Geneva: WHO; 2016. Available from: http://www.who.int/tb/publications/global_report/en
4. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2016 [Internet]. Stockholm: ECDC; 2016. Available from: <http://ecdc.europa.eu/en/publications/Publications/ecdc-tuberculosis-surveillance-monitoring-Europe-2016.pdf>
5. World Health Organization. Definitions and reporting framework for tuberculosis 2013 revision, updated December 2014. Geneva, World Health Organization; 2015. Available from: <http://www.who.int/tb/publications/definitions/en>
6. World Health Organization. Framework towards tuberculosis elimination in low-incidence countries. Geneva: WHO; 2014. Available from: http://www.who.int/tb/publications/elimination_framework/en
7. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis (5th edition), Geneva, WHO, 2015. Available from: http://www.who.int/tb/publications/2015/drs_guidelines/en
8. Aldridge RW, Zenner D, White PJ, Williamson EJ, Muzyamba MC, Dhavan P, et al. Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519 955 migrants screened before entry to England, Wales and Northern Ireland. *Lancet*. 2016. Nov 19;388(10059):2510-8.
9. Van der Werf MJ, Ködmön C, Zucs P, Hollo V, Amato-Gauci AJ, Pharris A. Tuberculosis and HIV co-infection in Europe: looking at one reality from two angles. *AIDS*. 2016 Nov 28;30(18):2845-2853
10. Biadglegne F, Rodloff AC, Sack U. Review of the prevalence and drug resistance of tuberculosis in prisons: a hidden epidemic. *Epidemiol Infect*. 2015; 143(5):887-900.

Table: Monitoring framework for follow up of the TB Action Plan for the WHO European Region, 2016–2020

| Area of intervention | Indicator | Baseline for EU/EEA (2014) ² | Target | EU/EEA status 2016 | Number of EU/EEA Member States reporting the data | Number of EU/EEA Member States having reached the target |
|---|--|---|-------------|--------------------|---|--|
| 1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION | | | | | | |
| 1.A. | Systematic screening of contacts and high-risk groups | | | | | |
| 1.A. | 1 Coverage of population at risk with systematic screening for active TB and LTBI ³ | N/A | 80% | 85.6% | 5 | 4 |
| 1.B. | Early diagnosis of all forms of tuberculosis and universal access to drug-susceptibility testing, including the use of rapid tests | | | | | |
| 1.B. | 1 Percentage of newly notified TB patients diagnosed using WHO-recommended rapid tests (G9) | N/A | 40% | 24.7% | 26 | 9 |
| 1.B. | 2 First line DST coverage among all bacteriologically confirmed TB cases (G7) | 90.0% | 100% | 88.1% | 30 | 7 |
| 1.B. | 3 RR/MDR TB case detection rate | 85.4% | 85% | 66.9% | 24 | 9 |
| 1.B. | 4 TB notification rate per 100 000 population for new and relapse cases (E1) | 12.2 | 24.6 | 10.9 | 30 | 27 |
| 1.B. | 5 TB case detection rate (%) | 82.4% | increase | 89.0% | 30 | 26 |
| 1.B. | 6 Percentage of RR/MDR TB among new TB patients (E2) | 2.4% | decrease | 2.4% | 24 | 11 |
| 1.B. | 7 Percentage of RR/MDR TB among previously treated TB patients | 17.7% | decrease | 15.0% | 22 | 17 |
| 1.C. | Equitable access to quality treatment and continuum of care for all people with tuberculosis, including drug-resistant tuberculosis; and patient support to facilitate treatment adherence | | | | | |
| 1.C. | 1 Percentage of hospitalisation of new TB patients (E3) | N/A | decrease | 60.7% | 19 | – |
| 1.C. | 2 Percentage of detected RR/MDR TB enrolled in treatment (G3) (E4) | 93.3% | 100% | 99.5% | 26 | 21 |
| 1.C. | 3 TB treatment success rate (G2) | 73.0% | 85% | 74.1% | 24 | 6 |
| 1.C. | 4 RR/MDR TB treatment success rate (G2) (E5) | 40.7% | 75% | 34.2% | 20 | 4 |
| 1.C. | 5 TB mortality rate (ICD A15-19) (G10) (E6) | 4.1 | 2.7 | 0.8 | 30 | 28 |
| 1.D. | Collaborative tuberculosis/HIV activities, and management of relevant comorbidities | | | | | |
| 1.D. | 1 Percentage of detected out of incidence TB/HIV estimated | 63.1% | 90% | 59.3% | 17 | 1 |
| 1.D. | 2 HIV testing coverage (G9) (E7) | 64.6% | 100% | 68.7% | 20 | 1 |
| 1.D. | 3 Percentage of HIV among all TB | 4.9% | decrease | 4.4% | 16 | 8 |
| 1.D. | 4 Percentage of TB/HIV patients enrolled in ART | 80.7% | 100% | 94.2% | 8 | 4 |
| 1.D. | 5 LTBI treatment coverage among PLHIV (G5a) | 5% | 30% | – | – | – |
| 1.E. | Management of latent tuberculosis infection and preventive treatment of persons at high risk, and vaccination against tuberculosis | | | | | |
| 1.E. | 1 Contact investigation coverage (G2) (E7) | N/A | 90% | 95.8% | 4 | 3 |
| 1.E. | 2 LTBI treatment coverage of childhood TB contacts aged under five years (G5b) (E8) | N/A | 90% | 47.9% | 3 | 1 |
| 2. BOLD POLICIES AND SUPPORTIVE SYSTEMS | | | | | | |
| 2.A. | Political commitment with adequate resources, including universal health coverage policy | | | | | |
| 2.A. | 1 Number of Member States that have a TB control/elimination performance publicly available (E8) | N/A | 53 | – | – | – |
| 2.B. | Health systems strengthening in all functions, including well-aligned financing mechanisms for tuberculosis and human resources ⁴ | | | | | |
| 2.B. | 1 Percentage of TB-affected households that experience catastrophic costs due to TB (G3) (E10) | N/A | Close to 0 | – | – | – |
| 2.C. | Regulatory frameworks for case-based surveillance, strengthening vital registration, quality and rational use of medicines, and pharmacovigilance ⁴ | | | | | |
| 2.C. | 1 Treatment coverage with new TB drugs (G8) (E9) | N/A | 30% | – | – | – |
| 2.D. | Community systems and civil society engagement | | | | | |
| 2.D. | 1 Number of Member States with functioning multi-stakeholder coalitions advocating for TB care and resources ⁴ | N/A | 53 | – | – | – |
| 2.E. | Social protection, poverty alleviation and actions on other determinants of tuberculosis, such as migration and prisons | | | | | |
| 2.E. | 1 Treatment success rate (%) of new and relapse TB cases among prisoners | 63.2% | 85.0% | 68.4% | 13 | 4 |
| 3. INTENSIFIED RESEARCH AND INNOVATION | | | | | | |
| 3.A. | Discovery, development and rapid uptake of new tools, interventions and strategies ⁴ | | | | | |
| 3.A. | 1 European Tuberculosis Research Initiative established by mid-2016 | N/A | Established | N/A | – | – |

¹ Some of data for 'desk review' assessment are collected through routine reporting at European level and analysed in this report.


² Baseline: as reported for or calculated from 2014 data

³ Currently analysed only for TB contacts.

⁴ Assessed against baseline (2014).


⁵ Data are not available or indicator defined for this report.

Figure 4.1.10. Trend in treatment success rate for new and relapsed TB cases enrolled into treatment 2012-2015 in each of the high-priority countries and totally for 18 high-priority countries and WHO European Region, 2012-2016



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

Figure 4.1.11. Trend in treatment success rate among MDR TB cohort enrolled in treatment between 2010 and 2014 in each of the 18 high-priority countries, and as a total for the 18 high-priority countries and WHO European Region, 2010–2014



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

Figure 4.1.12. Trend in TB mortality rate for the 18 high-priority countries and WHO European Region, 2010–2016



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

Figure 4.1.13. Percentage of cases detected against the estimated number of incident TB/HIV co-infected cases for 18 high-priority countries and WHO European Region, 2016




Figure 4.1.14. HIV testing coverage among new and relapse TB patients for the 18 high-priority countries and WHO European Region, 2016





Figure 4.1.15. Percentage of HIV co-infection among new and relapse TB cases for the 18 high-priority countries and WHO European Region, 2012–2016



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

Figure 4.1.16. Number of HIV cases detected and number enrolled in ART for the 18 high-priority countries, 2011–2016



Horizontal dash-line shows target 25% reduction of notification rate by 2020 against 2015

Figure 4.1.17. LTBI treatment coverage for the 18 high-priority countries and WHO European Region, 2016




Figure 4.1.18. Contact investigation coverage for the 18 high-priority countries and WHO European Region, 2016




Figure 4.1.19. LTBI treatment coverage of childhood TB contacts aged under five years for the 18 high-priority countries and WHO European Region




Figure 4.1.20. Treatment success (%) of new and relapse TB cases among prisoners for the 18 high-priority countries and WHO European Region, 2015




Figure 4.2.1. Indicator 1.A.1: Coverage of population at risk with systematic screening for active TB and LTBI (only TB contacts evaluated), 2016




Figure 4.2.2. Indicator 1.B.1: Percentage of TB patients diagnosed using WHO-recommended rapid tests, 2016




Figure 4.2.3. Indicator 1.B.2: First-line DST coverage among all bacteriologically confirmed TB patients, 2016




Figure 4.2.4. Indicator 1.B.3. RR/MDR TB case detection rate (%), 2016




Figure 4.2.5. Indicator 1.B.4. TB notification rate per 100 000 population (E1), 2016




Figure 4.2.6. Indicator 1.B.5. TB case detection rate (%), 2016




Figure 4.2.7. Indicator 1.B.6 Percentage of RR/MDR TB among new TB patients (E2), 2014 and 2016




Figure 4.2.8. Indicator 1.B.7 Percentage of RR/MDR TB among previously treated TB patients, 2016




Figure 4.2.9. Indicator 1.C.1 Percentage of hospitalisation for new TB patients, 2016 (E3)




Figure 4.2.10. Indicator 1.C.2 Percentage of detected RR/MDR TB enrolled in treatment, 2016 (G3) (E4)




Figure 4.2.11. Indicator 1.C.3 TB treatment success, 2016 (G2)




Figure 4.2.12. Indicator 1.C.4 TB treatment success rate among the RR/MDR TB cohort, 2016 (G4), (E4)




Figure 4.2.13. Indicator 1.C.5 TB mortality rate, 2016 (ICD A15-19)




Figure 4.2.14. Indicator 1.D.1 Percentage of detected cases out of estimated incident TB/HIV co-infected cases, 2016




Figure 4.2.15. Indicator 1.D.2 HIV testing coverage, 2016 (G9) (E7)




Figure 4.2.16. Indicator 1.D.3 Percentage of HIV among all TB cases, 2016




Figure 4.2.17. Indicator 1.D.4 Percentage of TB/HIV patients enrolled in ART, 2016




Figure 4.2.18. Indicator 1.E.1 Contact investigation coverage (%) (G2) (E7)




Figure 4.2.19. Indicator 1.E.2 Contact-tracing coverage for children under five years (%) (G2) (E7)






Figure 4.2.20. Treatment success (%) of new and relapse TB cases among prisoners





5. Annexes

Annex 1: Tuberculosis surveillance system overview, 2016

| Country | Data source | Legal character ^a | Comprehensiveness ^b | Type ^c | National coverage ^d | Data available: | | |
|----------------------|----------------------------------|------------------------------|--------------------------------|-------------------|--------------------------------|------------------------|-------------------------------------|------------------------------------|
| | | | | | | EuroTB aggregated data | EuroTB case-based data ^e | TESSy case-based data ^f |
| Austria | AT-TUBERKULOSEGESETZ | Cp | Co | C | Y | – | – | 1995–2016 |
| Belgium | BE-TUBERCULOSIS | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Bulgaria | BG-MOH | Cp | Co | C | – | 1995–2006 | – | 2007–2016 |
| Croatia ^g | HR-CNIPH | Cp | Co | C | Y | 1995–2007 | – | 2012–2016 |
| Cyprus | CY-NOTIFIED_DISEASES | Cp | Co | C | Y | 1995–2001 | 2002–2004 | 2005–2016 |
| Czech Republic | CZ-TUBERCULOSIS | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Denmark | DK-MIS | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Estonia | EE-TBC | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Finland | FI-NIDR | Cp | Co | C | Y | – | – | 1995–2016 |
| France ^h | FR-MANDATORY_INFECTIOUS_DISEASES | Cp | Co | C | Y | 2016 | 1995–1999 | 2000–2015 |
| Germany | DE-SURVNET@RKI-7.1/6 | Cp | Co | C | Y | 1995–2000 | 2001–2004 | 2005–2016 |
| Greece | EL-NOTIFIABLE_DISEASES | Cp | Co | C | Y | 1995–2001 | 2002–2004 | 2006–2016 |
| Hungary | HU-TUBERCULOSIS | Cp | Co | C | Y | 1995–1998 | 1999–2004 | 2005–2016 |
| Iceland | IS-TUBERCULOSIS | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Ireland | IE-CIDR | Cp | Co | C | Y | 1995–1997 | 1998–2004 | 2005–2016 |
| Italy | IT-NRS | Cp | Co | C | – | – | 1995–2004 | 2005–2016 |
| Latvia | LV-TB | Cp | Co | C | Y | 1995–2000 | 2001–2004 | 2005–2016 |
| Liechtenstein | – | Cp | Co | C | – | – | – | 2007 |
| Lithuania | LT-TB_REGISTER | Cp | Co | C | Y | 1995–2002 | 2003, 2004 | 2005–2016 |
| Luxembourg | LU-SYSTEM1 | Cp | Co | C | Y | – | 1995–2006 | 2007–2016 |
| Malta | MT-DISEASE_SURVEILLANCE | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Netherlands | NL-NTR | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Norway | NO-MSIS_A | Cp | Co | C | Y | – | 1995–2005 | 2006–2016 |
| Poland | PL_CR | Cp | Co | C | Y | 1995–1999 | 2000–2003 | 2004–2016 |
| Portugal | PT-TUBERCULOSIS | Cp | Co | C | Y | 1995–1999 | 2000–2004 | 2005–2016 |
| Romania | RO-NTBSy | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Slovakia | SK-NRT | Cp | Co | C | Y | 1995 | 1996–2004 | 2005–2016 |
| Slovenia | SI-TUBERCULOSIS | Cp | Co | C | Y | – | 1995–2004 | 2005–2016 |
| Spain | ES-STATUTORY_DISEASES | Cp | Co | C | Y | 1995–2006 | – | 2007–2016 |
| Sweden | SE-SweTBReg | Cp | Co | C | Y | – | 1995–2006 | 2007–2016 |
| United Kingdom | UK-TUBERCULOSIS | Cp | Co | C | Y | 1995–1997 | – | 1998–2016 |

^a Legal: compulsory reporting – Cp.

^b Comprehensiveness: comprehensive – Co.

^c Type: case based – C.

^d Coverage: national – Y. Not specified in TESSy – ‘–’.

^e Data uploaded to TESSy in 2010, not updated later.

^f WHO TB Monitoring and Evaluation data (TME) for DST analysis of France, Spain and Italy.

^g Data reported since 2012 to TESSy, historical data extracted from WHO Global TB monitoring and evaluation data (TME).

^h Data reported to TESSy until 2015, 2016 data extracted from WHO Global TB monitoring and evaluation data (TME).

Annex 2: List of variables for 2017 TB data collection^a

| List | Description |
|------------------------------------|---|
| Common set of variables | |
| 1 RecordId | Unique identifier for each record generated by the national surveillance system |
| 2 RecordType | Structure and format of the data |
| 3 RecordTypeVersion | Indicates which version the sender uses when generating the data for upload |
| 4 Subject | Disease to report |
| 5 Status | Status of reporting NEW/UPDATE or DELETE (inactivate) |
| 6 DataSource | The data source (surveillance system) that the record originates from |
| 7 ReportingCountry | The country reporting the record |
| 8 PlaceOfNotification ^b | Place of the first notification of the case to a regional authority |
| 9 PlaceOfResidence ^b | Place of residence of patient at the time of disease onset |
| 10 Age | Age of patient in years as reported in the national system |
| 11 Gender | Gender of the reported case |
| 12 DateOfDiagnosis | First date of clinical or lab diagnosis |
| 13 DateOfNotification | Date when the case is first reported to public health authorities |
| 14 DateUsedForStatistics | The reference date used for standard reports. Usually one of the above |
| 15 Classification | Case classification according to EU case definition |
| 16 LaboratoryResult | Laboratory criteria used to classify a case as confirmed or probable |
| Disease-specific variables | |
| 17 BornReportingCountry | The patient was born in the country of report |
| 18 CountryOfBirth | Country of birth of patient |
| 19 CountryOfNationality | Country of nationality of patient |
| 20 NationalityReportingCountry | Origin of the patient (based on citizenship) |
| 21 MajorSiteOfTB | Major site of the disease |
| 22 MinorSiteOfTB | Minor site of the disease |
| 23 PrevDiagnosis | Previous diagnosis of tuberculosis in the past |
| 24 PrevDiagnosisYear | Year of previous diagnosis |
| 25 PrevTreatment | Previous anti-TB drug treatment (at least one month of drug combination) |
| 26 PrevTreatmentCompletion | Completion of the previous anti-tuberculosis drug treatment |
| 27 DiagnosedAnteMortem | Vital status of the patient at the time of diagnosis |
| 28 EnrolledToTreatment | Patient started appropriate TB treatment according to international recommendations |
| 29 Outcome12Months | Patient first outcome at 12 months from the start of the treatment |
| 30 Outcome24Months | The first outcome observed 13 to 24 months from the start of treatment |
| 31 Outcome36Months | The first outcome observed 25 to 36 months from the start of treatment |
| 32 ResultCulture | The result of the culture test for <i>Mycobacterium tuberculosis</i> complex |
| 33 ResultMicroscopy | The result of the microscopy test performed |
| 34 ResultOtherTest | Additional lab test results |
| 35 Pathogen | Species and gene (<i>M. tuberculosis</i> complex) of the pathogen which is the cause of the reported disease |
| 36 HIVStatus | Result of the last HIV test |
| 37 SIR_AMK | Susceptibility to Amikacin (without Intermediate) |
| 38 SIR_BDQ | Susceptibility to Bedaquiline |
| 39 SIR_CAP | Susceptibility to Capreomycin (without Intermediate) |
| 40 SIR_CIP | Susceptibility to Ciprofloxacin (without Intermediate) |
| 41 SIR_DLM | Susceptibility to Delamanid |
| 42 SIR_ETH | Susceptibility to Ethambutol |
| 43 SIR_GAT | Susceptibility to Gatifloxacin |
| 44 SIR_INH | Susceptibility to Isoniazid |
| 45 SIR_KAN | Susceptibility to Kanamycin |
| 46 SIR_LVX | Susceptibility to Levofloxacin |
| 47 SIR_MFX | Susceptibility to Moxifloxacin |
| 48 SIR_OFX | Susceptibility to Ofloxacin |
| 49 SIR_RIF | Susceptibility to Rifampicin |
| 50 SIR_STR | Susceptibility to Streptomycin |
| 51 IsolateID | Unique identifier for each isolate within the data source / lab system related to the case |
| 52 ECDCIsolateID | Identifier for each isolate record that is guaranteed to be unique across countries/labs/pathogens and not contain additional encoded information |
| 53 SpoligoCode | Spoligo pattern code |
| 54 RflpCode | National cluster code based on IS6110 RFLP |
| 55 MiruCode | MIRU pattern code |
| 56 BeijingGenotype | Beijing genotype identification |

Note: Variables 51–56 are optional, complementary for TB molecular surveillance.

^a Notification of TB cases for 2016, treatment outcome data updated for cohort 2015 and MDR TB treatment outcome data updated for cohort 2014 and XDR TB treatment outcome data for cohort 2013.

^b Optional for TB reporting.

Annex 3: Reporting completeness of main variables used for the report^a

| Country | Age | Gender | Origin ^b | CountryOfOrigin | Site | Previous treatment history ^c | Diagnosed ante mortem | Result Culture | Result Microscopy | Result Other test | DST FLD ^d | DST SLD ^e | HIV Status ^f | Enrolled in treatment | Outcome12Months ^g | Outcome24Months ^h | Outcome36Months ⁱ |
|-------------------------------|---------------|---------------|---------------------|-----------------|---------------|---|-----------------------|----------------|-------------------|-------------------|----------------------|----------------------|-------------------------|-----------------------|------------------------------|------------------------------|------------------------------|
| Austria | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (76.2) | (100.0) | (91.8) | (84.2) | (83.1) | (96.7) | (100.0) | (0.0) | (0.0) | (88.9) | (75.0) | (100.0) |
| Belgium | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (78.1) | (100.0) | (95.4) | (96.5) | (59.8) | (96.0) | (100.0) | (45.7) | (98.5) | (96.9) | (90.6) | - |
| Bulgaria | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (85.9) | (86.8) | (5.5) | (87.7) | (100.0) | (78.6) | (100.0) | (99.2) | (100.0) | (100.0) |
| Croatia | (100.0) | (100.0) | (35.7) | (100.0) | (74.1) | (68.0) | (0.0) | (57.0) | (0.0) | (0.0) | (100.0) | - | (0.0) | (83.7) | (20.0) | (50.0) | - |
| Cyprus | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (90.0) | (81.7) | (13.3) | (97.6) | (100.0) | (80.0) | (100.0) | (69.8) | - | - |
| Czech Republic | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (98.3) | (88.6) | (58.3) | (93.6) | (83.3) | (39.7) | (100.0) | (99.0) | (60.0) | - |
| Denmark | (100.0) | (100.0) | (100.0) | (99.1) | (98.8) | (100.0) | (100.0) | (95.8) | (97.3) | (69.4) | (97.7) | (100.0) | (45.5) | (100.0) | (58.8) | (50.0) | (100.0) |
| Estonia | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (98.4) | (98.4) | (79.7) | (97.4) | (100.0) | (95.8) | (100.0) | (96.0) | (96.0) | (100.0) |
| Finland | (100.0) | (100.0) | (96.6) | (95.3) | (100.0) | (97.9) | (100.0) | (78.8) | (78.4) | (39.8) | (98.4) | (100.0) | (0.0) | (89.8) | (41.5) | (0.0) | - |
| France | (94.3) | (94.3) | (55.6) | (0.0) | (94.3) | (5.7) | (0.0) | (53.1) | (0.0) | (0.0) | (100.0) | (97.2) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) |
| Germany | (100.0) | (99.8) | (93.9) | (94.9) | (100.0) | (11.3) | (98.6) | (83.1) | (55.2) | (75.3) | (90.2) | (63.4) | (0.0) | (99.6) | (82.5) | (58.7) | (0.0) |
| Greece | (98.9) | (100.0) | (100.0) | (96.6) | (97.1) | (95.0) | (0.0) | (48.5) | (81.5) | (39.3) | (50.4) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | - |
| Hungary | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (92.0) | (91.1) | (0.0) | (84.2) | (83.3) | (2.4) | (100.0) | (96.5) | (100.0) | (100.0) |
| Iceland | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (80.0) | - | (100.0) | (100.0) | (100.0) | - | - |
| Ireland | (100.0) | (100.0) | (96.2) | (96.2) | (96.9) | (75.8) | (100.0) | (83.6) | (53.5) | (47.2) | (97.1) | (83.3) | (41.5) | (100.0) | (61.8) | (50.0) | (100.0) |
| Italy | (91.7) | (98.6) | (91.5) | (84.9) | (100.0) | (79.3) | (0.0) | (80.9) | (63.9) | (0.0) | (100.0) | (78.6) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) |
| Larvia | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (95.8) | (93.6) | (9.5) | (95.9) | (100.0) | (76.8) | (100.0) | (100.0) | (98.6) | (100.0) |
| Liechtenstein | - | - | - | - | - | - | - | - | - | - | - | - | (0.0) | - | - | - | - |
| Lithuania | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (1.6) | (100.0) | (100.0) | (78.9) | (100.0) | (100.0) | (98.2) | (100.0) |
| Luxembourg | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (3.4) | (100.0) | (100.0) | (100.0) | (0.0) | (96.2) | (0.0) | (17.2) | (100.0) | (0.0) | (0.0) | - |
| Malta | (100.0) | (100.0) | (100.0) | (98.0) | (100.0) | (100.0) | (100.0) | (84.0) | (68.0) | (34.0) | (100.0) | - | (92.0) | (100.0) | (0.0) | - | (0.0) |
| Netherlands | (100.0) | (100.0) | (99.3) | (99.3) | (99.7) | (99.4) | (100.0) | (79.3) | (71.9) | (16.0) | (100.0) | (100.0) | (62.3) | (100.0) | (97.4) | (85.7) | - |
| Norway | (100.0) | (100.0) | (100.0) | (100.0) | (99.7) | (92.6) | (100.0) | (89.3) | (85.6) | (84.6) | (99.1) | (100.0) | (86.0) | (99.3) | (100.0) | (90.9) | (0.0) |
| Poland | (100.0) | (100.0) | (100.0) | (99.9) | (100.0) | (100.0) | (100.0) | (89.1) | (87.7) | (14.1) | (91.7) | (84.8) | (0.0) | (0.1) | (74.1) | (57.1) | (100.0) |
| Portugal | (99.7) | (100.0) | (100.0) | (100.0) | (99.2) | (100.0) | (100.0) | (67.1) | (76.1) | (29.7) | (70.3) | (41.7) | (66.0) | (100.0) | (100.0) | (84.0) | (100.0) |
| Romania | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (94.6) | (95.6) | (11.1) | (88.7) | (45.4) | (78.1) | (100.0) | (99.9) | (100.0) | (100.0) |
| Slovakia | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (94.6) | (92.2) | (26.7) | (96.6) | (100.0) | (44.6) | (100.0) | (94.3) | (100.0) | - |
| Slovenia | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (100.0) | (86.4) | (86.4) | (93.2) | (100.0) | - | (80.5) | (100.0) | (100.0) | - | - |
| Spain | (100.0) | (100.0) | (87.7) | (78.1) | (100.0) | (61.5) | (0.0) | (82.9) | (86.1) | (26.1) | (26.6) | (92.9) | (60.0) | (0.0) | (0.0) | (0.0) | (0.0) |
| Sweden | (100.0) | (100.0) | (100.0) | (99.9) | (100.0) | (92.3) | (100.0) | (100.0) | (74.8) | (69.6) | (99.7) | (100.0) | (0.0) | (100.0) | (95.3) | (93.3) | (100.0) |
| United Kingdom | (100.0) | (100.0) | (97.7) | (93.6) | (99.6) | (94.9) | (100.0) | (63.1) | (64.7) | (14.5) | (97.0) | (89.3) | (0.0) | (98.5) | (98.1) | (94.6) | (100.0) |
| Total EU/EEA countries | (98.9) | (99.4) | (93.3) | (87.5) | (99.2) | (76.8) | (74.8) | (82.2) | (72.5) | (22.3) | (87.4) | (74.4) | (33.9) | (63.4) | (70.6) | (78.5) | (80.1) |

^a Data in green obtained from WHO tuberculosis monitoring and evaluation database (TME).

^b For determining the origin two variables merged: BornReportingCountry and NationalityReportingCountry depending on Member State's preference.

^c History of previous treatment defined by previous diagnosis of TB for cases reported by Belgium, Denmark, Ireland, Norway and the United Kingdom.

^d FLD DST – drug susceptibility testing for first line TB drugs calculated for confirmed TB cases.

^e DST SLD – drug susceptibility testing for second line TB drugs, calculated only for MDR TB cases (Croatia, Iceland, Malta and Slovenia reported zero MDR TB cases for 2016).

^f Finland reported only positive HIV cases to WHO Global TB database; they are therefore not published in this report.

^g Data for 2015 cohort.

^h Data for MDR 2014 cohort (Cyprus, Iceland, Malta and Slovenia reported zero MDR TB cases in 2014).

ⁱ Data for XDR 2013 cohort (Belgium, Croatia, Cyprus, Finland, Luxembourg, Slovakia and Slovenia reported zero XDR TB cases in 2013).

Annex 4: Reporting completeness into Global TB database, 2016

| Country | Identification (%) (17 fields) | Notification (%) (53 fields) | Anti-tuberculosis drug resistance surveillance (%) (40 fields) | Treatment outcome of TB cases by risk categories (%) (87 fields) | Implementing Stop TB strategy (%) (83 fields) | Budget and expenditure (%) (87 fields) |
|--|-----------------------------------|---------------------------------|---|---|---|--|
| EU/EEA | | | | | | |
| Austria | (82.4) | (83.0) | (75.0) | (43.7) | (7.2) | (4.6) |
| Belgium | (100.0) | (84.9) | (90.0) | (93.1) | (48.2) | (8.0) |
| <i>Bulgaria</i> | <i>(94.1)</i> | <i>(90.6)</i> | <i>(90.0)</i> | <i>(58.6)</i> | <i>(85.5)</i> | <i>(85.1)</i> |
| Croatia | (64.7) | (84.9) | (57.5) | (50.6) | (47.0) | (5.7) |
| Cyprus | (0.0) | (60.4) | (90.0) | (35.6) | (0.0) | (2.3) |
| Czech Republic | (70.6) | (92.5) | (90.0) | (93.1) | (61.4) | (12.6) |
| Denmark | (0.0) | (54.7) | (90.0) | (49.4) | (0.0) | (2.3) |
| <i>Estonia</i> | <i>(100.0)</i> | <i>(90.6)</i> | <i>(90.0)</i> | <i>(90.8)</i> | <i>(80.7)</i> | <i>(100.0)</i> |
| Finland | (58.8) | (84.9) | (75.0) | (29.9) | (49.4) | (12.6) |
| France | (82.4) | (77.4) | (42.5) | (1.1) | (44.6) | (11.5) |
| Germany | (88.2) | (62.3) | (75.0) | (43.7) | (37.3) | (5.7) |
| Greece | (41.2) | (60.4) | (57.5) | (0.0) | (0.0) | (2.3) |
| Hungary | (100.0) | (79.2) | (90.0) | (59.8) | (59.0) | (10.3) |
| Iceland | (0.0) | (60.4) | (72.5) | (35.6) | (0.0) | (2.3) |
| Ireland | (88.2) | (86.8) | (90.0) | (72.4) | (66.3) | (9.2) |
| Italy | (29.4) | (15.1) | (90.0) | (0.0) | (38.6) | (4.6) |
| <i>Latvia</i> | <i>(100.0)</i> | <i>(92.5)</i> | <i>(90.0)</i> | <i>(100.0)</i> | <i>(78.3)</i> | <i>(49.4)</i> |
| Liechtenstein | - | - | - | - | - | - |
| <i>Lithuania</i> | <i>(58.8)</i> | <i>(94.3)</i> | <i>(90.0)</i> | <i>(100.0)</i> | <i>(80.7)</i> | <i>(29.9)</i> |
| Luxembourg | (88.2) | (84.9) | (72.5) | (23.0) | (51.8) | (6.9) |
| Malta | (64.7) | (96.2) | (72.5) | (23.0) | (42.2) | (6.9) |
| Netherlands | (88.2) | (92.5) | (90.0) | (78.2) | (54.2) | (11.5) |
| Norway | (58.8) | (75.5) | (90.0) | (50.6) | (59.0) | (12.6) |
| Poland | (94.1) | (81.1) | (75.0) | (58.6) | (45.8) | (4.6) |
| Portugal | (76.5) | (88.7) | (90.0) | (100.0) | (69.9) | (27.6) |
| <i>Romania</i> | <i>(100.0)</i> | <i>(90.6)</i> | <i>(90.0)</i> | <i>(100.0)</i> | <i>(90.4)</i> | <i>(100.0)</i> |
| Slovakia | (70.6) | (92.5) | (90.0) | (93.1) | (77.1) | (14.9) |
| Slovenia | (88.2) | (92.5) | (72.5) | (79.3) | (79.5) | (12.6) |
| Spain | (0.0) | (60.4) | (80.0) | (0.0) | (0.0) | (2.3) |
| Sweden | (58.8) | (86.8) | (75.0) | (49.4) | (39.8) | (11.5) |
| United Kingdom | (94.1) | (81.1) | (75.0) | (63.2) | (54.2) | (5.7) |
| Subtotal EU/EEA | (65.8) | (76.7) | (78.0) | (52.0) | (46.7) | (18.6) |
| Non-EU/EEA | | | | | | |
| Albania | (88.2) | (94.3) | (72.5) | (86.2) | (92.8) | (27.6) |
| Andorra | (70.6) | (92.5) | (100.0) | (100.0) | (54.2) | (12.6) |
| <i>Armenia</i> | <i>(100.0)</i> | <i>(98.1)</i> | <i>(100.0)</i> | <i>(79.3)</i> | <i>(73.5)</i> | <i>(92.0)</i> |
| <i>Azerbaijan</i> | <i>(88.2)</i> | <i>(94.3)</i> | <i>(82.5)</i> | <i>(79.3)</i> | <i>(71.1)</i> | <i>(21.8)</i> |
| <i>Belarus</i> | <i>(88.2)</i> | <i>(98.1)</i> | <i>(100.0)</i> | <i>(100.0)</i> | <i>(90.4)</i> | <i>(80.5)</i> |
| Bosnia and Herzegovina | (100.0) | (92.5) | (100.0) | (72.4) | (74.7) | (94.3) |
| former Yugoslav Republic of Macedonia, the | (88.2) | (94.3) | (100.0) | (100.0) | (100.0) | (34.5) |
| <i>Georgia</i> | <i>(100.0)</i> | <i>(98.1)</i> | <i>(85.0)</i> | <i>(93.1)</i> | <i>(91.6)</i> | <i>(98.9)</i> |
| Israel | (88.2) | (86.8) | (90.0) | (79.3) | (38.6) | (5.7) |
| <i>Kazakhstan</i> | <i>(100.0)</i> | <i>(94.3)</i> | <i>(27.5)</i> | <i>(65.5)</i> | <i>(71.1)</i> | <i>(98.9)</i> |
| <i>Kyrgyzstan</i> | <i>(100.0)</i> | <i>(96.2)</i> | <i>(70.0)</i> | <i>(65.5)</i> | <i>(81.9)</i> | <i>(98.9)</i> |
| <i>Moldova</i> | <i>(100.0)</i> | <i>(100.0)</i> | <i>(100.0)</i> | <i>(79.3)</i> | <i>(89.2)</i> | <i>(98.9)</i> |
| Monaco | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2.3) |
| Montenegro | (88.2) | (94.3) | (70.0) | (100.0) | (73.5) | (73.6) |
| <i>Russia</i> | <i>(70.6)</i> | <i>(90.6)</i> | <i>(22.5)</i> | <i>(67.8)</i> | <i>(68.7)</i> | <i>(100.0)</i> |
| San Marino | (88.2) | (90.6) | (100.0) | (100.0) | (65.1) | (14.9) |
| Serbia | (100.0) | (90.6) | (87.5) | (65.5) | (90.4) | (100.0) |
| Serbia excluding UN Administered Province of Kosovo ^a | (100.0) | (90.6) | (87.5) | (76.0) | (90.4) | (100.0) |
| UN Administered Province of Kosovo ^a | (88.2) | (81.1) | (80.0) | (78.2) | 65.1 | (48.3) |
| Switzerland | (82.4) | (73.6) | (80.0) | (14.9) | (44.6) | (14.9) |
| <i>Tajikistan</i> | <i>(100.0)</i> | <i>(100.0)</i> | <i>(100.0)</i> | <i>(86.2)</i> | <i>(100.0)</i> | <i>(98.9)</i> |
| <i>Turkey</i> | <i>(100.0)</i> | <i>(88.7)</i> | <i>(100.0)</i> | <i>(82.8)</i> | <i>(78.3)</i> | <i>(31.0)</i> |
| <i>Turkmenistan</i> | <i>(82.4)</i> | <i>(62.3)</i> | <i>(15.0)</i> | <i>(23.0)</i> | <i>(49.4)</i> | <i>(33.3)</i> |
| <i>Ukraine</i> | <i>(100.0)</i> | <i>(96.2)</i> | <i>(55.0)</i> | <i>(100.0)</i> | <i>(91.6)</i> | <i>(97.7)</i> |
| <i>Uzbekistan</i> | <i>(76.5)</i> | <i>(96.2)</i> | <i>(27.5)</i> | <i>(21.8)</i> | <i>(34.9)</i> | <i>(21.8)</i> |
| Subtotal non-EU/EEA | (90.8) | (91.5) | (76.7) | (76.1) | (70.7) | (60.9) |
| Total European Region | (76.5) | (83.0) | (77.5) | (63.5) | (56.9) | (36.6) |
| Subtotal 18 HPC | (92.2) | (92.9) | (74.2) | (77.4) | (78.2) | (74.3) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in *italics*.

^a In accordance with the UN Security Council Resolution No. 1244 (1999).

Annex 5: Laboratory network capacity, European Region, 2016^a

| Country | Country laboratory network | | | | | | | | | | |
|--|-------------------------------|-------------------------|-------------|----------------------------------|-------------------------------|------------------|-------------------|--|-------------|--------------------------------------|-----------|
| | Microscopy | | Culture | DST for Isoniazid and Rifampicin | | Line Probe Assay | Xpert MTB/Rif (N) | International proficiency testing of national reference laboratory | | | |
| | No of laboratories performing | EQA passed ^b | | No of laboratories performing | No of laboratories performing | | | EQA passed ^b | Year | Percentage agreement of results for: | |
| | | | Isoniazid | | | Rifampicin | | | | | |
| EU/EEA | | | | | | | | | | | |
| Austria | – | – | – | – | – | – | – | – | – | – | – |
| Belgium | 103 | 0 | 114 | 14 | 14 | – | 20 | 2016 | 100 | 100 | Y |
| Bulgaria | 33 | 33 | 30 | 33 | 33 | 1 | 4 | 2015 | 100 | 100 | Y |
| Croatia | 15 | 1 | 5 | 5 | 5 | 0 | 1 | 2016 | – | – | – |
| Cyprus | – | – | – | – | – | – | – | – | – | – | – |
| Czech Republic | 39 | 39 | 39 | 18 | 18 | 8 | 5 | 2016 | 100 | 100 | Y |
| Denmark | – | – | – | – | – | – | – | – | – | – | – |
| Estonia | 6 | 6 | 2 | 0 | 0 | 0 | 4 | 2016 | 100 | 100 | Y |
| Finland | 9 | 9 | 9 | 0 | 0 | 2 | 5 | 2016 | 100 | 100 | Y |
| France | 150 | 150 | 150 | 58 | 0 | 0 | 60 | 2016 | 100 | 100 | Y |
| Germany | 255 | 255 | 191 | 0 | 0 | 0 | 71 | 2016 | 100 | 100 | Y |
| Greece | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 11 | 10 | 11 | 7 | 4 | 2 | 3 | 2016 | 100 | 100 | Y |
| Iceland | – | – | – | – | – | – | – | – | – | – | – |
| Ireland | 10 | 9 | 10 | 2 | 2 | 0 | 6 | 2016 | 100 | 100 | Y |
| Italy | 42 | 0 | 42 | 42 | 35 | 12 | 32 | 2016 | 99 | 99 | Y |
| Latvia | 12 | 12 | 5 | 1 | 1 | 1 | 2 | 2016 | 100 | 100 | Y |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 11 | 9 | 6 | 6 | 5 | 1 | 5 | 2016 | – | – | – |
| Luxembourg | 1 | 1 | 1 | 1 | 1 | – | 0 | 2016 | 100 | 100 | Y |
| Malta | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | – | – | – |
| Netherlands | – | – | 30 | 7 | – | – | – | 2016 | 100 | 100 | Y |
| Norway | 15 | 15 | 9 | 3 | 3 | 0 | 4 | 2016 | 100 | 100 | Y |
| Poland | 54 | 1 | 54 | 30 | 1 | 1 | 10 | 2016 | 100 | 100 | Y |
| Portugal | – | – | – | – | – | – | – | – | – | – | – |
| Romania | 96 | 73 | 87 | 40 | 2 | 0 | 19 | 2016 | 100 | 100 | Y |
| Slovakia | 4 | 4 | 4 | 2 | 2 | 1 | 1 | 2016 | 100 | 100 | Y |
| Slovenia | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2016 | 100 | 100 | Y |
| Spain | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | 5 | 5 | 5 | 0 | – | – | – | 2016 | 100 | 100 | Y |
| United Kingdom | 77 | 77 | 68 | 1 | 1 | – | – | 2016 | 100 | 100 | Y |
| Subtotal EU/EEA | 951 | 712 | 875 | 271 | 128 | 30 | 255 | 2015–2016 | 100 | 100 | 20 |
| Non-EU/EEA | | | | | | | | | | | |
| Albania | 12 | 1 | 1 | 1 | 1 | 0 | 0 | 2016 | 100 | 100 | Y |
| Andorra | 8 | 0 | 8 | 8 | 0 | 0 | 0 | – | – | – | N |
| Armenia | 26 | 26 | 1 | 0 | 0 | 1 | 2 | 2016 | 100 | 100 | Y |
| Azerbaijan | 67 | 23 | 7 | 3 | 3 | 2 | 10 | 2016 | – | – | N |
| Belarus | 151 | 94 | 28 | 0 | 0 | 0 | 28 | 2016 | 100 | 100 | Y |
| Bosnia and Herzegovina | 9 | 9 | 13 | 7 | 3 | 2 | 0 | 2016 | 100 | 100 | Y |
| former Yugoslav Republic of Macedonia, the | 7 | 7 | 3 | 1 | 0 | 0 | 1 | 2015 | 100 | 100 | Y |
| Georgia | 11 | 11 | 2 | 1 | 1 | 2 | 13 | 2015 | 100 | 100 | Y |
| Israel | 19 | 0 | 19 | 2 | 2 | 1 | 0 | 2016 | 100 | 100 | Y |
| Kazakhstan | 332 | 332 | 50 | 22 | 16 | 9 | 22 | 2015 | 100 | 100 | Y |
| Kyrgyzstan | 131 | 129 | 5 | 0 | 0 | 2 | 13 | 2016 | 100 | 100 | Y |
| Moldova | 58 | 58 | 4 | 0 | 0 | 0 | 58 | 2016 | 95 | 95 | N |
| Monaco | – | – | – | – | – | – | – | – | – | – | – |
| Montenegro | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2016 | 100 | 100 | Y |
| Russia | 6076 | 635 | 397 | 303 | 96 | 12 | 189 | – | – | – | N |
| San Marino | 1 | 1 | 1 | 0 | 0 | 0 | 1 | – | – | – | N |
| Serbia | 40 | 10 | 32 | 6 | 6 | 1 | 4 | 2016 | 100 | 100 | Y |
| Serbia excluding UN Administered Province of Kosovo ^d | 31 | 1 | 29 | 4 | 4 | 1 | 2 | 2016 | 100 | 100 | Y |
| UN Administered Province of Kosovo ^d | 9 | 9 | 3 | 2 | 2 | 0 | 2 | 0 | 100 | 100 | Y |
| Switzerland | 34 | 34 | 21 | 11 | 11 | 5 | 33 | 2016 | – | – | N |
| Tajikistan | 84 | 81 | 6 | 1 | 1 | 3 | 15 | 2016 | 100 | 100 | Y |
| Turkey | 307 | 119 | 126 | 66 | 0 | 5 | 25 | 2016 | 100 | 100 | Y |
| Turkmenistan | 61 | 61 | 5 | 4 | 1 | 1 | 6 | – | – | – | N |
| Ukraine | 883 | 666 | 94 | 35 | 25 | 3 | 53 | – | – | – | N |
| Uzbekistan | 294 | 2 | 6 | 2 | 2 | 6 | 20 | – | – | – | N |
| Subtotal non-EU/EEA | 8612 | 2300 | 830 | 474 | 169 | 55 | 494 | 2016 | 99.7 | 99.7 | 14 |
| Total European Region | 9563 | 3012 | 1705 | 745 | 297 | 85 | 749 | 2015–2016 | 97.1 | 97.1 | 34 |
| Subtotal 18 HPC | 8578 | 2309 | 856 | 513 | 185 | 48 | 478 | 2015–2016 | 91.9 | 91.9 | 13 |

^a 'European Region' comprises the 53 high-priority countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

DST – drug susceptibility testing.

^b Data obtained from WHO Tuberculosis Monitoring and Evaluation database (TME).

^c EQA – External quality assessment.

^d Acceptable performance defined as reference laboratory achieving 95% performance (smear and DST).

^e In accordance with the UN Security Council Resolution No. 1244 (1999).

Annex 6: Monitoring framework for follow up of the TB Action Plan for the WHO European Region, 2016 – 2020

| Area of intervention | Indicator | Baseline for WHO European Region (2014) | Target | Frequency of assessment | Data source | Monitoring mechanism | Indicator definition ¹ | Input-impact level |
|--|--|---|----------|-------------------------|------------------------|------------------------------------|---|--------------------|
| 1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION | | | | | | | | |
| 1.A. Systematic screening of contacts and high-risk groups | | | | | | | | |
| 1.A. 1 | Coverage of population at risk with systematic screening for active TB and latent TB infection (LTBI) ³ | N/A | 80% | Annually | National TB Programme | Desk review/ routine reporting | Numerator: total number of people screened for TB and/or LTBI in a defined period. Denominator: total number of people at risk according to the national guidelines in the same period. | Output |
| 1.B. Early diagnosis of all forms of tuberculosis and universal access to drug-susceptibility testing, including the use of rapid tests | | | | | | | | |
| 1.B. 1 | Percentage of newly notified TB patients diagnosed using WHO-recommended rapid tests (G9) ⁴ | N/A | 40% | Annually | National TB Programme | Desk review/ routine reporting | Numerator: total number of newly notified TB patients Denominator: total number of newly notified TB patients Percentage of newly notified TB patients diagnosed using WHO-recommended rapid tests: number of newly notified TB patients diagnosed with WHO-recommended rapid tests, divided by the total number of newly notified TB patients. | Outcome |
| 1.B. 2 | First line DST coverage among all bacteriologically confirmed TB cases (G7) | 92% | 100% | Annually | WHO Global TB database | Routine reporting | Numerator: total number of TB patients with FLD DST results (includes results from molecular (e.g. Xpert MTB/RIF) as well as conventional phenotypic DST results) Denominator: total number of bacteriologically confirmed TB patients notified. WHO-HQ indicator 7 DST coverage for TB patients: number of TB patients with DST results divided by the number of notified cases in the same year, expressed as a percentage. DST coverage includes results from molecular (e.g. Xpert MTB/RIF) as well as conventional phenotypic DST results. | Outcome |
| 1.B. 3 | RR/MDR TB case detection rate ⁵ | 47% | 85% | Annually | WHO Global TB database | Routine reporting/ WHO estimate | Numerator: total number of notified TB cases Denominator: total number of estimated TB cases | Outcome |
| 1.B. 4 | TB notification rate per 100 000 population (E1) | 32.8 | 24.6 | Annually | WHO Global TB database | Routine reporting | Numerator: total number of new and relapse TB cases notified Denominator: population number/100000 | Impact |
| 1.B. 5 | TB case detection rate (%) | 84% | Increase | Annually | WHO Global TB database | Routine reporting/ WHO estimate | Numerator: total number of notified TB cases Denominator: total number of estimated TB cases | Outcome |
| 1.B. 6 | Percentage of RR/MDR TB among new TB patients (E2) | 17% | Decrease | Annually | WHO Global TB database | Routine reporting | Numerator: total number of laboratory confirmed new MDR TB cases Denominator: total number of new TB cases with DST results | Impact |
| 1.B. 7 | Percentage of RR/MDR TB among previously treated TB patients | 48% | Decrease | Annually | WHO Global TB database | Routine reporting | Numerator: total number of laboratory confirmed previously treated MDR TB cases Denominator: total number of previously treated TB cases with DST results | Impact |
| 1.C. Equitable access to quality treatment and continuum of care for all people with tuberculosis, including drug-resistant tuberculosis, and patient support to facilitate treatment adherence | | | | | | | | |
| 1.C. 1 | Percentage of hospitalisation of new TB patients (E3) | N/A | Decrease | 2016 and 2020 | National TB Programme | Desk review/ routine reporting | Numerator: total number of new TB cases hospitalized in a specified period Denominator: total number of new TB cases registered in the same period | Outcome |
| 1.C. 2 | Percentage of detected RR/MDR TB enrolled in treatment (G3) (E4) | 62% | 100% | Annually | WHO Global TB database | Routine reporting | Numerator: total number of laboratory confirmed RR/MDR TB cases enrolled into SLD treatment inline with WHO recommendations Denominator: total number of laboratory confirmed RR/MDR TB cases notified WHO-HQ indicator 1 TB treatment coverage: number of new and relapse cases that were notified and treated, divided by the estimated number of incident TB cases in the same year, expressed as a percentage | Output |
| 1.C. 3 | TB treatment success rate (G2) | 75% | 85% | Annually | WHO Global TB database | Routine reporting | Numerator: new and relapse TB cases registered in a specified period that were successfully treated Denominator: total number of new and relapse TB cases registered in the same period WHO-HQ indicator 2 TB treatment success rate: percentage of notified TB patients who were successfully treated. The target is for drug-susceptible and drug-resistant TB combined, although outcomes should also be reported separately. | Outcome |

¹ Some of data for 'desk review' assessment are collected through routine reporting at European level and analysed in this report.

² Two indicators of 'MDR TB' in the 'Roadmap to implement the tuberculosis action plan for the WHO European Region 2016-2020' were updated to 'RR/MDR TB' in the follow-up process.

³ In this report analysed only for TB contacts (check the indicator 1.E.1).

⁴ End TB Strategy global indicators marked with (G) and WHO European Region indicators with (E).

⁵ Updated to RR/MDR TB compared to the original document (MDR TB); Roadmap to implement the tuberculosis action plan for the WHO European Region 2016-2020.

Annex 6: Monitoring framework for follow up of the TB Action Plan for the WHO European Region, 2016 – 2020, cont.


| Area of intervention | Indicator | Baseline for WHO European Region (2014) | Target | Frequency of assessment | Data source | Monitoring mechanism | Indicator definition | Input-impact level |
|--|--|---|----------|-------------------------|------------------------|--------------------------------------|---|--------------------|
| 1.C. 4 | RR/MDR TB treatment success rate (G2) (E5) | 49% | 75% | Annually | WHO Global TB database | Routine reporting | Numerator: number of confirmed RR/MDR TB cases during the specified period that were successfully treated Denominator: number of confirmed RR/MDR TB cases that started on a prescribed MDR TB treatment regimen during the specified period. WHO-HQ indicator 2b | Outcome |
| 1.C. 5 | TB mortality rate (ICD A15–19) (G10) (E6) | 4.1 | 2.7 | Annually | WHO Global TB database | Routine reporting | TB treatment success rate: percentage of notified TB patients who were successfully treated. The target is for drug-susceptible and drug-resistant TB combined, although outcomes should also be reported separately. Numerator: estimated number of TB deaths (from VRS) Denominator: total population/100 000 WHO-HQ indicator 10. Case fatality ratio (CFR): number of TB deaths (from a national VR system) divided by estimated number of incident cases in the same year, expressed as a percentage | Impact |
| 1.D Collaborative tuberculosis/HIV activities, and management of relevant comorbidities | | | | | | | | |
| 1.D. 1 | Percentage of detected out of estimated incident TB/HIV co-infected cases | 85% | 90% | Annually | WHO Global TB database | Routine reporting/ WHO estimation | Numerator: total number of registered HIV co-infected TB patients in a specified period Denominator: total number of estimated TB/HIV co-infected patients | Outcome |
| 1.D. 2 | HIV testing coverage (G9) (E7) | 68% | 100% | Annually | WHO Global TB database | Routine reporting | Numerator: total number of registered TB patients in a specified period with reported HIV status Denominator: total number of registered TB patients in the same period WHO-HQ indicator 9. Documentation of HIV status among TB patients: number of new and relapse TB patients with documented HIV status divided by the number of new and relapse TB patients notified in the same year, expressed as percentage | Process |
| 1.D. 3 | Percentage of HIV among all TB | 8% | Decrease | Annually | WHO Global TB database | Routine reporting | Numerator: total number of registered TB patients in a specified period who are HIV positive Denominator: total number of registered TB patients in the same period with documented HIV test results | Impact |
| 1.D. 4 | Percentage of TB/HIV patients enrolled in ART | 54% | 100% | Annually | WHO Global TB database | Routine reporting | Numerator: total number of registered TB/HIV patients in a specified period who are enrolled in antiretroviral therapy (ART) Denominator: total number of registered TB patients in the same period who are HIV positive | Output |
| 1.D. 5 | LTBI treatment coverage among PLHIV (G5a) | 5% | 30% | Annually | WHO Global TB database | Routine reporting | Numerator: total number of new HIV cases enrolled in LTBI treatment in a specified period Denominator: total number of new HIV cases eligible for LTBI treatment in the same period WHO-HQ indicator 5a (composed) LTBI treatment coverage: number of people living with HIV newly enrolled in HIV care started on LTBI treatment, divided by the number eligible for treatment, expressed as percentage | Output |
| 1.E Management of latent tuberculosis infection and preventive treatment of persons at high risk and vaccination against tuberculosis | | | | | | | | |
| 1.E. 1 | Contact investigation coverage (G2) (E7) | N/A | 90% | 2016 and 2020 | National TB Programme | Desk review/ routine reporting | Numerator: number of contacts of people with bacteriologically-confirmed TB who were investigated for TB/LTBI in a defined period Denominator: the number of contacts eligible for contact investigation in the same period WHO-HQ indicator 6 Contact investigation coverage: number of contacts of people with bacteriologically-confirmed TB who were investigated for TB divided by the number eligible, expressed as a percentage | Output |
| 1.E. 2 | LTBI treatment coverage of childhood TB contacts aged under 5 years (G5b) (E8) | N/A | 90% | 2016 and 2020 | | Desk review/ routine reporting | Numerator: total number of child TB contacts age 5 years enrolled in LTBI treatment in a defined period Denominator: number of child TB contact cases eligible for LTBI treatment in the same period WHO-HQ indicator 5b (composed) LTBI treatment coverage: number of children who are contacts of cases started on LTBI treatment, divided by the number eligible for treatment, expressed as percentage | Output |

* Some of data for 'desk review' assessment are collected through routine reporting at European level and analysed in this report.

Annex 6: Monitoring framework for follow up of the TB Action Plan for the WHO European Region, 2016 – 2020, cont.

| Area of intervention | Indicator | Baseline for WHO European Region (2014) | Target | Frequency of assessment | Data source | Monitoring mechanism ¹ | Indicator definition | Input-impact level |
|---|--|---|-------------|-------------------------|-----------------------|-----------------------------------|--|--------------------|
| 2. BOLD POLICIES AND SUPPORTIVE SYSTEMS | | | | | | | | |
| 2.A. Political commitment with adequate resources, including universal health coverage policy | | | | | | | | |
| 2.A. 1 | Number of Member States that have TB control/elimination performance publicly available (E8) | N/A | 53 | cumulative 2016–2020 | National TB Programme | Desk review | Not assessed for this publication | Output |
| 2.B. Health systems strengthening in all functions, including well-aligned financing mechanisms for tuberculosis and human resources² | | | | | | | | |
| 2.B. 1 | Percentage of TB-affected households that experience catastrophic costs due to TB (G3) (E9) | N/A | Close to 0 | annually | National TB Programme | Desk review | Percentage of TB-affected households that experience catastrophic costs due to TB: number of people treated for TB (and their households) who incur catastrophic costs (direct and indirect combined), divided by the total number of people treated for TB | Impact |
| 2.C. Regulatory frameworks for case-based surveillance, strengthening vital registration, quality and rational use of medicines, and pharmacovigilance | | | | | | | | |
| 2.C. 1 | Treatment coverage with new TB drugs (G8) (E9) ³ | N/A | 30% | cumulative 2016–2020 | National TB Programme | Desk review | Numerator: number of TB patients treated with regimens including new drugs Denominator: number of notified patients eligible for treatment with new TB drugs WHO-HQ indicator 3 Treatment coverage, new TB drugs Number of TB patients treated with regimens that include new TB drugs, divided by the number of notified patients eligible for treatment with new TB drugs, expressed as a percentage | Process |
| 2.D. Regulatory frameworks for case-based surveillance, strengthening vital registration, quality and rational use of medicines, and pharmacovigilance | | | | | | | | |
| 2.D. 1 | Number of Member States with functioning multi-stakeholder coalitions advocating for TB care and resources | N/A | 53 | cumulative 2016–2020 | National TB Programme | Desk review | Not defined yet | Output |
| 2.E. Social protection, poverty alleviation and actions on other determinants of tuberculosis, such as migration and prisons | | | | | | | | |
| 2.E. 1 | Treatment success rate (%) of new and relapsed TB cases among prisoners | 63.2% | 85.0% | annually | National TB Programme | Routine reporting | Numerator: new and relapse TB cases registered in a specified period that were successfully treated in prisons Denominator: total number of new and relapse TB cases registered in the same period in prisons | Impact |
| 3. INTENSIFIED RESEARCH AND INNOVATION | | | | | | | | |
| 3.A. Social protection, poverty alleviation and actions on other determinants of tuberculosis, such as migration and prisons | | | | | | | | |
| 3.A. 1 | European Tuberculosis Research Initiative established by mid 2016 | N/A | Established | cumulative 2016–2020 | National TB Programme | Desk review | Not defined yet | Output |

¹ Some of data for 'desk review' assessment are collected through routine reporting at European level and analysed in this report.² Data are not available for this report.



6. Tables

Summary table: Tuberculosis surveillance data by region, European Region, 2016

| | Table showing data by country | Region | | | | | | | |
|---|-------------------------------|--|--------------|--|--------------|--|--------------|--|--------------|
| | | EU/EEA | | Non-EU/EEA | | Total | | 18 High-Priority Countries (HPC) | |
| | | Number of reporting countries ^a | | Number of reporting countries ^a | | Number of reporting countries ^a | | Number of reporting countries ^a | |
| Total population (millions) | - | 30 | 515.8 | 23 | 402.5 | 53 | 916.3 | 18 | 400.9 |
| Estimates of TB disease burden 2016^b | | | | | | | | | |
| Estimated TB mortality rate (excluding HIV-related deaths) per 100 000 population | 1 | 30 | 0.8 | 23 | 5.5 | 53 | 2.8 | 18 | 5.7 |
| Estimated TB incidence rate per 100 000 population | 1 | 30 | 12.3 | 23 | 56.6 | 53 | 32.0 | 18 | 60.4 |
| TB mortality rate per 100 000 population | 1 | 30 | 0.8 | 23 | 5.5 | 53 | 2.8 | 18 | 5.7 |
| Estimated RR TB among all notified pulmonary TB cases | 1 | 30 | 1800 | 23 | 70 000 | 53 | 71 000 | 18 | 70 000 |
| Estimated proportion of HIV-infection among incident TB cases (new and relapses) | 2 | 30 | 5.9 | 23 | 13.1 | 53 | 12.0 | 18 | 12.5 |
| Notifications of TB cases, 2016 | | | | | | | | | |
| Total number of TB cases | 3 | 30 | 58 994 | 22 | 238 138 | 52 | 297 132 | 17 | 251 625 |
| All TB cases per 100 000 population | 3 | 30 | 11.4 | 22 | 59.2 | 52 | 32.8 | 17 | 64.2 |
| Mean annual % change of notification rate (2012-2016) | 3 | 30 | -4.5% | 20 | -6.1% | 50 | -5.3% | 17 | -5.6% |
| Number of new TB cases and relapses | 4 | 30 | 56 062 | 21 | 197 034 | 51 | 253 096 | 17 | 209 554 |
| New TB cases and relapses per 100 000 population | 4 | 30 | 10.9 | 21 | 48.9 | 51 | 28.0 | 17 | 53.5 |
| Mean annual % change of notification rate of new TB cases and relapses (2012-2016) | 4 | 30 | -4.3% | 20 | -5.1% | 50 | -4.4% | 17 | -4.7% |
| Percentage of new cases among all TB cases | 5 | 30 | 70.4% | 21 | 69.7% | 50 | 69.8% | 17 | 70.0% |
| Percentage of retreatment cases among all TB cases | 5 | 30 | 10.5% | 21 | 30.3% | 51 | 26.4% | 17 | 30.0% |
| Percentage of pulmonary TB among all TB cases | 6 | 30 | 76.3% | 21 | 70.7% | 51 | 71.8% | 17 | 71.5% |
| Percentage of bacteriologically-confirmed TB cases among all TB cases | 8 | 29 | 71.0% | - | - | - | - | - | - |
| Male-to-female ratio of new TB cases and relapse | 9 | 29 | 1.5 | 21 | 2.0 | 50 | 2.0 | 17 | 2.0 |
| Percentage of foreign TB cases among all TB cases | 10 | 30 | 32.7% | 20 | 2.0% | 50 | 8.2% | 17 | 1.6% |
| TB case confirmation, multidrug resistance (MDR) and extensive drug resistance (XDR), 2016 | | | | | | | | | |
| Percentage of laboratory-confirmed cases among new pulmonary TB cases ^c | 12 | 30 | 79.0% | 21 | 58.3% | 51 | 62.0% | 17 | 59.6% |
| Percentage of DST results reported among new bacteriologically confirmed pulmonary TB cases | 12 | 30 | 92.7% | 21 | 80.9% | 51 | 83.6% | 17 | 81.7% |
| Percentage of MDR TB among new pulmonary TB cases | 12 | 30 | 2.4% | 21 | 22.8% | 51 | 17.7% | 17 | 21.2% |
| Percentage of MDR TB among previously treated pulmonary TB cases | 12 | 30 | 15.0% | 21 | 55.4% | 51 | 51.9% | 17 | 53.5% |
| Percentage of DST results reported among all confirmed TB cases | 13 | 30 | 87.4% | - | - | - | - | - | - |
| Percentage of MDR TB among all TB cases | 13 | 30 | 3.7% | - | - | - | - | - | - |
| Percentage of XDR-TB among all MDR TB cases with DST for SLD ^d | 14 | 30 | 20.1% | 19 | 12.9% | 49 | 13.1% | 14 | 13.1% |
| TB-HIV coinfection, 2016 | | | | | | | | | |
| Percentage of new TB cases and relapses with known HIV status | 16 | 20 | 68.8% | 20 | 88.5% | 40 | 86.1% | 17 | 88.6% |
| Percentage of HIV-positive cases among new TB cases and relapses with known HIV status | 16 | 20 | 4.4% | 20 | 14.4% | 40 | 13.4% | 17 | 13.6% |
| Percentage of HIV-positive started at ART | 16 | 12 | 94.2% | 18 | 65.9% | 30 | 65.1% | 14 | 66.1% |
| Percentage of all TB cases with known HIV status | 16a | 20 | 69.0% | - | - | - | - | - | - |
| Percentage of HIV-positive cases among all TB cases with known HIV status | 16a | 20 | 4.5% | - | - | - | - | - | - |
| Treatment outcome | | | | | | | | | |
| Treatment success of all TB cases reported in 2015 | 18 | 24 | 71.5% | 21 | 76.3% | 45 | 75.3% | 18 | 76.4% |
| Treatment success of new TB cases and relapses notified in 2015 | 19 | 24 | 74.1% | 21 | 78.0% | 45 | 77.2% | 18 | 78.5% |
| Treatment success of childhood TB cases notified in 2015 | 20 | 21 | 86.7% | 17 | 93.5% | 38 | 91.9% | 15 | 93.6% |
| Treatment success of TB/HIV cases notified in 2015 | 21 | 15 | 62.2% | 20 | 62.2% | 35 | 62.2% | 16 | 62.4% |
| Treatment success of RR/MDR TB cases enrolled in SLD treatment in 2014 | 22 | 20 | 39.4% | 21 | 55.2% | 41 | 54.7% | 18 | 54.8% |
| Treatment success of all MDR TB cases notified in 2014 | 23 | 19 | 37.5% | - | - | - | - | - | - |
| Treatment success of all XDR TB cases notified in 2014 | 24 | 21 | 16.7% | 19 | 29.9% | 40 | 29.4% | 16 | 29.4% |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

HPC: 18 'high priority' countries to STOP TB in the WHO European Region: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine, Uzbekistan.

^b Number of countries with available data included in the statistics.

^c WHO estimates, as published in report: Global tuberculosis control 2016.

^d Laboratory-confirmed means confirmation according to EU case definition for EU/EEA countries and smear and/or culture confirmation for non-EU/EEA countries.

^e SLD: anti-TB treatment with second-line drugs.

Table 1: Estimates of the TB disease burden, European Region 2016

| Country | Population ^a | Estimated number of deaths from TB (all forms, excluding HIV) | | | | | | Estimated number of incident cases (all forms) | | | | | |
|--|-------------------------|---|---------------|---------------|-------------|------------|------------|--|----------------|----------------|--------------|--------------|--------------|
| | | Number | | | per 100 000 | | | Number | | | per 100 000 | | |
| | | Best | Low | High | Best | Low | High | Best | Low | High | Best | Low | High |
| EU/EEA | | | | | | | | | | | | | |
| Austria | 8 712 137 | 71 | 71 | 72 | 0.8 | 0.8 | 0.8 | 710 | 610 | 820 | 8.2 | 7.0 | 9.5 |
| Belgium | 11 358 379 | 42 | 41 | 43 | 0.4 | 0.4 | 0.4 | 1100 | 970 | 1300 | 10.0 | 8.5 | 12.0 |
| <i>Bulgaria</i> | <i>7 131 494</i> | <i>120</i> | <i>120</i> | <i>130</i> | <i>1.7</i> | <i>1.7</i> | <i>1.8</i> | <i>1900</i> | <i>1500</i> | <i>2400</i> | <i>27.0</i> | <i>20.0</i> | <i>34.0</i> |
| Croatia | 4 213 265 | 27 | 26 | 27 | 0.6 | 0.6 | 0.6 | 520 | 440 | 600 | 12.0 | 10.0 | 14.0 |
| Cyprus | 1 170 125 | 5 | 5 | 5 | 0.4 | 0.4 | 0.4 | 66 | 56 | 76 | 5.6 | 4.8 | 6.5 |
| Czech Republic | 10 610 947 | 57 | 56 | 57 | 0.5 | 0.5 | 0.5 | 530 | 450 | 610 | 5.0 | 4.3 | 5.8 |
| Denmark | 5 711 870 | 13 | 13 | 14 | 0.2 | 0.2 | 0.2 | 350 | 300 | 410 | 6.1 | 5.3 | 7.1 |
| <i>Estonia</i> | <i>1 312 442</i> | <i>16</i> | <i>16</i> | <i>16</i> | <i>1.2</i> | <i>1.2</i> | <i>1.2</i> | <i>220</i> | <i>180</i> | <i>250</i> | <i>16.0</i> | <i>14.0</i> | <i>19.0</i> |
| Finland | 5 503 132 | 31 | 30 | 31 | 0.6 | 0.5 | 0.6 | 260 | 220 | 300 | 4.7 | 4.0 | 5.4 |
| France | 64 720 690 | 410 | 390 | 430 | 0.6 | 0.6 | 0.7 | 5000 | 4400 | 5600 | 7.7 | 6.7 | 8.6 |
| Germany | 81 914 672 | 320 | 320 | 330 | 0.4 | 0.4 | 0.4 | 6600 | 5600 | 7600 | 8.1 | 6.9 | 9.3 |
| Greece | 11 183 716 | 55 | 53 | 57 | 0.5 | 0.5 | 0.5 | 490 | 420 | 570 | 4.4 | 3.7 | 5.1 |
| Hungary | 9 753 281 | 72 | 71 | 73 | 0.7 | 0.7 | 0.7 | 860 | 730 | 990 | 8.8 | 7.5 | 10.0 |
| Iceland | 332 474 | 2 | 2 | 2 | 0.6 | 0.6 | 0.6 | 7 | 6 | 8 | 2.1 | 1.8 | 2.4 |
| Ireland | 4 726 078 | 23 | 23 | 23 | 0.5 | 0.5 | 0.5 | 340 | 290 | 390 | 7.1 | 6.1 | 8.2 |
| Italy | 59 429 938 | 330 | 330 | 340 | 0.6 | 0.6 | 0.6 | 3700 | 3100 | 4200 | 6.1 | 5.3 | 7.1 |
| <i>Latvia</i> | <i>1 970 530</i> | <i>39</i> | <i>38</i> | <i>39</i> | <i>2.0</i> | <i>1.9</i> | <i>2.0</i> | <i>740</i> | <i>630</i> | <i>850</i> | <i>37.0</i> | <i>32.0</i> | <i>43.0</i> |
| Liechtenstein | - | - | - | - | - | - | - | - | - | - | - | - | - |
| <i>Lithuania</i> | <i>2 908 249</i> | <i>190</i> | <i>190</i> | <i>190</i> | <i>6.5</i> | <i>6.5</i> | <i>6.5</i> | <i>1500</i> | <i>1300</i> | <i>1800</i> | <i>53.0</i> | <i>46.0</i> | <i>62.0</i> |
| Luxembourg | 575 747 | 1 | 1 | 1 | 0.2 | 0.2 | 0.2 | 33 | 29 | 39 | 5.8 | 5.0 | 6.7 |
| Malta | 429 362 | 1 | 1 | 1 | 0.2 | 0.2 | 0.2 | 58 | 49 | 66 | 13.0 | 11.0 | 15.0 |
| Netherlands | 16 987 330 | 38 | 37 | 38 | 0.2 | 0.2 | 0.2 | 1000 | 860 | 1200 | 5.9 | 5.1 | 6.9 |
| Norway | 5 254 694 | 13 | 13 | 13 | 0.2 | 0.2 | 0.2 | 320 | 270 | 370 | 6.1 | 5.2 | 7.0 |
| Poland | 38 224 410 | 480 | 460 | 510 | 1.3 | 1.2 | 1.3 | 7100 | 6000 | 8200 | 18.0 | 16.0 | 21.0 |
| Portugal | 10 371 627 | 210 | 210 | 220 | 2.0 | 2.0 | 2.1 | 2100 | 1800 | 2400 | 20.0 | 17.0 | 23.0 |
| <i>Romania</i> | <i>19 778 083</i> | <i>1000</i> | <i>1000</i> | <i>1000</i> | <i>5.1</i> | <i>5.1</i> | <i>5.1</i> | <i>15000</i> | <i>13000</i> | <i>17000</i> | <i>74.0</i> | <i>64.0</i> | <i>86.0</i> |
| Slovakia | 5 444 218 | 35 | 34 | 35 | 0.6 | 0.6 | 0.6 | 320 | 280 | 370 | 5.9 | 5.1 | 6.9 |
| Slovenia | 2 077 862 | 13 | 13 | 13 | 0.6 | 0.6 | 0.6 | 140 | 120 | 160 | 6.5 | 5.6 | 7.5 |
| Spain | 46 347 576 | 280 | 280 | 290 | 0.6 | 0.6 | 0.6 | 4700 | 4000 | 5500 | 10.0 | 8.7 | 12.0 |
| Sweden | 9 837 533 | 25 | 25 | 25 | 0.3 | 0.3 | 0.3 | 810 | 690 | 930 | 8.2 | 7.0 | 9.5 |
| United Kingdom | 65 788 574 | 350 | 350 | 360 | 0.5 | 0.5 | 0.5 | 6500 | 5900 | 7200 | 9.9 | 8.9 | 11.0 |
| Subtotal EU/EEA | 513 780 435 | 4270 | 4220 | 4300 | 0.8 | 0.8 | 0.8 | 63000 | 60000 | 66000 | 12.3 | 11.7 | 12.8 |
| Non-EU/EEA | | | | | | | | | | | | | |
| Albania | 2 926 348 | 8 | 4 | 15 | 0.3 | 0.1 | 0.5 | 480 | 410 | 550 | 16 | 14 | 19 |
| Andorra | 77 281 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 5 | 4 | 5 | 6 | 5.1 | 6.9 |
| Armenia | 2 924 816 | 62 | 37 | 94 | 2.1 | 1.3 | 3.2 | 1300 | 980 | 1600 | 44.0 | 34.0 | 56.0 |
| <i>Azerbaijan</i> | <i>9 725 376</i> | <i>620</i> | <i>610</i> | <i>630</i> | <i>6.4</i> | <i>6.3</i> | <i>6.5</i> | <i>6400</i> | <i>4900</i> | <i>8200</i> | <i>66.0</i> | <i>51.0</i> | <i>84.0</i> |
| <i>Belarus</i> | <i>9 480 042</i> | <i>230</i> | <i>200</i> | <i>260</i> | <i>2.4</i> | <i>2.1</i> | <i>2.8</i> | <i>4900</i> | <i>3500</i> | <i>6500</i> | <i>52.0</i> | <i>37.0</i> | <i>69.0</i> |
| Bosnia and Herzegovina | 3 516 816 | 140 | 120 | 150 | 3.9 | 3.4 | 4.4 | 1100 | 870 | 1400 | 32 | 25 | 41 |
| former Yugoslav Republic of Macedonia, the | 2 081 206 | 20 | 20 | 21 | 1.0 | 1.0 | 1.0 | 330 | 250 | 420 | 16 | 12 | 20 |
| <i>Georgia</i> | <i>3 925 405</i> | <i>190</i> | <i>130</i> | <i>260</i> | <i>4.8</i> | <i>3.4</i> | <i>6.5</i> | <i>3600</i> | <i>3000</i> | <i>4300</i> | <i>92.0</i> | <i>77.0</i> | <i>109.0</i> |
| Israel | 8 191 828 | 15 | 15 | 16 | 0.2 | 0.2 | 0.2 | 290 | 250 | 330 | 4 | 3 | 4.1 |
| <i>Kazakhstan</i> | <i>17 987 736</i> | <i>440</i> | <i>400</i> | <i>480</i> | <i>2.4</i> | <i>2.2</i> | <i>2.7</i> | <i>12000</i> | <i>7700</i> | <i>17000</i> | <i>67.0</i> | <i>43.0</i> | <i>95.0</i> |
| <i>Kyrgyzstan</i> | <i>5 955 734</i> | <i>430</i> | <i>420</i> | <i>440</i> | <i>7.2</i> | <i>7.0</i> | <i>7.3</i> | <i>8700</i> | <i>7700</i> | <i>9600</i> | <i>145.0</i> | <i>130.0</i> | <i>162.0</i> |
| <i>Moldova</i> | <i>4 059 608</i> | <i>260</i> | <i>240</i> | <i>270</i> | <i>6.3</i> | <i>5.9</i> | <i>6.7</i> | <i>4100</i> | <i>3500</i> | <i>4700</i> | <i>101.0</i> | <i>87.0</i> | <i>117.0</i> |
| Monaco | 38 499 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Montenegro | 628 615 | 1 | 1 | 1 | 0.2 | 0.2 | 0.2 | 100 | 86 | 120 | 16 | 14 | 18 |
| <i>Russia</i> | <i>143 964 513</i> | <i>12 000</i> | <i>11 000</i> | <i>12 000</i> | <i>8.2</i> | <i>7.8</i> | <i>8.6</i> | <i>94 000</i> | <i>61 000</i> | <i>135 000</i> | <i>66.0</i> | <i>42.0</i> | <i>94.0</i> |
| San Marino | 33 203 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Serbia | 8 820 083 | 84 | 73 | 96 | 1.0 | 0.8 | 1.1 | 1700 | 1400 | 2000 | 19 | 16 | 22 |
| Switzerland | 8 401 739 | 20 | 20 | 21 | 0.2 | 0.2 | 0.3 | 660 | 560 | 760 | 8 | 6.7 | 9.1 |
| <i>Tajikistan</i> | <i>8 734 951</i> | <i>520</i> | <i>400</i> | <i>660</i> | <i>6.0</i> | <i>4.6</i> | <i>7.6</i> | <i>7500</i> | <i>5700</i> | <i>9400</i> | <i>85.0</i> | <i>65.0</i> | <i>108.0</i> |
| <i>Turkey</i> | <i>79 512 426</i> | <i>480</i> | <i>350</i> | <i>630</i> | <i>0.6</i> | <i>0.4</i> | <i>0.8</i> | <i>14 000</i> | <i>12 000</i> | <i>16 000</i> | <i>18.0</i> | <i>15.0</i> | <i>20.0</i> |
| <i>Turkmenistan</i> | <i>5 662 544</i> | <i>430</i> | <i>380</i> | <i>480</i> | <i>7.6</i> | <i>6.7</i> | <i>8.5</i> | <i>3400</i> | <i>2600</i> | <i>4300</i> | <i>60.0</i> | <i>46.0</i> | <i>76.0</i> |
| <i>Ukraine</i> | <i>44 438 625</i> | <i>4200</i> | <i>4200</i> | <i>4300</i> | <i>9.5</i> | <i>9.4</i> | <i>9.6</i> | <i>39 000</i> | <i>25 000</i> | <i>55 000</i> | <i>87.0</i> | <i>56.0</i> | <i>124.0</i> |
| <i>Uzbekistan</i> | <i>31 446 795</i> | <i>1900</i> | <i>1800</i> | <i>1900</i> | <i>5.9</i> | <i>5.9</i> | <i>5.9</i> | <i>24 000</i> | <i>17 000</i> | <i>32 000</i> | <i>76.0</i> | <i>53.0</i> | <i>103.0</i> |
| Subtotal non-EU/EEA | 402 534 189 | 22 000 | 21 000 | 23 000 | 5.5 | 5.2 | 5.7 | 228 000 | 188 000 | 268 000 | 56.6 | 46.7 | 66.6 |
| Total European Region | 916 314 624 | 26 000 | 25 000 | 27 000 | 2.8 | 2.8 | 2.9 | 290 000 | 251 000 | 333 000 | 32.0 | 27.3 | 36.3 |
| Subtotal 18 HPC | 400 919 369 | 23 000 | 22 000 | 24 000 | 5.7 | 5.5 | 6.0 | 242 000 | 202 000 | 282 000 | 60.4 | 50.4 | 70.3 |

^a 'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB high-priority countries presented in italics.

^a Population estimate 2016 by UN Statistical Database for all countries.

| | Estimated incidence of child TB cases | | | | | | Estimated incidence of TB among females | | | | | | Country | |
|--|---------------------------------------|--------------|--------------|-------------|-------------|-------------|---|--------------|---------------|-------------|-------------|-------------|---------|--|
| | Number | | | per 100 000 | | | Number | | | per 100 000 | | | | |
| | Best | Low | High | Best | Low | High | Best | Low | High | Best | Low | High | | |
| | | | | | | | | | | | | | | EU/EEA |
| | 62 | 53 | 71 | 5.0 | 4.3 | 5.8 | 240 | 200 | 280 | 5.4 | 4.5 | 6.3 | | Austria |
| | 100 | 89 | 120 | 5.2 | 4.6 | 6.2 | 380 | 320 | 440 | 6.6 | 5.5 | 7.6 | | Belgium |
| | 190 | 140 | 240 | 18.9 | 13.9 | 23.9 | 630 | 470 | 790 | 17.2 | 12.8 | 21.6 | | Bulgaria |
| | 49 | 41 | 56 | 7.9 | 6.6 | 9.0 | 180 | 150 | 210 | 8.2 | 6.9 | 9.6 | | Croatia |
| | 5 | 5 | 6 | 2.5 | 2.5 | 3.0 | 21 | 18 | 25 | 3.6 | 3.1 | 4.3 | | Cyprus |
| | 43 | 37 | 50 | 2.7 | 2.3 | 3.1 | 180 | 150 | 200 | 3.3 | 2.8 | 3.7 | | Czech Republic |
| | 30 | 26 | 35 | 3.2 | 2.7 | 3.7 | 120 | 99 | 130 | 4.2 | 3.4 | 4.5 | | Denmark |
| | 21 | 18 | 24 | 9.9 | 8.5 | 11.3 | 78 | 66 | 90 | 11.2 | 9.5 | 12.9 | | Estonia |
| | 23 | 20 | 27 | 2.6 | 2.2 | 3.0 | 87 | 74 | 100 | 3.1 | 2.6 | 3.6 | | Finland |
| | 460 | 400 | 520 | 3.9 | 3.4 | 4.4 | 2000 | 1700 | 2200 | 6.1 | 5.2 | 6.7 | | France |
| | 510 | 440 | 590 | 4.8 | 4.1 | 5.5 | 2200 | 1800 | 2500 | 5.3 | 4.3 | 6.0 | | Germany |
| | 37 | 31 | 42 | 2.3 | 1.9 | 2.6 | 160 | 140 | 190 | 2.8 | 2.5 | 3.3 | | Greece |
| | 93 | 79 | 110 | 6.6 | 5.6 | 7.9 | 300 | 260 | 350 | 5.9 | 5.1 | 6.8 | | Hungary |
| | 1 | 1 | 1 | 1.5 | 1.5 | 1.5 | 2 | 2 | 3 | 1.2 | 1.2 | 1.8 | | Iceland |
| | 35 | 30 | 41 | 3.4 | 2.9 | 4.0 | 110 | 96 | 130 | 4.6 | 4.0 | 5.5 | | Ireland |
| | 300 | 250 | 340 | 3.7 | 3.1 | 4.2 | 1300 | 1100 | 1500 | 4.3 | 3.6 | 4.9 | | Italy |
| | 79 | 67 | 91 | 26.3 | 22.3 | 30.3 | 270 | 230 | 310 | 25.3 | 21.6 | 29.1 | | Latvia |
| | - | - | - | - | - | - | - | - | - | - | - | - | | Liechtenstein |
| | 170 | 140 | 190 | 39.8 | 32.8 | 44.5 | 480 | 400 | 550 | 30.6 | 25.5 | 35.1 | | Lithuania |
| | 2 | 2 | 3 | 2.1 | 2.1 | 3.2 | 11 | 9 | 12 | 3.8 | 3.1 | 4.2 | | Luxembourg |
| | 5 | 5 | 6 | 8.1 | 8.1 | 9.7 | 19 | 16 | 22 | 8.9 | 7.5 | 10.3 | | Malta |
| | 83 | 71 | 96 | 2.9 | 2.5 | 3.4 | 330 | 280 | 380 | 3.9 | 3.3 | 4.5 | | Netherlands |
| | 28 | 24 | 33 | 3.0 | 2.6 | 3.5 | 100 | 88 | 120 | 3.8 | 3.4 | 4.6 | | Norway |
| | 690 | 590 | 800 | 12.2 | 10.4 | 14.1 | 2300 | 2000 | 2700 | 11.6 | 10.1 | 13.7 | | Poland |
| | 190 | 160 | 220 | 13.2 | 11.1 | 15.3 | 730 | 620 | 840 | 13.4 | 11.4 | 15.4 | | Portugal |
| | 1600 | 1400 | 1900 | 52.8 | 46.2 | 62.7 | 4800 | 4100 | 5500 | 47.1 | 40.2 | 54.0 | | Romania |
| | 31 | 27 | 36 | 3.7 | 3.2 | 4.3 | 110 | 94 | 130 | 3.9 | 3.4 | 4.6 | | Slovakia |
| | 12 | 10 | 14 | 3.9 | 3.2 | 4.5 | 45 | 38 | 52 | 4.3 | 3.6 | 5.0 | | Slovenia |
| | 420 | 350 | 480 | 6.1 | 5.1 | 7.0 | 1800 | 1600 | 2100 | 7.6 | 6.8 | 8.9 | | Spain |
| | 78 | 66 | 90 | 4.6 | 3.9 | 5.3 | 270 | 230 | 310 | 5.5 | 4.7 | 6.3 | | Sweden |
| | 630 | 570 | 700 | 5.4 | 4.9 | 6.0 | 2700 | 2400 | 3000 | 8.1 | 7.2 | 9.0 | | United Kingdom |
| | 5980 | 5670 | 6290 | 7.5 | 7.1 | 7.9 | 22000 | 21000 | 23000 | 8.4 | 8.0 | 8.8 | | Subtotal EU/EEA |
| | | | | | | | | | | | | | | Non-EU/EEA |
| | 46 | 39 | 53 | 8.9 | 7.5 | 10.2 | 160 | 130 | 180 | 0.0 | 9.0 | 12.4 | | Albania |
| | 0 | 0 | 1 | 0.0 | 0.0 | 19.0 | 2 | 1 | 2 | 5.7 | 2.8 | 5.7 | | Andorra |
| | 140 | 100 | 170 | 24.0 | 17.2 | 29.2 | 330 | 250 | 410 | 21.3 | 16.1 | 26.5 | | Armenia |
| | 760 | 570 | 940 | 33.7 | 25.3 | 41.7 | 2200 | 1600 | 2700 | 45.1 | 32.8 | 55.3 | | Azerbaijan |
| | 570 | 400 | 740 | 36.5 | 25.6 | 47.4 | 1500 | 1000 | 2000 | 29.6 | 19.7 | 39.5 | | Belarus |
| | 89 | 67 | 110 | 17.8 | 13.4 | 22.0 | 380 | 280 | 470 | 21.2 | 15.6 | 26.2 | | Bosnia and Herzegovina |
| | 33 | 25 | 41 | 9.4 | 7.2 | 11.7 | 110 | 82 | 140 | 10.6 | 7.9 | 13.5 | | former Yugoslav Republic of Macedonia, the |
| | 450 | 370 | 520 | 60.5 | 49.7 | 69.9 | 1200 | 1000 | 1500 | 58.5 | 48.7 | 73.1 | | Georgia |
| | 22 | 18 | 25 | 1.0 | 0.8 | 1.1 | 96 | 81 | 110 | 2.3 | 2.0 | 2.7 | | Israel |
| | 1200 | 740 | 1700 | 24.3 | 15.0 | 34.5 | 4600 | 2800 | 6400 | 49.6 | 30.2 | 69.0 | | Kazakhstan |
| | 1000 | 920 | 1100 | 53.3 | 49.0 | 58.6 | 3700 | 3300 | 4100 | 123.2 | 109.9 | 136.6 | | Kyrgyzstan |
| | 400 | 340 | 460 | 62.7 | 53.3 | 72.1 | 1200 | 1000 | 1400 | 56.9 | 47.4 | 66.3 | | Moldova |
| | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | | Monaco |
| | 11 | 9 | 12 | 9.6 | 7.8 | 10.5 | 34 | 29 | 39 | 10.7 | 9.1 | 12.2 | | Montenegro |
| | 10000 | 6100 | 14000 | 40.2 | 24.5 | 56.2 | 30000 | 18000 | 42000 | 38.9 | 23.4 | 54.5 | | Russia |
| | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | | San Marino |
| | 150 | 130 | 180 | 10.3 | 8.9 | 12.3 | 740 | 630 | 850 | 16.4 | 14.0 | 18.8 | | Serbia |
| | 59 | 50 | 68 | 4.7 | 4.0 | 5.5 | 220 | 190 | 250 | 5.2 | 4.5 | 5.9 | | Switzerland |
| | 830 | 620 | 1000 | 27.0 | 20.2 | 32.6 | 3400 | 2500 | 4200 | 78.2 | 57.5 | 96.6 | | Tajikistan |
| | 1500 | 1300 | 1700 | 7.5 | 6.5 | 8.5 | 6000 | 5100 | 6900 | 14.9 | 12.6 | 17.1 | | Turkey |
| | 390 | 290 | 490 | 22.3 | 16.6 | 28.1 | 1200 | 880 | 1500 | 41.7 | 30.6 | 52.2 | | Turkmenistan |
| | 4400 | 2700 | 6100 | 65.0 | 39.9 | 90.1 | 11000 | 6900 | 16000 | 46.0 | 28.9 | 67.0 | | Ukraine |
| | 2600 | 1800 | 3500 | 29.6 | 20.5 | 39.8 | 10000 | 6800 | 14000 | 63.4 | 43.1 | 88.8 | | Uzbekistan |
| | 25000 | 21000 | 29000 | 29.6 | 24.9 | 34.3 | 78000 | 65000 | 91000 | 37.2 | 31.0 | 43.4 | | Subtotal non-EU/EEA |
| | 31000 | 22000 | 41000 | 18.9 | 13.4 | 25.0 | 102000 | 73000 | 132000 | 21.6 | 15.5 | 28.0 | | Total European Region |
| | 26000 | 22000 | 30000 | 31.3 | 26.5 | 36.2 | 84000 | 71000 | 97000 | 40.1 | 33.9 | 46.3 | | Subtotal 18 HPC |

Table 2: Estimates for TB/HIV co-infection and MDR TB, European Region, 2016

| Country | Estimated HIV-infection among TB incidence (new and relapses) | | | | | | Estimated percentage of RR TB cases among new TB patients | | |
|--|---|--------------|--------------|-------------|-------------|-------------|---|-------------|-------------|
| | Number | | | % | | | Number | | |
| | Best | Low | High | Best | Low | High | Best | Low | High |
| EU/EEA | | | | | | | | | |
| Austria | 38 | 21 | 59 | 5.3 | 3.1 | 8.0 | 2.3 | 0.8 | 4.9 |
| Belgium | 89 | 73 | 110 | 7.8 | 7.0 | 8.7 | 1.6 | 0.7 | 3.3 |
| <i>Bulgaria</i> | 2 | 1 | 3 | 0.1 | 0.1 | 0.1 | 1.2 | 0.5 | 2.5 |
| Croatia | 3 | 2 | 5 | 0.7 | 0.4 | 1.0 | 0.0 | 0.0 | 1.4 |
| Cyprus | 2 | 1 | 4 | 3.6 | 2.0 | 5.5 | 0.0 | 0.0 | 10.0 |
| Czech Republic | 9 | 5 | 15 | 1.8 | 1.0 | 2.7 | 2.2 | 0.9 | 4.6 |
| Denmark | 11 | 8 | 13 | 3.0 | 2.4 | 3.6 | 1.9 | 0.5 | 4.9 |
| <i>Estonia</i> | 23 | 15 | 33 | 11.0 | 10.0 | 11.0 | 14.0 | 8.3 | 21.0 |
| Finland | 10 | 6 | 14 | 3.7 | 2.1 | 5.7 | 1.6 | 0.2 | 5.7 |
| France | 670 | 400 | 1000 | 14.0 | 8.3 | 20.0 | 1.0 | 0.7 | 1.5 |
| Germany | 350 | 200 | 540 | 5.3 | 3.1 | 8.1 | 2.2 | 0.8 | 4.8 |
| Greece | 39 | 22 | 60 | 7.9 | 4.7 | 12.0 | 1.5 | 0.0 | 8.0 |
| Hungary | 23 | 13 | 37 | 2.7 | 1.5 | 4.2 | 2.9 | 1.6 | 4.8 |
| Iceland | 0 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 60.0 |
| Ireland | 23 | 13 | 36 | 7.0 | 4.1 | 11.0 | 1.1 | 0.0 | 5.8 |
| Italy | 410 | 240 | 630 | 11.0 | 6.7 | 17.0 | 2.8 | 1.8 | 4.3 |
| <i>Latvia</i> | 91 | 77 | 110 | 12.0 | 12.0 | 13.0 | 7.6 | 5.2 | 11.0 |
| Liechtenstein | – | – | – | – | – | – | – | – | – |
| <i>Lithuania</i> | 50 | 42 | 59 | 3.2 | 3.0 | 3.5 | 12.0 | 10.0 | 15.0 |
| Luxembourg | 5 | 3 | 7 | 15.0 | 9.0 | 21.0 | 0.0 | 0.0 | 0.0 |
| Malta | 15 | 13 | 17 | 26.0 | 26.0 | 27.0 | 0.0 | 0.0 | 11.0 |
| Netherlands | 34 | 28 | 40 | 3.4 | 3.1 | 3.7 | 2.0 | 0.8 | 4.2 |
| Norway | 14 | 9 | 21 | 4.5 | 2.6 | 6.9 | 2.6 | 0.7 | 6.4 |
| Poland | 180 | 99 | 280 | 2.5 | 1.4 | 3.9 | 0.8 | 0.6 | 1.2 |
| Portugal | 290 | 240 | 340 | 14.0 | 13.0 | 15.0 | 1.0 | 0.5 | 1.7 |
| <i>Romania</i> | 370 | 310 | 430 | 2.5 | 2.3 | 2.7 | 2.8 | 2.4 | 3.3 |
| Slovakia | 0 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 2.6 |
| Slovenia | 1 | 1 | 2 | 0.8 | 0.7 | 0.9 | 0.0 | 0.0 | 3.9 |
| Spain | 340 | 290 | 410 | 7.3 | 6.7 | 8.0 | 4.2 | 2.9 | 5.8 |
| Sweden | 48 | 27 | 74 | 5.9 | 3.5 | 9.0 | 4.0 | 2.3 | 6.3 |
| United Kingdom | 560 | 330 | 850 | 8.5 | 5.1 | 13.0 | 1.4 | 1.0 | 2.0 |
| Subtotal EU/EEA | 3700 | 3220 | 4180 | 5.9 | 5.4 | 6.3 | 2.5 | 1.7 | 3.7 |
| Non-EU/EEA | | | | | | | | | |
| Albania | 6 | 4 | 9 | 1.2 | 0.7 | 1.8 | 2.3 | 0.6 | 5.8 |
| Andorra | 0 | 0 | 0 | – | – | – | 0.0 | 0.0 | 84.0 |
| Armenia | 74 | 48 | 110 | 5.7 | 5.5 | 6.0 | 11.0 | 8.0 | 14.0 |
| <i>Azerbaijan</i> | 130 | 83 | 180 | 2.0 | 1.8 | 2.2 | 13.0 | 10.0 | 16.0 |
| <i>Belarus</i> | 400 | 260 | 570 | 8.1 | 7.3 | 8.8 | 38.0 | 36.0 | 40.0 |
| Bosnia and Herzegovina | 2 | 1 | 3 | 0.2 | 0.1 | 0.3 | 0.0 | 0.0 | 0.7 |
| former Yugoslav Republic of Macedonia, the | 0 | 0 | 0 | 0.1 | 0.1 | 0.1 | 1.3 | 0.2 | 4.8 |
| <i>Georgia</i> | 77 | 64 | 91 | 2.1 | 2.0 | 2.3 | 11.0 | 9.3 | 12.0 |
| Israel | 21 | 13 | 30 | 7.2 | 7.0 | 7.4 | 7.4 | 3.5 | 14.0 |
| <i>Kazakhstan</i> | 580 | 370 | 820 | 4.7 | 4.5 | 4.8 | 26.0 | 25.0 | 28.0 |
| <i>Kyrgyzstan</i> | 280 | 250 | 320 | 3.3 | 3.1 | 3.5 | 27.0 | 25.0 | 29.0 |
| <i>Moldova</i> | 370 | 310 | 430 | 9.1 | 8.6 | 9.6 | 26.0 | 24.0 | 28.0 |
| Monaco | 0 | 0 | 0 | – | – | – | 2.4 | 1.6 | 3.2 |
| Montenegro | 0 | 0 | 0 | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 7.1 |
| <i>Russia</i> | 18000 | 12000 | 26000 | 19.0 | 18.0 | 21.0 | 27.0 | 27.0 | 28.0 |
| San Marino | 0 | 0 | 0 | – | – | – | 2.4 | 1.6 | 3.2 |
| Serbia | 10 | 6 | 14 | 0.6 | 0.3 | 1.0 | 1.1 | 0.5 | 2.2 |
| Switzerland | 68 | 40 | 100 | 10.0 | 6.2 | 15.0 | 3.2 | 1.3 | 6.4 |
| <i>Tajikistan</i> | 250 | 160 | 350 | 3.3 | 3.1 | 3.5 | 22.0 | 21.0 | 24.0 |
| <i>Turkey</i> | 92 | 77 | 110 | 0.7 | 0.6 | 0.7 | 2.9 | 2.5 | 3.4 |
| <i>Turkmenistan</i> | 180 | 84 | 310 | 5.3 | 2.6 | 8.8 | 14.0 | 11.0 | 17.0 |
| <i>Ukraine</i> | 8100 | 5200 | 12000 | 21.0 | 19.0 | 22.0 | 27.0 | 26.0 | 27.0 |
| <i>Uzbekistan</i> | 1200 | 800 | 1700 | 5.0 | 4.3 | 5.7 | 24.0 | 18.0 | 30.0 |
| Subtotal non-EU/EEA | 29800 | 22000 | 37000 | 13.1 | 11.7 | 13.8 | 22.0 | 15.0 | 29.0 |
| Total European Region | 34000 | 26000 | 42000 | 12.0 | 8.6 | 15.0 | 19.0 | 12.0 | 26.0 |
| Subtotal 18 HPC | 30300 | 23000 | 38000 | 12.5 | 11.4 | 13.5 | 22.0 | 15.0 | 29.0 |

'European Region' comprises the 53 countries of the WHO European Region. WHO European Region 18 TB high-priority countries presented in italics.

| | Estimated percentage of RR TB cases among retreated TB patient | | | Estimated RR TB cases among notified pulmonary TB patients | | | Country |
|--|--|-------------|-------------|--|--------------|--------------|--|
| | Number | | | Number | | | |
| | Best | Low | High | Best | Low | High | |
| | | | | | | | EU/EEA |
| | 18.0 | 3.8 | 43.0 | 16 | 6 | 26 | Austria |
| | 8.8 | 1.9 | 24.0 | 16 | 6 | 26 | Belgium |
| | 19.0 | 11.0 | 29.0 | 44 | 27 | 61 | Bulgaria |
| | 0.0 | 0.0 | 37.0 | 0 | 0 | 0 | Croatia |
| | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | Cyprus |
| | 12.0 | 2.4 | 30.0 | 13 | 3 | 22 | Czech Republic |
| | 4.5 | 0.1 | 23.0 | 1 | 0 | 4 | Denmark |
| | 54.0 | 25.0 | 81.0 | 34 | 23 | 45 | Estonia |
| | 0.0 | 0.0 | 46.0 | 3 | 0 | 6 | Finland |
| | 10.0 | 7.1 | 15.0 | 63 | 47 | 79 | France |
| | 23.0 | 16.0 | 30.0 | 160 | 85 | 240 | Germany |
| | 9.1 | 0.2 | 41.0 | 10 | 0 | 23 | Greece |
| | 8.1 | 3.3 | 16.0 | 30 | 17 | 43 | Hungary |
| | 0.0 | 0.0 | 0.0 | 0 | 0 | 4 | Iceland |
| | 0.0 | 0.0 | 31.0 | 2 | 0 | 6 | Ireland |
| | 13.0 | 7.7 | 21.0 | 110 | 76 | 150 | Italy |
| | 23.0 | 15.0 | 33.0 | 62 | 47 | 78 | Latvia |
| | - | - | - | - | - | - | Liechtenstein |
| | 47.0 | 41.0 | 53.0 | 260 | 240 | 290 | Lithuania |
| | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 | Luxembourg |
| | 0.0 | 0.0 | 0.0 | 0 | 0 | 4 | Malta |
| | 30.0 | 6.7 | 65.0 | 15 | 6 | 24 | Netherlands |
| | 5.9 | 0.2 | 29.0 | 6 | 1 | 10 | Norway |
| | 4.4 | 2.7 | 6.8 | 77 | 56 | 98 | Poland |
| | 6.9 | 2.8 | 14.0 | 19 | 10 | 27 | Portugal |
| | 17.0 | 16.0 | 19.0 | 730 | 670 | 790 | Romania |
| | 3.7 | 0.1 | 19.0 | 1 | 0 | 4 | Slovakia |
| | 0.0 | 0.0 | 71.0 | 0 | 0 | 0 | Slovenia |
| | 18.0 | 9.4 | 30.0 | 25 | 10 | 40 | Spain |
| | 16.0 | 3.4 | 40.0 | 23 | 13 | 32 | Sweden |
| | 3.4 | 1.1 | 7.9 | 58 | 39 | 78 | United Kingdom |
| | 14.0 | 9.8 | 21.3 | 1800 | 1680 | 1900 | Subtotal EU/EEA |
| | | | | | | | Non-EU/EEA |
| | 6.7 | 0.2 | 32.0 | 7 | 1 | 14 | Albania |
| | 0.0 | 0.0 | 0.0 | 0 | 0 | 3 | Andorra |
| | 47.0 | 40.0 | 55.0 | 180 | 160 | 210 | Armenia |
| | 39.0 | 37.0 | 42.0 | 1500 | 1400 | 1600 | Azerbaijan |
| | 72.0 | 68.0 | 75.0 | 1600 | 1500 | 1600 | Belarus |
| | 0.0 | 0.0 | 6.8 | 0 | 0 | 0 | Bosnia and Herzegovina |
| | 0.0 | 0.0 | 23.0 | 3 | 0 | 6 | former Yugoslav Republic of Macedonia, the |
| | 31.0 | 27.0 | 35.0 | 460 | 420 | 500 | Georgia |
| | 0.0 | 0.0 | 84.0 | 13 | 5 | 22 | Israel |
| | 44.0 | 42.0 | 46.0 | 3500 | 3400 | 3600 | Kazakhstan |
| | 60.0 | 57.0 | 63.0 | 2500 | 2400 | 2600 | Kyrgyzstan |
| | 56.0 | 51.0 | 60.0 | 1400 | 1300 | 1400 | Moldova |
| | 11.0 | 9.1 | 14.0 | 0 | 0 | 0 | Monaco |
| | 0.0 | 0.0 | 41.0 | 0 | 0 | 0 | Montenegro |
| | 65.0 | 65.0 | 66.0 | 47000 | 46000 | 47000 | Russia |
| | 11.0 | 9.1 | 14.0 | 0 | 0 | 0 | San Marino |
| | 4.7 | 1.3 | 11.0 | 19 | 8 | 29 | Serbia |
| | 26.0 | 9.1 | 51.0 | 22 | 11 | 34 | Switzerland |
| | 45.0 | 40.0 | 50.0 | 1200 | 1200 | 1300 | Tajikistan |
| | 16.0 | 13.0 | 19.0 | 350 | 300 | 390 | Turkey |
| | 38.0 | 28.0 | 49.0 | 450 | 390 | 520 | Turkmenistan |
| | 47.0 | 46.0 | 48.0 | 10000 | 10000 | 11000 | Ukraine |
| | 63.0 | 50.0 | 75.0 | 5800 | 4900 | 6600 | Uzbekistan |
| | 55.0 | 43.0 | 67.0 | 70000 | 69000 | 71000 | Subtotal non-EU/EEA |
| | 55.0 | 43.0 | 67.0 | 71000 | 71000 | 72000 | Total European Region |
| | 55.0 | 43.0 | 67.0 | 71000 | 69000 | 71000 | Subtotal 18 HPC |

Table 3: Tuberculosis cases, notification rates per 100 000 population and mean annual change in rates, European Region, 2012–2016

| Country | 2012 | | 2013 | | 2014 | | 2015 | | 2016 | | Mean annual % change in rate, 2012–2016 |
|--|---------------|-------------|---------------|-------------|---------------|-------------|---------------|-------------|---------------|-------------|---|
| | N | Rate | |
| EU/EEA | | | | | | | | | | | |
| Austria | 646 | 7.7 | 653 | 7.7 | 586 | 6.9 | 583 | 6.8 | 634 | 7.3 | -1.3% |
| Belgium | 976 | 8.8 | 963 | 8.6 | 949 | 8.5 | 977 | 8.7 | 1047 | 9.3 | 1.2% |
| Bulgaria | 2280 | 31.1 | 1932 | 26.5 | 1872 | 25.8 | 1660 | 23.0 | 1603 | 22.4 | -7.9% |
| Croatia ^a | 575 | 13.4 | 517 | 12.1 | 499 | 11.7 | 486 | 11.5 | 460 | 11.0 | -4.9% |
| Cyprus | 69 | 8.0 | 41 | 4.7 | 41 | 4.8 | 63 | 7.4 | 60 | 7.1 | -3.0% |
| Czech Republic | 597 | 5.7 | 497 | 4.7 | 511 | 4.9 | 517 | 4.9 | 516 | 4.9 | -3.7% |
| Denmark | 389 | 7.0 | 356 | 6.4 | 320 | 5.7 | 357 | 6.3 | 330 | 5.8 | -4.6% |
| Estonia | 289 | 21.8 | 290 | 22.0 | 248 | 18.8 | 217 | 16.5 | 192 | 14.6 | -9.6% |
| Finland | 274 | 5.1 | 273 | 5.0 | 263 | 4.8 | 272 | 5.0 | 236 | 4.3 | -4.0% |
| France ^b | 5003 | 7.7 | 4947 | 7.5 | 4888 | 7.4 | 4741 | 7.1 | 4958 | 7.4 | -0.8% |
| Germany | 4213 | 5.2 | 4340 | 5.4 | 4526 | 5.6 | 5852 | 7.2 | 5915 | 7.2 | 8.2% |
| Greece | 558 | 5.0 | 540 | 4.9 | 519 | 4.7 | 482 | 4.4 | 443 | 4.1 | -5.0% |
| Hungary | 1223 | 12.3 | 1045 | 10.5 | 851 | 8.6 | 906 | 9.2 | 786 | 8.0 | -10.2% |
| Iceland | 11 | 3.4 | 11 | 3.4 | 9 | 2.8 | 7 | 2.1 | 6 | 1.8 | -14.9% |
| Ireland | 359 | 7.8 | 374 | 8.1 | 311 | 6.8 | 294 | 6.4 | 318 | 6.7 | -3.7% |
| Italy | 4252 | 7.2 | 3973 | 6.7 | 3916 | 6.4 | 3769 | 6.2 | 4032 | 6.6 | -1.8% |
| Latvia | 993 | 48.6 | 904 | 44.7 | 761 | 38.0 | 721 | 36.3 | 660 | 33.5 | -8.9% |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 1781 | 59.3 | 1705 | 57.4 | 1607 | 54.6 | 1507 | 51.6 | 1442 | 49.9 | -4.2% |
| Luxembourg | 45 | 8.6 | 38 | 7.1 | 24 | 4.4 | 30 | 5.3 | 29 | 5.0 | -12.5% |
| Malta | 42 | 10.1 | 50 | 11.9 | 46 | 10.8 | 32 | 7.5 | 50 | 11.5 | 3.4% |
| Netherlands | 956 | 5.7 | 845 | 5.0 | 814 | 4.8 | 862 | 5.1 | 889 | 5.2 | -2.2% |
| Norway | 374 | 7.5 | 392 | 7.8 | 324 | 6.3 | 313 | 6.1 | 299 | 5.7 | -6.5% |
| Poland | 7542 | 19.8 | 7250 | 19.0 | 6698 | 17.6 | 6430 | 16.9 | 6444 | 17.0 | -3.8% |
| Portugal | 2606 | 24.7 | 2410 | 23.0 | 2278 | 21.8 | 2178 | 21.0 | 1836 | 17.8 | -7.9% |
| Romania | 18190 | 90.5 | 16689 | 83.4 | 15879 | 79.6 | 15183 | 76.4 | 13617 | 68.9 | -6.6% |
| Slovakia | 345 | 6.4 | 401 | 7.4 | 336 | 6.2 | 317 | 5.8 | 296 | 5.5 | -3.9% |
| Slovenia | 138 | 6.7 | 140 | 6.8 | 144 | 7.0 | 130 | 6.3 | 118 | 5.7 | -3.9% |
| Spain | 6070 | 13.0 | 5632 | 12.1 | 4914 | 10.6 | 4997 | 10.8 | 4877 | 10.5 | -5.1% |
| Sweden | 623 | 6.6 | 639 | 6.7 | 659 | 6.8 | 815 | 8.4 | 726 | 7.4 | 2.9% |
| United Kingdom | 8711 | 13.7 | 7868 | 12.3 | 7049 | 11.0 | 6234 | 9.6 | 6175 | 9.4 | -8.9% |
| Total EU/EEA countries | 70130 | 13.8 | 65715 | 12.9 | 61842 | 12.1 | 60932 | 11.9 | 58994 | 11.4 | -4.5% |
| Non-EU/EEA | | | | | | | | | | | |
| Albania | 420 | 14.6 | 474 | 16.5 | 408 | 14.2 | 415 | 14.4 | 415 | 14.2 | -0.6% |
| Andorra | 9 | 10.9 | 5 | 6.3 | 6 | 7.9 | 4 | 5.5 | 4 | 5.2 | -17.0% |
| Armenia | 1518 | 51.1 | 1417 | 47.6 | 1342 | 44.9 | 1104 | 36.7 | 1080 | 36.9 | -7.8% |
| Azerbaijan | 8140 | 88.2 | 8597 | 91.8 | 7539 | 79.4 | 7501 | 77.9 | 6707 | 69.0 | -6.0% |
| Belarus | 5246 | 55.3 | 4859 | 51.2 | 4274 | 45.0 | 4177 | 44.0 | 3598 | 38.0 | -9.0% |
| Bosnia and Herzegovina | 1420 | 37.1 | 1261 | 32.9 | 1196 | 31.3 | 1095 | 28.7 | 907 | 25.8 | -8.7% |
| former Yugoslav Republic of Macedonia, the | 355 | 17.2 | 323 | 15.6 | 285 | 13.8 | 284 | 13.7 | 267 | 12.8 | -7.0% |
| Georgia | 4974 | 118.5 | 4319 | 104.4 | 3850 | 94.3 | 3611 | 89.5 | 3330 | 84.8 | -8.0% |
| Israel | 509 | 6.7 | 308 | 4.0 | 361 | 4.6 | 280 | 3.5 | 250 | 3.1 | -17.9% |
| Kazakhstan | 21523 | 130.0 | 19857 | 118.0 | 15718 | 91.9 | 14631 | 84.2 | 12658 | 70.4 | -14.2% |
| Kyrgyzstan | 6916 | 124.5 | 7209 | 127.6 | 7423 | 129.2 | 7833 | 134.0 | 7995 | 134.2 | 1.9% |
| Moldova | 5341 | 131.0 | 5051 | 124.0 | 4636 | 113.8 | 4211 | 103.4 | 4134 | 101.8 | -6.1% |
| Monaco | 0 | – | 0 | – | 0 | – | 0 | 0.0 | 0 | 0.0 | – |
| Montenegro | 107 | 17.2 | 120 | 19.2 | 113 | 18.1 | 80 | 12.8 | 87 | 13.8 | -5.3% |
| Russia | 149921 | 104.7 | 142533 | 99.5 | 136168 | 95.0 | 130904 | 91.3 | 121046 | 84.1 | -5.3% |
| San Marino | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | – |
| Serbia | 1917 | 21.2 | 2127 | 23.7 | 1832 | 20.5 | 1658 | 18.6 | 1488 | 16.9 | -5.6% |
| Serbia excluding UN Administered Province of Kosovo ^c | 1215 | 16.9 | 1205 | 16.6 | 998 | 14.0 | 888 | 12.7 | 767 | 11.0 | -10.1% |
| UN Administered Province of Kosovo ^c | 702 | 38.7 | 922 | 50.2 | 834 | 44.8 | 770 | 41.8 | 721 | 38.8 | 0.1% |
| Switzerland | 463 | 5.8 | 526 | 6.6 | 473 | 5.8 | 564 | 6.9 | 609 | 7.2 | 5.5% |
| Tajikistan | 6929 | 89.4 | 6495 | 81.9 | 6260 | 77.2 | 6232 | 75.1 | 6241 | 71.4 | -5.4% |
| Turkey | 14691 | 20.0 | 13409 | 17.9 | 13378 | 17.6 | 12772 | 16.5 | 12417 | 15.6 | -6.0% |
| Turkmenistan | 3422 | 67.0 | 3675 | 71.0 | 2887 | 55.1 | 3309 | 62.3 | 2376 | – | – |
| Ukraine | 45569 | 100.2 | 48134 | 106.2 | 40302 | 89.2 | 35304 | 78.4 | 34088 | 76.7 | -6.5% |
| Uzbekistan | 16810 | 59.7 | 25168 | 88.0 | 22804 | 78.5 | 19055 | 64.7 | 18441 | 58.6 | -0.4% |
| Subtotal non-EU/EEA | 296200 | 76.1 | 295867 | 75.5 | 271255 | 69.2 | 255024 | 64.2 | 238138 | 59.2 | -6.1% |
| Total European Region | 366330 | 40.8 | 361582 | 40.4 | 333097 | 37.2 | 315956 | 34.8 | 297132 | 32.8 | -5.3% |
| Subtotal 18 HPC | 314533 | 80.8 | 312243 | 79.8 | 286948 | 72.9 | 269932 | 68.2 | 251625 | 64.2 | -5.6% |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB High Priority Countries are presented in *italics*.

Note 1: For TB cases and notification rates by country and year for the period 1995–2016, see <http://ecdc.europa.eu/en/data-tools/atlas/Pages/atlas.aspx>.

Note 2: The data published in this report might differ from figures in national reports due to different times of reporting. The deadline for correcting and updating the data used in this report in the joint database was 1 October 2017.

^a These data are subject to change as the national TB registry was under review when this report was being produced.

^b Provisional data for 2016 including overseas territories reported to WHO Global TB database.

^c In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 4: New TB cases and relapses, notification rates per 100 000 population and mean annual change in rates, European Region, 2012–2016

| Country | 2012 | | 2013 | | 2014 | | 2015 | | 2016 | | Mean annual % change in rate, 2012–2016 |
|--|---------------|-------------|---------------|-------------|---------------|-------------|---------------|-------------|---------------|-------------|---|
| | N | Rate | |
| EU/EEA | | | | | | | | | | | |
| Austria | 623 | 7.4 | 628 | 7.4 | 567 | 6.7 | 564 | 6.6 | 619 | 7.1 | -1.0% |
| Belgium | 898 | 8.1 | 890 | 8.0 | 878 | 7.9 | 919 | 8.2 | 986 | 8.7 | 1.8% |
| Bulgaria | 2212 | 30.2 | 1930 | 26.5 | 1825 | 25.2 | 1619 | 22.5 | 1525 | 21.3 | -8.3% |
| Croatia ^a | 539 | 12.6 | 511 | 12.0 | 498 | 11.7 | 484 | 11.5 | 449 | 10.7 | -4.0% |
| Cyprus | 65 | 7.5 | 41 | 4.7 | 39 | 4.5 | 63 | 7.4 | 57 | 6.7 | -2.8% |
| Czech Republic | 557 | 5.3 | 468 | 4.5 | 472 | 4.5 | 507 | 4.8 | 511 | 4.8 | -2.2% |
| Denmark | 342 | 6.1 | 330 | 5.9 | 293 | 5.2 | 320 | 5.7 | 292 | 5.1 | -4.4% |
| Estonia | 269 | 20.3 | 265 | 20.1 | 237 | 18.0 | 206 | 15.7 | 188 | 14.3 | -8.4% |
| Finland | 264 | 4.9 | 267 | 4.9 | 257 | 4.7 | 269 | 4.9 | 225 | 4.1 | -4.3% |
| France ^b | 5003 | 7.7 | 4947 | 7.5 | 4888 | 7.4 | 4447 | 6.7 | 4675 | 7.0 | -2.2% |
| Germany | 4038 | 5.0 | 4094 | 5.1 | 4352 | 5.4 | 5646 | 7.0 | 5737 | 7.0 | 8.6% |
| Greece | 520 | 4.7 | 494 | 4.5 | 484 | 4.4 | 438 | 4.0 | 407 | 3.8 | -5.3% |
| Hungary | 1182 | 11.9 | 1040 | 10.5 | 799 | 8.1 | 858 | 8.7 | 737 | 7.5 | -10.9% |
| Iceland | 11 | 3.4 | 11 | 3.4 | 9 | 2.8 | 7 | 2.1 | 6 | 1.8 | -14.9% |
| Ireland | 333 | 7.3 | 350 | 7.6 | 290 | 6.3 | 266 | 5.7 | 293 | 6.2 | -3.9% |
| Italy | 3512 | 5.9 | 3435 | 5.8 | 3663 | 6.0 | 3476 | 5.7 | 3778 | 6.2 | 1.3% |
| Latvia | 971 | 47.5 | 872 | 43.1 | 738 | 36.9 | 697 | 35.1 | 641 | 32.6 | -9.0% |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 1640 | 54.6 | 1573 | 52.9 | 1481 | 50.3 | 1395 | 47.8 | 1347 | 46.6 | -3.9% |
| Luxembourg | 45 | 8.6 | 38 | 7.1 | 24 | 4.4 | 30 | 5.3 | 29 | 5.0 | -12.5% |
| Malta | 41 | 9.8 | 50 | 11.9 | 45 | 10.6 | 32 | 7.5 | 50 | 11.5 | 4.1% |
| Netherlands | 934 | 5.6 | 828 | 4.9 | 805 | 4.8 | 846 | 5.0 | 877 | 5.2 | -1.9% |
| Norway | 340 | 6.8 | 354 | 7.0 | 300 | 5.9 | 281 | 5.4 | 278 | 5.3 | -6.0% |
| Poland | 7285 | 19.1 | 7043 | 18.5 | 6539 | 17.2 | 6237 | 16.4 | 6143 | 16.2 | -4.1% |
| Portugal | 2558 | 24.3 | 2356 | 22.5 | 2223 | 21.3 | 2137 | 20.6 | 1794 | 17.3 | -8.0% |
| Romania | 16764 | 83.4 | 15505 | 77.4 | 14834 | 74.4 | 14215 | 71.5 | 12790 | 64.7 | -6.1% |
| Slovakia | 344 | 6.4 | 398 | 7.4 | 320 | 5.9 | 308 | 5.7 | 281 | 5.2 | -5.0% |
| Slovenia | 138 | 6.7 | 139 | 6.8 | 142 | 6.9 | 129 | 6.3 | 118 | 5.7 | -3.9% |
| Spain | 5738 | 12.3 | 5328 | 11.4 | 4686 | 10.1 | 4791 | 10.3 | 4734 | 10.2 | -4.5% |
| Sweden | 591 | 6.2 | 603 | 6.3 | 625 | 6.5 | 776 | 8.0 | 702 | 7.1 | 3.4% |
| United Kingdom | 8171 | 12.9 | 7339 | 11.5 | 6587 | 10.2 | 5849 | 9.0 | 5793 | 8.9 | -8.9% |
| Total EU/EEA countries | 65928 | 12.9 | 62127 | 12.2 | 58900 | 11.5 | 57812 | 11.2 | 56062 | 10.9 | -4.3% |
| Non-EU/EEA | | | | | | | | | | | |
| Albania | 408 | 14.1 | 474 | 16.5 | 408 | 14.2 | 415 | 14.4 | 415 | 14.2 | 0.1% |
| Andorra | 9 | 10.9 | 5 | 6.3 | 6 | 7.9 | 4 | 5.5 | 4 | 5.2 | -17.0% |
| Armenia | 1213 | 40.9 | 1397 | 46.9 | 1329 | 44.4 | 1090 | 36.3 | 1027 | 35.1 | -3.7% |
| Azerbaijan | 6363 | 69.0 | 5860 | 62.6 | 5788 | 60.9 | 5456 | 56.7 | 5159 | 53.0 | -6.3% |
| Belarus | 4783 | 50.4 | 4470 | 47.1 | 3858 | 40.6 | 3765 | 39.6 | 3211 | 33.9 | -9.5% |
| Bosnia and Herzegovina | 1409 | 36.8 | 1261 | 32.9 | 1196 | 31.3 | 1092 | 28.6 | 907 | 25.8 | -8.5% |
| former Yugoslav Republic of Macedonia, the | 346 | 16.7 | 318 | 15.4 | 284 | 13.7 | 282 | 13.6 | 263 | 12.6 | -6.8% |
| Georgia | 3940 | 93.9 | 3434 | 83.0 | 3200 | 78.4 | 3152 | 78.1 | 2983 | 76.0 | -5.1% |
| Israel | 506 | 6.7 | 308 | 4.0 | 361 | 4.6 | 280 | 3.5 | 250 | 3.1 | -17.8% |
| Kazakhstan | 18006 | 108.8 | 18958 | 112.7 | 15244 | 89.1 | 14006 | 80.6 | 12322 | 68.5 | -10.9% |
| Kyrgyzstan | 6195 | 111.5 | 7075 | 125.3 | 6390 | 111.2 | 7027 | 120.3 | 7026 | 118.0 | 1.4% |
| Moldova | 4409 | 108.1 | 4485 | 110.1 | 4058 | 99.6 | 3608 | 88.6 | 3571 | 88.0 | -5.0% |
| Monaco | 0 | – | 0 | – | 0 | – | 0 | 0.0 | – | – | – |
| Montenegro | 98 | 15.7 | 119 | 19.1 | 113 | 18.1 | 80 | 12.8 | 87 | 13.8 | -3.2% |
| Russia | 105753 | 73.8 | 106053 | 74.0 | 102340 | 71.4 | 99590 | 69.4 | 92407 | 64.2 | -3.4% |
| San Marino | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | – |
| Serbia | 1872 | 20.7 | 2106 | 23.4 | 1818 | 20.3 | 1649 | 18.5 | 1472 | 16.7 | -5.3% |
| Serbia excluding UN Administered Province of Kosovo ^c | 1168 | 16.2 | 1161 | 16.2 | 984 | 13.8 | 879 | 12.5 | 755 | 10.8 | -9.5% |
| UN Administered Province of Kosovo ^c | 702 | 38.7 | 992 | 54.0 | 834 | 44.8 | 770 | 41.8 | 717 | 38.6 | -0.1% |
| Switzerland | 416 | 5.2 | 466 | 5.8 | 423 | 5.2 | 531 | 6.5 | 573 | 6.8 | 6.8% |
| Tajikistan | 6508 | 83.9 | 5576 | 70.3 | 5807 | 71.6 | 5894 | 71.0 | 5965 | 68.3 | -5.0% |
| Turkey | 14139 | 19.2 | 13170 | 17.6 | 13108 | 17.2 | 12550 | 16.2 | 12186 | 15.3 | -5.5% |
| Turkmenistan | 2937 | 57.5 | 3046 | 58.9 | 2570 | 49.0 | 3028 | 57.1 | 2104 | 37.2 | -10.3% |
| Ukraine | 40990 | 90.1 | 36510 | 80.6 | 31701 | 70.2 | 30151 | 67.0 | 29052 | 65.4 | -7.7% |
| Uzbekistan | 14832 | 52.7 | 20812 | 72.8 | 18345 | 63.2 | 16315 | 55.4 | 16050 | 51.0 | -0.8% |
| Subtotal non-EU/EEA | 235132 | 60.4 | 235903 | 60.2 | 218347 | 55.7 | 209965 | 52.9 | 197034 | 48.9 | -5.1% |
| Total European Region | 301060 | 33.5 | 298030 | 33.3 | 277247 | 31.0 | 267777 | 29.5 | 253096 | 28.0 | -4.4% |
| Subtotal 18 HPC | 251924 | 64.7 | 250991 | 64.1 | 232853 | 59.2 | 223764 | 56.6 | 209554 | 53.5 | -4.7% |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

Note: The data published in this report might differ from figures in national reports due to different times of reporting. The deadline for correcting and updating the data used in this report in the joint database was 1 October 2016.

^b These data are subject to change as the national TB registry was under review when this report was being produced.

^c Provisional data for 2016 including overseas territories.

^d In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 5: Tuberculosis cases by history of previous TB treatment, European Region, 2016

| Country | New | | Unknown previous TB history | | Previously treated | | | | | | | | All TB cases N | | | |
|--|---------------|------------------|-----------------------------|------------------|--------------------------|------------------|------------------------------|------------------|---------------------------|------------------|------------------------------|------------------|-------------------|--------------------------------|---------------|------------------|
| | N | (%) ^a | N | (%) ^a | Previously treated total | | Previous treatment completed | | Previous treatment failed | | Previous treatment defaulted | | | Other retreatment ^c | | |
| | N | (%) ^a | N | (%) ^a | N | (%) ^a | N | (%) ^b | N | (%) ^b | N | (%) ^b | N | (%) ^b | N | (%) ^b |
| EU/EEA | | | | | | | | | | | | | | | | |
| Austria | 449 | (70.8) | 151 | (23.8) | 34 | (5.4) | 19 | (55.9) | 0 | (0.0) | 0 | (0.0) | 15 | (44.1) | 634 | |
| Belgium ^c | 757 | (72.3) | 229 | (21.9) | 61 | (5.8) | – | – | – | – | – | – | 61 | (100.0) | 1047 | |
| Bulgaria | 1416 | (88.3) | 0 | (0.0) | 187 | (11.7) | 109 | (58.3) | 23 | (12.3) | 24 | (12.8) | 31 | (16.6) | 1603 | |
| Croatia ^d | 293 | (63.7) | 147 | (32.0) | 20 | (4.3) | 9 | (45.0) | 0 | (0.0) | 0 | (0.0) | 11 | (55.0) | 4460 | |
| Cyprus | 55 | (91.7) | 0 | (0.0) | 5 | (8.3) | 2 | (40.0) | 0 | (0.0) | 0 | (0.0) | 3 | (60.0) | 60 | |
| Czech Republic | 490 | (95.0) | 0 | (0.0) | 26 | (5.0) | 21 | (80.8) | 0 | (0.0) | 1 | (3.8) | 4 | (15.4) | 516 | |
| Denmark ^c | 292 | (88.5) | 0 | (0.0) | 38 | (11.5) | – | – | – | – | – | – | 38 | (100.0) | 330 | |
| Estonia | 167 | (87.0) | 0 | (0.0) | 25 | (13.0) | 21 | (84.0) | 1 | (4.0) | 3 | (12.0) | 0 | (0.0) | 192 | |
| Finland | 219 | (92.8) | 5 | (2.1) | 12 | (5.1) | 1 | (8.3) | 0 | (0.0) | 0 | (0.0) | 11 | (91.7) | 236 | |
| France ^e | 2441 | (49.2) | 2234 | (45.1) | 283 | (5.7) | – | – | – | – | – | – | – | – | 4958 | |
| Germany | 340 | (5.7) | 5249 | (88.7) | 326 | (5.5) | 148 | (45.4) | 1 | (0.3) | 54 | (16.6) | 123 | (37.7) | 5915 | |
| Greece | 385 | (86.9) | 22 | (5.0) | 36 | (8.1) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 36 | (100.0) | 443 | |
| Hungary | 677 | (86.1) | 0 | (0.0) | 109 | (13.9) | 60 | (55.0) | 0 | (0.0) | 31 | (28.4) | 18 | (16.5) | 786 | |
| Iceland | 6 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | – | 0 | – | 0 | – | 0 | – | 6 | |
| Ireland ^d | 216 | (67.9) | 77 | (24.2) | 25 | (7.9) | – | – | – | – | – | – | 25 | (100.0) | 318 | |
| Italy | 2943 | (73.0) | 835 | (20.7) | 254 | (6.3) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 254 | (100.0) | 4032 | |
| Latvia | 560 | (84.8) | 0 | (0.0) | 100 | (15.2) | 81 | (81.0) | 0 | (0.0) | 19 | (19.0) | 0 | (0.0) | 660 | |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| Lithuania | 1150 | (79.8) | 0 | (0.0) | 292 | (20.2) | 197 | (67.5) | 29 | (9.9) | 66 | (22.6) | 0 | (0.0) | 1442 | |
| Luxembourg | 1 | (3.4) | 28 | (96.6) | 0 | (0.0) | 0 | – | 0 | – | 0 | – | 0 | – | 29 | |
| Malta | 50 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | – | 0 | – | 0 | – | 0 | – | 50 | |
| Netherlands | 857 | (96.4) | 5 | (0.6) | 27 | (3.0) | 15 | (55.6) | 0 | (0.0) | 4 | (14.8) | 8 | (29.6) | 889 | |
| Norway ^c | 256 | (85.6) | 22 | (7.4) | 21 | (7.0) | – | – | – | – | – | – | 21 | (100.0) | 299 | |
| Poland | 5713 | (88.7) | 0 | (0.0) | 731 | (11.3) | 430 | (58.8) | 0 | (0.0) | 0 | (0.0) | 301 | (41.2) | 6444 | |
| Portugal | 1715 | (93.4) | 0 | (0.0) | 121 | (6.6) | 79 | (65.3) | 1 | (0.8) | 13 | (10.7) | 28 | (23.1) | 1836 | |
| Romania | 10741 | (78.9) | 0 | (0.0) | 2876 | (21.1) | 2049 | (71.2) | 404 | (14.0) | 423 | (14.7) | 0 | (0.0) | 13617 | |
| Slovakia | 257 | (86.8) | 0 | (0.0) | 39 | (13.2) | 24 | (61.5) | 3 | (7.7) | 0 | (0.0) | 12 | (30.8) | 296 | |
| Slovenia | 113 | (95.8) | 0 | (0.0) | 5 | (4.2) | 5 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 118 | |
| Spain | 2855 | (58.5) | 1879 | (38.5) | 143 | (2.9) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 143 | (100.0) | 4877 | |
| Sweden | 641 | (88.3) | 56 | (7.7) | 29 | (4.0) | 5 | (17.2) | 0 | (0.0) | 1 | (3.4) | 23 | (79.3) | 726 | |
| United Kingdom ^c | 5476 | (88.7) | 317 | (5.1) | 382 | (6.2) | – | – | – | – | – | – | 382 | (100.0) | 6175 | |
| Subtotal EU/EEA | 41531 | (70.4) | 11256 | (19.1) | 6207 | (10.5) | 3275 | (52.8) | 462 | (7.4) | 639 | (10.3) | 1548 | (24.9) | 58994 | |
| Non-EU/EEA | | | | | | | | | | | | | | | | |
| Albania | 405 | (97.6) | – | – | 10 | (2.4) | 10 | (100.0) | – | – | – | – | – | – | 415 | |
| Andorra | 4 | (100.0) | – | – | 0 | (0.0) | 0 | (0.0) | – | – | – | – | – | – | 4 | |
| Armenia | 818 | (75.7) | – | – | 262 | (24.3) | 209 | (79.8) | – | – | – | – | – | – | 1080 | |
| Azerbaijan | 3793 | (56.6) | – | – | 2914 | (43.4) | 1366 | (46.9) | – | – | – | – | – | – | 6707 | |
| Belarus | 2653 | (73.7) | – | – | 945 | (26.3) | 558 | (59.0) | – | – | – | – | – | – | 3598 | |
| Bosnia and Herzegovina | 829 | (91.4) | – | – | 78 | (8.6) | 78 | (100.0) | – | – | – | – | – | – | 907 | |
| former Yugoslav Republic of Macedonia, the | 243 | (91.0) | – | – | 24 | (9.0) | 20 | (83.3) | – | – | – | – | – | – | 267 | |
| Georgia | 2463 | (74.0) | – | – | 867 | (26.0) | 520 | (60.0) | – | – | – | – | – | – | 3330 | |
| Israel | 242 | (96.8) | – | – | 8 | (3.2) | 8 | (100.0) | – | – | – | – | – | – | 250 | |
| Kazakhstan | 9381 | (74.1) | – | – | 3277 | (25.9) | 2941 | (89.7) | – | – | – | – | – | – | 12658 | |
| Kyrgyzstan | 5702 | (71.3) | – | – | 2293 | (28.7) | 1324 | (57.7) | – | – | – | – | – | – | 7995 | |
| Moldova | 2846 | (68.8) | – | – | 1288 | (31.2) | 725 | (56.3) | – | – | – | – | – | – | 4134 | |
| Monaco | – | – | – | – | 0 | (0.0) | 0 | (0.0) | – | – | – | – | – | – | 0 | |
| Montenegro | 73 | (83.9) | – | – | 14 | (16.1) | 14 | (100.0) | – | – | – | – | – | – | 87 | |
| Russia | 78121 | (64.5) | – | – | 42925 | (35.5) | 14286 | (33.3) | – | – | – | – | – | – | 121046 | |
| San Marino | – | – | – | – | 0 | (0.0) | 0 | (0.0) | – | – | – | – | – | – | 0 | |
| Serbia | 1348 | (90.6) | – | – | 140 | (9.4) | 124 | (88.6) | – | – | – | – | – | – | 1488 | |
| Serbia excluding UN Administered Province of Kosovo ^f | 672 | (87.6) | – | – | 95 | (12.4) | 83 | (87.4) | – | – | – | – | – | – | 767 | |
| UN Administered Province of Kosovo ^f | 676 | (93.8) | – | – | 45 | (6.2) | 41 | (91.1) | – | – | – | – | – | – | 721 | |
| Switzerland | 573 | (94.1) | – | – | 36 | (5.9) | 0 | (0.0) | – | – | – | – | – | – | 609 | |
| Tajikistan | 5241 | (84.0) | – | – | 1000 | (16.0) | 724 | (72.4) | – | – | – | – | – | – | 6241 | |
| Turkey | 11442 | (92.1) | – | – | 975 | (7.9) | 744 | (76.3) | – | – | – | – | – | – | 12417 | |
| Turkmenistan | 1952 | (82.2) | – | – | 424 | (17.8) | 152 | (35.8) | – | – | – | – | – | – | 2376 | |
| Ukraine | 23316 | (68.4) | – | – | 10772 | (31.6) | 5736 | (53.2) | – | – | – | – | – | – | 34088 | |
| Uzbekistan | 14436 | (78.3) | – | – | 4005 | (21.7) | 1614 | (40.3) | – | – | – | – | – | – | 18441 | |
| Subtotal non-EU/EEA | 165881 | (69.7) | – | – | 72257 | (30.3) | 31153 | (43.1) | – | – | – | – | – | – | 238138 | |
| Total European Region | 207412 | (69.8) | 11256 | (3.8) | 78464 | (26.4) | 34428 | (43.9) | – | – | – | – | – | – | 297132 | |
| Subtotal 18 HPC | 176198 | (70.0) | – | – | 75427 | (30.0) | 33356 | (44.2) | – | – | – | – | – | – | 251625 | |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.
^b WHO European Region 18 TB high-priority countries presented in italics.

^c Percentage among all TB cases.

^d Percentage among previously treated TB cases.

^e Distribution by previous diagnosis.

^f These data are subject to change as the national TB registry was under review when this report was being produced.

^g Provisional data for 2016 including overseas territories.

^h In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 6: Tuberculosis cases by site of disease, European Region, 2016

| Country | Pulmonary | | | | | | Extrapulmonary | | No site reported | | Total |
|--|----------------|---------------|----------------------------|---------------|-----------------|---------------|----------------|---------------|------------------|---------------|---------------|
| | Pulmonary only | | Pulmonary + extrapulmonary | | Total pulmonary | | N | (%) | N | (%) | |
| | N | (%) | N | (%) | N | (%) | | | | | |
| EU/EEA | | | | | | | | | | | |
| Austria | 425 | (67.0) | 57 | (9.0) | 482 | (76.0) | 152 | (24.0) | 0 | (0.0) | 634 |
| Belgium | 586 | (56.0) | 129 | (12.3) | 715 | (68.3) | 332 | (31.7) | 0 | (0.0) | 1047 |
| Bulgaria | 1129 | (70.4) | 57 | (3.6) | 1186 | (74.0) | 417 | (26.0) | 0 | (0.0) | 1603 |
| Croatia ^a | 293 | (63.7) | 14 | (3.0) | 307 | (66.7) | 34 | (7.4) | 119 | (25.9) | 460 |
| Cyprus | 50 | (83.3) | 1 | (1.7) | 51 | (85.0) | 9 | (15.0) | 0 | (0.0) | 60 |
| Czech Republic | 420 | (81.4) | 26 | (5.0) | 446 | (86.4) | 70 | (13.6) | 0 | (0.0) | 516 |
| Denmark | 242 | (73.3) | 20 | (6.1) | 262 | (79.4) | 64 | (19.4) | 4 | (1.2) | 330 |
| Estonia | 146 | (76.0) | 31 | (16.1) | 177 | (92.2) | 15 | (7.8) | 0 | (0.0) | 192 |
| Finland | 175 | (74.2) | 0 | (0.0) | 175 | (74.2) | 61 | (25.8) | 0 | (0.0) | 236 |
| France ^b | - | - | 3319 | (66.9) | 3319 | (71.0) | 1356 | (27.3) | 283 | (5.7) | 4958 |
| Germany | 3784 | (64.0) | 613 | (10.4) | 4397 | (74.3) | 1468 | (24.8) | 50 | (0.8) | 5915 |
| Greece | 341 | (77.0) | 53 | (12.0) | 394 | (88.9) | 36 | (8.1) | 13 | (2.9) | 443 |
| Hungary | 742 | (94.4) | 15 | (1.9) | 757 | (96.3) | 29 | (3.7) | 0 | (0.0) | 786 |
| Iceland | 4 | (66.7) | 2 | (33.3) | 6 | (100.0) | 0 | (0.0) | 0 | (0.0) | 6 |
| Ireland | 177 | (55.7) | 34 | (10.7) | 211 | (66.4) | 97 | (30.5) | 10 | (3.1) | 318 |
| Italy | 2757 | (68.4) | 63 | (1.6) | 2820 | (69.9) | 1212 | (30.1) | 0 | (0.0) | 4032 |
| Latvia | 574 | (87.0) | 45 | (6.8) | 619 | (93.8) | 41 | (6.2) | 0 | (0.0) | 660 |
| Liechtenstein | - | - | - | - | - | - | - | - | - | - | - |
| Lithuania | 1327 | (92.0) | 0 | (0.0) | 1327 | (92.0) | 115 | (8.0) | 0 | (0.0) | 1442 |
| Luxembourg | 24 | (82.8) | 0 | (0.0) | 24 | (82.8) | 5 | (17.2) | 0 | (0.0) | 29 |
| Malta | 22 | (44.0) | 15 | (30.0) | 37 | (74.0) | 13 | (26.0) | 0 | (0.0) | 50 |
| Netherlands | 365 | (41.1) | 112 | (12.6) | 477 | (53.7) | 409 | (46.0) | 3 | (0.3) | 889 |
| Norway | 140 | (46.8) | 47 | (15.7) | 187 | (62.5) | 111 | (37.1) | 1 | (0.3) | 299 |
| Poland | 6085 | (94.4) | 31 | (0.5) | 6116 | (94.9) | 328 | (5.1) | 0 | (0.0) | 6444 |
| Portugal | 1145 | (62.4) | 157 | (8.6) | 1302 | (70.9) | 519 | (28.3) | 15 | (0.8) | 1836 |
| Romania | 10747 | (78.9) | 776 | (5.7) | 11523 | (84.6) | 2094 | (15.4) | 0 | (0.0) | 13617 |
| Slovakia | 202 | (68.2) | 51 | (17.2) | 253 | (85.5) | 43 | (14.5) | 0 | (0.0) | 296 |
| Slovenia | 80 | (67.8) | 23 | (19.5) | 103 | (87.3) | 15 | (12.7) | 0 | (0.0) | 118 |
| Spain | 3192 | (65.5) | 323 | (6.6) | 3515 | (72.1) | 1362 | (27.9) | 0 | (0.0) | 4877 |
| Sweden | 389 | (53.6) | 93 | (12.8) | 482 | (66.4) | 244 | (33.6) | 0 | (0.0) | 726 |
| United Kingdom | 2539 | (41.1) | 815 | (13.2) | 3354 | (54.3) | 2799 | (45.3) | 22 | (0.4) | 6175 |
| Subtotal EU/EEA | 38102 | (64.6) | 6922 | (11.7) | 45024 | (76.3) | 13450 | (22.8) | 520 | (0.9) | 58994 |
| Non-EU/EEA | | | | | | | | | | | |
| Albania | - | - | - | - | 301 | (72.5) | 114 | (27.5) | 0 | (0.0) | 415 |
| Andorra | - | - | - | - | 3 | (75.0) | 1 | (25.0) | 0 | (0.0) | 4 |
| Armenia | - | - | - | - | 829 | (76.8) | 198 | (18.3) | 53 | (4.9) | 1080 |
| Azerbaijan | - | - | - | - | 4122 | (61.5) | 1037 | (15.5) | 1548 | (23.1) | 6707 |
| Belarus | - | - | - | - | 2964 | (82.4) | 247 | (6.9) | 387 | (10.8) | 3598 |
| Bosnia and Herzegovina | - | - | - | - | 792 | (87.3) | 115 | (12.7) | 0 | (0.0) | 907 |
| former Yugoslav Republic of Macedonia, the | - | - | - | - | 211 | (79.0) | 52 | (19.5) | 4 | (1.5) | 267 |
| Georgia | - | - | - | - | 2371 | (71.2) | 612 | (18.4) | 347 | (10.4) | 3330 |
| Israel | - | - | - | - | 184 | (73.6) | 66 | (26.4) | 0 | (0.0) | 250 |
| Kazakhstan | - | - | - | - | 10927 | (86.3) | 1395 | (11.0) | 336 | (2.7) | 12658 |
| Kyrgyzstan | - | - | - | - | 5514 | (69.0) | 1512 | (18.9) | 969 | (12.1) | 7995 |
| Moldova | - | - | - | - | 3235 | (78.3) | 336 | (8.1) | 563 | (13.6) | 4134 |
| Monaco | - | - | - | - | - | - | - | - | 0 | - | 0 |
| Montenegro | - | - | - | - | 77 | (88.5) | 10 | (11.5) | 0 | (0.0) | 87 |
| Russia | - | - | - | - | 84066 | (69.4) | 8341 | (6.9) | 28639 | (23.7) | 121046 |
| San Marino | - | - | - | - | - | - | - | - | - | - | 0 |
| Serbia | - | - | - | - | 1206 | (81.0) | 266 | (17.9) | 16 | (1.1) | 1488 |
| Serbia excluding UN Administered Province of Kosovo ^c | - | - | - | - | 673 | (87.7) | 82 | (10.7) | 12 | (1.6) | 767 |
| UN Administered Province of Kosovo ^c | - | - | - | - | 533 | (73.9) | 184 | (25.5) | 4 | (0.6) | 721 |
| Switzerland | - | - | - | - | 402 | (66.0) | 171 | (28.1) | 36 | (5.9) | 609 |
| Tajikistan | - | - | - | - | 4368 | (70.0) | 1597 | (25.6) | 276 | (4.4) | 6241 |
| Turkey | - | - | - | - | 8044 | (64.8) | 4142 | (33.4) | 231 | (1.9) | 12417 |
| Turkmenistan | - | - | - | - | 1616 | (68.0) | 488 | (20.5) | 272 | (11.4) | 2376 |
| Ukraine | - | - | - | - | 26357 | (77.3) | 2695 | (7.9) | 5036 | (14.8) | 34088 |
| Uzbekistan | - | - | - | - | 10709 | (58.1) | 5341 | (29.0) | 2391 | (13.0) | 18441 |
| Subtotal non-EU/EEA | - | - | - | - | 168298 | (70.7) | 28736 | (12.1) | 41104 | (17.3) | 238138 |
| Total European Region | - | - | - | - | 213322 | (71.8) | 42186 | (14.2) | 41624 | (14.0) | 297132 |
| Subtotal 18 HPC | - | - | - | - | 179954 | (71.5) | 30623 | (12.2) | 41048 | (16.3) | 251625 |

^a "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^b These data are subject to change as the national TB registry was under review when this report was being produced.

^c Provisional data on new and relapse cases including overseas territories reported to WHO Global TB database.

^d In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 7: New and relapse pulmonary tuberculosis cases by diagnostic method, European Region, 2016

| Country | New ^a and relapse pulmonary tuberculosis cases | | | | | | | | Clinically diagnosed cases | | All pulmonary TB cases | |
|--|---|------------------|---|------------------|---|------------------|---|------------------|----------------------------|------------------|------------------------|---------------|
| | N | (%) ^b | Confirmed by culture, smear and/or nucleic acid amplification test ^b | | | | Confirmed by other bacteriological test | | | | | |
| | | | N | (%) ^c | Confirmed cases by WHO-recommended rapid diagnostics such as Xpert MTB/RIF ^d | | | | | | | |
| | N | (%) ^e | | | N | (%) ^e | N | (%) ^e | N | (%) ^f | | |
| EU/EEA | | | | | | | | | | | | |
| Austria | 470 | (97.5) | 401 | (85.3) | 15 | (3.7) | 386 | (96.3) | 69 | (14.7) | 482 | (76.0) |
| Belgium | 666 | (93.1) | 577 | (86.6) | 13 | (2.3) | 564 | (97.7) | 89 | (13.4) | 715 | (88.3) |
| Bulgaria | 1113 | (93.8) | 758 | (68.1) | 1 | (0.1) | 757 | (99.9) | 355 | (31.9) | 1186 | (74.0) |
| Croatia ^g | 297 | (96.7) | 188 | (63.3) | 0 | (0.0) | 188 | (100.0) | 109 | (36.7) | 307 | (66.7) |
| Cyprus | 48 | (94.1) | 37 | (77.1) | 0 | (0.0) | 37 | (100.0) | 11 | (22.9) | 51 | (85.0) |
| Czech Republic | 441 | (98.9) | 368 | (83.4) | 18 | (4.9) | 350 | (95.1) | 73 | (16.6) | 446 | (86.4) |
| Denmark | 232 | (88.5) | 187 | (80.6) | 0 | (0.0) | 187 | (100.0) | 45 | (19.4) | 262 | (79.4) |
| Estonia | 174 | (98.3) | 150 | (86.2) | 4 | (2.7) | 146 | (97.3) | 24 | (13.8) | 177 | (92.2) |
| Finland | 168 | (96.0) | 135 | (80.4) | 3 | (2.2) | 132 | (97.8) | 33 | (19.6) | 175 | (74.2) |
| France ^h | 3319 | (100.0) | 2338 | (70.4) | – | – | – | – | 981 | (29.6) | 3319 | (100.0) |
| Germany | 4248 | (96.6) | 3450 | (81.2) | 220 | (6.4) | 3230 | (93.6) | 798 | (18.8) | 4397 | (74.3) |
| Greece | 360 | (91.4) | 308 | (85.6) | 18 | (5.8) | 290 | (94.2) | 52 | (14.4) | 394 | (88.9) |
| Hungary | 708 | (93.5) | 385 | (54.4) | 0 | (0.0) | 385 | (100.0) | 323 | (45.6) | 757 | (96.3) |
| Iceland | 6 | (100.0) | 5 | (83.3) | 0 | (0.0) | 5 | (100.0) | 1 | (16.7) | 6 | (100.0) |
| Ireland | 193 | (91.5) | 163 | (84.5) | 0 | (0.0) | 163 | (100.0) | 30 | (15.5) | 211 | (66.4) |
| Italy | 2610 | (92.6) | 2387 | (91.5) | 0 | (0.0) | 2387 | (100.0) | 223 | (8.5) | 2820 | (69.9) |
| Latvia | 600 | (96.9) | 517 | (86.2) | 0 | (0.0) | 517 | (100.0) | 83 | (13.8) | 619 | (93.8) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 1232 | (92.8) | 1076 | (87.3) | 0 | (0.0) | 1076 | (100.0) | 156 | (12.7) | 1327 | (92.0) |
| Luxembourg | 24 | (100.0) | 22 | (91.7) | 0 | (0.0) | 22 | (100.0) | 2 | (8.3) | 24 | (82.8) |
| Malta | 37 | (100.0) | 33 | (89.2) | 0 | (0.0) | 33 | (100.0) | 4 | (10.8) | 37 | (74.0) |
| Netherlands | 470 | (98.5) | 356 | (75.7) | 0 | (0.0) | 356 | (100.0) | 114 | (24.3) | 477 | (53.7) |
| Norway | 173 | (92.5) | 150 | (86.7) | 2 | (1.3) | 148 | (98.7) | 23 | (13.3) | 187 | (62.5) |
| Poland | 5820 | (95.2) | 4369 | (75.1) | 72 | (1.6) | 4297 | (98.4) | 1451 | (24.9) | 6116 | (94.9) |
| Portugal | 1269 | (97.5) | 1113 | (87.7) | 30 | (2.7) | 1083 | (97.3) | 156 | (12.3) | 1302 | (70.9) |
| Romania | 10706 | (92.9) | 8791 | (82.1) | 35 | (0.4) | 8756 | (99.6) | 1915 | (17.9) | 11523 | (84.6) |
| Slovakia | 238 | (94.1) | 143 | (60.1) | 22 | (15.4) | 121 | (84.6) | 95 | (39.9) | 253 | (85.5) |
| Slovenia | 103 | (100.0) | 96 | (93.2) | 0 | (0.0) | 96 | (100.0) | 7 | (6.8) | 103 | (87.3) |
| Spain | 3399 | (96.7) | 2918 | (85.8) | 106 | (3.6) | 2812 | (96.4) | 481 | (14.2) | 3515 | (72.1) |
| Sweden | 463 | (96.1) | 411 | (88.8) | 8 | (1.9) | 403 | (98.1) | 52 | (11.2) | 482 | (66.4) |
| United Kingdom | 3133 | (93.4) | 2472 | (78.9) | 10 | (0.4) | 2462 | (99.6) | 661 | (21.1) | 3354 | (54.3) |
| Subtotal EU/EEA | 42720 | (94.9) | 34304 | (80.3) | 577 | (1.7) | 31389 | (91.5) | 8416 | (18.7) | 45024 | (80.3) |
| Non-EU/EEA | | | | | | | | | | | | |
| Albania | 301 | – | 207 | (68.8) | – | – | – | – | 94 | (31.2) | – | – |
| Andorra | 3 | – | 2 | (66.7) | – | – | – | – | 1 | (33.3) | – | – |
| Armenia | 829 | – | 438 | (52.8) | – | – | – | – | 391 | (47.2) | – | – |
| Azerbaijan | 4122 | – | 2529 | (61.4) | – | – | – | – | 1593 | (38.6) | – | – |
| Belarus | 2964 | – | 2350 | (79.3) | – | – | – | – | 614 | (20.7) | – | – |
| Bosnia and Herzegovina | 792 | – | 597 | (75.4) | – | – | – | – | 195 | (24.6) | – | – |
| former Yugoslav Republic of Macedonia, the | 211 | – | 178 | (84.4) | – | – | – | – | 33 | (15.6) | – | – |
| Georgia | 2371 | – | 1998 | (84.3) | – | – | – | – | 373 | (15.7) | – | – |
| Israel | 184 | – | 132 | (71.7) | – | – | – | – | 52 | (28.3) | – | – |
| Kazakhstan | 10927 | – | 9679 | (88.6) | – | – | – | – | 1248 | (11.4) | – | – |
| Kyrgyzstan | 5514 | – | 3183 | (57.7) | – | – | – | – | 2331 | (42.3) | – | – |
| Moldova | 3235 | – | 2019 | (62.4) | – | – | – | – | 1216 | (37.6) | – | – |
| Monaco | – | – | – | – | – | – | – | – | 0 | – | – | – |
| Montenegro | 77 | – | 58 | (75.3) | – | – | – | – | 19 | (24.7) | – | – |
| Russia | 84066 | – | 42681 | (50.8) | – | – | – | – | 41385 | (49.2) | – | – |
| San Marino | – | – | – | – | – | – | – | – | 0 | – | – | – |
| Serbia | 1206 | – | 815 | (67.6) | – | – | – | – | 391 | (32.4) | – | – |
| Serbia excluding UN Administered Province of Kosovo ⁱ | 673 | – | 541 | (80.4) | – | – | – | – | 132 | (19.6) | – | – |
| UN Administered Province of Kosovo ⁱ | 533 | – | 274 | (51.4) | – | – | – | – | 259 | (48.6) | – | – |
| Switzerland | 402 | – | 362 | (90.0) | – | – | – | – | 40 | (10.0) | – | – |
| Tajikistan | 4368 | – | 3011 | (68.9) | – | – | – | – | 1357 | (31.1) | – | – |
| Turkey | 8044 | – | 6334 | (78.7) | – | – | – | – | 1710 | (21.3) | – | – |
| Turkmenistan | 1616 | – | 1616 | (100.0) | – | – | – | – | 0 | (0.0) | – | – |
| Ukraine | 26357 | – | 18125 | (68.8) | – | – | – | – | 8232 | (31.2) | – | – |
| Uzbekistan | 10709 | – | 4854 | (45.3) | – | – | – | – | 5855 | (54.7) | – | – |
| Subtotal non-EU/EEA | 168298 | – | 101168 | (60.1) | – | – | – | – | 67130 | (39.9) | – | – |
| Total European Region | 211018 | – | 135472 | (64.2) | 577 | – | 31389 | – | 75546 | (35.8) | 45024 | – |
| Subtotal 18 HPC | 178947 | – | 110109 | (61.5) | 40 | – | 11252 | – | 68838 | (38.5) | 14832 | – |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.
^b WHO European Region 18 TB high-priority countries presented in italics.

^c Cases with unknown previous TB history are included among new TB cases.

^d Microscopy results from any specimen are included for EU/EEA countries.

^e Percentage among pulmonary TB cases.

^f All nucleic acid amplification tests are counted as 'confirmed by WHO-recommended rapid diagnostics' for EU/EEA member states.

^g Percentage among confirmed new and relapse pulmonary TB cases.

^h Percentage among all TB cases.

ⁱ These data are subject to change as the national TB registry was under review when this report was being produced.

^j Provisional data on new and relapse cases including overseas territories reported to WHO Global TB database.

^k In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 7a: New and relapse tuberculosis cases by diagnostic method, European Region, 2016

| Country | New ^a and relapse pulmonary tuberculosis cases | | | | | | | | Clinically diagnosed cases | | All pulmonary TB cases |
|--|---|------------------|--|------------------|---|------------------|---|------------------|----------------------------|---------------|------------------------|
| | N | (%) ^b | Confirmed by culture, smear and/or nucleic acid amplification test | | | | Confirmed by other bacteriological test | | | | |
| | | | N | (%) ^c | Confirmed cases by WHO-recommended rapid diagnostics such as Xpert MTB/RIF ^d | | | | | | |
| | N | (%) ^e | | | N | (%) ^e | N | (%) ^e | | | |
| EU/EEA | | | | | | | | | | | |
| Austria | 619 | (97.6) | 525 | (82.8) | 319 | (50.3) | 206 | (32.5) | 94 | (14.8) | 634 |
| Belgium | 986 | (94.2) | 808 | (77.2) | 473 | (45.2) | 335 | (32.0) | 178 | (17.0) | 1047 |
| <i>Bulgaria</i> | 1525 | (95.1) | 781 | (48.7) | 6 | (0.4) | 775 | (48.3) | 744 | (46.4) | 1603 |
| Croatia ^f | 449 | (97.6) | 256 | (55.7) | 0 | – | 256 | (55.7) | 193 | (42.0) | 460 |
| Cyprus | 57 | (95.0) | 40 | (66.7) | 4 | (6.7) | 36 | (60.0) | 17 | (28.3) | 60 |
| Czech Republic | 511 | (99.0) | 419 | (81.2) | 204 | (39.5) | 215 | (41.7) | 92 | (17.8) | 516 |
| Denmark | 292 | (88.5) | 235 | (71.2) | 118 | (35.8) | 117 | (35.5) | 57 | (17.3) | 330 |
| <i>Estonia</i> | 188 | (97.9) | 156 | (81.3) | 143 | (74.5) | 13 | (6.8) | 32 | (16.7) | 192 |
| Finland | 225 | (95.3) | 187 | (79.2) | 62 | (26.3) | 125 | (53.0) | 38 | (16.1) | 236 |
| France ^g | – | – | – | – | – | – | – | – | – | – | – |
| Germany | 5737 | (97.0) | 4545 | (76.8) | 3161 | (53.4) | 1384 | (23.4) | 1192 | (20.2) | 5915 |
| Greece | 407 | (91.9) | 333 | (75.2) | 163 | (36.8) | 170 | (38.4) | 74 | (16.7) | 443 |
| Hungary | 737 | (93.8) | 393 | (50.0) | 0 | – | 393 | (50.0) | 344 | (43.8) | 786 |
| Iceland | 6 | (100.0) | 5 | (83.3) | 5 | (83.3) | 0 | (0.0) | 1 | (16.7) | 6 |
| Ireland | 293 | (92.1) | 227 | (71.4) | 112 | (35.2) | 115 | (36.2) | 66 | (20.8) | 318 |
| Italy | – | – | – | – | – | – | – | – | – | – | – |
| <i>Latvia</i> | 641 | (97.1) | 541 | (82.0) | 0 | (0.0) | 541 | (82.0) | 100 | (15.2) | 660 |
| Liechtenstein | – | – | – | – | – | – | – | – | 0 | – | – |
| <i>Lithuania</i> | 1347 | (93.4) | 1106 | (76.7) | 0 | (0.0) | 1106 | (76.7) | 241 | (16.7) | 1442 |
| Luxembourg | 29 | (100.0) | 26 | (89.7) | 0 | (0.0) | 26 | (89.7) | 3 | (10.3) | 29 |
| Malta | 50 | (100.0) | 42 | (84.0) | 17 | (0.0) | 25 | (50.0) | 8 | (16.0) | 50 |
| Netherlands | 877 | (98.7) | 589 | (66.3) | 0 | (0.0) | 589 | (66.3) | 288 | (32.4) | 889 |
| Norway | 278 | (93.0) | 225 | (75.3) | 132 | (44.1) | 93 | (31.1) | 53 | (17.7) | 299 |
| Poland | 6143 | (95.3) | 4528 | (70.3) | 888 | (13.8) | 3640 | (56.5) | 1615 | (25.1) | 6444 |
| Portugal | 1794 | (97.7) | 1312 | (71.5) | 284 | (15.5) | 1028 | (56.0) | 482 | (26.3) | 1836 |
| <i>Romania</i> | 12790 | (93.9) | 9143 | (67.1) | 689 | (5.1) | 8454 | (62.1) | 3647 | (26.8) | 13617 |
| Slovakia | 281 | (94.9) | 147 | (49.7) | 58 | (19.6) | 89 | (30.1) | 134 | (45.3) | 296 |
| Slovenia | 118 | (100.0) | 109 | (92.4) | 61 | (51.7) | 48 | (40.7) | 9 | (7.6) | 118 |
| Spain | 4734 | (97.1) | 3723 | (76.3) | 941 | (19.3) | 2782 | (57.0) | 1011 | (20.7) | 4877 |
| Sweden | 702 | (96.7) | 591 | (81.4) | 463 | (63.8) | 128 | (17.6) | 111 | (15.3) | 726 |
| United Kingdom | 5793 | (93.8) | 3874 | (62.7) | 298 | (4.8) | 3576 | (57.9) | 1919 | (31.1) | 6175 |
| Subtotal EU/EEA | 47 609 | (95.2) | 34 866 | (73.2) | 8 601 | (24.7) | 26 265 | (75.3) | 12 743 | (25.5) | 50 004 |
| Non-EU/EEA | | | | | | | | | | | |
| Albania | 415 | (100.0) | 207 | (49.9) | – | – | – | – | 94 | (22.7) | 415 |
| Andorra | 4 | (100.0) | 2 | (50.0) | – | – | – | – | 1 | (25.0) | 4 |
| Armenia | 1027 | (95.1) | 438 | (40.6) | – | – | – | – | 391 | (36.2) | 1080 |
| <i>Azerbaijan</i> | 5159 | (76.9) | 2529 | (37.7) | – | – | – | – | 1593 | (23.8) | 6707 |
| Belarus | 3211 | (89.2) | 2350 | (65.3) | – | – | – | – | 614 | (17.1) | 3598 |
| Bosnia and Herzegovina | 907 | (100.0) | 597 | (65.8) | – | – | – | – | 195 | (21.5) | 907 |
| former Yugoslav Republic of Macedonia, the | 263 | (98.5) | 178 | (66.7) | – | – | – | – | 33 | (12.4) | 267 |
| <i>Georgia</i> | 2983 | (89.6) | 1998 | (60.0) | – | – | – | – | 373 | (11.2) | 3330 |
| Israel | 250 | (100.0) | 132 | (52.8) | – | – | – | – | 52 | (20.8) | 250 |
| <i>Kazakhstan</i> | 12322 | (97.3) | 9679 | (76.5) | – | – | – | – | 1248 | (9.9) | 12658 |
| <i>Kyrgyzstan</i> | 7026 | (87.9) | 3183 | (39.8) | – | – | – | – | 2331 | (29.2) | 7995 |
| <i>Moldova</i> | 3571 | (86.4) | 2019 | (48.8) | – | – | – | – | 1216 | (29.4) | 4134 |
| Monaco | – | – | – | – | – | – | – | – | – | – | 0 |
| Montenegro | 87 | (100.0) | 58 | (66.7) | – | – | – | – | 19 | (21.8) | 87 |
| <i>Russia</i> | 92407 | (76.3) | 42 681 | (35.3) | – | – | – | – | 41 385 | (34.2) | 121 046 |
| San Marino | – | (0.0) | 0 | (0.0) | – | – | – | – | 0 | (0.0) | 0 |
| Serbia | 1472 | (98.9) | 815 | (54.8) | – | – | – | – | 391 | (26.3) | 1488 |
| Serbia excluding UN Administered Province of Kosovo ^h | 755 | (98.4) | 541 | (70.5) | – | – | – | – | 132 | (17.2) | 767 |
| UN Administered Province of Kosovo ^h | 717 | (99.4) | 274 | (38.0) | – | – | – | – | 259 | (35.9) | 721 |
| Switzerland | 573 | (94.1) | 362 | (59.4) | – | – | – | – | 40 | (6.6) | 609 |
| <i>Tajikistan</i> | 5965 | (95.6) | 3011 | (48.2) | – | – | – | – | 1357 | (21.7) | 6241 |
| <i>Turkey</i> | 12186 | (98.1) | 6334 | (51.0) | – | – | – | – | 1710 | (13.8) | 12417 |
| <i>Turkmenistan</i> | 2104 | (88.6) | 1616 | (68.0) | – | – | – | – | 0 | (0.0) | 2376 |
| <i>Ukraine</i> | 29052 | (85.2) | 18125 | (53.2) | – | – | – | – | 8232 | (24.1) | 34 088 |
| <i>Uzbekistan</i> | 16050 | (87.0) | 4854 | (26.3) | – | – | – | – | 5855 | (31.7) | 18441 |
| Subtotal non-EU/EEA | 197 034 | (82.7) | 101 168 | (51.3) | – | – | – | – | 67 130 | (28.2) | 238 138 |
| Total European Region | 244 643 | (84.9) | 136 034 | (55.6) | 8 601 | – | 26 265 | – | 79 873 | (27.7) | 288 142 |
| Subtotal 18 HPC | 209 554 | (83.3) | 110 544 | (52.8) | 838 | – | 10 889 | – | 71 069 | (28.2) | 251 625 |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

^b WHO European Region 18 TB high-priority countries presented in italics.

^c Cases with unknown previous TB history are included among new TB cases.

^d Microscopy results from any specimen are included for EU/EEA countries.

^e Percentage among pulmonary TB cases.

^f All nucleic acid amplification tests are counted as 'confirmed by WHO-recommended rapid diagnostics' for EU/EEA member states.

^g Percentage among confirmed new and relapse pulmonary TB cases.

^h These data are subject to change as the national TB registry was under review when this report was being produced.

ⁱ Provisional data on new and relapse cases including overseas territories reported to WHO Global TB database.

^j In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 8: Tuberculosis cases according to EU case definition, EU/EEA, 2016

| Country | All laboratory-confirmed cases ^a | | | | | | Confirmed cases ^b | | Probable cases | | Possible cases | | All tuberculosis cases (N) |
|----------------------|---|------------------|-----------------------|------------------|-----------------------|------------------|------------------------------|------------------|----------------|------------------|----------------|------------------|----------------------------|
| | Sputum smear-positive and nucleic-acid-test-positive only | | Culture-positive only | | Meeting both criteria | | | | | | | | |
| | N | (%) ^c | N | (%) ^c | N | (%) ^c | N | (%) ^d | N | (%) ^d | N | (%) ^d | |
| Austria | 15 | (3.1) | 344 | (70.3) | 130 | (26.6) | 489 | (77.1) | 56 | (8.8) | 89 | (14.0) | 634 |
| Belgium | 6 | (0.7) | 551 | (68.8) | 244 | (30.5) | 801 | (76.5) | 111 | (10.6) | 135 | (12.9) | 1047 |
| <i>Bulgaria</i> | 0 | (0.0) | 764 | (100.0) | 0 | (0.0) | 764 | (47.7) | 123 | (7.7) | 716 | (44.7) | 1603 |
| Croatia ^e | 0 | (0.0) | 262 | (100.0) | 0 | (0.0) | 262 | (57.0) | 0 | (0.0) | 198 | (43.0) | 460 |
| Cyprus | 1 | (2.4) | 40 | (95.2) | 1 | (2.4) | 42 | (70.0) | 3 | (5.0) | 15 | (25.0) | 60 |
| Czech Republic | 3 | (0.8) | 288 | (73.5) | 101 | (25.8) | 392 | (76.0) | 56 | (10.9) | 68 | (13.2) | 516 |
| Denmark | 2 | (0.8) | 161 | (62.4) | 95 | (36.8) | 258 | (78.2) | 2 | (0.6) | 70 | (21.2) | 330 |
| <i>Estonia</i> | 2 | (1.3) | 68 | (43.6) | 86 | (55.1) | 156 | (81.3) | 11 | (5.7) | 25 | (13.0) | 192 |
| Finland | 0 | (0.0) | 168 | (90.3) | 18 | (9.7) | 186 | (78.8) | 20 | (8.5) | 30 | (12.7) | 236 |
| France ^g | – | – | – | – | – | – | 4197 | (84.7) | – | – | 761 | (15.3) | 4958 |
| Germany | 65 | (1.6) | 3013 | (72.4) | 1086 | (26.1) | 4164 | (70.4) | 514 | (8.7) | 1237 | (20.9) | 5915 |
| Greece | 41 | (16.7) | 149 | (60.6) | 56 | (22.8) | 246 | (55.5) | 107 | (24.2) | 90 | (20.3) | 443 |
| Hungary | 0 | (0.0) | 404 | (100.0) | 0 | (0.0) | 404 | (51.4) | 22 | (2.8) | 360 | (45.8) | 786 |
| Iceland | 0 | (0.0) | 0 | (0.0) | 5 | (100.0) | 5 | (83.3) | 1 | (16.7) | 0 | (0.0) | 6 |
| Ireland | 0 | (0.0) | 191 | (80.3) | 47 | (19.7) | 238 | (74.8) | 26 | (7.5) | 55 | (17.6) | 318 |
| Italy ^f | 0 | (0.0) | 3261 | (100.0) | 0 | (0.0) | 3261 | (80.9) | 141 | (3.5) | 630 | (15.6) | 4032 |
| <i>Latvia</i> | 0 | (0.0) | 559 | (100.0) | 0 | (0.0) | 559 | (84.7) | 32 | (4.8) | 69 | (10.5) | 660 |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Lithuania</i> | 0 | (0.0) | 1201 | (100.0) | 0 | (0.0) | 1201 | (83.3) | 6 | (0.4) | 235 | (16.3) | 1442 |
| Luxembourg | 0 | (0.0) | 26 | (100.0) | 0 | (0.0) | 26 | (89.7) | 0 | (0.0) | 3 | (10.3) | 29 |
| Malta | 0 | (0.0) | 29 | (69.0) | 13 | (31.0) | 42 | (84.0) | 0 | (0.0) | 8 | (16.0) | 50 |
| Netherlands | 0 | (0.0) | 583 | (100.0) | 0 | (0.0) | 583 | (65.6) | 54 | (6.1) | 252 | (28.3) | 889 |
| Norway | 2 | (0.9) | 162 | (70.1) | 67 | (29.0) | 231 | (77.3) | 13 | (4.3) | 55 | (18.4) | 299 |
| Poland | 0 | (0.0) | 4057 | (87.8) | 562 | (12.2) | 4619 | (71.7) | 123 | (1.9) | 1702 | (26.4) | 6444 |
| Portugal | 20 | (1.8) | 989 | (88.1) | 114 | (10.2) | 1123 | (61.2) | 381 | (20.8) | 332 | (18.1) | 1836 |
| <i>Romania</i> | 7 | (0.1) | 8962 | (94.2) | 548 | (5.8) | 9517 | (69.9) | 896 | (6.6) | 3204 | (23.5) | 13617 |
| Slovakia | 4 | (3.4) | 94 | (80.3) | 19 | (16.2) | 117 | (39.5) | 52 | (17.6) | 127 | (42.9) | 296 |
| Slovenia | 0 | (0.0) | 62 | (56.9) | 47 | (43.1) | 109 | (92.4) | 5 | (4.2) | 4 | (3.4) | 118 |
| Spain ^f | 65 | (1.9) | 2903 | (86.1) | 404 | (12.0) | 3372 | (69.1) | 620 | (12.7) | 885 | (18.1) | 4877 |
| Sweden | 0 | (0.0) | 474 | (79.4) | 123 | (20.6) | 597 | (82.2) | 32 | (4.4) | 97 | (13.4) | 726 |
| United Kingdom | 9 | (0.2) | 3746 | (95.9) | 152 | (3.9) | 3907 | (63.3) | 483 | (7.8) | 1785 | (28.9) | 6175 |
| Total EU/EEA | 242 | (0.6) | 33511 | (80.0) | 3918 | (9.4) | 41868 | (71.0) | 3888 | (6.6) | 13237 | (22.4) | 58994 |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. EU/EEA countries designated as high-priority countries by WHO are presented in italics.

^b Laboratory-confirmed TB cases according to EU case definition.

^c Confirmed by microscopy and nucleic acid amplification or culture.

^d Percentage among all laboratory-confirmed TB cases.

^e Percentage among all TB cases.

^f These data are subject to change as the national TB registry was under review when this report was being produced.

^g Data reported to TESSy may differ from numbers reported to TME by French, Italian and Spanish National Reference Laboratories.

^h Provisional data for 2016 including overseas territories reported to WHO Global TB database.

Table 9: New TB cases and relapses by age group and male-to-female ratio, European Region, 2016^a

| Country | 0-4 | | | | 5-14 | | | | 15-24 | | | | 25-44 | | | |
|--|-------------|--------------|------------|------------|-------------|--------------|-------------|------------|--------------|---------------|-------------|------------|---------------|---------------|-------------|------------|
| | N | (%) | Rate | M:F ratio | N | (%) | Rate | M:F ratio | N | (%) | Rate | M:F ratio | N | (%) | Rate | M:F ratio |
| EU/EEA | | | | | | | | | | | | | | | | |
| Austria | 19 | (3.1) | 4.6 | 1.4 | 12 | (1.9) | 1.4 | 3.0 | 138 | (22.3) | 13.6 | 3.3 | 186 | (30.0) | 8.0 | 1.7 |
| Belgium | 26 | (2.6) | 4.1 | 1.4 | 31 | (3.1) | 2.4 | 2.1 | 159 | (16.1) | 12.0 | 1.4 | 378 | (38.3) | 12.8 | 1.8 |
| Bulgaria | 30 | (2.0) | 9.0 | 1.1 | 94 | (6.2) | 14.2 | 0.9 | 101 | (6.6) | 14.7 | 1.1 | 477 | (31.3) | 23.5 | 2.1 |
| Croatia ^b | 0 | (0.0) | 0.0 | – | 6 | (1.3) | 1.5 | 0.5 | 20 | (4.5) | 4.2 | 0.4 | 96 | (21.4) | 8.6 | 2.4 |
| Cyprus | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 7 | (12.3) | 6.0 | 0.8 | 36 | (63.2) | 14.0 | 1.4 |
| Czech Republic | 10 | (2.0) | 1.8 | 1.5 | 0 | (0.0) | 0.0 | – | 28 | (5.5) | 2.7 | 1.3 | 152 | (29.7) | 4.8 | 2.7 |
| Denmark | 6 | (2.1) | 2.0 | 5.0 | 12 | (4.1) | 1.8 | 0.3 | 37 | (12.7) | 5.0 | 2.1 | 117 | (40.1) | 8.2 | 1.9 |
| Estonia | 2 | (1.1) | 2.8 | N/M | 2 | (1.1) | 1.4 | N/M | 5 | (2.7) | 3.7 | 0.7 | 51 | (27.1) | 13.6 | 2.9 |
| Finland | 1 | (0.4) | 0.3 | N/F | 5 | (2.2) | 0.8 | 0.3 | 40 | (17.8) | 6.2 | 1.7 | 57 | (25.3) | 4.2 | 1.1 |
| France ^c | 127 | (2.7) | 3.2 | 1.4 | 142 | (3.0) | 1.7 | 1.2 | 618 | (13.2) | 7.9 | 2.1 | 1730 | (37.0) | 10.4 | 2.1 |
| Germany | 104 | (1.8) | 2.9 | 1.0 | 126 | (2.2) | 1.7 | 1.3 | 1456 | (25.4) | 16.6 | 3.5 | 2005 | (34.9) | 9.8 | 2.0 |
| Greece | 8 | (2.0) | 1.7 | 7.0 | 12 | (2.9) | 1.1 | 1.0 | 36 | (8.8) | 3.3 | 5.0 | 111 | (27.3) | 3.8 | 2.1 |
| Hungary | 3 | (0.4) | 0.7 | N/F | 3 | (0.4) | 0.3 | N/F | 39 | (5.3) | 3.5 | 1.3 | 151 | (20.5) | 5.3 | 1.1 |
| Iceland | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 4 | (66.7) | 4.4 | 3.0 |
| Ireland | 4 | (1.4) | 1.1 | 0.3 | 12 | (4.1) | 1.8 | 1.0 | 28 | (9.6) | 5.3 | 1.2 | 120 | (41.0) | 8.5 | 2.0 |
| Italy | 73 | (1.9) | 2.8 | 1.5 | 77 | (2.0) | 1.3 | 1.1 | 702 | (18.6) | 11.9 | 3.7 | 1326 | (35.1) | 8.5 | 1.8 |
| Latvia | 10 | (1.6) | 9.7 | 0.7 | 13 | (2.0) | 6.6 | 1.6 | 32 | (5.0) | 16.0 | 1.3 | 251 | (39.2) | 46.3 | 2.2 |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 12 | (0.9) | 7.9 | 2.0 | 35 | (2.6) | 12.9 | 1.3 | 85 | (6.3) | 23.7 | 1.1 | 446 | (33.1) | 60.1 | 2.4 |
| Luxembourg | 0 | (0.0) | 0.0 | – | 1 | (3.4) | 1.6 | N/F | 3 | (10.3) | 4.4 | N/F | 11 | (37.9) | 6.3 | 4.5 |
| Malta | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 11 | (22.0) | 20.8 | 2.7 | 35 | (70.0) | 28.1 | 2.9 |
| Netherlands | 18 | (2.1) | 2.1 | 1.3 | 31 | (3.5) | 1.6 | 0.6 | 167 | (19.0) | 8.0 | 1.5 | 340 | (38.8) | 8.1 | 1.5 |
| Norway | 4 | (1.4) | 1.3 | 1.0 | 10 | (3.6) | 1.6 | 1.5 | 67 | (24.1) | 10.0 | 2.4 | 126 | (45.3) | 8.8 | 0.9 |
| Poland | 30 | (0.5) | 1.6 | 0.9 | 73 | (1.2) | 1.9 | 1.0 | 250 | (4.1) | 5.7 | 1.2 | 1555 | (25.3) | 13.4 | 2.1 |
| Portugal | 20 | (1.1) | 4.6 | 0.8 | 13 | (0.7) | 1.3 | 0.6 | 154 | (8.6) | 13.9 | 1.1 | 520 | (29.0) | 18.8 | 1.4 |
| Romania | 180 | (1.4) | 18.9 | 1.2 | 416 | (3.3) | 19.7 | 1.0 | 1515 | (11.8) | 70.1 | 1.2 | 4378 | (34.2) | 76.6 | 2.0 |
| Slovakia | 44 | (15.7) | 15.4 | 0.9 | 16 | (5.7) | 2.9 | 0.6 | 8 | (2.8) | 1.3 | 7.0 | 56 | (19.9) | 3.3 | 1.8 |
| Slovenia | 2 | (1.7) | 1.9 | 1.0 | 1 | (0.8) | 0.5 | N/M | 6 | (5.1) | 3.0 | 1.0 | 21 | (17.8) | 3.6 | 2.5 |
| Spain | 135 | (2.9) | 6.1 | 1.0 | 132 | (2.8) | 2.7 | 0.9 | 389 | (8.2) | 8.7 | 1.4 | 1605 | (33.9) | 11.9 | 1.4 |
| Sweden | 11 | (1.6) | 1.9 | 0.8 | 46 | (6.6) | 4.1 | 1.6 | 236 | (33.6) | 20.0 | 5.1 | 248 | (35.3) | 9.7 | 1.6 |
| United Kingdom | 98 | (1.7) | 2.4 | 1.1 | 126 | (2.2) | 1.7 | 0.8 | 702 | (12.1) | 8.7 | 1.4 | 2524 | (43.6) | 14.6 | 1.5 |
| Subtotal EU/EEA | 977 | (1.7) | 3.7 | 1.1 | 1447 | (2.6) | 2.7 | 1.0 | 7039 | (12.6) | 12.3 | 1.9 | 19113 | (34.1) | 13.8 | 1.8 |
| Non-EU/EEA | | | | | | | | | | | | | | | | |
| Albania | 3 | (0.7) | 1.7 | 0.0 | 10 | (2.4) | 2.9 | 1.0 | 86 | (20.7) | 18.2 | 2.4 | 122 | (29.4) | 15.4 | 2.1 |
| Andorra | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 1 | (25.0) | 10.1 | N/F |
| Armenia | 6 | (0.6) | 3.0 | 0.2 | 15 | (1.5) | 3.9 | 2.0 | 149 | (14.5) | 37.2 | 2.5 | 342 | (33.3) | 38.5 | 2.6 |
| Azerbaijan | 32 | (0.8) | 3.6 | 1.9 | 143 | (3.8) | 10.5 | 1.8 | 989 | (26.1) | 63.8 | 1.9 | 1411 | (37.2) | 45.2 | 2.1 |
| Belarus | 3 | (0.1) | 0.5 | 2.0 | 10 | (0.3) | 1.0 | 0.7 | 176 | (5.5) | 17.2 | 1.6 | 1314 | (40.9) | 46.0 | 2.4 |
| Bosnia and Herzegovina | 3 | (0.3) | 1.9 | 2.0 | 7 | (0.8) | 2.0 | 0.8 | 88 | (9.7) | 19.1 | 1.3 | 183 | (20.2) | 18.7 | 1.3 |
| former Yugoslav Republic of Macedonia, the | 11 | (4.2) | 9.3 | 1.2 | 14 | (5.3) | 6.1 | 0.8 | 33 | (12.5) | 11.9 | 0.7 | 84 | (31.9) | 13.3 | 2.0 |
| Georgia | 34 | (1.1) | 12.5 | 1.8 | 89 | (3.0) | 18.8 | 1.4 | 364 | (12.2) | 73.6 | 0.9 | 1190 | (39.9) | 109.5 | 1.9 |
| Israel | 11 | (4.4) | 1.3 | 4.5 | 2 | (0.8) | 0.1 | N/F | 12 | (4.8) | 1.0 | 2.0 | 125 | (50.0) | 5.7 | 1.7 |
| Kazakhstan | 84 | (0.7) | 4.2 | 1.0 | 242 | (2.0) | 8.3 | 0.8 | 2073 | (16.8) | 82.1 | 1.1 | 5529 | (44.9) | 100.1 | 1.7 |
| Kyrgyzstan | 77 | (1.1) | 10.1 | 0.9 | 330 | (4.7) | 29.6 | 1.3 | 1637 | (23.3) | 156.6 | 1.2 | 2581 | (36.7) | 148.4 | 1.3 |
| Moldova | 35 | (1.0) | 16.1 | 1.1 | 68 | (1.9) | 16.2 | 1.4 | 302 | (8.5) | 56.0 | 1.4 | 1616 | (45.3) | 117.4 | 2.6 |
| Monaco | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Montenegro | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 8 | (9.2) | 9.5 | – | 22 | (25.3) | 12.6 | – |
| Russia | 1094 | (1.2) | 11.4 | 1.0 | 1782 | (1.9) | 11.6 | 1.0 | 6296 | (6.8) | 43.6 | 1.3 | 50841 | (55.0) | 112.4 | 2.4 |
| San Marino | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – |
| Serbia | 3 | (0.2) | 0.6 | 0.0 | 14 | (1.0) | 1.4 | 1.0 | 201 | (13.7) | 18.3 | 0.9 | 378 | (25.7) | 15.6 | 1.4 |
| Serbia excluding UN Administered Province of Kosovo ^d | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 62 | (8.2) | 8.1 | – | 177 | (23.4) | 9.5 | – |
| UN Administered Province of Kosovo ^d | 3 | (0.4) | 1.9 | 0.0 | 14 | (2.0) | 4.2 | 1.0 | 139 | (19.4) | 41.3 | 0.9 | 201 | (28.0) | 35.4 | 1.1 |
| Switzerland | 13 | (2.3) | 3.0 | 0.6 | 17 | (3.0) | 2.1 | 1.8 | 159 | (27.7) | 16.9 | 2.9 | 220 | (38.4) | 9.5 | 1.7 |
| Tajikistan | 107 | (1.8) | 9.0 | 1.2 | 282 | (4.7) | 14.9 | 1.0 | 1536 | (25.8) | 90.2 | 1.3 | 2294 | (38.5) | 93.9 | 1.3 |
| Turkey | 208 | (1.7) | 3.1 | 1.4 | 420 | (3.4) | 3.1 | 0.8 | 1908 | (15.7) | 14.5 | 1.1 | 3767 | (30.9) | 15.5 | 1.2 |
| Turkmenistan | 0 | (0.0) | 0.0 | – | 0 | (0.0) | 0.0 | – | 387 | (18.6) | 38.8 | – | 970 | (46.7) | 56.2 | – |
| Ukraine | 262 | (0.9) | 11.2 | 1.1 | 309 | (1.1) | 7.0 | 1.0 | 2000 | (6.9) | 43.5 | 1.4 | 15599 | (53.7) | 113.7 | 2.7 |
| Uzbekistan | 393 | (2.4) | 12.3 | 1.4 | 1617 | (10.1) | 28.8 | 1.4 | 1793 | (11.2) | 30.5 | 1.2 | 5444 | (33.9) | 54.8 | 1.4 |
| Subtotal non-EU/EEA | 2379 | (1.2) | 7.7 | 1.1 | 5371 | (2.7) | 10.0 | 1.1 | 20197 | (10.3) | 38.2 | 1.3 | 94033 | (48.1) | 76.2 | 2.1 |
| Total European Region | 3356 | (1.3) | 5.9 | 1.1 | 6818 | (2.7) | 6.4 | 1.1 | 27236 | (10.8) | 25.0 | 1.4 | 113146 | (45.0) | 43.6 | 2.1 |
| Subtotal 18 HPC | 2569 | (1.2) | 8.5 | 1.1 | 5867 | (2.8) | 11.1 | 1.1 | 21348 | (10.3) | 41.2 | 1.3 | 98501 | (47.3) | 79.9 | 2.1 |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

N/F: no female in subgroup.

N/M: no male in subgroup.

^b Cases with missing information on previous history of TB treatment are included among new cases.

^c These data are subject to change as the national TB registry was under review when this report was being produced.

^d Provisional data on new and relapse cases including overseas territories reported to WHO Global TB database.

^e In accordance with the UN Security Council Resolution No. 1244 (1999).

| | 45-64 | | | | > 64 | | | | Unknown | | | Total | | Country |
|--|--------------|---------------|-------------|------------|--------------|---------------|-------------|------------|------------|--------------|-----------|---------------|------------|--|
| | N | (%) | Rate | M:F ratio | N | (%) | Rate | M:F ratio | N | (%) | M:F ratio | N | M:F ratio | |
| | | | | | | | | | | | | | | EU/EEA |
| | 152 | (24.6) | 6.1 | 2.1 | 112 | (18.1) | 7.0 | 1.4 | 0 | (0.0) | - | 619 | 2.0 | Austria |
| | 233 | (23.6) | 7.6 | 2.1 | 159 | (16.1) | 7.7 | 1.7 | 0 | (0.0) | - | 986 | 1.8 | Belgium |
| | 522 | (34.2) | 26.4 | 3.0 | 301 | (19.7) | 20.6 | 1.8 | 0 | (0.0) | - | 1525 | 2.0 | Bulgaria |
| | 170 | (37.9) | 14.4 | 2.5 | 157 | (35.0) | 19.5 | 0.9 | 0 | (0.0) | - | 449 | 1.5 | Croatia ^b |
| | 12 | (21.1) | 5.8 | 1.0 | 2 | (3.5) | 1.6 | N/M | 0 | (0.0) | - | 57 | 1.1 | Cyprus |
| | 188 | (36.8) | 6.8 | 3.5 | 133 | (26.0) | 6.9 | 1.2 | 0 | (0.0) | - | 511 | 2.2 | Czech Republic |
| | 89 | (30.5) | 5.9 | 2.0 | 31 | (10.6) | 2.9 | 1.1 | 0 | (0.0) | - | 292 | 1.7 | Denmark |
| | 81 | (43.1) | 23.5 | 5.2 | 47 | (25.0) | 18.8 | 1.0 | 0 | (0.0) | - | 188 | 2.4 | Estonia |
| | 40 | (17.8) | 2.7 | 1.7 | 82 | (36.4) | 7.3 | 1.2 | 0 | (0.0) | - | 225 | 1.3 | Finland |
| | 1084 | (23.2) | 6.3 | 2.3 | 974 | (20.8) | 7.8 | 1.9 | 0 | (0.0) | - | 4675 | 2.0 | France ^c |
| | 1109 | (19.3) | 4.5 | 2.2 | 936 | (16.3) | 5.4 | 1.3 | 1 | (0.0) | - | 5737 | 2.1 | Germany |
| | 115 | (28.3) | 3.9 | 3.0 | 121 | (29.7) | 5.3 | 2.1 | 4 | (1.0) | - | 407 | 2.4 | Greece |
| | 375 | (50.9) | 14.1 | 2.6 | 166 | (22.5) | 9.2 | 1.0 | 0 | (0.0) | - | 737 | 1.7 | Hungary |
| | 1 | (16.7) | 1.2 | - | 1 | (16.7) | 2.2 | N/M | 0 | (0.0) | - | 6 | 2.0 | Iceland |
| | 77 | (26.3) | 6.8 | 1.3 | 51 | (17.4) | 8.2 | 1.2 | 1 | (0.3) | - | 293 | 1.5 | Ireland |
| | 713 | (18.9) | 4.1 | 2.0 | 554 | (14.7) | 4.1 | 1.3 | 333 | (8.8) | - | 3778 | 1.9 | Italy |
| | 261 | (40.7) | 48.3 | 3.9 | 74 | (11.5) | 19.1 | 1.0 | 0 | (0.0) | - | 641 | 2.3 | Latvia |
| | - | - | - | - | - | - | - | - | - | - | - | - | - | Liechtenstein |
| | 593 | (44.0) | 72.7 | 3.5 | 176 | (13.1) | 32.1 | 1.5 | 0 | (0.0) | - | 1347 | 2.4 | Lithuania |
| | 11 | (37.9) | 7.1 | N/F | 3 | (10.3) | 3.7 | 0.5 | 0 | - | - | 29 | 4.8 | Luxembourg |
| | 2 | (4.0) | 1.8 | 1.0 | 2 | (4.0) | 2.4 | N/F | 0 | (0.0) | - | 50 | 2.8 | Malta |
| | 190 | (21.7) | 4.0 | 1.4 | 131 | (14.9) | 4.2 | 1.2 | 0 | (0.0) | - | 877 | 1.4 | Netherlands |
| | 46 | (16.5) | 3.5 | 1.6 | 25 | (9.0) | 2.9 | 1.5 | 0 | (0.0) | - | 278 | 1.3 | Norway |
| | 2668 | (43.4) | 26.2 | 3.5 | 1567 | (25.5) | 25.9 | 1.3 | 0 | (0.0) | - | 6143 | 2.2 | Poland |
| | 640 | (35.7) | 22.3 | 3.0 | 443 | (24.7) | 20.7 | 1.9 | 4 | (0.2) | - | 1794 | 1.9 | Portugal |
| | 4503 | (35.2) | 83.7 | 4.2 | 1798 | (14.1) | 52.3 | 1.4 | 0 | (0.0) | - | 12790 | 2.2 | Romania |
| | 84 | (29.9) | 5.8 | 1.7 | 73 | (26.0) | 9.3 | 1.4 | 0 | (0.0) | - | 281 | 1.4 | Slovakia |
| | 39 | (33.1) | 6.5 | 2.5 | 49 | (41.5) | 12.9 | 0.8 | 0 | (0.0) | - | 118 | 1.4 | Slovenia |
| | 1376 | (29.1) | 10.7 | 2.3 | 1096 | (23.2) | 12.6 | 1.7 | 1 | (0.0) | - | 4734 | 1.6 | Spain |
| | 99 | (14.1) | 4.0 | 1.5 | 62 | (8.8) | 3.2 | 0.9 | 0 | (0.0) | - | 702 | 2.0 | Sweden |
| | 1463 | (25.3) | 8.7 | 1.6 | 880 | (15.2) | 7.5 | 1.2 | 0 | (0.0) | - | 5793 | 1.4 | United Kingdom |
| | 16936 | (30.2) | 12.0 | 2.9 | 10206 | (18.2) | 10.3 | 1.4 | 344 | (0.6) | - | 56062 | 1.5 | Subtotal EU/EEA |
| | | | | | | | | | | | | | | Non-EU/EEA |
| | 95 | (22.9) | 12.4 | 2.7 | 99 | (23.9) | 26.4 | 2.5 | 0 | (0.0) | - | 415 | 2.3 | Albania |
| | 1 | (25.0) | 10.2 | N/F | 2 | (50.0) | 35.3 | - | 0 | (0.0) | - | 4 | - | Andorra |
| | 404 | (39.3) | 55.4 | 4.8 | 111 | (10.8) | 34.3 | 3.0 | 0 | (0.0) | - | 1027 | 3.2 | Armenia |
| | 1036 | (27.3) | 46.4 | 2.6 | 182 | (4.8) | 32.0 | 1.5 | 0 | (0.0) | - | 3793 | 2.1 | Azerbaijan |
| | 1288 | (40.1) | 48.4 | 4.5 | 420 | (13.1) | 30.4 | 0.9 | 0 | (0.0) | - | 3211 | 2.5 | Belarus |
| | 278 | (30.7) | 27.6 | 2.4 | 348 | (38.4) | 61.3 | 0.7 | 0 | (0.0) | - | 907 | 1.3 | Bosnia and Herzegovina |
| | 77 | (29.3) | 13.9 | 3.1 | 44 | (16.7) | 16.4 | 1.8 | 0 | (0.0) | - | 263 | 1.8 | former Yugoslav Republic of Macedonia, the |
| | 951 | (31.9) | 93.0 | 3.8 | 355 | (11.9) | 61.4 | 1.7 | 0 | (0.0) | - | 2983 | 2.0 | Georgia |
| | 60 | (24.0) | 3.8 | 1.3 | 40 | (16.0) | 4.3 | 0.4 | 0 | (0.0) | - | 250 | 1.3 | Israel |
| | 3319 | (26.9) | 87.8 | 2.6 | 1075 | (8.7) | 87.4 | 1.0 | 0 | (0.0) | - | 12322 | 1.6 | Kazakhstan |
| | 1747 | (24.9) | 168.8 | 1.8 | 654 | (9.3) | 252.1 | 1.2 | 0 | (0.0) | - | 7026 | 1.3 | Kyrgyzstan |
| | 1288 | (36.1) | 118.6 | 3.7 | 262 | (7.3) | 62.5 | 1.6 | 0 | (0.0) | - | 3571 | 2.6 | Moldova |
| | - | - | - | - | - | - | - | - | - | - | - | - | - | Monaco |
| | 39 | (44.8) | 23.6 | - | 18 | (20.7) | 20.0 | - | 0 | (0.0) | - | 87 | - | Montenegro |
| | 26152 | (28.3) | 66.2 | 3.2 | 5845 | (6.3) | 29.4 | 1.2 | 397 | (0.4) | - | 92407 | 2.3 | Russia |
| | 0 | (0.0) | 0.0 | - | 0 | (0.0) | 0.0 | - | 0 | (0.0) | - | 0 | - | San Marino |
| | 483 | (32.8) | 20.6 | 2.0 | 393 | (26.7) | 26.5 | 0.9 | 0 | (0.0) | - | 1472 | 1.3 | Serbia |
| | 288 | (38.1) | 14.3 | - | 228 | (30.2) | 16.8 | - | 0 | (0.0) | - | 755 | - | Serbia excluding UN Administered Province of Kosovo ^d |
| | 195 | (27.2) | 57.8 | 1.4 | 165 | (23.0) | 128.0 | 0.8 | 0 | (0.0) | - | 717 | 1.0 | UN Administered Province of Kosovo ^d |
| | 85 | (14.8) | 3.6 | 1.7 | 79 | (13.8) | 5.2 | 1.0 | 0 | (0.0) | - | 573 | 1.8 | Switzerland |
| | 1273 | (21.3) | 104.2 | 1.2 | 473 | (7.9) | 160.0 | 0.8 | 0 | (0.0) | - | 5965 | 1.2 | Tajikistan |
| | 3680 | (30.2) | 23.4 | 1.8 | 2203 | (18.1) | 34.8 | 1.2 | 0 | (0.0) | - | 12186 | 1.3 | Turkey |
| | 557 | (26.8) | 58.1 | - | 128 | (6.2) | 54.4 | - | 36 | (1.7) | - | 2078 | - | Turkmenistan |
| | 8586 | (29.6) | 70.5 | 4.3 | 2296 | (7.9) | 32.0 | 1.2 | 0 | (0.0) | - | 29052 | 2.7 | Ukraine |
| | 4694 | (29.2) | 85.6 | 1.4 | 2109 | (13.1) | 154.9 | 1.0 | 0 | (0.0) | - | 16050 | 1.3 | Uzbekistan |
| | 56093 | (28.7) | 58.2 | 2.8 | 17136 | (8.8) | 37.8 | 1.2 | 433 | (0.2) | - | 195642 | 2.0 | Subtotal non-EU/EEA |
| | 73029 | (29.0) | 30.6 | 2.8 | 27342 | (10.9) | 18.8 | 1.2 | 777 | (0.3) | - | 251704 | 2.0 | Total European Region |
| | 60935 | (29.3) | 63.0 | 2.9 | 18509 | (8.9) | 40.1 | 1.2 | 433 | (0.2) | - | 208162 | 2.0 | Subtotal ≥ 8 HPC |

Table 10: Tuberculosis cases by origin, European Region, 2016

| Country | Origin criterion | Native | | Foreign | | Unknown origin | | All TB cases |
|--|------------------|---------------|---------------|--------------|---------------|----------------|--------------|---------------|
| | | N | (%) | N | (%) | N | (%) | N |
| EU/EEA | | | | | | | | |
| Austria | citizenship | 210 | (33.1) | 424 | (66.9) | 0 | (0.0) | 634 |
| Belgium | citizenship | 500 | (47.8) | 547 | (52.2) | 0 | (0.0) | 1047 |
| Bulgaria | birthplace | 1599 | (99.8) | 4 | (0.2) | 0 | (0.0) | 1603 |
| Croatia ^a | birthplace | 161 | (35.0) | 3 | (0.7) | 296 | (64.3) | 460 |
| Cyprus | birthplace | 4 | (6.7) | 56 | (93.3) | 0 | (0.0) | 60 |
| Czech Republic | birthplace | 365 | (70.7) | 151 | (29.3) | 0 | (0.0) | 516 |
| Denmark ^b | birthplace | 109 | (33.0) | 221 | (67.0) | 0 | (0.0) | 330 |
| Estonia | birthplace | 150 | (78.1) | 42 | (21.9) | 0 | (0.0) | 192 |
| Finland | birthplace | 117 | (49.6) | 111 | (47.0) | 8 | (3.4) | 236 |
| France ^c | birthplace | 2200 | (44.4) | 2758 | (55.6) | - | - | 4958 |
| Germany | birthplace | 1427 | (24.1) | 4125 | (69.7) | 363 | (6.1) | 5915 |
| Greece | citizenship | 254 | (57.3) | 189 | (42.7) | 0 | (0.0) | 443 |
| Hungary | citizenship | 756 | (96.2) | 30 | (3.8) | 0 | (0.0) | 786 |
| Iceland | birthplace | 2 | (33.3) | 4 | (66.7) | 0 | (0.0) | 6 |
| Ireland | birthplace | 145 | (45.6) | 160 | (50.3) | 13 | (4.1) | 318 |
| Italy | birthplace | 1180 | (29.3) | 2509 | (62.2) | 343 | (8.5) | 4032 |
| Latvia | birthplace | 617 | (93.5) | 43 | (6.5) | 0 | (0.0) | 660 |
| Liechtenstein | - | - | - | - | - | - | - | - |
| Lithuania | birthplace | 1429 | (99.1) | 13 | (0.9) | 0 | (0.0) | 1442 |
| Luxembourg | birthplace | 7 | (24.1) | 22 | (75.9) | 0 | (0.0) | 29 |
| Malta | birthplace | 2 | (4.0) | 48 | (96.0) | 0 | (0.0) | 50 |
| Netherlands | birthplace | 214 | (24.1) | 669 | (75.3) | 6 | (0.7) | 889 |
| Norway | birthplace | 34 | (11.4) | 265 | (88.6) | 0 | (0.0) | 299 |
| Poland | citizenship | 6352 | (98.6) | 92 | (1.4) | 0 | (0.0) | 6444 |
| Portugal | birthplace | 1500 | (81.7) | 336 | (18.3) | 0 | (0.0) | 1836 |
| Romania | birthplace | 13593 | (99.8) | 24 | (0.2) | 0 | (0.0) | 13617 |
| Slovakia | birthplace | 285 | (96.3) | 11 | (3.7) | 0 | (0.0) | 296 |
| Slovenia | birthplace | 75 | (63.6) | 43 | (36.4) | 0 | (0.0) | 118 |
| Spain | birthplace | 2886 | (59.2) | 1391 | (28.5) | 600 | (12.3) | 4877 |
| Sweden | birthplace | 74 | (10.2) | 652 | (89.8) | 0 | (0.0) | 726 |
| United Kingdom | birthplace | 1662 | (26.9) | 4369 | (70.8) | 144 | (2.3) | 6175 |
| Subtotal EU/EEA | | 37909 | (64.3) | 19312 | (32.7) | 1773 | (3.0) | 58994 |
| Non-EU/EEA | | | | | | | | |
| Albania | citizenship | 415 | (100.0) | 0 | 0 | - | - | 415 |
| Andorra | citizenship | 4 | (100.0) | 0 | 0 | - | - | 4 |
| Armenia | citizenship | 1080 | (100.0) | 0 | 0 | - | - | 1080 |
| Azerbaijan | citizenship | 6695 | (99.8) | 12 | 0 | - | - | 6707 |
| Belarus | citizenship | 3598 | (100.0) | 0 | 0 | - | - | 3598 |
| Bosnia and Herzegovina | citizenship | 907 | (100.0) | 0 | 0 | - | - | 907 |
| former Yugoslav Republic of Macedonia, the | birthplace | 259 | (97.0) | 8 | 3 | - | - | 267 |
| Georgia | citizenship | - | - | - | - | - | - | - |
| Israel | birthplace | 48 | (19.2) | 202 | 81 | - | - | 250 |
| Kazakhstan | citizenship | 12505 | (98.8) | 153 | 1 | - | - | 12658 |
| Kyrgyzstan | birthplace | 7995 | (100.0) | 0 | 0 | - | - | 7995 |
| Moldova | citizenship | 4095 | (99.1) | 39 | 1 | - | - | 4134 |
| Monaco | birthplace | - | - | - | - | - | - | - |
| Montenegro | citizenship | 85 | (97.7) | 2 | 2 | - | - | 87 |
| Russia | citizenship | 118249 | (97.7) | 2797 | 2 | - | - | 121046 |
| San Marino | - | 0 | - | 0 | - | - | - | 0 |
| Serbia | - | 1483 | (99.7) | 5 | 0 | - | - | 1488 |
| Serbia excluding UN Administered Province of Kosovo ^d | citizenship | 766 | (99.9) | 1 | 0 | - | - | 767 |
| UN Administered Province of Kosovo ^d | birthplace | 717 | (99.4) | 4 | 1 | - | - | 721 |
| Switzerland | birthplace | 123 | (20.2) | 486 | 80 | - | - | 609 |
| Tajikistan | birthplace | 6241 | (100.0) | 0 | 0 | - | - | 6241 |
| Turkey | birthplace | 11513 | (92.7) | 904 | 7 | - | - | 12417 |
| Turkmenistan | citizenship | - | - | - | - | - | - | - |
| Ukraine | citizenship | 34068 | (99.9) | 20 | 0 | - | - | 34088 |
| Uzbekistan | birthplace | 18441 | (100.0) | 0 | 0 | - | - | 18441 |
| Subtotal non-EU/EEA | | 227804 | (98.0) | 4628 | (2.0) | - | - | 232432 |
| Total European Region | | 265713 | (91.2) | 23940 | (8.2) | 1773 | (0.6) | 291426 |
| Subtotal 18 HPC | | 241868 | (98.4) | 4051 | (1.6) | 0 | (0.0) | 245919 |

'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^a These data are subject to change as the national TB registry was under review when this report was being produced.

^b By birthplace of parents for Danish-born cases under 26 years of age.

^c Provisional data on new and relapse cases including overseas territories reported to WHO Global TB database. Cases with unknown origin are included among natives.

^d In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 11: Drug resistance surveillance of pulmonary bacteriologically-confirmed^a tuberculosis cases, European Region, 2016

| Country | Source of data | Coverage | Bacteriologically-confirmed cases ^a | | Cases with DST results at least RIF and INH | | Cases resistant to any anti-TB drug ^b | | Multidrug-resistant TB cases | | Reporting completeness ^c |
|--|----------------------|--------------|--|---------------|---|---------------|--|--------------|------------------------------|---------------|-------------------------------------|
| | | | N | (%) | N | (%) | N | (%) | N | (%) | |
| EU/EEA | | | | | | | | | | | |
| Austria | TESSy | national | 400 | (83.0) | 374 | (93.5) | 45 | (3.7) | 14 | (12.0) | Y |
| Belgium | TESSy | national | 606 | (84.8) | 568 | (93.7) | 34 | (1.6) | 9 | (6.0) | Y |
| Bulgaria | TESSy | national | 746 | (62.9) | 653 | (87.5) | 71 | (2.9) | 19 | (10.9) | Y |
| Croatia ^d | TESSy | national | 193 | (62.9) | 193 | (100.0) | 6 | (0.0) | 0 | (3.1) | Y |
| Cyprus | TESSy | national | 39 | (76.5) | 38 | (97.4) | 6 | (0.0) | 0 | (15.8) | Y |
| Czech Republic | TESSy | national | 368 | (82.5) | 330 | (89.7) | 22 | (1.8) | 6 | (6.7) | Y |
| Denmark | TESSy | national | 208 | (79.4) | 203 | (97.6) | 12 | (1.5) | 3 | (5.9) | Y |
| Estonia | TESSy | national | 153 | (86.4) | 145 | (94.8) | 48 | (15.9) | 23 | (33.1) | Y |
| Finland | TESSy | national | 139 | (79.4) | 134 | (96.4) | 12 | (2.2) | 3 | (9.0) | Y |
| France ^e | NRL-TME ^f | sub-national | 3120 | (84.7) | 3120 | (100.0) | – | – | 51 | (4.1) | Y |
| Germany | TESSy | national | 3501 | (79.6) | 2959 | (84.5) | 361 | (3.0) | 90 | (12.2) | Y |
| Greece | TESSy | – | 246 | (62.4) | 115 | (46.7) | 19 | (4.3) | 5 | (16.5) | N |
| Hungary | TESSy | national | 396 | (52.3) | 332 | (83.8) | 48 | (5.4) | 18 | (14.5) | Y |
| Iceland | TESSy | national | 5 | (83.3) | 4 | (80.0) | 0 | (0.0) | 0 | (0.0) | Y |
| Ireland | TESSy | national | 171 | (81.0) | 167 | (97.7) | 20 | (3.6) | 6 | (12.0) | Y |
| Italy ^e | NRL-TME ^f | sub-national | 1967 | (69.8) | 869 | (44.2) | – | – | 33 | (3.8) | N |
| Latvia | TESSy | national | 535 | (86.4) | 512 | (95.7) | 138 | (10.4) | 53 | (27.0) | Y |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | TESSy | national | 1171 | (88.2) | 1171 | (100.0) | 382 | (20.7) | 242 | (32.6) | Y |
| Luxembourg | TESSy | national | 22 | (91.7) | 21 | (95.5) | 2 | (4.8) | 1 | (9.5) | Y |
| Malta | TESSy | national | 33 | (89.2) | 33 | (100.0) | 1 | (0.0) | 0 | (3.0) | Y |
| Netherlands | TESSy | national | 353 | (74.0) | 353 | (100.0) | 44 | (2.3) | 8 | (12.5) | Y |
| Norway | TESSy | national | 162 | (86.6) | 157 | (96.9) | 23 | (5.1) | 8 | (14.6) | Y |
| Poland | TESSy | national | 4548 | (74.4) | 4114 | (90.5) | 235 | (1.1) | 45 | (5.7) | Y |
| Portugal | TESSy | national | 975 | (74.9) | 677 | (69.4) | 64 | (1.5) | 10 | (9.5) | N |
| Romania | TESSy | national | 9222 | (80.0) | 8211 | (89.0) | 863 | (5.6) | 458 | (10.5) | Y |
| Slovakia | TESSy | national | 137 | (54.2) | 111 | (81.0) | 8 | (2.7) | 3 | (7.2) | Y |
| Slovenia | TESSy | national | 96 | (93.2) | 96 | (100.0) | 6 | (0.0) | 0 | (6.3) | Y |
| Spain ^e | NRL-TME ^f | sub-national | 896 | (100.0) | 896 | (100.0) | – | (4.4) | 39 | (4.4) | N |
| Sweden | TESSy | national | 427 | (88.6) | 418 | (97.9) | 50 | (3.3) | 14 | (12.0) | Y |
| United Kingdom | TESSy | national | 2548 | (76.0) | 2452 | (96.2) | 198 | (1.8) | 43 | (8.1) | Y |
| Subtotal EU/EEA | | | 33383 | (80.0) | 29426 | (88.1) | 2718 | (9.8) | 1204 | (4.1) | |
| Non-EU/EEA | | | | | | | | | | | |
| Albania | NRL-TME | national | 97 | – | 40 | (41.2) | – | – | 1 | (2.5) | N |
| Andorra | NRL-TME | national | 2 | – | 1 | (50.0) | – | – | 0 | (0.0) | N |
| Armenia | NRL-TME | national | 485 | – | 461 | (95.1) | – | – | 115 | (24.9) | Y |
| Azerbaijan | NRL-TME | national | 3759 | – | 2614 | (69.5) | – | – | 777 | (29.7) | N |
| Belarus | NRL-TME | national | 2621 | – | 2555 | (97.5) | – | – | 1222 | (47.8) | Y |
| Bosnia and Herzegovina | NRL-TME | national | 597 | – | 597 | (100.0) | – | – | 0 | (0.0) | Y |
| former Yugoslav Republic of Macedonia, the | NRL-TME | national | 178 | – | 143 | (80.3) | – | – | 2 | (1.4) | Y |
| Georgia | NRL-TME | national | 2313 | – | 1791 | (77.4) | – | – | 296 | (16.5) | Y |
| Israel | NRL-TME | national | 132 | – | 123 | (93.2) | – | – | 9 | (7.3) | Y |
| Kazakhstan | NRL-TME | national | 10015 | – | 5213 | (52.1) | – | – | 1231 | (23.6) | N |
| Kyrgyzstan | NRL-TME | national | 3753 | – | 2642 | (70.4) | – | – | 864 | (32.7) | N |
| Moldova | NRL-TME | national | 2454 | – | 1574 | (64.1) | – | – | 525 | (33.4) | N |
| Monaco | – | – | – | – | – | – | – | – | – | – | Y |
| Montenegro | NRL-TME | national | 57 | – | 57 | (100.0) | – | – | 0 | (0.0) | Y |
| Russia | NRL-TME | national | 63638 | – | 57910 | (91.0) | – | – | 25971 | (44.8) | Y |
| San Marino | – | – | 0 | – | 0 | (0.0) | – | – | 0 | (0.0) | N |
| Serbia | – | national | 815 | – | 668 | (82.0) | – | – | 8 | (1.2) | Y |
| Serbia excluding UN Administered Province of Kosovo ^g | NRL-TME | national | 541 | – | 398 | (73.6) | – | – | 6 | (1.5) | N |
| UN Administered Province of Kosovo ^g | – | national | 274 | – | 270 | (98.5) | – | – | 2 | (0.7) | Y |
| Switzerland | NRL-TME | national | 314 | – | 296 | (94.3) | – | – | 13 | (4.4) | Y |
| Tajikistan | NRL-TME | sub-national | 3011 | – | 2702 | (89.7) | – | – | 646 | (23.9) | Y |
| Turkey | NRL-TME | national | 6514 | – | 5612 | (86.2) | – | – | 190 | (3.4) | Y |
| Turkmenistan | NRL-TME | – | – | – | – | – | – | – | – | – | N |
| Ukraine | NRL-TME | national | 21957 | – | 20147 | (91.8) | – | – | 5756 | (28.6) | Y |
| Uzbekistan | NRL-TME | sub-national | 2309 | – | 1086 | (47.0) | – | – | 603 | (55.5) | N |
| Subtotal non-EU/EEA | | | 125021 | (0.0) | 106232 | (85.0) | – | – | 38226 | (36.0) | |
| Total European Region | | | 158404 | (0.0) | 135658 | (85.6) | 2718 | (9.8) | 39433 | (29.1) | |
| Subtotal 18 HPC | | | 134656 | (0.0) | 114999 | (85.4) | 1502 | (1.3) | 38991 | (33.9) | |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^b Bacteriologically confirmed cases – cases with positive identification for *Mycobacterium tuberculosis* complex confirmed by culture and/or line probe assay for all countries.

^c Any resistance to isoniazid, rifampicin, ethambutol or streptomycin expressed as a percentage of cases with DST results available for at least isoniazid and rifampicin. No routine testing for ethambutol and streptomycin in all countries.

^d Data considered complete when national coverage 100% or culture results available for 90% of all cases, and 50% of all cases culture-positive, and 75% of them with DST results, and EQA results accurate in 95% of samples of reported year.

^e These data are subject to change as the national TB registry was under review when this report was being produced.

^f Data from France, Italy and Spain reported by NRL may differ from data shown elsewhere in this report. Spain reported the DST results only for pulmonary TB cases.

^g NRL: National reference laboratory; TME: WHO Tuberculosis Monitoring and Evaluation Database.

^h In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 12: Drug resistance surveillance of bacteriologically-confirmed^a pulmonary tuberculosis cases by previous TB treatment history^b, European Region, 2016

| Country | New... | | | | | | | | Previously treated... | | | | | | | |
|--|------------------------|------------------|--------------|------------------|--|------------------|------------------------|---------------|------------------------|------------------|--------------|------------------|--|------------------|------------------------|---------------|
| | Cases with DST results | | MDR-TB | | bacteriologically confirmed pulmonary TB cases | | ... pulmonary TB cases | | Cases with DST results | | MDR-TB | | bacteriologically confirmed pulmonary TB cases | | ... pulmonary TB cases | |
| | N | (%) ^d | N | (%) ^e | N | (%) ^f | N | (%) | N | (%) ^g | N | (%) ^e | N | (%) ^f | N | (%) |
| EU/EEA | | | | | | | | | | | | | | | | |
| Austria | | (97.8) | 6 | (2.2) | 273 | (80.3) | 340 | (92.4) | 17 | (94.4) | 3 | (17.6) | 18 | (64.3) | 28 | (7.6) |
| Belgium | 429 | (97.1) | 6 | (1.4) | 442 | (83.7) | 528 | (91.5) | 35 | (87.5) | 2 | (5.7) | 40 | (81.6) | 49 | (8.5) |
| Bulgaria | 572 | (87.7) | 5 | (0.9) | 652 | (63.8) | 1022 | (86.2) | 81 | (87.1) | 14 | (17.3) | 93 | (56.7) | 164 | (13.8) |
| Croatia ^h | 168 | (100.0) | 0 | (0.0) | 168 | (64.1) | 262 | (93.2) | 8 | (100.0) | 0 | (0.0) | 8 | (42.1) | 19 | (6.8) |
| Cyprus | 36 | (97.3) | 0 | (0.0) | 37 | (78.7) | 47 | (92.2) | 2 | (100.0) | 0 | (0.0) | 2 | (50.0) | 4 | (7.8) |
| Czech Republic | 318 | (95.2) | 4 | (1.3) | 334 | (78.8) | 424 | (95.1) | 12 | (80.0) | 2 | (16.7) | 15 | (68.2) | 22 | (4.9) |
| Denmark | 181 | (0.0) | 3 | (1.7) | 186 | (0.0) | 232 | (88.5) | 22 | (100.0) | 0 | (0.0) | 22 | (73.3) | 30 | (11.5) |
| Estonia | 132 | (99.2) | 17 | (12.9) | 133 | (85.8) | 155 | (87.6) | 13 | (81.3) | 6 | (46.2) | 16 | (72.7) | 22 | (12.4) |
| Finland | 125 | (98.4) | 2 | (1.6) | 127 | (77.4) | 164 | (95.3) | 6 | (100.0) | 0 | (0.0) | 6 | (75.0) | 8 | (4.7) |
| France | 2441 | (100.0) | 33 | (1.4) | 2441 | (100.0) | 2441 | (68.1) | 264 | (100.0) | 18 | (6.8) | 264 | (100.0) | 264 | (7.4) |
| Germany | 179 | (93.7) | 4 | (2.2) | 191 | (72.9) | 262 | (49.3) | 133 | (89.3) | 19 | (14.3) | 149 | (55.4) | 269 | (50.7) |
| Greece | 102 | (49.3) | 2 | (2.0) | 207 | (60.0) | 345 | (91.0) | 11 | (84.6) | 3 | (27.3) | 13 | (38.2) | 34 | (9.0) |
| Hungary | 295 | (85.5) | 12 | (4.1) | 345 | (53.0) | 651 | (86.0) | 37 | (72.5) | 6 | (16.2) | 51 | (48.1) | 106 | (14.0) |
| Iceland | 4 | (80.0) | 0 | (0.0) | 5 | (83.3) | 6 | (100.0) | 0 | – | 0 | – | 0 | – | 0 | (0.0) |
| Ireland | 127 | (98.4) | 4 | (3.1) | 129 | (84.9) | 152 | (89.4) | 11 | (100.0) | 2 | (18.2) | 11 | (61.1) | 18 | (10.6) |
| Italy | 772 | (100.0) | 24 | (3.1) | 772 | (100.0) | 772 | (78.6) | 97 | (100.0) | 9 | (9.3) | 97 | (46.2) | 210 | (21.4) |
| Latvia | 422 | (95.5) | 32 | (7.6) | 442 | (84.8) | 521 | (84.2) | 90 | (96.8) | 21 | (23.3) | 93 | (94.9) | 98 | (15.8) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 880 | (100.0) | 117 | (13.3) | 880 | (84.9) | 1036 | (78.1) | 291 | (100.0) | 125 | (43.0) | 291 | (100.0) | 291 | (21.9) |
| Luxembourg | 1 | (100.0) | 0 | (0.0) | 1 | (100.0) | 1 | (100.0) | 0 | – | 0 | – | 0 | – | 0 | (0.0) |
| Malta | 33 | (100.0) | 0 | (0.0) | 33 | (89.2) | 37 | (100.0) | 0 | – | 0 | – | 0 | – | 0 | (0.0) |
| Netherlands | 341 | (100.0) | 6 | (1.8) | 341 | (74.1) | 460 | (97.0) | 10 | (100.0) | 2 | (20.0) | 10 | (71.4) | 14 | (3.0) |
| Norway | 136 | (99.3) | 7 | (5.1) | 137 | (86.2) | 159 | (91.9) | 11 | (91.7) | 0 | (0.0) | 12 | (85.7) | 14 | (8.1) |
| Poland | 3660 | (92.1) | 27 | (0.7) | 3973 | (73.5) | 5407 | (88.4) | 454 | (90.4) | 18 | (4.0) | 502 | (70.8) | 709 | (11.6) |
| Portugal | 626 | (70.9) | 8 | (1.3) | 883 | (72.8) | 1213 | (93.2) | 51 | (82.3) | 2 | (3.9) | 62 | (69.7) | 89 | (6.8) |
| Romania | 6074 | (88.7) | 124 | (2.0) | 6844 | (78.1) | 8761 | (76.0) | 2137 | (91.3) | 334 | (15.6) | 2341 | (84.8) | 2762 | (24.0) |
| Slovakia | 93 | (96.9) | 2 | (2.2) | 96 | (44.4) | 216 | (85.4) | 18 | (94.7) | 1 | (5.6) | 19 | (51.4) | 37 | (14.6) |
| Slovenia | 93 | (100.0) | 0 | (0.0) | 93 | (93.9) | 99 | (96.1) | 3 | (100.0) | 0 | (0.0) | 3 | (75.0) | 4 | (3.9) |
| Spain | 855 | (100.0) | 34 | (4.0) | 855 | (100.0) | 855 | (88.1) | 41 | (100.0) | 5 | (12.2) | 41 | (35.3) | 116 | (11.9) |
| Sweden | 369 | (99.7) | 11 | (3.0) | 370 | (87.3) | 424 | (94.9) | 19 | (100.0) | 3 | (15.8) | 19 | (82.6) | 23 | (5.1) |
| United Kingdom | 2184 | (96.7) | 34 | (1.6) | 2258 | (76.8) | 2942 | (93.0) | 148 | (97.4) | 7 | (4.7) | 152 | (68.8) | 221 | (7.0) |
| Subtotal EU/EEA | 21915 | (92.7) | 524 | (2.4) | 23648 | (79.0) | 29934 | (82.1) | 4022 | (92.5) | 602 | (15.0) | 4350 | (77.3) | 5625 | (15.4) |
| Non-EU/EEA | | | | | | | | | | | | | | | | |
| Albania | 38 | (40.9) | 0 | (0.0) | 93 | (31.8) | 292 | – | 2 | (50.0) | 1 | (50.0) | 4 | – | – | – |
| Andorra | 1 | (50.0) | 0 | (0.0) | 2 | (66.7) | 3 | – | 0 | (0.0) | 0 | (0.0) | 0 | – | – | – |
| Armenia | 357 | (95.2) | 55 | (15.4) | 375 | (58.3) | 643 | – | 104 | (94.5) | 60 | (57.7) | 110 | – | – | – |
| Azerbaijan | 1047 | (63.1) | 161 | (15.4) | 1660 | (56.1) | 2960 | – | 1567 | (74.7) | 616 | (39.3) | 2099 | – | – | – |
| Belarus | 1762 | (97.7) | 654 | (37.1) | 1804 | (74.7) | 2416 | – | 793 | (97.1) | 568 | (71.6) | 817 | – | – | – |
| Bosnia and Herzegovina | 545 | (100.0) | 0 | (0.0) | 545 | (76.3) | 714 | – | 52 | (100.0) | 0 | (0.0) | 52 | – | – | – |
| former Yugoslav Republic of Macedonia, the | 131 | (81.4) | 2 | (1.5) | 161 | (83.4) | 193 | – | 12 | (70.6) | 0 | (0.0) | 17 | – | – | – |
| Georgia | 1386 | (84.7) | 142 | (10.2) | 1636 | (86.1) | 1901 | – | 405 | (59.8) | 154 | (38.0) | 677 | – | – | – |
| Israel | 121 | (93.1) | 9 | (7.4) | 130 | (73.0) | 178 | – | 2 | (100.0) | 0 | (0.0) | 2 | – | – | – |
| Kazakhstan | 3264 | (47.1) | 832 | (25.5) | 6930 | (84.7) | 8178 | – | 1949 | (63.2) | 399 | (20.5) | 3085 | – | – | – |
| Kyrgyzstan | 1815 | (71.8) | 398 | (21.9) | 2527 | (58.7) | 4303 | – | 827 | (67.5) | 466 | (56.3) | 1226 | – | – | – |
| Moldova | 1189 | (74.7) | 304 | (25.6) | 1592 | (62.7) | 2539 | – | 385 | (44.7) | 221 | (57.4) | 862 | – | – | – |
| Monaco | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Montenegro | 50 | (100.0) | 0 | (0.0) | 50 | (78.1) | 64 | – | 7 | (100.0) | 0 | (0.0) | 7 | – | – | – |
| Russia | 31039 | (88.4) | 8463 | (27.3) | 35109 | (49.8) | 70436 | – | 26871 | (94.2) | 17508 | (65.2) | 28529 | – | – | – |
| San Marino | 0 | – | 0 | – | 0 | – | 0 | (0.0) | 0 | – | 0 | – | 0 | – | – | – |
| Serbia | 596 | (81.5) | 3 | (0.5) | 731 | (67.2) | 1088 | – | 72 | (85.7) | 5 | (6.9) | 84 | – | – | – |
| Serbia excluding UN Administered Province of Kosovo ⁱ | 358 | (73.2) | 3 | (0.8) | 489 | (82.6) | 592 | – | 40 | (76.9) | 3 | (7.5) | 52 | – | – | – |
| UN Administered Province of Kosovo ⁱ | 238 | (98.3) | 0 | (0.0) | 242 | (48.8) | 496 | – | 32 | (100.0) | 2 | (6.3) | 32 | – | – | – |
| Switzerland | 282 | (94.6) | 12 | (4.3) | 298 | (74.1) | 402 | – | 14 | (87.5) | 1 | (7.1) | 16 | – | – | – |
| Tajikistan | 2376 | (91.6) | 495 | (20.8) | 2593 | (68.4) | 3792 | – | 326 | (78.0) | 151 | (46.3) | 418 | – | – | – |
| Turkey | 5029 | (86.0) | 110 | (2.2) | 5845 | (78.3) | 7463 | – | 583 | (87.1) | 80 | (13.7) | 669 | – | – | – |
| Turkmenistan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ukraine | 13097 | (93.2) | 2881 | (22.0) | 14049 | (67.1) | 20953 | – | 7050 | (89.2) | 2875 | (40.8) | 7908 | – | – | – |
| Uzbekistan | 757 | (18.5) | 292 | (38.6) | 4093 | (45.0) | 9100 | – | 1229 | (80.2) | 311 | (25.3) | 1533 | – | – | – |
| Subtotal non-EU/EEA | 64125 | (80.9) | 14813 | (22.8) | 80223 | (58.3) | 137618 | – | 42250 | (87.8) | 23416 | (55.4) | 48115 | – | – | – |
| Total European Region | 86797 | (83.6) | 15337 | (17.7) | 103871 | (62.0) | 167552 | – | 46272 | (88.2) | 24018 | (51.9) | 52465 | – | – | – |
| Subtotal 18 HPC | 71198 | (81.7) | 15085 | (21.2) | 87164 | (59.6) | 146179 | – | 44701 | (88.1) | 23909 | (53.5) | 50767 | – | – | – |

^aEuropean Region^a comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^b Bacteriologically-confirmed cases – cases with positive identification for *Mycobacterium tuberculosis* complex confirmed by culture and/or line probe assay for non-EU countries, culture-positive and microscopy-positive/nucleic acid amplification test-positive cases for EU/EEA countries.

| | Total ^c | | | | | | | | Country |
|--|------------------------|------------------|--------------|------------------|--|------------------|------------------------|------------------|--|
| | Cases with DST results | | MDR-TB | | All bacteriologically confirmed pulmonary TB cases | | All pulmonary TB cases | | |
| | N | (%) ^d | N | (%) ^e | N | (%) ^f | N | (%) ^g | |
| | | | | | | | | | EU/EEA |
| | 284 | (97.6) | 9 | (3.2) | 291 | (79.1) | 368 | (76.2) | Austria |
| | 464 | (96.3) | 8 | (1.7) | 482 | (83.5) | 577 | (70.5) | Belgium |
| | 653 | (87.7) | 19 | (2.9) | 745 | (62.8) | 1186 | (74.0) | Bulgaria |
| | 176 | (100.0) | 0 | (0.0) | 176 | (62.6) | 281 | (89.8) | Croatia ^h |
| | 38 | (97.4) | 0 | (0.0) | 39 | (76.5) | 51 | (85.0) | Cyprus |
| | 330 | (94.6) | 6 | (1.8) | 349 | (78.3) | 446 | (86.4) | Czech Republic |
| | 203 | (97.6) | 3 | (1.5) | 208 | (79.4) | 262 | (689.5) | Denmark |
| | 145 | (97.3) | 23 | (15.9) | 149 | (84.2) | 177 | (92.2) | Estonia |
| | 131 | (98.5) | 2 | (1.5) | 133 | (77.3) | 172 | (74.5) | Finland |
| | 2705 | (100.0) | 51 | (1.9) | 2705 | (75.4) | 3587 | (76.7) | France |
| | 312 | (91.8) | 23 | (7.4) | 340 | (64.0) | 531 | (79.7) | Germany |
| | 113 | (51.4) | 5 | (4.4) | 220 | (58.0) | 379 | (90.0) | Greece |
| | 332 | (83.8) | 18 | (5.4) | 396 | (52.3) | 757 | (96.3) | Hungary |
| | 4 | (80.0) | 0 | (0.0) | 5 | (83.3) | 6 | (100.0) | Iceland |
| | 138 | (98.6) | 6 | (4.3) | 140 | (82.4) | 170 | (70.5) | Ireland |
| | 869 | (100.0) | 33 | (3.8) | 869 | (88.5) | 982 | (30.7) | Italy |
| | 512 | (95.7) | 53 | (10.4) | 535 | (86.4) | 619 | (93.8) | Latvia |
| | – | – | – | – | – | – | – | – | Liechtenstein |
| | 1171 | (100.0) | 242 | (20.7) | 1171 | (88.2) | 1327 | (92.0) | Lithuania |
| | 1 | (100.0) | 0 | (0.0) | 1 | (100.0) | 1 | (100.0) | Luxembourg |
| | 33 | (100.0) | 0 | (0.0) | 33 | (89.2) | 37 | (74.0) | Malta |
| | 351 | (100.0) | 8 | (2.3) | 351 | (74.1) | 474 | (53.6) | Netherlands |
| | 147 | (98.7) | 7 | (4.8) | 149 | (86.1) | 173 | (62.5) | Norway |
| | 4114 | (91.9) | 45 | (1.1) | 4475 | (73.2) | 6116 | (94.9) | Poland |
| | 677 | (71.6) | 10 | (1.5) | 945 | (72.6) | 1302 | (70.9) | Portugal |
| | 8211 | (89.4) | 458 | (5.6) | 9185 | (79.7) | 11523 | (84.6) | Romania |
| | 111 | (96.5) | 3 | (2.7) | 115 | (45.5) | 253 | (85.5) | Slovakia |
| | 96 | (100.0) | 0 | (0.0) | 96 | (93.2) | 103 | (87.3) | Slovenia |
| | 896 | (100.0) | 39 | (4.4) | 896 | (92.3) | 971 | (32.4) | Spain |
| | 388 | (99.7) | 14 | (3.6) | 389 | (87.0) | 447 | (66.7) | Sweden |
| | 2332 | (96.8) | 41 | (1.8) | 2410 | (76.2) | 3163 | (54.0) | United Kingdom |
| | 25937 | (92.6) | 1126 | (4.3) | 27998 | (76.8) | 36441 | (76.3) | Subtotal EU/EEA |
| | | | | | | | | | Non-EU/EEA |
| | 40 | (41.2) | 1 | (2.5) | 97 | – | – | – | Albania |
| | 1 | (50.0) | 0 | (0.0) | 2 | – | – | – | Andorra |
| | 461 | (95.1) | 115 | (24.9) | 485 | – | – | – | Armenia |
| | 2614 | (69.5) | 777 | (29.7) | 3759 | – | – | – | Azerbaijan |
| | 2555 | (97.5) | 1222 | (47.8) | 2621 | – | – | – | Belarus |
| | 597 | (100.0) | 0 | (0.0) | 597 | – | – | – | Bosnia and Herzegovina |
| | 143 | (80.3) | 2 | (1.4) | 178 | – | – | – | former Yugoslav Republic of Macedonia, the |
| | 1791 | (77.4) | 296 | (16.5) | 2313 | – | – | – | Georgia |
| | 123 | (93.2) | 9 | (7.3) | 132 | – | – | – | Israel |
| | 5213 | (52.1) | 1231 | (23.6) | 10015 | – | – | – | Kazakhstan |
| | 2642 | (70.4) | 864 | (32.7) | 3753 | – | – | – | Kyrgyzstan |
| | 1574 | (64.1) | 525 | (33.4) | 2454 | – | – | – | Moldova |
| | – | – | – | – | – | – | – | – | Monaco |
| | 57 | (100.0) | 0 | (0.0) | 57 | – | – | – | Montenegro |
| | 57910 | (91.0) | 25971 | (44.8) | 63638 | – | – | – | Russia |
| | 0 | (0.0) | 0 | (0.0) | 0 | – | – | – | San Marino |
| | 668 | (82.0) | 8 | (1.2) | 815 | – | – | – | Serbia |
| | 398 | (73.6) | 6 | (1.5) | 541 | – | – | – | Serbia excluding UN Administered Province of Kosovo ⁱ |
| | 270 | (98.5) | 2 | (0.7) | 274 | – | – | – | UN Administered Province of Kosovo ⁱ |
| | 296 | (94.3) | 13 | (4.4) | 314 | – | – | – | Switzerland |
| | 2702 | (89.7) | 646 | (23.9) | 3011 | – | – | – | Tajikistan |
| | 5612 | (86.2) | 190 | (3.4) | 6514 | – | – | – | Turkey |
| | – | – | – | – | – | – | – | – | Turkmenistan |
| | 20147 | (91.8) | 5756 | (28.6) | 21957 | – | – | – | Ukraine |
| | 1986 | (35.3) | 603 | (30.4) | 5626 | – | – | – | Uzbekistan |
| | 107132 | (83.5) | 38229 | (35.7) | 128338 | – | – | – | Subtotal non-EU/EEA |
| | 133069 | (85.1) | 39355 | (29.6) | 156339 | – | – | – | Total European Region |
| | 115899 | (84.0) | 38991 | (33.6) | 137931 | – | – | – | Subtotal 18 HPC |

^b Cases classified according to previous TB treatment history. For Belgium, Denmark, Ireland, Norway and the United Kingdom previous diagnosis was used as a proxy for previous treatment.

^c Previous treatment unknown pulmonary TB cases are excluded.

^d Percentage among laboratory-confirmed pulmonary TB cases.

^e Percentage among laboratory-confirmed pulmonary TB cases with DST results.

^f Percentage among all pulmonary TB cases.

^g Percentage among all TB cases.

^h These data are subject to change as the national TB registry was under review when this report was being produced.

ⁱ In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 13: Drug resistance in all laboratory-confirmed tuberculosis cases, EU/EEA, 2016

| Country | Source of data | Coverage | Laboratory-confirmed TB cases ^a | | Cases with DST results (at least Isoniazid and Rifampicin) | | Cases resistant to any anti-TB drug ^b | | MDR cases | | Reporting completeness ^c |
|----------------------|----------------------|-----------------|--|---------------|--|----------------|--|---------------|-------------|---------------|-------------------------------------|
| | | | N | (%) | N | (%) | N | (%) | N | (%) | |
| EU/EEA | | | | | | | | | | | |
| Austria | TESSy | national | 489 | (77.1) | 473 | (96.7) | 60 | (12.3) | 16 | (3.4) | Y |
| Belgium | TESSy | national | 801 | (76.5) | 769 | (96.0) | 48 | (6.0) | 10 | (1.3) | Y |
| <i>Bulgaria</i> | <i>TESSy</i> | <i>national</i> | <i>764</i> | <i>(47.7)</i> | <i>670</i> | <i>(87.7)</i> | <i>72</i> | <i>(9.4)</i> | <i>19</i> | <i>(2.8)</i> | <i>N</i> |
| Croatia ^d | TESSy | national | 262 | (57.0) | 262 | (100.0) | 9 | (3.4) | 0 | (0.0) | Y |
| Cyprus | TESSy | national | 42 | (70.0) | 41 | (97.6) | 7 | (16.7) | 1 | (2.4) | Y |
| Czech Republic | TESSy | national | 392 | (76.0) | 367 | (93.6) | 23 | (5.9) | 6 | (1.6) | Y |
| Denmark | TESSy | national | 258 | (78.2) | 252 | (97.7) | 15 | (5.8) | 4 | (1.6) | Y |
| <i>Estonia</i> | <i>TESSy</i> | <i>national</i> | <i>156</i> | <i>(81.3)</i> | <i>152</i> | <i>(97.4)</i> | <i>49</i> | <i>(31.4)</i> | <i>24</i> | <i>(15.8)</i> | <i>Y</i> |
| Finland | TESSy | national | 186 | (78.8) | 183 | (98.4) | 17 | (9.1) | 6 | (3.3) | Y |
| France ^e | NRL-TME ^f | sub-national | 4197 | (84.7) | 4197 | (100.0) | 71 | (1.7) | 71 | (1.7) | Y |
| Germany | TESSy | national | 4164 | (70.4) | 3757 | (90.2) | 422 | (10.1) | 101 | (2.7) | Y |
| Greece | TESSy | national | 246 | (55.5) | 124 | (50.4) | 21 | (8.5) | 5 | (4.0) | N |
| Hungary | TESSy | national | 404 | (51.4) | 340 | (84.2) | 48 | (11.9) | 18 | (5.3) | Y |
| Iceland | TESSy | national | 5 | (83.3) | 4 | (80.0) | 0 | (0.0) | 0 | (0.0) | Y |
| Ireland | TESSy | national | 238 | (74.8) | 231 | (97.1) | 28 | (11.8) | 6 | (2.6) | Y |
| Italy ^e | NRL-TME ^f | sub-national | 2666 | (66.1) | 2666 | (100.0) | 85 | (3.2) | 70 | (2.6) | Y |
| <i>Latvia</i> | <i>TESSy</i> | <i>national</i> | <i>559</i> | <i>(84.7)</i> | <i>536</i> | <i>(95.9)</i> | <i>144</i> | <i>(25.8)</i> | <i>56</i> | <i>(10.4)</i> | <i>Y</i> |
| Liechtenstein | - | - | - | - | - | - | - | - | - | - | - |
| <i>Lithuania</i> | <i>TESSy</i> | <i>national</i> | <i>1201</i> | <i>(83.3)</i> | <i>1201</i> | <i>(100.0)</i> | <i>387</i> | <i>(32.2)</i> | <i>244</i> | <i>(20.3)</i> | <i>Y</i> |
| Luxembourg | TESSy | national | 26 | (89.7) | 25 | (96.2) | 2 | (7.7) | 1 | (4.0) | Y |
| Malta | TESSy | national | 42 | (84.0) | 42 | (100.0) | 1 | (2.4) | 0 | (0.0) | Y |
| Netherlands | TESSy | national | 583 | (65.6) | 583 | (100.0) | 77 | (13.2) | 12 | (2.1) | Y |
| Norway | TESSy | national | 231 | (77.3) | 229 | (99.1) | 30 | (13.0) | 11 | (4.8) | Y |
| Poland | TESSy | national | 4619 | (71.7) | 4236 | (91.7) | 242 | (5.2) | 46 | (1.1) | Y |
| Portugal | TESSy | national | 1123 | (61.2) | 789 | (70.3) | 84 | (7.5) | 12 | (1.5) | N |
| <i>Romania</i> | <i>TESSy</i> | <i>national</i> | <i>9517</i> | <i>(69.9)</i> | <i>8440</i> | <i>(88.7)</i> | <i>877</i> | <i>(9.2)</i> | <i>463</i> | <i>(5.5)</i> | <i>Y</i> |
| Slovakia | TESSy | national | 117 | (39.5) | 113 | (96.6) | 8 | (6.8) | 3 | (2.7) | N |
| Slovenia | TESSy | national | 109 | (92.4) | 109 | (100.0) | 6 | (5.5) | 0 | (0.0) | Y |
| Spain ^e | NRL-TME ^f | sub-national | 3372 | (69.1) | 896 | (26.6) | 39 | (1.2) | 39 | (4.4) | N |
| Sweden | TESSy | national | 597 | (82.2) | 595 | (99.7) | 73 | (12.2) | 22 | (3.7) | Y |
| United Kingdom | TESSy | national | 3907 | (63.3) | 3789 | (97.0) | 271 | (6.9) | 56 | (1.5) | Y |
| Total EU/EEA | | | 41273 | (76.4) | 36071 | (87.4) | 3216 | (9.9) | 1322 | (3.7) | |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^a Includes only countries reporting first-line anti-TB drug susceptibility testing. Laboratory-confirmed cases consist of culture-positive and smear-positive/nucleic acid amplification test-positive cases.

^b Any resistance to isoniazid, rifampicin, ethambutol or streptomycin expressed as a percentage of cases with available DST results, at least for isoniazid and rifampicin. No routine testing for ethambutol and streptomycin in all countries.

^c Data considered complete when national coverage 100% or culture results available for 90% of all cases, 50% of all cases culture-positive, 75% of them with DST results, and EQA results accurate in 95% of samples for reported year.

^d These data are subject to change as the national TB registry was under review when this report was being produced.

^e Data from France, Italy and Spain reported from NRL may differ from data shown elsewhere in this report.

^f NRL: National reference laboratory; TME: WHO Tuberculosis Monitoring and Evaluation Database.

Table 14: XDR TB cases among all laboratory-confirmed MDR TB cases, European Region, 2016

| Country | TB cases with first-line DST ^a | MDR TB among all TB cases | | MDR TB with second-line DST ^{b,c} | | XDR TB | |
|--|---|---------------------------|---------------|--|---------------|--------------|---------------|
| | | N | % | N | % | N | % |
| EU/EEA | | | | | | | |
| Austria | 473 | 16 | (3.4) | 16 | (100.0) | 2 | (12.5) |
| Belgium | 769 | 10 | (1.3) | 10 | (100.0) | 0 | (0.0) |
| Bulgaria | 670 | 19 | (2.8) | 19 | (100.0) | 0 | (0.0) |
| Croatia ^d | 262 | 0 | (0.0) | 0 | – | 0 | – |
| Cyprus | 41 | 1 | (2.4) | 1 | (100.0) | 0 | (0.0) |
| Czech Republic | 367 | 6 | (1.6) | 5 | (83.3) | 0 | (0.0) |
| Denmark | 252 | 4 | (1.6) | 4 | (100.0) | 0 | (0.0) |
| Estonia | 152 | 24 | (15.8) | 24 | (100.0) | 7 | (29.2) |
| Finland | 183 | 6 | (3.3) | 6 | (100.0) | 1 | (16.7) |
| France | 4 197 | 71 | (1.7) | 69 | (97.2) | 6 | (8.7) |
| Germany | 3 757 | 101 | (2.7) | 64 | (63.4) | 5 | (7.8) |
| Greece | 124 | 5 | (4.0) | 0 | (0.0) | 0 | – |
| Hungary | 340 | 18 | (5.3) | 15 | (83.3) | 7 | (46.7) |
| Iceland | 4 | 0 | (0.0) | 0 | – | 0 | – |
| Ireland | 231 | 6 | (2.6) | 5 | (83.3) | 0 | (0.0) |
| Italy | 2 666 | 70 | (2.6) | 55 | (78.6) | 7 | (12.7) |
| Latvia | 536 | 56 | (10.4) | 56 | (100.0) | 21 | (37.5) |
| Liechtenstein | – | – | – | – | – | – | – |
| Lithuania | 1 201 | 244 | (20.3) | 244 | (100.0) | 58 | (23.8) |
| Luxembourg | 25 | 1 | (4.0) | 0 | (0.0) | 0 | – |
| Malta | 42 | 0 | (0.0) | 0 | – | 0 | – |
| Netherlands | 583 | 12 | (2.1) | 12 | (100.0) | 0 | (0.0) |
| Norway | 229 | 11 | (4.8) | 11 | (100.0) | 0 | (0.0) |
| Poland | 4 236 | 46 | (1.1) | 39 | (84.8) | 8 | (20.5) |
| Portugal | 789 | 12 | (1.5) | 5 | (41.7) | 2 | (40.0) |
| Romania | 8 440 | 463 | (5.5) | 210 | (45.4) | 63 | (30.0) |
| Slovakia | 113 | 3 | (2.7) | 3 | (100.0) | 0 | (0.0) |
| Slovenia | 109 | 0 | (0.0) | 0 | – | 0 | – |
| Spain | 898 | 39 | (4.7) | 39 | (92.9) | 0 | (0.0) |
| Sweden | 595 | 22 | (3.7) | 22 | (100.0) | 4 | (18.2) |
| United Kingdom | 3 789 | 56 | (1.5) | 50 | (89.3) | 7 | (14.0) |
| Subtotal EU/EEA | 36 073 | 1 322 | (3.7) | 984 | (74.4) | 198 | (20.1) |
| Non-EU/EEA | | | | | | | |
| Albania | – | – | – | – | – | – | – |
| Andorra | 1 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Armenia | 461 | 115 | (24.9) | 53 | (48.6) | 6 | (11.3) |
| Azerbaijan | 2 614 | 777 | (29.7) | 535 | (68.9) | 71 | (13.3) |
| Belarus | 2 555 | 1 222 | (47.8) | 1 246 | (102.0) | 572 | (45.9) |
| Bosnia and Herzegovina | 597 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| former Yugoslav Republic of Macedonia, the | 143 | 2 | (1.4) | 0 | (0.0) | 0 | (0.0) |
| Georgia | 1 791 | 296 | (16.5) | 296 | (100.0) | 52 | (17.6) |
| Israel | 123 | 9 | (7.3) | 9 | (100.0) | 2 | (22.2) |
| Kazakhstan | – | – | – | – | – | – | – |
| Kyrgyzstan | 2 642 | 864 | (32.7) | 407 | (47.1) | 72 | (17.7) |
| Moldova | 1 574 | 525 | (33.4) | 514 | (97.9) | 42 | (8.2) |
| Monaco | – | – | – | – | – | – | – |
| Montenegro | 57 | 0 | (0.0) | 0 | – | 0 | – |
| Russia | 57 910 | 25 971 | (44.8) | 25 258 | (97.3) | 3 402 | (13.5) |
| San Marino | 0 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Serbia | 668 | 8 | (1.2) | 14 | (175.0) | 1 | (7.1) |
| Serbia excluding UN Administered Province of Kosovo ^e | 398 | 6 | (1.5) | 14 | (233.3) | 1 | (7.1) |
| UN Administered Province of Kosovo ^e | 270 | 2 | (0.7) | 0 | (0.0) | 0 | (0.0) |
| Switzerland | 296 | 13 | (4.4) | 13 | (100.0) | 0 | (0.0) |
| Tajikistan | 2 702 | 646 | (23.9) | 646 | (100.0) | 59 | (8.5) |
| Turkey | 5 612 | 190 | (3.4) | 130 | (68.4) | 9 | (6.9) |
| Turkmenistan | – | – | – | – | – | – | – |
| Ukraine | 20 147 | 5 756 | (28.6) | 5 756 | (100.0) | 247 | (3.3) |
| Uzbekistan | – | – | – | 1 802 | – | 184 | (10.2) |
| Subtotal non-EU/EEA | 99 893 | 36 394 | (36.4) | 34 877 | (95.8) | 4 719 | (12.9) |
| Total European Region | 135 966 | 37 716 | (27.7) | 35 861 | (95.1) | 4 917 | (13.1) |
| Subtotal 18 HPC | 109 007 | 37 168 | (34.1) | 35 394 | (95.2) | 4 865 | (13.1) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

XDR TB – Extensively drug-resistant tuberculosis.

MDR TB – Multidrug-resistant tuberculosis.

^a First-line DST – drug susceptibility testing for at least 2 main first-line TB drugs: isoniazid and rifampicin.

^b Second-line DST – drug susceptibility testing for second-line TB drugs.

^c Includes only countries reporting second-line anti-TB drug susceptibility testing (at least one fluoroquinolone (ofloxacin, moxifloxacin and levofloxacin) and one injectable drug (amikacin, kanamycin and capreomycin)).

^d These data are subject to change as the national TB registry was under review when this report was being produced.

^e In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 15: MDR and XDR TB cases enrolled in treatment, European Region, 2016

| Country | Total number of RR/MDR TB detected ^a | RR/MDR TB cases enrolled on treatment | | Total number of XDR TB detected | XDR TB cases enrolled on treatment | |
|--|---|---------------------------------------|---------------|---------------------------------|------------------------------------|---------------|
| | N | N | % | N | N | % |
| EU/EEA | | | | | | |
| Austria | 14 | 14 | (100.0) | 1 | 1 | (100.0) |
| Belgium | 9 | 9 | (100.0) | 0 | 0 | – |
| <i>Bulgaria</i> | 15 | 15 | (100.0) | 0 | 0 | – |
| Croatia ^b | 0 | 0 | – | 0 | 0 | – |
| Cyprus | 1 | 1 | (100.0) | 0 | 0 | – |
| Czech Republic | 5 | 4 | (80.0) | 0 | 0 | – |
| Denmark | 4 | 4 | (100.0) | 0 | 0 | – |
| <i>Estonia</i> | 23 | 22 | (95.7) | 6 | 5 | (83.3) |
| Finland | 6 | 6 | (100.0) | 1 | 1 | (100.0) |
| France | 71 | 71 | (100.0) | 6 | 6 | (100.0) |
| Germany | 101 | 101 | (100.0) | 3 | 3 | (100.0) |
| Greece | 3 | 3 | (100.0) | 0 | 0 | – |
| Hungary | 15 | 15 | (100.0) | 6 | 6 | – |
| Iceland | 0 | 0 | – | 0 | 0 | – |
| Ireland | 5 | 5 | (100.0) | 0 | 0 | – |
| Italy | 70 | 70 | (100.0) | 7 | 7 | (100.0) |
| <i>Latvia</i> | 49 | 49 | (100.0) | 16 | 16 | (100.0) |
| Liechtenstein | – | – | – | – | – | – |
| <i>Lithuania</i> | 195 | 195 | (100.0) | 29 | 29 | (100.0) |
| Luxembourg | 1 | 1 | (100.0) | 0 | 0 | – |
| Malta | 0 | 0 | – | 0 | 0 | – |
| Netherlands | 12 | 12 | (100.0) | 0 | 0 | – |
| Norway | 11 | 11 | (100.0) | 0 | 0 | – |
| Poland | 44 | 44 | (100.0) | 8 | 8 | (100.0) |
| Portugal | 15 | 15 | (100.0) | 2 | 2 | (100.0) |
| <i>Romania</i> | 311 | 309 | (99.4) | 19 | 19 | (100.0) |
| Slovakia | 2 | 2 | (100.0) | 0 | 0 | – |
| Slovenia | 0 | 0 | – | 0 | 0 | – |
| Spain | 39 | 39 | (100.0) | 0 | 0 | – |
| Sweden | 22 | 22 | (100.0) | 3 | 3 | (100.0) |
| United Kingdom | 50 | 48 | (96.0) | 6 | 6 | (100.0) |
| Subtotal EU/EEA | 1093 | 1087 | (99.5) | 113 | 112 | (99.1) |
| Non-EU/EEA | | | | | | |
| Albania | 4 | 1 | (25.0) | 0 | 0 | (0.0) |
| Andorra | 0 | 0 | (0.0) | 0 | 0 | (0.0) |
| <i>Armenia</i> | 128 | 128 | (100.0) | 29 | 29 | (100.0) |
| <i>Azerbaijan</i> | 925 | 798 | (86.3) | 77 | 0 | (0.0) |
| <i>Belarus</i> | 1543 | 1345 | (87.2) | 572 | 572 | (100.0) |
| Bosnia and Herzegovina | 0 | 0 | (0.0) | 0 | 0 | (0.0) |
| former Yugoslav Republic of Macedonia, the | 2 | 2 | (100.0) | 0 | 0 | (0.0) |
| <i>Georgia</i> | 401 | 351 | (87.5) | 56 | 51 | (91.1) |
| Israel | 11 | 11 | (100.0) | 2 | 2 | (100.0) |
| <i>Kazakhstan</i> | 5817 | 5817 | (100.0) | 386 | 435 | (112.7) |
| <i>Kyrgyzstan</i> | 1236 | 1200 | (97.1) | 73 | 67 | (91.8) |
| <i>Moldova</i> | 1031 | 979 | (95.0) | 72 | 65 | (90.3) |
| Monaco | – | – | – | – | – | – |
| Montenegro | 0 | 0 | (0.0) | 0 | 0 | (0.0) |
| <i>Russia</i> | 27363 | 25713 | (94.0) | 3402 | 1772 | (52.1) |
| San Marino | 0 | 0 | (0.0) | 0 | 0 | (0.0) |
| Serbia | 12 | 10 | (83.3) | 3 | 1 | (33.3) |
| Serbia excluding UN Administered Province of Kosovo ^c | 8 | 8 | (100.0) | 1 | 1 | (100.0) |
| UN Administered Province of Kosovo ^c | 4 | 2 | (50.0) | 2 | 0 | (0.0) |
| Switzerland | 18 | 18 | (100.0) | 0 | 0 | (0.0) |
| <i>Tajikistan</i> | 748 | 681 | (91.0) | 59 | 43 | (72.9) |
| <i>Turkey</i> | 256 | 211 | (82.4) | 9 | 9 | (100.0) |
| <i>Turkmenistan</i> | 557 | 557 | (100.0) | – | – | – |
| <i>Ukraine</i> | 8651 | 8581 | (99.2) | 1195 | 1429 | (119.6) |
| <i>Uzbekistan</i> | 1956 | 1956 | (100.0) | 184 | 184 | (100.0) |
| Subtotal non-EU/EEA | 50 659 | 48 359 | (95.5) | 6 119 | 4 659 | (76.1) |
| Total European Region | 51 752 | 49 446 | (95.5) | 6 232 | 4 771 | (76.6) |
| Subtotal 18 HPC | 51 205 | 48 907 | (95.5) | 6 184 | 4 725 | (76.4) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

RR-MDR TB – rifampicin-resistant and multidrug-resistant tuberculosis.

XDR TB – Extensively drug-resistant tuberculosis.

^b For countries that do not provide information on treatment start all reported cases were used as proxy.

^c These data are subject to change as the national TB registry was under review when this report was being produced.

^d In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 16: New and relapse tuberculosis cases with HIV infection, European Region, 2016

| Country | New and relapse TB cases (N) ^a | Cases with known HIV-status | | HIV-positive TB cases | | HIV-positive cases started ART ^b | |
|--|---|-----------------------------|---------------|-----------------------|---------------|---|---------------|
| | | N | % | N | % | N | % |
| EU/EEA | | | | | | | |
| Austria | – | – | – | – | – | – | – |
| Belgium | 986 | 448 | (45.4) | 32 | (7.1) | – | – |
| <i>Bulgaria</i> | 1525 | 1205 | (79.0) | 0 | (0.0) | 0 | (0.0) |
| Croatia | – | – | – | – | – | – | – |
| Cyprus | 57 | 46 | (80.7) | 0 | (0.0) | 0 | – |
| Czech Republic | 511 | 202 | (39.5) | 5 | (2.5) | – | – |
| Denmark | 292 | 134 | (45.9) | 9 | (6.7) | – | – |
| Estonia | 188 | 180 | (95.7) | 21 | (11.7) | 20 | (95.2) |
| Finland ^c | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | – |
| Germany | – | – | – | – | – | – | – |
| Greece | – | – | – | – | – | – | – |
| Hungary | 737 | 18 | (2.4) | 1 | (5.6) | – | – |
| Iceland | 6 | 6 | (100.0) | 0 | (0.0) | 0 | – |
| Ireland | 293 | 121 | (41.3) | 4 | (3.3) | 3 | (75.0) |
| Italy | – | – | – | – | – | – | – |
| Latvia | 641 | 500 | (78.0) | 55 | (11.0) | 34 | (61.8) |
| Liechtenstein | – | – | – | – | – | – | – |
| Lithuania | 1347 | 1047 | (77.7) | 34 | (3.2) | – | – |
| Luxembourg | 29 | 5 | (17.2) | 2 | (40.0) | – | – |
| Malta | 50 | 46 | (92.0) | 8 | (17.4) | 8 | (100.0) |
| Netherlands | 877 | 546 | (62.3) | 21 | (3.8) | 15 | (71.4) |
| Norway | 278 | 239 | (86.0) | 8 | (3.3) | 8 | (100.0) |
| Poland ^c | – | – | – | – | – | – | – |
| Portugal | 1794 | 1184 | (66.0) | 164 | (13.9) | – | – |
| Romania | 12790 | 9968 | (77.9) | 254 | (2.5) | 254 | (100.0) |
| Slovakia | 281 | 124 | (44.1) | 0 | (0.0) | 0 | – |
| Slovenia | 118 | 95 | (80.5) | 1 | (1.1) | 1 | (100.0) |
| Spain | 4734 | 2823 | (59.6) | 207 | (7.3) | – | – |
| Sweden | – | – | – | – | – | – | – |
| United Kingdom | – | – | – | – | – | – | – |
| Subtotal EU/EEA | 27534 | 18937 | (68.8) | 826 | (4.4) | 343 | (94.2) |
| Non-EU/EEA | | | | | | | |
| Albania | 415 | 223 | (53.7) | 6 | (2.7) | 6 | (100.0) |
| Andorra | 4 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Armenia | 1027 | 1027 | (100.0) | 57 | (5.6) | 57 | (100.0) |
| Azerbaijan | 5159 | 4722 | (91.5) | 99 | (2.1) | 78 | (78.8) |
| Belarus | 3211 | 3148 | (98.0) | 275 | (8.7) | 229 | (83.3) |
| Bosnia and Herzegovina | 907 | 1 | (0.1) | 1 | (100.0) | 1 | (100.0) |
| former Yugoslav Republic of Macedonia, the | 263 | 207 | (78.7) | 0 | (0.0) | 0 | (0.0) |
| Georgia | 2983 | 2866 | (96.1) | 61 | (2.1) | 56 | (91.8) |
| Israel | 250 | 250 | (100.0) | 18 | (7.2) | 16 | (88.9) |
| Kazakhstan | 12322 | 10616 | (86.2) | 576 | (5.4) | 478 | (83.0) |
| Kyrgyzstan | 7026 | 6254 | (89.0) | 210 | (3.4) | 144 | (68.6) |
| Moldova | 3571 | 3366 | (94.3) | 293 | (8.7) | 193 | (65.9) |
| Monaco | – | – | – | – | – | – | – |
| Montenegro | 87 | 60 | (69.0) | 0 | (0.0) | 0 | (0.0) |
| Russia ^e | 92407 | 79935 | (86.5) | 16570 | (20.7) | 10549 | (63.7) |
| San Marino | 0 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Serbia | 1472 | 482 | (32.7) | 5 | (1.0) | 5 | (100.0) |
| Serbia excluding UN Administered Province of Kosovo ^d | 755 | 84 | (11.1) | 5 | (6.0) | 5 | (100.0) |
| UN Administered Province of Kosovo ^d | 717 | 398 | (55.5) | 0 | (0.0) | 0 | (0.0) |
| Switzerland | – | – | – | – | – | – | – |
| Tajikistan | 5965 | 5850 | (98.1) | 201 | (3.4) | 182 | (90.5) |
| Turkey | 12186 | 8549 | (70.2) | 56 | (0.7) | 51 | (91.1) |
| Turkmenistan | 0 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Ukraine | 29052 | 28194 | (97.0) | 5832 | (20.7) | 3945 | (67.6) |
| Uzbekistan ^e | 18441 | 18441 | (100.0) | 758 | (4.1) | 496 | (65.4) |
| Subtotal non-EU/EEA | 196748 | 174191 | (88.5) | 25018 | (14.4) | 16486 | (65.9) |
| Total European Region | 224282 | 193128 | (86.1) | 25844 | (13.4) | 16829 | (65.1) |
| Subtotal 18 HPC | 209841 | 185868 | (88.6) | 25352 | (13.6) | 16766 | (66.1) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

HIV – Human immunodeficiency virus.

ART – Antiretroviral therapy.

^a Countries were only included in this analysis if total number of cases tested for HIV and test results were provided.

^b Data from WHO Global TB database. Percentages calculated for countries which reported antiretroviral treatment (ART).

^c Finland reported HIV-positive cases, but not the number of cases tested for HIV, therefore excluded from this analysis.

^d In accordance with the UN Security Council Resolution No. 1244 (1999).

^e Uzbekistan reported data among all TB cases.

Table 16a: All tuberculosis cases with HIV infection, EU/EEA, 2016

| Country | All TB cases (N) ^a | Cases with known HIV-status | | HIV-positive TB cases | |
|----------------------|-------------------------------|-----------------------------|---------------|-----------------------|---------------|
| | | N | % | N | % |
| EU/EEA | | | | | |
| Austria | - | - | - | - | - |
| Belgium | 1047 | 479 | (45.7) | 33 | (6.9) |
| <i>Bulgaria</i> | <i>1603</i> | <i>1260</i> | <i>(78.6)</i> | <i>0</i> | <i>(0.0)</i> |
| Croatia | - | - | - | - | - |
| Cyprus | 60 | 48 | (80.0) | 0 | (0.0) |
| Czech Republic | 516 | 205 | (39.7) | 5 | (2.4) |
| Denmark | 330 | 150 | (45.5) | 9 | (6.0) |
| <i>Estonia</i> | <i>192</i> | <i>184</i> | <i>(95.8)</i> | <i>22</i> | <i>(12.0)</i> |
| Finland ^b | - | - | - | - | - |
| France | - | - | - | - | - |
| Germany | - | - | - | - | - |
| Greece | - | - | - | - | - |
| Hungary | 786 | 19 | (2.4) | 1 | (5.3) |
| Iceland | 6 | 6 | (100.0) | 0 | (0.0) |
| Ireland | 318 | 132 | (41.5) | 4 | (3.0) |
| Italy | - | - | - | - | - |
| <i>Latvia</i> | <i>660</i> | <i>507</i> | <i>(76.8)</i> | <i>57</i> | <i>(11.2)</i> |
| Liechtenstein | - | - | - | - | - |
| <i>Lithuania</i> | <i>1442</i> | <i>1138</i> | <i>(78.9)</i> | <i>41</i> | <i>(3.6)</i> |
| Luxembourg | 29 | 5 | (17.2) | 2 | (40.0) |
| Malta | 50 | 46 | (92.0) | 8 | (17.4) |
| Netherlands | 889 | 554 | (62.3) | 21 | (3.8) |
| Norway | 299 | 257 | (86.0) | 10 | (3.9) |
| Poland | - | - | - | - | - |
| Portugal | 1836 | 1212 | (66.0) | 168 | (13.9) |
| <i>Romania</i> | <i>13 617</i> | <i>10 634</i> | <i>(78.1)</i> | <i>287</i> | <i>(2.7)</i> |
| Slovakia | 296 | 132 | (44.6) | 0 | (0.0) |
| Slovenia | 118 | 95 | (80.5) | 1 | (1.1) |
| Spain | 4877 | 2925 | (60.0) | 226 | (7.7) |
| Sweden | - | - | - | - | - |
| United Kingdom | - | - | - | - | - |
| Total EU/EEA | 28 971 | 19 988 | (69.0) | 895 | (4.5) |

WHO European Region 18 TB high-priority countries presented in italics.
HIV – Human immunodeficiency virus.

^a Countries were only included in this analysis if total number of cases tested for HIV and test results were provided.

^b Finland reported HIV-positive cases, but not the number of cases tested for HIV, therefore excluded from this analysis.

Table 17: Tuberculosis in prisons, European Region, 2016^a

| Country | Prison population (N) | New and relapsed TB cases (all forms) notified in prisons | | Proportion of new and relapsed TB cases in prisons out of the country total (%) | TB relative risk in prisons (RR) ^b |
|--|-----------------------|---|---------------|---|---|
| | | N | Rate | | |
| EU/EEA | | | | | |
| Austria | - | - | - | - | - |
| Belgium | 11769 | 19 | 161.4 | (1.9) | 18.4 |
| Bulgaria | 7921 | 22 | 277.7 | (1.4) | 13.1 |
| Croatia | - | - | - | - | - |
| Cyprus | - | - | - | - | - |
| Czech Republic | 22481 | 14 | 62.3 | (2.7) | 12.8 |
| Denmark | - | - | - | - | - |
| Estonia | 2841 | 8 | 281.6 | (4.3) | 19.7 |
| Finland | - | - | - | - | - |
| France | 66474 | 65 | 97.8 | (1.4) | 13.9 |
| Germany | - | - | - | - | - |
| Greece | - | - | - | - | - |
| Hungary | 19000 | 9 | 47.4 | (1.2) | - |
| Iceland | - | - | - | - | - |
| Ireland | 12579 | 0 | 0.0 | (0.0) | 0.0 |
| Italy | - | - | - | - | - |
| Latvia | 4243 | 32 | 754.2 | (5.0) | 23.4 |
| Liechtenstein | - | - | - | - | - |
| Lithuania | 6815 | 35 | 513.6 | (2.6) | 11.1 |
| Luxembourg | 700 | 0 | 0.0 | (0.0) | 0.0 |
| Malta | 569 | 0 | 0.0 | (0.0) | 0.0 |
| Netherlands | 37166 | 14 | 37.7 | (1.6) | 7.3 |
| Norway | - | - | - | - | - |
| Poland | 71456 | 216 | 302.3 | (3.5) | 18.7 |
| Portugal | 13779 | 36 | 261.3 | (2.0) | 15.1 |
| Romania | 27114 | 157 | 579.0 | (1.2) | 9.0 |
| Slovakia | 8023 | 17 | 211.9 | (6.0) | 40.9 |
| Slovenia | 3730 | 0 | 0.0 | (0.0) | 0.0 |
| Spain | - | - | - | - | - |
| Sweden | - | - | - | - | - |
| United Kingdom | 93097 | 27 | 29.0 | (0.5) | 3.2 |
| Subtotal EU/EEA | 409757 | 671 | 163.8 | (1.7) | (11.1) |
| Non-EU/EEA | | | | | |
| Albania | 6100 | 3 | 49.2 | (0.7) | 3.5 |
| Andorra | 41 | 0 | 0.0 | (0.0) | 0.0 |
| Armenia | 4873 | 9 | 184.7 | (0.9) | 5.3 |
| Azerbaijan | 20860 | 254 | 1217.6 | (4.9) | 23.0 |
| Belarus | 29776 | 121 | 406.4 | (3.8) | 12.0 |
| Bosnia and Herzegovina | 0 | 0 | 0.0 | (0.0) | 0.0 |
| former Yugoslav Republic of Macedonia, the | 2700 | 3 | 111.1 | (1.1) | 8.8 |
| Georgia | 9334 | 57 | 610.7 | (1.9) | 8.0 |
| Israel | 0 | 0 | 0.0 | (0.0) | 0.0 |
| Kazakhstan | 0 | 0 | 0.0 | (0.0) | 0.0 |
| Kyrgyzstan | 8300 | 216 | 2602.4 | (3.1) | 22.1 |
| Moldova | 7762 | 173 | 2228.8 | (4.8) | 25.3 |
| Monaco | - | - | - | - | - |
| Montenegro | - | - | - | - | - |
| Russia | 639042 | 9610 | 1503.8 | (10.4) | 23.4 |
| San Marino | 10 | 0 | 0.0 | (0.0) | 0.0 |
| Serbia | 11641 | 12 | 103.1 | (0.8) | 6.2 |
| Serbia excluding UN Administered Province of Kosovo ^c | 10069 | 11 | 109.2 | (1.5) | 10.1 |
| UN Administered Province of Kosovo ^c | 1572 | 1 | 63.6 | (0.1) | 1.6 |
| Switzerland | - | - | - | - | - |
| Tajikistan | 10000 | 99 | 990.0 | (1.7) | 14.5 |
| Turkey | 200600 | 151 | 75.3 | (1.2) | 4.9 |
| Turkmenistan | - | - | - | - | - |
| Ukraine | 65398 | 919 | 1405.2 | (3.2) | 21.5 |
| Uzbekistan | - | - | - | - | - |
| Subtotal non-EU/EEA | 1016437 | 11627 | 1143.9 | (7.1) | 22.7 |
| Total European Region | 1426194 | 12298 | 862.3 | (6.0) | 25.0 |
| Subtotal 18 HPC | 1044879 | 11863 | 1135.3 | (6.6) | 21.9 |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^b Data obtained from WHO Tuberculosis Monitoring and Evaluation database (TME).

^c In the calculation of summary results only countries reporting data on prison population and TB notification in prisons are included.

^d In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 18: Treatment outcome for all TB cases notified in 2014, European Region, 2016

| Country | Cases notified in 2015 | Success | | Died | | Failed | | Lost to follow-up ^a | | Still on treatment | | Not evaluated ^b | |
|--|------------------------|----------------|---------------|---------------|--------------|---------------|--------------|--------------------------------|--------------|--------------------|--------------|----------------------------|--------------|
| | | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| EU/EEA | | | | | | | | | | | | | |
| Austria | 583 | 417 | (71.5) | 37 | (6.3) | 0 | (0.0) | 12 | (2.1) | 52 | (8.9) | 65 | (11.1) |
| Belgium | 977 | 764 | (78.2) | 68 | (7.0) | 1 | (0.1) | 85 | (8.7) | 29 | (3.0) | 30 | (3.1) |
| Bulgaria | 1 660 | 1 385 | (83.4) | 139 | (8.4) | 23 | (1.4) | 90 | (5.4) | 8 | (0.5) | 15 | (0.9) |
| Croatia ^c | 486 | 50 | (10.3) | 43 | (8.8) | 0 | (0.0) | 0 | (0.0) | 2 | (0.4) | 391 | (80.5) |
| Cyprus | 63 | 35 | (55.6) | 3 | (4.8) | 0 | (0.0) | 3 | (4.8) | 2 | (3.2) | 20 | (31.7) |
| Czech Republic | 517 | 350 | (67.7) | 97 | (18.8) | 5 | (1.0) | 24 | (4.6) | 24 | (4.6) | 17 | (3.3) |
| Denmark | 357 | 171 | (47.9) | 10 | (2.8) | 10 | (2.8) | 1 | (0.3) | 14 | (3.9) | 151 | (42.3) |
| Estonia | 217 | 149 | (68.7) | 33 | (15.2) | 0 | (0.0) | 7 | (3.2) | 26 | (12.0) | 2 | (0.9) |
| Finland ^d | 272 | 95 | (34.9) | 15 | (5.5) | 0 | (0.0) | 1 | (0.4) | 2 | (0.7) | 159 | (58.5) |
| France | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Germany | 5 852 | 3 728 | (63.7) | 382 | (6.5) | 6 | (0.1) | 160 | (2.7) | 307 | (5.2) | 1 269 | (21.7) |
| Greece | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Hungary | 906 | 631 | (69.6) | 107 | (11.8) | 18 | (2.0) | 89 | (9.8) | 24 | (2.6) | 37 | (4.1) |
| Iceland | 7 | 7 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Ireland | 283 | 157 | (55.5) | 10 | (3.5) | 0 | (0.0) | 1 | (0.4) | 1 | (0.4) | 114 | (40.3) |
| Italy | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Latvia | 721 | 551 | (76.4) | 71 | (9.8) | 1 | (0.1) | 36 | (5.0) | 59 | (8.2) | 3 | (0.4) |
| Liechtenstein | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Lithuania | 1 507 | 987 | (65.5) | 192 | (12.7) | 15 | (1.0) | 118 | (7.8) | 194 | (12.9) | 1 | (0.1) |
| Luxembourg | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Malta | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Netherlands | 862 | 733 | (85.0) | 38 | (4.4) | 0 | (0.0) | 23 | (2.7) | 22 | (2.6) | 46 | (5.3) |
| Norway | 313 | 268 | (85.6) | 7 | (2.2) | 3 | (1.0) | 9 | (2.9) | 11 | (3.5) | 15 | (4.8) |
| Poland | 6 430 | 3 387 | (52.7) | 632 | (9.8) | 4 | (0.1) | 391 | (6.1) | 12 | (0.2) | 2 004 | (31.2) |
| Portugal | 2 178 | 1 539 | (70.7) | 151 | (6.9) | 0 | (0.0) | 84 | (3.9) | 344 | (15.8) | 60 | (2.8) |
| Romania | 15 183 | 12 185 | (80.3) | 1 227 | (8.1) | 496 | (3.3) | 971 | (6.4) | 284 | (1.9) | 20 | (0.1) |
| Slovakia | 317 | 271 | (85.5) | 23 | (7.3) | 0 | (0.0) | 2 | (0.6) | 2 | (0.6) | 19 | (6.0) |
| Slovenia | 130 | 106 | (81.5) | 21 | (16.2) | 0 | (0.0) | 0 | (0.0) | 3 | (2.3) | 0 | (0.0) |
| Spain | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Sweden | 815 | 688 | (84.4) | 24 | (2.9) | 1 | (0.1) | 10 | (1.2) | 40 | (4.9) | 52 | (6.4) |
| United Kingdom | 6 234 | 4 865 | (78.0) | 379 | (6.1) | 0 | (0.0) | 325 | (5.2) | 549 | (8.8) | 116 | (1.9) |
| Subtotal EU/EEA | 46 870 | 33 519 | (71.5) | 3 709 | (7.9) | 583 | (1.2) | 2 442 | (5.2) | 2 011 | (4.3) | 4 606 | (9.8) |
| Non-EU/EEA | | | | | | | | | | | | | |
| Albania | 409 | 354 | (86.6) | 11 | (2.7) | 3 | (0.7) | 21 | (5.1) | - | - | 20 | (4.9) |
| Andorra | 4 | 4 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - | - | 0 | (0.0) |
| Armenia | 923 | 731 | (79.2) | 47 | (5.1) | 11 | (1.2) | 134 | (14.5) | - | - | 0 | (0.0) |
| Azerbaijan | 4 213 | 3 230 | (76.7) | 216 | (5.1) | 146 | (3.5) | 488 | (11.6) | - | - | 133 | (3.2) |
| Belarus | 2 788 | 2 444 | (87.7) | 100 | (3.6) | 87 | (3.1) | 100 | (3.6) | - | - | 57 | (2.0) |
| Bosnia and Herzegovina | 1 095 | 707 | (64.6) | 84 | (7.7) | 19 | (1.7) | 2 | (0.2) | - | - | 283 | (25.8) |
| former Yugoslav Republic of Macedonia, the | 284 | 245 | (86.3) | 25 | (8.8) | 3 | (1.1) | 7 | (2.5) | - | - | 4 | (1.4) |
| Georgia | 3 144 | 2 582 | (82.1) | 135 | (4.3) | 70 | (2.2) | 293 | (9.3) | - | - | 64 | (2.0) |
| Israel | 263 | 218 | (82.9) | 19 | (7.2) | 1 | (0.4) | 8 | (3.0) | - | - | 17 | (6.5) |
| Kazakhstan | 14 631 | 13 172 | (90.0) | 751 | (5.1) | 476 | (3.3) | 232 | (1.6) | - | - | 0 | (0.0) |
| Kyrgyzstan | 6 686 | 5 423 | (81.1) | 418 | (6.3) | 159 | (2.4) | 674 | (10.1) | - | - | 12 | (0.2) |
| Moldova | 3 209 | 2 480 | (77.3) | 375 | (11.7) | 102 | (3.2) | 177 | (5.5) | - | - | 75 | (2.3) |
| Monaco | - | - | - | - | - | - | - | 0 | - | - | - | - | - |
| Montenegro | 80 | 74 | (92.5) | 3 | (3.8) | 0 | (0.0) | 3 | (3.8) | - | - | 0 | (0.0) |
| Russia | 88 718 | 61 238 | (69.0) | 9 174 | (10.3) | 6 861 | (7.7) | 4 986 | (5.6) | - | - | 6 459 | (7.3) |
| San Marino | 0 | - | - | - | - | - | - | 0 | - | - | - | - | - |
| Serbia | 1 669 | 1 484 | (88.9) | 83 | (5.0) | 13 | (0.8) | 65 | (3.9) | - | - | 24 | (1.4) |
| Serbia excluding UN Administered Province of Kosovo ^e | 897 | 739 | (82.4) | 67 | (7.5) | 12 | (1.3) | 56 | (6.2) | - | - | 23 | (2.6) |
| UN Administered Province of Kosovo ^e | 772 | 745 | (96.5) | 16 | (2.1) | 1 | (0.1) | 9 | (1.2) | - | - | 1 | (0.1) |
| Switzerland | - | - | - | - | - | - | - | 0 | - | - | - | - | - |
| Tajikistan | 5 584 | 4 964 | (88.9) | 265 | (4.7) | 116 | (2.1) | 194 | (3.5) | - | - | 45 | (0.8) |
| Turkey | 12 520 | 10 807 | (86.3) | 707 | (5.6) | 34 | (0.3) | 480 | (3.8) | - | - | 492 | (3.9) |
| Turkmenistan | 2 753 | 2 352 | (85.4) | 125 | (4.5) | 115 | (4.2) | 96 | (3.5) | - | - | 65 | (2.4) |
| Ukraine | 27 548 | 20 034 | (72.7) | 2 926 | (10.6) | 2 376 | (8.6) | 2 141 | (7.8) | - | - | 71 | (0.3) |
| Uzbekistan | 17 837 | 15 694 | (88.0) | 826 | (4.6) | 227 | (1.3) | 209 | (1.2) | - | - | 881 | (4.9) |
| Subtotal non-EU/EEA | 194 358 | 148 237 | (76.3) | 16 290 | (8.4) | 10 819 | (5.6) | 10 310 | (5.3) | 0 | (0.0) | 8 702 | (4.5) |
| Total European Region | 241 228 | 181 756 | (75.3) | 19 999 | (8.3) | 11 402 | (4.7) | 12 752 | (5.3) | 2 011 | (0.8) | 13 308 | (5.5) |
| Subtotal 18 HPC | 209 842 | 160 408 | (76.4) | 17 727 | (8.4) | 11 315 | (5.4) | 11 426 | (4.7) | 571 | (0.2) | 8 395 | (3.5) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^b In previous reports defined as 'defaulted'.

^c In previous reports defined as 'transferred out and unknown'.

^d These data are subject to change as the national TB registry was under review when this report was being produced.

^e Treatment outcome data collected consistently only for confirmed pulmonary cases.

^f In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 19: Treatment outcome of new tuberculosis cases and relapses notified in 2014, European Region, 2016

| Country | New and relapsed TB cases started on treatment in 2014 ^a | Success | | Died | | Failed | | Lost to follow-up ^b | | Still on treatment | | Not evaluated ^c | |
|--|---|----------------|---------------|---------------|--------------|--------------|--------------|--------------------------------|--------------|--------------------|--------------|----------------------------|--------------|
| | | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| EU/EEA | | | | | | | | | | | | | |
| Austria | 553 | 402 | (72.7) | 37 | (6.7) | 0 | (0.0) | 10 | (1.8) | 45 | (8.1) | 59 | (10.7) |
| Belgium | 905 | 719 | (79.4) | 62 | (6.9) | 1 | (0.1) | 79 | (8.7) | 15 | (1.7) | 29 | (3.2) |
| Bulgaria | 1598 | 1350 | (84.5) | 133 | (8.3) | 20 | (1.3) | 80 | (5.0) | 2 | (0.1) | 13 | (0.8) |
| Croatia ^d | 483 | 50 | (10.4) | 43 | (8.9) | 0 | (0.0) | 0 | (0.0) | 2 | (0.4) | 388 | (80.3) |
| Cyprus | 63 | 35 | (55.6) | 3 | (4.8) | 0 | (0.0) | 3 | (4.8) | 2 | (3.2) | 20 | (31.7) |
| Czech Republic | 499 | 343 | (68.7) | 95 | (19.0) | 5 | (1.0) | 23 | (4.6) | 17 | (3.4) | 16 | (3.2) |
| Denmark | 314 | 157 | (50.0) | 9 | (2.9) | 6 | (1.9) | 1 | (0.3) | 11 | (3.5) | 130 | (41.4) |
| Estonia | 172 | 142 | (82.6) | 25 | (14.5) | 0 | (0.0) | 3 | (1.7) | 0 | (0.0) | 2 | (1.2) |
| Finland ^e | 260 | 94 | (36.2) | 15 | (5.8) | 0 | (0.0) | 1 | (0.4) | 2 | (0.8) | 148 | (56.9) |
| France | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Germany | 5543 | 3600 | (64.9) | 366 | (6.6) | 6 | (0.1) | 141 | (2.5) | 259 | (4.7) | 1171 | (21.1) |
| Greece | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Hungary | 851 | 600 | (70.5) | 101 | (11.9) | 18 | (2.1) | 80 | (9.4) | 19 | (2.2) | 33 | (3.9) |
| Iceland | 7 | 7 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Ireland | 265 | 151 | (57.0) | 8 | (3.0) | 0 | (0.0) | 1 | (0.4) | 0 | (0.0) | 105 | (39.6) |
| Italy | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Latvia | 642 | 540 | (84.1) | 63 | (9.8) | 1 | (0.2) | 32 | (5.0) | 3 | (0.5) | 3 | (0.5) |
| Liechtenstein | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Lithuania | 1219 | 962 | (78.9) | 135 | (11.1) | 14 | (1.1) | 79 | (6.5) | 28 | (2.3) | 1 | (0.1) |
| Luxembourg | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Malta | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Netherlands | 837 | 723 | (86.4) | 37 | (4.4) | 0 | (0.0) | 20 | (2.4) | 16 | (1.9) | 41 | (4.9) |
| Norway | 276 | 243 | (88.0) | 6 | (2.2) | 3 | (1.1) | 8 | (2.9) | 4 | (1.4) | 12 | (4.3) |
| Poland | 6196 | 3293 | (53.1) | 607 | (9.8) | 4 | (0.1) | 368 | (5.9) | 4 | (0.1) | 1920 | (31.0) |
| Portugal | 2114 | 1516 | (71.7) | 146 | (6.9) | 0 | (0.0) | 79 | (3.7) | 321 | (15.2) | 52 | (2.5) |
| Romania | 13908 | 11828 | (85.0) | 1070 | (7.7) | 234 | (1.7) | 732 | (5.3) | 24 | (0.2) | 20 | (0.1) |
| Slovakia | 305 | 263 | (86.2) | 22 | (7.2) | 0 | (0.0) | 2 | (0.7) | 0 | (0.0) | 18 | (5.9) |
| Slovenia | 129 | 105 | (81.4) | 21 | (16.3) | 0 | (0.0) | 0 | (0.0) | 3 | (2.3) | 0 | (0.0) |
| Spain | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Sweden | 754 | 659 | (87.4) | 23 | (3.1) | 1 | (0.1) | 9 | (1.2) | 17 | (2.3) | 45 | (6.0) |
| United Kingdom | 5802 | 4594 | (79.2) | 341 | (5.9) | 0 | (0.0) | 297 | (5.1) | 461 | (7.9) | 109 | (1.9) |
| Subtotal EU/EEA | 43 695 | 32 376 | (74.1) | 3 368 | (7.7) | 313 | (0.7) | 2 048 | (4.7) | 1 255 | (2.9) | 4 335 | (9.9) |
| Non-EU/EEA | | | | | | | | | | | | | |
| Albania | 409 | 354 | (86.6) | 11 | (2.7) | 3 | (0.7) | 21 | (5.1) | - | - | 20 | (4.9) |
| Andorra | 4 | 4 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - | - | 0 | (0.0) |
| Armenia | 910 | 721 | (79.2) | 47 | (5.2) | 11 | (1.2) | 131 | (14.4) | - | - | 0 | (0.0) |
| Azerbaijan | 1475 | 1221 | (82.8) | 49 | (3.3) | 34 | (2.3) | 132 | (8.9) | - | - | 39 | (2.6) |
| Belarus | 2525 | 2243 | (88.8) | 76 | (3.0) | 72 | (2.9) | 77 | (3.0) | - | - | 57 | (2.3) |
| Bosnia and Herzegovina | 1092 | 707 | (64.7) | 84 | (7.7) | 19 | (1.7) | 2 | (0.2) | - | - | 280 | (25.6) |
| former Yugoslav Republic of Macedonia, the | 282 | 243 | (86.2) | 25 | (8.9) | 3 | (1.1) | 7 | (2.5) | - | - | 4 | (1.4) |
| Georgia | 2841 | 2386 | (84.0) | 110 | (3.9) | 60 | (2.1) | 225 | (7.9) | - | - | 60 | (2.1) |
| Israel | 263 | 218 | (82.9) | 19 | (7.2) | 1 | (0.4) | 8 | (3.0) | - | - | 17 | (6.5) |
| Kazakhstan | 14 006 | 12 691 | (90.6) | 674 | (4.8) | 440 | (3.1) | 201 | (1.4) | - | - | 0 | (0.0) |
| Kyrgyzstan | 6 139 | 5 063 | (82.5) | 364 | (5.9) | 138 | (2.2) | 564 | (9.2) | - | - | 10 | (0.2) |
| Moldova | 2 992 | 2 379 | (79.5) | 338 | (11.3) | 86 | (2.9) | 137 | (4.6) | - | - | 52 | (1.7) |
| Monaco | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Montenegro | 80 | 74 | (92.5) | 3 | (3.8) | 0 | (0.0) | 3 | (3.8) | - | - | 0 | (0.0) |
| Russia | 80 424 | 57 060 | (70.9) | 8 035 | (10.0) | 5 646 | (7.0) | 4 074 | (5.1) | - | - | 5 609 | (7.0) |
| San Marino | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| Serbia | 1 647 | 1 471 | (89.3) | 82 | (5.0) | 12 | (0.7) | 60 | (3.6) | - | - | 22 | (1.3) |
| Serbia excluding UN Administered Province of Kosovo ^f | 882 | 733 | (83.1) | 66 | (7.5) | 11 | (1.2) | 51 | (5.8) | - | - | 21 | (2.4) |
| UN Administered Province of Kosovo ^f | 765 | 738 | (96.5) | 16 | (2.1) | 1 | (0.1) | 9 | (1.2) | - | - | 1 | (0.1) |
| Switzerland | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Tajikistan | 5 298 | 4 734 | (89.4) | 237 | (4.5) | 111 | (2.1) | 172 | (3.2) | - | - | 44 | (0.8) |
| Turkey | 12 362 | 10 735 | (86.8) | 695 | (5.6) | 30 | (0.2) | 432 | (3.5) | - | - | 470 | (3.8) |
| Turkmenistan | 2 472 | 2 126 | (86.0) | 105 | (4.2) | 105 | (4.2) | 82 | (3.3) | - | - | 54 | (2.2) |
| Ukraine | 23 892 | 17 939 | (75.1) | 2 393 | (10.0) | 1 950 | (8.2) | 1 552 | (6.5) | - | - | 58 | (0.2) |
| Uzbekistan | 15 220 | 13 536 | (88.9) | 688 | (4.5) | 193 | (1.3) | 172 | (1.1) | - | - | 631 | (4.1) |
| Subtotal non-EU/EEA | 174 333 | 135 905 | (78.0) | 14 035 | (8.1) | 8 914 | (5.1) | 8 052 | (4.6) | - | - | 7 427 | (4.3) |
| Total European Region | 218 028 | 168 281 | (77.2) | 17 403 | (8.0) | 9 227 | (4.2) | 10 100 | (4.6) | 1 255 | (0.6) | 11 762 | (5.4) |
| Subtotal 18 HPC | 188 095 | 147 656 | (78.5) | 15 237 | (8.1) | 9 145 | (4.9) | 8 877 | (4.7) | 57 | (0.0) | 7 123 | (3.8) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^b Patients started on second-line treatment are excluded.

^c in previous annual reports classified as 'defaulted'.

^d in previous reports defined as 'transferred out and unknown'.

^e These data are subject to change as the national TB registry was under review when this report was being produced.

^f Treatment outcome collected consistently only for confirmed pulmonary cases.

^g In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 20: Treatment outcome of new and relapse tuberculosis cases in children (0-14 years) notified in 2015, European Region, 2016

| Country | All TB cases reported in 2015 under 15 year of age ^a | Success | | Died | | Failed | | Lost to follow-up ^b | | Still on treatment | | Not evaluated ^c | |
|--|---|-------------|---------------|-----------|--------------|-----------|--------------|--------------------------------|--------------|--------------------|--------------|----------------------------|--------------|
| | | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| EU/EEA | | | | | | | | | | | | | |
| Austria | 19 | 14 | (73.7) | 1 | (5.3) | 0 | (0.0) | 0 | (0.0) | 2 | (10.5) | 2 | (10.5) |
| Belgium | 69 | 67 | (97.1) | 1 | (1.4) | 0 | (0.0) | 0 | (0.0) | 1 | (1.4) | 0 | (0.0) |
| Bulgaria | 118 | 112 | (94.9) | 1 | (0.8) | 0 | (0.0) | 5 | (4.2) | 0 | (0.0) | 0 | (0.0) |
| Croatia ^d | 13 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 13 | (100.0) |
| Cyprus | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Czech Republic | 5 | 5 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Denmark | 14 | 2 | (14.3) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 12 | (85.7) |
| Estonia | 2 | 2 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Finland ^e | 11 | 3 | (27.3) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 8 | (72.7) |
| France | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | 192 | 128 | (66.7) | 2 | (1.0) | 0 | (0.0) | 5 | (2.6) | 14 | (7.3) | 43 | (22.4) |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 9 | 8 | (88.9) | 0 | (0.0) | 0 | (0.0) | 1 | (11.1) | 0 | (0.0) | 0 | (0.0) |
| Iceland | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Ireland | 14 | 11 | (78.6) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 3 | (21.4) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Latvia | 25 | 25 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 34 | 31 | (91.2) | 1 | (2.9) | 0 | (0.0) | 1 | (2.9) | 1 | (2.9) | 0 | (0.0) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Netherlands | 42 | 39 | (92.9) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (2.4) | 2 | (4.8) |
| Norway | 18 | 18 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Poland | 81 | 44 | (54.3) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 37 | (45.7) |
| Portugal | 33 | 29 | (87.9) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 4 | (12.1) | 0 | (0.0) |
| Romania | 651 | 614 | (94.3) | 9 | (1.4) | 0 | (0.0) | 23 | (3.5) | 2 | (0.3) | 3 | (0.5) |
| Slovakia | 65 | 65 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Slovenia | 1 | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Spain | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | 46 | 42 | (91.3) | 0 | (0.0) | 1 | (2.2) | 0 | (0.0) | 0 | (0.0) | 3 | (6.5) |
| United Kingdom | 224 | 202 | (90.2) | 1 | (0.4) | 0 | (0.0) | 5 | (2.2) | 14 | (6.3) | 2 | (0.9) |
| Subtotal EU/EEA | 1686 | 1462 | (86.7) | 16 | (0.9) | 1 | (0.1) | 40 | (2.4) | 39 | (2.3) | 128 | (7.6) |
| Non-EU/EEA | | | | | | | | | | | | | |
| Albania | 11 | 10 | (90.9) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | – | – | 1 | (9.1) |
| Andorra | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Armenia | 23 | 19 | (82.6) | 0 | (0.0) | 0 | (0.0) | 4 | (17.4) | – | – | 0 | (0.0) |
| Azerbaijan | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Belarus | 7 | 7 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | – | – | 0 | (0.0) |
| Bosnia and Herzegovina | 14 | 12 | (85.7) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | – | – | 2 | (14.3) |
| former Yugoslav Republic of Macedonia, the | 14 | 14 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | – | – | 0 | (0.0) |
| Georgia | 137 | 127 | (92.7) | 1 | (0.7) | 0 | (0.0) | 6 | (4.4) | – | – | 3 | (2.2) |
| Israel | 9 | 7 | (77.8) | 0 | (0.0) | 0 | (0.0) | 1 | (11.1) | – | – | 1 | (11.1) |
| Kazakhstan | 354 | 348 | (98.3) | 1 | (0.3) | 4 | (1.1) | 1 | (0.3) | – | – | 0 | (0.0) |
| Kyrgyzstan | 516 | 488 | (94.6) | 4 | (0.8) | 4 | (0.8) | 20 | (3.9) | – | – | 0 | (0.0) |
| Moldova | 101 | 96 | (95.0) | 1 | (1.0) | 1 | (1.0) | 2 | (2.0) | – | – | 1 | (1.0) |
| Monaco | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Montenegro | 1 | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | – | – | 0 | (0.0) |
| Russia | 2906 | 2736 | (94.2) | 19 | (0.7) | 20 | (0.7) | 5 | (0.2) | – | – | 126 | (4.3) |
| San Marino | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Serbia | 28 | 27 | (96.4) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | – | – | 1 | (3.6) |
| Serbia excluding UN Administered Province of Kosovo ^f | 9 | 8 | (88.9) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | – | – | 1 | (11.1) |
| UN Administered Province of Kosovo ^f | 19 | 19 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | – | – | 0 | (0.0) |
| Switzerland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Tajikistan | 316 | 296 | (93.7) | 7 | (2.2) | 2 | (0.6) | 9 | (2.8) | – | – | 2 | (0.6) |
| Turkey | 623 | 545 | (87.5) | 15 | (2.4) | 1 | (0.2) | 11 | (1.8) | – | – | 51 | (8.2) |
| Turkmenistan | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ukraine | 469 | 434 | (92.5) | 7 | (1.5) | 23 | (4.9) | 4 | (0.9) | – | – | 1 | (0.2) |
| Uzbekistan | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Subtotal non-EU/EEA | 5529 | 5167 | (93.5) | 55 | (1.0) | 55 | (1.0) | 63 | (1.1) | 0 | (0.0) | 189 | (3.4) |
| Total European Region | 7215 | 6629 | (91.9) | 71 | (1.0) | 56 | (0.8) | 103 | (1.4) | 39 | (0.5) | 317 | (4.4) |
| Subtotal 18 HPC | 6282 | 5880 | (93.6) | 66 | (1.1) | 55 | (0.9) | 91 | (1.4) | 3 | (0.0) | 187 | (3.0) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

^b Patients started on second-line treatment are excluded.

^c In previous reports defined as 'defaulted'.

^d In previous reports defined as 'transferred out and unknown'.

^e These data are subject to change as the national TB registry was under review when this report was being produced.

^f Treatment outcome collected consistently only for confirmed pulmonary cases.

^g In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 21: Treatment outcome of HIV positive new and relapse tuberculosis cases notified in 2015, European Region, 2016

| Country | HIV positive TB cases notified in 2015 ^a | Success | | Died | | Failed | | Lost to follow-up ^b | | Still on treatment | | Not evaluated ^c | |
|--|---|-------------|---------------|-------------|---------------|------------|--------------|--------------------------------|--------------|--------------------|--------------|----------------------------|--------------|
| | | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| EU/EEA | | | | | | | | | | | | | |
| Austria | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Belgium | 29 | 21 | (72.4) | 1 | (3.4) | 0 | (0.0) | 6 | (20.7) | 0 | (0.0) | 1 | (3.4) |
| <i>Bulgaria</i> | 1 | 0 | (0.0) | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Croatia | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Cyprus | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Czech Republic | 1 | 0 | (0.0) | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Denmark | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Estonia</i> | 16 | 13 | (81.3) | 3 | (18.8) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Finland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Iceland | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Ireland | 7 | 3 | (42.9) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 4 | (57.1) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Latvia</i> | 66 | 50 | (75.8) | 11 | (16.7) | 0 | (0.0) | 4 | (6.1) | 1 | (1.5) | 0 | (0.0) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Lithuania</i> | 26 | 17 | (65.4) | 4 | (15.4) | 1 | (3.8) | 2 | (7.7) | 2 | (7.7) | 0 | (0.0) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Netherlands | 34 | 29 | (85.3) | 3 | (8.8) | 0 | (0.0) | 0 | (0.0) | 2 | (5.9) | 0 | (0.0) |
| Norway | 5 | 4 | (80.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (20.0) |
| Poland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Portugal | 218 | 112 | (51.4) | 17 | (7.8) | 0 | (0.0) | 19 | (8.7) | 56 | (25.7) | 14 | (6.4) |
| <i>Romania</i> | 261 | 164 | (62.8) | 54 | (20.7) | 4 | (1.5) | 35 | (13.4) | 3 | (1.1) | 1 | (0.4) |
| Slovakia | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Slovenia | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Spain | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | – | – | – | – | – | – | – | – | – | – | – | – | – |
| United Kingdom | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Subtotal EU/EEA | 664 | 413 | (62.2) | 95 | (14.3) | 5 | (0.8) | 66 | (9.9) | 64 | (9.6) | 21 | (3.2) |
| Non-EU/EEA | | | | | | | | | | | | | |
| Albania | 6 | 3 | (50.0) | 2 | (33.3) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (16.7) |
| Andorra | 0 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Armenia | 72 | 47 | (65.3) | 18 | (25.0) | 0 | (0.0) | 7 | (9.7) | 0 | (0.0) | 0 | (0.0) |
| Azerbaijan | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Belarus | 113 | 89 | (78.8) | 11 | (9.7) | 0 | (0.0) | 1 | (0.9) | 0 | (0.0) | 12 | (10.6) |
| Bosnia and Herzegovina | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| former Yugoslav Republic of Macedonia, the | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Georgia | 71 | 49 | (69.0) | 11 | (15.5) | 2 | (2.8) | 6 | (8.5) | 0 | (0.0) | 3 | (4.2) |
| Israel | 14 | 10 | (71.4) | 2 | (14.3) | 0 | (0.0) | 1 | (7.1) | 0 | (0.0) | 1 | (7.1) |
| <i>Kazakhstan</i> | 376 | 260 | (69.1) | 77 | (20.5) | 19 | (5.1) | 20 | (5.3) | 0 | (0.0) | 0 | (0.0) |
| <i>Kyrgyzstan</i> | 151 | 92 | (60.9) | 41 | (27.2) | 6 | (4.0) | 12 | (7.9) | 0 | (0.0) | 0 | (0.0) |
| <i>Moldova</i> | 227 | 125 | (55.1) | 71 | (31.3) | 15 | (6.6) | 11 | (4.8) | 0 | (0.0) | 5 | (2.2) |
| Monaco | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Montenegro | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Russia</i> | 694 | 351 | (50.6) | 206 | (29.7) | 36 | (5.2) | 61 | (8.8) | 0 | (0.0) | 40 | (5.8) |
| San Marino | 0 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Serbia | 4 | 2 | (50.0) | 0 | (0.0) | 0 | (0.0) | 2 | (50.0) | 0 | (0.0) | 0 | (0.0) |
| Serbia excluding UN Administered Province of Kosovo ^d | 4 | 2 | (50.0) | 0 | (0.0) | 0 | (0.0) | 2 | (50.0) | 0 | (0.0) | 0 | (0.0) |
| UN Administered Province of Kosovo ^d | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Switzerland | 0 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| <i>Tajikistan</i> | 131 | 94 | (71.8) | 28 | (21.4) | 3 | (2.3) | 6 | (4.6) | 0 | (0.0) | 0 | (0.0) |
| <i>Turkey</i> | 57 | 33 | (57.9) | 7 | (12.3) | 0 | (0.0) | 6 | (10.5) | 0 | (0.0) | 11 | (19.3) |
| <i>Turkmenistan</i> | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Ukraine</i> | 4597 | 2893 | (62.9) | 973 | (21.2) | 370 | (8.0) | 355 | (7.7) | 0 | (0.0) | 6 | (0.1) |
| <i>Uzbekistan</i> | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Subtotal non-EU/EEA | 6513 | 4048 | (62.2) | 1447 | (22.2) | 451 | (6.9) | 488 | (7.5) | 0 | (0.0) | 79 | (1.2) |
| Total European Region | 7177 | 4461 | (62.2) | 1542 | (21.5) | 456 | (6.4) | 554 | (7.7) | 64 | (0.9) | 100 | (1.4) |
| Subtotal 18 HPC | 6859 | 4277 | (62.4) | 1516 | (22.1) | 456 | (6.6) | 526 | (7.7) | 6 | (0.1) | 78 | (1.1) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.
HIV – human immunodeficiency virus.

^b Patients started on second-line treatment are excluded.

^c In previous reports defined as 'defaulted'.

^d In previous reports defined as 'transferred out and unknown'.

^e In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 22: Treatment outcome after 24 months of RR TB/MDR TB cases started on second-line treatment in 2014, European Region, 2016

| Country | RR/MDR TB cases started on second-line treatment in 2014 ^a | Success | | Died | | Failed | | Lost to follow-up ^b | | Still on treatment | | Not evaluated ^c | |
|--|---|--------------|---------------|-------------|---------------|-------------|---------------|--------------------------------|---------------|--------------------|---------------|----------------------------|--------------|
| | | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| EU/EEA | | | | | | | | | | | | | |
| Austria | 21 | 13 | (61.9) | 0 | (0.0) | 0 | (0.0) | 1 | (4.8) | 1 | (4.8) | 6 | (28.6) |
| Belgium | 13 | 7 | (53.8) | 1 | (7.7) | 0 | (0.0) | 1 | (7.7) | 4 | (30.8) | 0 | (0.0) |
| Bulgaria | 44 | 22 | (50.0) | 13 | (29.5) | 0 | (0.0) | 7 | (15.9) | 0 | (0.0) | 2 | (4.5) |
| Croatia ^d | 2 | 0 | (0.0) | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) |
| Cyprus | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Czech Republic | 7 | 3 | (42.9) | 0 | (0.0) | 0 | (0.0) | 2 | (28.6) | 0 | (0.0) | 2 | (28.6) |
| Denmark | 2 | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) |
| Estonia | 50 | 32 | (64.0) | 7 | (14.0) | 3 | (6.0) | 3 | (6.0) | 3 | (6.0) | 2 | (4.0) |
| Finland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | 104 | 35 | (33.7) | 9 | (8.7) | 1 | (1.0) | 3 | (2.9) | 15 | (14.4) | 41 | – |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 4 | 4 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Iceland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ireland | 2 | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Latvia | 71 | 52 | (73.2) | 5 | (7.0) | 1 | (1.4) | 12 | (16.9) | 0 | (0.0) | 1 | (1.4) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 279 | 35 | (12.5) | 61 | (21.9) | 7 | (2.5) | 40 | (14.3) | 131 | (47.0) | 5 | (1.8) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Netherlands | 7 | 6 | (85.7) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (14.3) | 0 | (0.0) |
| Norway | 11 | 9 | (81.8) | 0 | (0.0) | 0 | (0.0) | 1 | (9.1) | 0 | (0.0) | 1 | (9.1) |
| Poland | 49 | 9 | (18.4) | 14 | (28.6) | 0 | (0.0) | 5 | (10.2) | 0 | (0.0) | 21 | (42.9) |
| Portugal | 28 | 15 | (53.6) | 7 | (25.0) | 0 | (0.0) | 0 | (0.0) | 1 | (3.6) | 5 | (17.9) |
| Romania | 596 | 245 | (41.1) | 99 | (16.6) | 163 | (27.3) | 85 | (14.3) | 4 | (0.7) | 0 | (0.0) |
| Slovakia | 4 | 2 | (50.0) | 2 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Slovenia | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Spain | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | 17 | 15 | (88.2) | 1 | (5.9) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (5.9) |
| United Kingdom | 56 | 33 | (58.9) | 2 | (3.6) | 0 | (0.0) | 7 | (12.5) | 11 | (19.6) | 3 | (5.4) |
| Subtotal EU/EEA | 1367 | 539 | (39.4) | 222 | (16.2) | 175 | (12.8) | 167 | (12.2) | 171 | (12.5) | 93 | (6.8) |
| Non-EU/EEA | | | | | | | | | | | | | |
| Albania | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Andorra | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Armenia | 118 | 68 | (57.6) | 8 | (6.8) | 19 | (16.1) | 23 | (19.5) | 0 | (0.0) | 0 | (0.0) |
| Azerbaijan | 745 | 441 | (59.2) | 127 | (17.0) | 135 | (18.1) | 42 | (5.6) | 0 | (0.0) | 0 | (0.0) |
| Belarus | 1472 | 872 | (59.2) | 126 | (8.6) | 289 | (19.6) | 181 | (12.3) | 0 | (0.0) | 4 | (0.3) |
| Bosnia and Herzegovina | 3 | 2 | (66.7) | 1 | (33.3) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| former Yugoslav Republic of Macedonia, the | 3 | 1 | (33.3) | 0 | (0.0) | 0 | (0.0) | 2 | (66.7) | 0 | (0.0) | 0 | (0.0) |
| Georgia | 411 | 201 | (48.9) | 32 | (7.8) | 27 | (6.6) | 118 | (28.7) | 0 | (0.0) | 33 | (8.0) |
| Israel | 16 | 12 | (75.0) | 2 | (12.5) | 0 | (0.0) | 1 | (6.3) | 0 | (0.0) | 1 | (6.3) |
| Kazakhstan | 6320 | 4813 | (76.2) | 604 | (9.6) | 371 | (5.9) | 468 | (7.4) | 0 | (0.0) | 64 | (1.0) |
| Kyrgyzstan | 1157 | 650 | (56.2) | 142 | (12.3) | 105 | (9.1) | 260 | (22.5) | 0 | (0.0) | 0 | (0.0) |
| Moldova | 919 | 457 | (49.7) | 129 | (14.0) | 142 | (15.5) | 188 | (20.5) | 0 | (0.0) | 3 | (0.3) |
| Monaco | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Montenegro | 2 | 0 | (0.0) | 1 | (50.0) | 0 | (0.0) | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) |
| Russia | 20089 | 10170 | (50.6) | 3409 | (17.0) | 2655 | (13.2) | 1830 | (9.1) | 0 | (0.0) | 2025 | (10.1) |
| San Marino | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Serbia | 19 | 12 | (63.2) | 2 | (10.5) | 2 | (10.5) | 3 | (15.8) | 0 | (0.0) | 0 | (0.0) |
| Serbia excluding UN Administered Province of Kosovo ^e | 13 | 7 | (53.8) | 2 | (15.4) | 1 | (7.7) | 3 | (23.1) | 0 | (0.0) | 0 | (0.0) |
| UN Administered Province of Kosovo ^e | 6 | 5 | (83.3) | 0 | (0.0) | 1 | (16.7) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Switzerland | 12 | 9 | (75.0) | 0 | (0.0) | 1 | (8.3) | 0 | (0.0) | 0 | (0.0) | 2 | (16.7) |
| Tajikistan | 804 | 398 | (49.5) | 170 | (21.1) | 67 | (8.3) | 159 | (19.8) | 0 | (0.0) | 10 | (1.2) |
| Turkey | 257 | 163 | (63.4) | 27 | (10.5) | 15 | (5.8) | 30 | (11.7) | 0 | (0.0) | 22 | (8.6) |
| Turkmenistan | 213 | 143 | (67.1) | 24 | (11.3) | 32 | (17.3) | 14 | (6.6) | 0 | (0.0) | 0 | (0.0) |
| Ukraine | 7174 | 3297 | (46.0) | 1210 | (16.9) | 1284 | (17.9) | 1186 | (16.5) | 0 | (0.0) | 197 | (2.7) |
| Uzbekistan | 3602 | 2216 | (61.5) | 587 | (16.3) | 221 | (6.1) | 220 | (6.1) | 0 | (0.0) | 358 | (9.9) |
| Subtotal non-EU/EEA | 43336 | 23925 | (55.2) | 6601 | (15.2) | 5365 | (12.4) | 4726 | (10.9) | 0 | (0.0) | 2719 | (6.3) |
| Total European Region | 44703 | 24624 | (54.7) | 6823 | (15.3) | 5540 | (12.4) | 4893 | (11.0) | 171 | (0.4) | 2812 | (6.3) |
| Subtotal 18 HPC | 44321 | 24275 | (54.8) | 6780 | (15.3) | 5536 | (12.5) | 4866 | (11.0) | 138 | (0.3) | 2726 | (6.2) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.
RR/MDR TB – rifampicin-resistant and multidrug-resistant tuberculosis.
WHO European Region 18 TB high-priority countries presented in italics.

^b For countries that do not provide information on treatment start, all reported cases were used as proxy.

^c In previous reports defined as 'defaulted'.

^d In previous reports defined as 'transferred out and unknown'.

^e These data are subject to change as the national TB registry was under review when this report was being produced.

^f In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 23: Treatment outcome after 24 months of laboratory-confirmed MDR TB cases notified in 2014, EU/EEA, 2016

| Country | All MDR TB cases notified in 2014 | Success | | Died | | Failed | | Lost to follow-up ^a | | Still on treatment | | Not evaluated ^b | |
|----------------------|-----------------------------------|------------|---------------|------------|---------------|------------|---------------|--------------------------------|---------------|--------------------|---------------|----------------------------|--------------|
| | | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| EU/EEA | | | | | | | | | | | | | |
| Austria | 20 | 13 | (65.0) | 0 | (0.0) | 0 | (0.0) | 1 | (5.0) | 1 | (5.0) | 5 | (25.0) |
| Belgium | 11 | 6 | (54.5) | 1 | (9.1) | 0 | (0.0) | 0 | (0.0) | 4 | (36.4) | 0 | (0.0) |
| <i>Bulgaria</i> | 37 | 18 | (48.6) | 12 | (32.4) | 0 | (0.0) | 5 | (13.5) | 0 | (0.0) | 2 | (5.4) |
| Croatia ^c | 2 | 0 | (0.0) | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) |
| Cyprus | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Czech Republic | 5 | 2 | (40.0) | 0 | (0.0) | 0 | (0.0) | 1 | (20.0) | 0 | (0.0) | 2 | (40.0) |
| Denmark | 2 | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) |
| <i>Estonia</i> | 50 | 29 | (58.0) | 10 | (20.0) | 3 | (6.0) | 3 | (6.0) | 3 | (6.0) | 2 | (4.0) |
| Finland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | 92 | 29 | (31.5) | 9 | (9.8) | 1 | (1.1) | 3 | (3.3) | 12 | (13.0) | 38 | (41.3) |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 3 | 3 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Iceland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ireland | 2 | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Latvia</i> | 70 | 52 | (74.3) | 5 | (7.1) | 1 | (1.4) | 11 | (15.7) | 0 | (0.0) | 1 | (1.4) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Lithuania</i> | 271 | 32 | (11.8) | 59 | (21.8) | 7 | (2.6) | 37 | (13.7) | 131 | (48.3) | 5 | (1.8) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Netherlands | 7 | 5 | (71.4) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (14.3) | 1 | (14.3) |
| Norway | 11 | 9 | (81.8) | 0 | (0.0) | 0 | (0.0) | 1 | (9.1) | 0 | (0.0) | 1 | (9.1) |
| Poland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Portugal | 25 | 13 | (52.0) | 7 | (28.0) | 0 | (0.0) | 0 | (0.0) | 1 | (4.0) | 4 | (16.0) |
| <i>Romania</i> | 532 | 199 | (37.4) | 93 | (17.5) | 156 | (29.3) | 80 | (15.0) | 4 | (0.8) | 0 | (0.0) |
| Slovakia | 3 | 1 | (33.3) | 2 | (66.7) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Slovenia | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Spain | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | 15 | 13 | (86.7) | 1 | (6.7) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (6.7) |
| United Kingdom | 56 | 29 | (51.8) | 2 | (3.6) | 0 | (0.0) | 12 | (21.4) | 10 | (17.9) | 3 | (5.4) |
| Total EU/EEA | 1214 | 455 | (37.5) | 202 | (16.6) | 168 | (13.8) | 154 | (12.7) | 167 | (13.8) | 68 | (5.6) |

European Region^c comprises the 53 countries of the WHO European Region and Liechtenstein

RR/MDR TB – Multidrug-resistant tuberculosis.

WHO European Region 18 TB high-priority countries presented in italics.

^a In previous reports defined as 'defaulted'.

^b In previous reports defined as 'transferred out and unknown'.

^c These data are subject to change as the national TB registry was under review when this report was being produced.

Table 24: Treatment outcome after 24 months of XDR TB cases started on second-line treatment in 2014, European Region, 2016

| Country | XDR TB cases started on second-line treatment in 2014 ^a | Success | | Died | | Failed | | Lost to follow-up ^b | | Still on treatment | | Not evaluated ^c | |
|--|--|-------------|---------------|-------------|---------------|-------------|---------------|--------------------------------|--------------|--------------------|---------------|----------------------------|---------------|
| | | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| EU/EEA | | | | | | | | | | | | | |
| Austria | 2 | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) | 0 | (0.0) |
| Belgium | 1 | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Bulgaria | 3 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 3 | (100.0) |
| Croatia ^d | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Cyprus | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Czech Republic | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Denmark | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Estonia | 8 | 1 | (12.5) | 1 | (12.5) | 3 | (37.5) | 0 | (0.0) | 2 | (25.0) | 1 | (12.5) |
| Finland | – | – | – | – | – | – | – | – | – | – | – | – | – |
| France ^e | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | 11 | 2 | (18.2) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 9 | (81.8) |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Iceland | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Ireland | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Latvia | 13 | 10 | (76.9) | 2 | (15.4) | 1 | (7.7) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 61 | 0 | (0.0) | 16 | (26.2) | 3 | (4.9) | 4 | (6.6) | 36 | (59.0) | 2 | (3.3) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Netherlands | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Norway | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Poland | 5 | 1 | (20.0) | 1 | (20.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 3 | (60.0) |
| Portugal | 3 | 2 | (66.7) | 1 | (33.3) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Romania | 57 | 9 | (15.8) | 15 | (26.3) | 28 | (49.1) | 5 | (8.8) | 0 | (0.0) | 0 | (0.0) |
| Slovakia | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Slovenia | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Spain | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | 1 | 0 | (0.0) | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| United Kingdom | 3 | 1 | (33.3) | 0 | (0.0) | 0 | (0.0) | 1 | (33.3) | 1 | (33.3) | 0 | (0.0) |
| Subtotal EU/EEA | 168 | 28 | (16.7) | 37 | (22.0) | 35 | (20.8) | 10 | (6.0) | 40 | (23.8) | 18 | (10.7) |
| Non-EU/EEA | | | | | | | | | | | | | |
| Albania | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Andorra | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Armenia | 10 | 4 | (40.0) | 0 | (0.0) | 5 | (50.0) | 1 | (10.0) | 0 | (0.0) | 0 | (0.0) |
| Azerbaijan | 69 | 16 | (23.2) | 17 | (24.6) | 31 | (44.9) | 5 | (7.2) | 0 | (0.0) | 0 | (0.0) |
| Belarus | 431 | 157 | (36.4) | 58 | (13.5) | 174 | (40.4) | 34 | (7.9) | 0 | (0.0) | 8 | (1.9) |
| Bosnia and Herzegovina | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| former Yugoslav Republic of Macedonia, the | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Georgia | 56 | 18 | (32.1) | 6 | (10.7) | 7 | (12.5) | 14 | (25.0) | 0 | (0.0) | 11 | (19.6) |
| Israel | 2 | 1 | (50.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) |
| Kazakhstan | 318 | 98 | (30.8) | 79 | (24.8) | 96 | (30.2) | 25 | (7.9) | 0 | (0.0) | 20 | (6.3) |
| Kyrgyzstan | 32 | 5 | (15.6) | 16 | (50.0) | 6 | (18.8) | 5 | (15.6) | 0 | (0.0) | 0 | (0.0) |
| Moldova | 9 | 3 | (33.3) | 3 | (33.3) | 2 | (22.2) | 1 | (11.1) | 0 | (0.0) | 0 | (0.0) |
| Monaco | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Montenegro | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Russia | 2209 | 687 | (31.1) | 507 | (23.0) | 502 | (22.7) | 157 | (7.1) | 0 | (0.0) | 356 | (16.1) |
| San Marino | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Serbia | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Serbia excluding UN Administered Province of Kosovo ^f | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| UN Administered Province of Kosovo ^f | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Switzerland | 1 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) |
| Tajikistan | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Turkey | 2 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 1 | (50.0) | 0 | (0.0) | 1 | (50.0) |
| Turkmenistan | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ukraine | 1097 | 278 | (25.3) | 285 | (26.0) | 330 | (30.1) | 167 | (15.2) | 0 | (0.0) | 37 | (3.4) |
| Uzbekistan | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Subtotal non-EU/EEA | 4236 | 1267 | (29.9) | 971 | (22.9) | 1153 | (27.2) | 411 | (9.7) | 0 | (0.0) | 434 | (10.2) |
| Total European Region | 4404 | 1295 | (29.4) | 1008 | (22.9) | 1188 | (27.0) | 421 | (9.6) | 40 | (0.9) | 452 | (10.3) |
| Subtotal 18 HPC | 4375 | 1286 | (29.4) | 1005 | (23.0) | 1188 | (27.2) | 419 | (9.6) | 38 | (0.9) | 439 | (10.0) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. XDR TB - Extensively drug-resistant tuberculosis.
WHO European Region 18 TB high-priority countries presented in italics.

^b For countries that do not provide information on treatment start, all reported cases were used as proxy.

^c In previous reports defined as 'defaulted'.

^d In previous reports defined as 'transferred out and unknown'.

^e These data are subject to change as the national TB registry was under review when this report was being produced.

^f In previous reports defined as 'transferred out and unknown'.

^g In accordance with the UN Security Council Resolution No. 1244 (1999).

Table 25: Treatment outcome after 36 months of XDR TB notified in 2013, EU/EEA, 2016

| Country | XDR TB notified in 2013 ^a | Success | | Died | | Failed | | Lost to follow-up ^b | | Not evaluated ^c | |
|---------------------|--------------------------------------|-----------|---------------|-----------|---------------|-----------|---------------|--------------------------------|---------------|----------------------------|--------------|
| | | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
| EU/EEA | | | | | | | | | | | |
| Austria | 3 | 2 | (66.7) | 1 | (33.3) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Belgium | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| <i>Bulgaria</i> | 4 | 0 | (0.0) | 2 | (50.0) | 1 | (25.0) | 1 | (25.0) | 0 | (0.0) |
| Croatia | – | – | – | – | – | – | – | – | – | – | – |
| Cyprus | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Czech Republic | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Denmark | 1 | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| <i>Estonia</i> | 10 | 5 | (50.0) | 1 | (10.0) | 2 | (20.0) | 2 | (20.0) | 0 | (0.0) |
| Finland | – | – | – | – | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | – | – | – | – | – |
| Germany | 3 | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 3 | (100.0) |
| Greece | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 1 | 0 | (0.0) | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Iceland | – | – | – | – | – | – | – | – | – | – | – |
| Ireland | 1 | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Italy | – | – | – | – | – | – | – | – | – | – | – |
| <i>Latvia</i> | 15 | 11 | (73.3) | 3 | (20.0) | 0 | (0.0) | 1 | (6.7) | 0 | (0.0) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – |
| <i>Lithuania</i> | 47 | 11 | (23.4) | 12 | (25.5) | 5 | (10.6) | 19 | (40.4) | 0 | (0.0) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – |
| Malta | – | – | – | – | – | – | – | – | – | – | – |
| Netherlands | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Norway | – | – | – | – | – | – | – | – | – | – | – |
| Poland | 1 | 0 | (0.0) | 1 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Portugal | 4 | 4 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| <i>Romania</i> | 56 | 11 | (19.6) | 12 | (21.4) | 29 | (51.8) | 4 | (7.1) | 0 | (0.0) |
| Slovakia | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Slovenia | 0 | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Spain | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | 2 | 2 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| United Kingdom | 3 | 3 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Total EU/EEA | 151 | 51 | (33.8) | 33 | (21.9) | 37 | (24.5) | 27 | (17.9) | 3 | (2.0) |

XDR TB – Extensively drug-resistant tuberculosis.

WHO European Region 18 TB high-priority countries presented in italics.

^a For countries that do not provide information on treatment start, all reported cases were used as proxy.^b In previous reports defined as 'defaulted'.

Table 26: Monitoring the WHO Europe Roadmap to Implement the Tuberculosis Action Plan for the WHO European Region, 2016 – 2020

| Country | 1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION | | | | | | | | | | | | |
|--|--|---|--|--|--|--|--|---|--|--|--|--|--|
| | Systematic screening of contacts and high-risk groups ¹ | Early diagnosis of all forms of tuberculosis and universal access to drug-susceptibility testing, including the use of rapid tests | | | | | | | Equitable access to quality treatment and continuum of care for all people with tuberculosis, including drug-resistant tuberculosis; and patient support to facilitate treatment adherence | | | | |
| | | 1A.1 Coverage of population at risk with systematic screening for active TB and LTBI (TB contacts for 20.16 assessment). Target = 80% | 1B.1 Percentage of TB patients diagnosed using WHO recommended rapid tests (G3). Target = 40% | 1B.2 First-line DST coverage (%) among all bacteriologically confirmed TB cases (G3). Target = 100% | 1B.3 RR/MDR-TB case detection rate (%) (G3). Target = 85% | 1B.4 TB notification rate per 100 000 population (E3). Target = 24.6 ² | 1B.5 TB case detection rate (%) Target: Increase | 1B.6 Percentage of RR/MDR-TB among new TB patients. Target = Decrease | 1B.7 Percentage of RR/MDR-TB among previously treated TB patients. Target = Decrease | 1C.1 Percentage of hospitalization of new TB patients (E3). Target = Decrease | 1C.2 Percentage of detected RR/MDR-TB enrolled in treatment (G3). Target = 100% | 1C.3 Treatment success rate (%) among all new and relapsed TB patients (G4). Target = 85% | 1C.4 Treatment success rate (%) among the MDR-TB treatment cohort (G4) (E4). Target = 75% |
| EU/EEA | | | | | | | | | | | | | |
| Austria | - | 50.3% | 93.5% | 87.5% | 7.1 | 87.2% | 2.2% | 17.6% | - | 100.0% | 72.7% | 61.9% | 0.8 |
| Belgium | - | 45.2% | 93.7% | 68.8% | 8.7 | 89.6% | 1.4% | 5.7% | 1% | 100.0% | 79.4% | 53.8% | 0.4 |
| Bulgaria | 96.7% | 0.4% | 87.5% | 50.0% | 21.3 | 80.3% | 0.9% | 17.3% | 90% | 100.0% | 84.5% | 50.0% | 1.7 |
| Croatia | - | - | 100.0% | - | 10.7 | 86.3% | 0.0% | 0.0% | - | - | 10.4% | 0.0% | 0.6 |
| Cyprus | - | 6.7% | 97.4% | - | 6.7 | 86.4% | 0.0% | 0.0% | 0% | 100.0% | 55.6% | - | 0.4 |
| Czech Republic | - | 39.5% | 89.7% | - | 4.8 | 96.4% | 1.3% | 16.7% | 95% | 80.0% | 68.7% | 42.9% | 0.5 |
| Denmark | - | 35.8% | 97.6% | - | 5.1 | 83.4% | 1.7% | 0.0% | - | 100.0% | 50.0% | 50.0% | 0.2 |
| Estonia | - | 74.5% | 94.8% | 73.5% | 14.3 | 85.5% | 12.9% | 46.2% | 64% | 95.7% | 82.6% | 64.0% | 1.2 |
| Finland | - | 26.3% | 96.4% | 100.0% | 4.1 | 86.5% | 1.6% | 0.0% | 80% | 100.0% | 36.2% | - | 0.6 |
| France ^c | - | - | 100.0% | - | 7.0 | 93.5% | 1.4% | 6.8% | 90% | 100.0% | - | - | 0.6 |
| Germany | - | 53.4% | 84.5% | 65.6% | 7.0 | 86.9% | 2.2% | 14.3% | - | 100.0% | 64.9% | 33.7% | 0.4 |
| Greece | - | 36.8% | 46.7% | - | 3.8 | 83.1% | 2.0% | 27.3% | - | 100.0% | - | - | 0.5 |
| Hungary | - | - | 83.8% | - | 7.5 | 85.7% | 4.1% | 16.2% | - | 100.0% | 70.5% | 100.0% | 0.7 |
| Iceland | - | 83.3% | 80.0% | - | 1.8 | 85.7% | 0.0% | 0.0% | 0% | - | 100.0% | - | 0.6 |
| Ireland | - | 35.2% | 97.7% | 300.0% | 6.2 | 86.2% | 3.1% | 18.2% | 59% | 100.0% | 57.0% | 50.0% | 0.5 |
| Italy | - | - | 81.6% | 62.7% | 6.2 | 102.1% | 3.1% | 9.3% | - | 100.0% | - | - | 0.6 |
| Latvia | - | 0.0% | 95.7% | 85.5% | 32.6 | 86.6% | 7.6% | 23.3% | 98% | 100.0% | 84.1% | 73.2% | 2.0 |
| Liechtenstein | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Lithuania | 100.0% | 0.0% | 100.0% | 97.3% | 46.6 | 89.8% | 13.3% | 43.0% | 92% | 100.0% | 78.9% | 12.5% | 6.5 |
| Luxembourg | - | 0.0% | 95.5% | - | 5.0 | 87.9% | 0.0% | 0.0% | 50% | 100.0% | - | - | 0.2 |
| Malta | - | 0.0% | 100.0% | - | 11.5 | 86.2% | 0.0% | 0.0% | - | - | - | - | 0.2 |
| Netherlands | - | 0.0% | 100.0% | 66.7% | 5.2 | 87.7% | 1.8% | 20.0% | 31% | 100.0% | 86.4% | 85.7% | 0.2 |
| Norway | 92.3% | 44.1% | 96.9% | 133.3% | 5.3 | 86.9% | 5.1% | 0.0% | 51% | 100.0% | 88.0% | 81.8% | 0.2 |
| Poland | - | 13.8% | 90.5% | 66.2% | 16.2 | 86.5% | 0.7% | 4.0% | - | 100.0% | 53.1% | 18.4% | 1.3 |
| Portugal | 62.9% | 15.5% | 69.4% | 68.4% | 17.3 | 85.4% | 1.3% | 3.9% | 30% | 100.0% | 71.7% | 53.6% | 2.0 |
| Romania | - | 5.1% | 89.0% | 73.6% | 64.7 | 85.3% | 2.0% | 15.6% | 86% | 99.4% | 85.0% | 41.1% | 5.1 |
| Slovakia | 100.0% | 19.6% | 81.0% | 300.0% | 5.2 | 87.8% | 2.2% | 5.6% | 90% | 100.0% | 86.2% | 50.0% | 0.6 |
| Slovenia | - | 51.7% | 100.0% | - | 5.7 | 84.3% | 0.0% | 0.0% | - | - | 81.4% | - | 0.6 |
| Spain | - | 19.3% | 100.0% | - | 10.2 | 100.7% | 4.0% | 12.2% | - | 100.0% | - | - | 0.6 |
| Sweden | - | 63.8% | 97.9% | 65.2% | 7.1 | 86.7% | 3.0% | 15.8% | 51% | 100.0% | 87.4% | 88.2% | 0.3 |
| United Kingdom | - | 4.8% | 96.2% | 82.8% | 8.9 | 89.1% | 1.6% | 4.7% | - | 96.0% | 79.2% | 58.9% | 0.5 |
| Subtotal EU/EEA | 85.6% | 24.7% | 88.1% | 74.3% | 10.9 | 89.0% | 2.4% | 15.0% | 55.7% | 99.5% | 74.1% | 39.4% | 0.8 |
| Non-EU/EEA | | | | | | | | | | | | | |
| Albania | 85.2% | - | 41.2% | 57.1% | 14.2 | 87% | 0.0% | 50.0% | 84% | 25.0% | 86.6% | - | 0.29 |
| Andorra | 100.0% | 100.0% | 50.0% | - | 5.2 | 87% | 0.0% | 0.0% | 100% | - | 100.0% | - | 0 |
| Armenia | 92.0% | 5.6% | 95.1% | 71.1% | 35.1 | 80% | 15.4% | 57.7% | 81% | 100.0% | 79.2% | 57.6% | 2.1 |
| Azerbaijan | - | 39.3% | 69.5% | 61.7% | 53.0 | 80% | 15.4% | 39.3% | - | 86.3% | 82.8% | 59.2% | 6.4 |
| Belarus | 100.0% | 79.6% | 97.5% | 96.4% | 33.9 | 65% | 37.1% | 71.6% | 100% | 87.2% | 88.8% | 59.2% | 2.4 |
| Bosnia and Herzegovina | - | 0.0% | 100.0% | - | 25.8 | 80% | 0.0% | 0.0% | 98% | - | 64.7% | 66.7% | 3.9 |
| former Yugoslav Republic of Macedonia, the | 72.3% | 35.7% | 80.3% | 66.7% | 12.6 | 80% | 1.5% | 0.0% | 60% | 100.0% | 86.2% | 33.3% | 0.98 |
| Georgia ^d | - | 81.2% | 77.4% | 87.2% | 76.0 | 82% | 10.2% | 38.0% | 25% | 87.5% | 84.0% | 48.9% | 4.8 |
| Israel | - | - | 93.2% | 84.6% | 3.1 | 87% | 7.4% | 0.0% | - | 100.0% | 82.9% | 75.0% | 0.19 |

¹ 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

RR/MDR TB – rifampicin-resistant and multidrug-resistant tuberculosis.

M/XDR-TB – Multidrug-resistant and extensively drug-resistant tuberculosis.

Figures in red – target not met. Figures in green – target met.

² Cases with missing information on previous history of TB treatment are included among new cases.

³ These data are liable to change as the national TB registry was under review when this report was being produced.

⁴ No data available for risk groups other than TB contacts.

| Collaborative tuberculosis/HIV activities, and management of relevant comorbidities | | | | | Management of latent tuberculosis infection and preventive treatment of persons at high risk, and vaccination against tuberculosis | | | | | 2. BOLD POLICIES AND SUPPORTIVE SYSTEMS | | | | | 3. INTENSIFIED RESEARCH AND INNOVATION | Country |
|---|--|---|--|--|--|---|---|---|---|---|--|---|---|--------|--|---------|
| 1D.1 TB/HIV case-detection rate (%). Target = Close to 100% | 1D.2 HIV testing coverage (%) (G6) (E6). Target = 100% | 1D.3 Percentage of HIV among all TB. Target = Decrease | D.4.1 ART enrollment rate (%) among TB-HIV co-infected. Target = Close to 100% | D.4.2 ART enrollment rate (%) among TB-HIV co-infected. Target = Close to 100% | 1E.1 Contact investigation coverage aged under 5 years (G2) (E7). Target = 90% | 1E.2 LTBI (treatment coverage of childhood TB contacts aged under 5 years (G5) (E8). Target = 90% | 2A.1 Number of Member States that have a regular TB control/elimination performance publication every five years (E8) Target: TB control/elimination | 2B.1 Percentage of TB patients and their households that experience catastrophic financial consequences due to TB (G6) (E9) Target: close to 0 | 2C.1 Treatment coverage (%) with new TB drugs. Target = 20% | 2D.1 Number of member states with functioning multi-stakeholder coalitions advocating for TB care and resource | 2E.1 Treatment success rate (%) of new and relapsed TB cases among prisoners. Target = 85.0% | 3A.1 European TB research initiative established by mid-2016 Target is not defined yet | | | | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | EU/EEA | |
| 36.0% | 45.4% | 6.9% | - | - | - | - | - | - | - | - | - | - | - | - | Austria | |
| - | 79.0% | 0.0% | - | - | - | - | - | - | - | - | - | - | - | 60.0% | Belgium | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.0% | Bulgaria | |
| 0.0% | 80.7% | 0.0% | - | - | - | - | - | - | - | - | - | - | - | - | Croatia ^b | |
| 55.6% | 39.5% | 2.4% | - | - | - | - | - | - | - | - | - | - | - | - | Cyprus | |
| 81.8% | 45.9% | 6.0% | - | - | - | - | - | - | - | - | - | - | - | 77.8% | Czech Republic | |
| 91.3% | 95.7% | 12.0% | 95.2% | - | - | - | - | - | - | - | - | - | - | - | Denmark | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Estonia | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Finland | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | France ^c | |
| 4.3% | 2.4% | 5.3% | - | - | - | - | - | - | - | - | - | - | - | - | Germany | |
| - | 100.0% | 0.0% | - | - | - | - | - | - | - | - | - | - | - | 50.0% | Greece | |
| 17.4% | 41.3% | 3.0% | 75.0% | - | - | - | - | - | - | - | - | - | - | - | Hungary | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Iceland | |
| 60.4% | 78.0% | 11.2% | 61.8% | - | - | - | - | - | - | - | - | - | - | - | Ireland | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Italy | |
| 68.0% | 77.7% | 3.6% | - | - | 100% | - | - | - | - | - | - | - | - | - | Latvia | |
| 40.0% | 17.2% | 40.0% | - | - | - | - | - | - | - | - | - | - | - | 75.8% | Liechtenstein | |
| 53.3% | 92.0% | 17.4% | 100% | - | - | - | - | - | - | - | - | - | - | 61.1% | Lithuania | |
| 61.8% | 62.3% | 3.8% | 71.4% | - | - | - | - | - | - | - | - | - | - | - | Luxembourg | |
| 57.1% | 86.0% | 3.9% | 100.0% | - | 93.0% | 15.4% | - | - | - | - | - | - | - | 50.0% | Malta | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Netherlands | |
| 56.6% | 66.0% | 13.9% | - | - | - | - | - | - | - | - | - | - | - | 44.4% | Norway | |
| 68.6% | 77.9% | 2.7% | 100% | - | - | - | - | - | - | - | - | - | - | 50.8% | Poland | |
| - | 44.1% | 0.0% | - | - | 100% | 100% | - | - | - | - | - | - | - | 91.3% | Portugal | |
| 100.0% | 80.5% | 1.1% | 100% | - | 90% | 75.0% | - | - | - | - | - | - | - | 100.0% | Romania | |
| 60.9% | 59.6% | 7.7% | - | - | - | - | - | - | - | - | - | - | - | - | Slovakia | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Slovenia | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Spain | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Sweden | |
| 59.3% | 68.8% | 4.4% | 94.2% | - | 95.8% | 47.9% | - | - | - | - | - | - | - | 62.1% | United Kingdom | |
| 100.0% | 53.7% | 2.7% | 100.0% | - | - | - | - | - | - | - | - | - | - | 68.4% | Subtotal EU/EEA | |
| 0.0% | 0.0% | 0.0% | - | - | 100% | 0.0% | - | - | - | - | - | - | - | - | Non-EU/EEA | |
| 77.0% | 100.0% | 5.6% | 100.0% | 23.2% | 92.0% | - | - | - | - | - | - | - | - | - | Albania | |
| 76.2% | 91.5% | 2.1% | 78.8% | 60.3% | - | 98.7% | - | - | - | - | - | - | - | 92.9% | Andorra | |
| 68.8% | 98.0% | 8.7% | 83.3% | 0.0% | 100% | 10.9% | - | - | - | - | - | - | - | 91.3% | Armenia | |
| 50.0% | 0.1% | 100.0% | 100.0% | 100.0% | - | - | - | - | - | - | - | - | - | 83.6% | Azerbaijan | |
| - | 78.7% | 0.0% | - | - | 72.3% | 67.0% | - | - | - | - | - | - | - | 0.0% | Belarus | |
| 79.2% | 96.1% | 2.1% | 91.8% | 20.1% | - | 29.3% | - | - | - | - | - | - | - | 0.0% | Bosnia and Herzegovina | |
| 85.7% | 100.0% | 7.2% | 88.9% | - | - | - | - | - | - | - | - | - | - | 50.0% | former Yugoslav Republic of Macedonia, the | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 83.6% | Georgia | |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100.0% | Israel | |

Table 26 cont.: Monitoring the WHO Europe Roadmap to Implement the Tuberculosis Action Plan for the WHO European Region, 2016 – 2020

| Country | 1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION | | | | | | | | | | | | |
|--|--|--|---|--|--|---|--|--|--|--|--|--|---|
| | Systematic screening of contacts and high-risk groups ^a | Early diagnosis of all forms of tuberculosis and universal access to drug-susceptibility testing, including the use of rapid tests | | | | | | | Equitable access to quality treatment and continuum of care for all people with tuberculosis, including drug-resistant tuberculosis; and patient support to facilitate treatment adherence | | | | |
| | | 1A.1 Coverage of population at risk with systematic screening for active TB and LTBI (TB contacts for 2016 assessment). Target = 80% | 1B.1 Percentage of TB patients diagnosed using WHO recommended rapid tests (G) Target = 40% | 1B.2 First-line DST coverage (%) among all bacteriologically confirmed TB cases (G). Target = 100% | 1B.3 RR/MDR-TB case detection rate (%) (G3) Target = 85% | 1B.4 TB notification rate per 100 000 population (E) Target = 24.6 ^b | 1B.5 TB case detection rate (%) Target: Increase | 1B.6 Percentage of RR/MDR-TB among new TB patients Target = Decrease | 1B.7 Percentage of RR/MDR-TB among previously treated TB patients Target = Decrease | 1C.1 Percentage of hospitalization of new TB patients (E3) Target = Decrease | 1C.2 Percentage of detected RR/MDR-TB enrolled in treatment (G2) Target = 100% | 1C.3 Treatment success rate (%) among all new and relapsed TB patients (G4) Target = 85% | 1C.4 Treatment success rate (%) among the MDR-TB treatment cohort (E4) Target = 75% |
| EU/EEA | | | | | | | | | | | | | |
| Kazakhstan ^a | – | 85.3% | 52.1% | 166.2% | 68.5 | 100% | 25.5% | 20.5% | 85% | 100.0% | 90.6% | 76.2% | 2.4 |
| Kyrgyzstan | – | 36.1% | 70.4% | 49.4% | 118.0 | 81% | 21.9% | 56.3% | 87% | 97.1% | 82.5% | 56.2% | 7.2 |
| Moldova | 96.2% | 50.8% | 64.1% | 73.6% | 88.0 | 87% | 25.6% | 57.4% | 62% | 95.0% | 79.5% | 49.7% | 6.3 |
| Monaco | – | – | – | – | – | – | – | – | – | – | – | – | 0 |
| Montenegro | – | 28.7% | 100.0% | – | 13.8 | 87% | 0.0% | 0.0% | – | – | 92.5% | – | 0.19 |
| Russia ^a | 100.0% | 69.8% | 91.0% | 58.2% | 64.2 | 98% | 27.3% | 65.2% | 65% | 94.0% | 70.9% | 50.6% | 8.2 |
| San Marino | – | – | – | – | – | – | 0.0% | 0.0% | – | – | – | – | 0 |
| Serbia | 83.2% | 48.7% | 82.0% | 42.1% | 16.7 | 87% | 0.5% | 6.9% | 70% | 83.3% | 89.3% | 63.2% | 0.96 |
| Serbia excluding UN Administered Province of Kosovo ^b | – | – | 73.6% | – | 10.8 | – | 0.8% | 7.5% | – | 100.0% | 83.1% | 53.8% | – |
| UN Administered Province of Kosovo ^b | – | 100.0% | 98.5% | – | 38.6 | – | 0.0% | 6.3% | – | 50.0% | 96.5% | 83.3% | – |
| Switzerland | – | – | 94.3% | 81.8% | 6.8 | 87% | 4.3% | 7.1% | 80% | 100.0% | 0.0% | 75.0% | 0.24 |
| Tajikistan | – | 73.2% | 89.7% | 62.3% | 68.3 | 80% | 20.8% | 46.3% | 56% | 91.0% | 89.4% | 49.5% | 6 |
| Turkey | – | – | 86.2% | 73.1% | 15.3 | 87% | 2.2% | 13.7% | 50% | 82.4% | 86.8% | 63.4% | 0.61 |
| Turkmenistan | 100.0% | 76.8% | – | – | 37.2 | 62% | – | – | – | 100.0% | 86.0% | 53.1% | 7.6 |
| Ukraine | – | – | 91.8% | 86.5% | 65.4 | 75% | 22.0% | 40.8% | 86% | 99.2% | 75.1% | 46.0% | 9.5 |
| Uzbekistan | – | 76.4% | – | – | 51.0 | 67% | – | – | – | 100.0% | 88.9% | 61.5% | 5.9 |
| Subtotal non-EU/EEA | 99.8% | 53.5% | 85.7% | 69.0% | 48.9 | 86.4% | 22.6% | 56.3% | 69.80% | 95.5% | 78.0% | 55.1% | 5.5 |
| Total European Region | 99.3% | 45.9% | 87.0% | 69.4% | 27.6 | 87.3% | 17.5% | 52.6% | 71.10% | 95.5% | 77.2% | 54.7% | 2.8 |
| Subtotal 18 HPC | 99.8% | 50.4% | 86.1% | 69.2% | 52.3 | 86.6% | 21.0% | 54.3% | 71.00% | 95.5% | 78.5% | 54.7% | 5.5 |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

RR/MDR TB – rifampicin-resistant and multidrug-resistant tuberculosis.

M/XDR-TB – Multidrug-resistant and extensively drug-resistant tuberculosis.


Figures in red – target not met. Figures in green – target met.

^b Cases with missing information on previous history of TB treatment are included among new cases.

^c These data are liable to change as the national TB registry was under review when this report was being produced.

^d No data available for risk groups other than TB contacts.

| Collaborative tuberculosis/HIV activities, and management of relevant comorbidities | | | | | Management of latent tuberculosis infection and preventive treatment of persons at high risk, and vaccination against tuberculosis | | 2. BOLD POLICIES AND SUPPORTIVE SYSTEMS | | | | | 3. INTENSIFIED RESEARCH AND INNOVATION | Country |
|---|--|--|---|---|--|---|--|---|---|---|--|---|--|
| 1D.1 TB/HIV case-detection rate (%) Target = Close to 100% | 1D.2 HIV testing coverage (%) (G6) (E6) Target = 100% | 1D.3 Percentage of HIV among all TB Target = Decrease | D.4 ART enrolment rate (%) among TB-HIV co-infected Target = Close to 100% | D.4 ART enrolment rate (%) among TB-HIV co-infected Target = Close to 100% | 1E.1 Contact investigation coverage aged under 5 years (G2) (F7) Target = 90% | 1E.2 LTBI treatment coverage of childhood TB contacts aged under 5 years (G5b) (E8) Target = 90% | 2A.1 Number of Member States that have a regular TB control/elimination (E8) Target: TB control/elimination | 2B.1 Percentage of TB patients and their households that experience catastrophic financial consequences due to TB (G6) (G9) Target: close to 0 | 2C.1 Treatment coverage (%) with new TB drugs Target = 20% | 2D.1 Number of member states with functioning multi-stakeholder coalitions advocating for TB care and resource | 2E.1 Treatment success rate (%) of new and relapsed TB cases among prisoners Target = 85.0% | 3A.1 European TB research initiative established by mid-2016 Target is not defined yet | |
| 99.3% | 86.2% | 5.4% | 83.0% | 42.9% | - | - | - | - | - | - | 79.3% | - | EU/EEA |
| 75.0% | 89.0% | 3.4% | 68.6% | 40.0% | - | 76.4% | - | - | - | - | 77.1% | - | Kazakhstan |
| 79.2% | 94.3% | 8.7% | 65.9% | 0.0% | 96% | 66.9% | - | - | - | - | 86.5% | - | Kyrgyzstan |
| - | - | - | - | - | - | - | - | - | - | - | - | - | Moldova |
| - | 69.0% | 0.0% | - | - | - | - | - | - | - | - | - | - | Monaco |
| 92.1% | 86.5% | 20.7% | 63.7% | 92.7% | 100% | 81.6% | - | - | - | - | 100.0% | - | Montenegro |
| - | - | - | - | - | - | - | - | - | - | - | 54.2% | - | Russia |
| 50.0% | 32.7% | 1.0% | 100.0% | - | 83.2% | - | - | - | - | - | 100.0% | - | San Marino |
| - | 11.1% | 6.0% | 100.0% | - | - | - | - | - | - | - | - | - | Serbia |
| - | 55.5% | 0.0% | - | - | - | - | - | - | - | - | - | - | Serbia excluding UN Administered Province of Kosovo ^d |
| - | - | - | - | - | - | - | - | - | - | - | - | - | UN Administered Province of Kosovo ^d |
| - | - | - | - | - | - | - | - | - | - | - | - | - | Switzerland |
| 80.4% | 98.1% | 3.4% | 90.5% | 57.1% | - | - | - | - | - | - | 93.4% | - | Tajikistan |
| 60.9% | 70.2% | 0.7% | 91.1% | - | - | 54.8% | - | - | - | - | 79.0% | - | Turkey |
| 0.0% | 0.0% | 0.0% | - | - | 100.0% | - | - | - | - | - | - | - | Turkmenistan |
| 72.0% | 97.0% | 20.7% | 67.6% | 51.6% | - | - | - | - | - | - | 73.5% | - | Ukraine |
| 63.2% | 100.0% | 4.1% | 65.4% | 100.0% | - | - | - | - | - | - | - | - | Uzbekistan |
| 84.0% | 88.5% | 14.4% | 65.9% | 70.0% | 99.8% | 79.5% | - | - | - | - | 59.5% | - | Subtotal non-EU/EEA |
| 82.9% | 86.1% | 13.4% | 65.1% | 70.1% | 99.3% | 75.3% | - | - | - | - | 55.9% | - | Total European Region |
| 83.8% | 88.6% | 13.6% | 66.1% | 70.1% | 99.8% | 75.9% | - | - | - | - | 59.8% | - | Subtotal 18 HPC |



7. Trend tables

Table I: Estimated TB mortality per 100 000 population, European Region, 2007–2016

| Country | 2007 | | 2008 | | 2009 | | 2010 | | 2011 | | 2012 | |
|--|--------------|------------------|--------------|------------------|--------------|------------------|--------------|------------------|--------------|------------------|--------------|------------------|
| | N | Rate per 100 000 |
| EU/EEA | | | | | | | | | | | | |
| Austria | 47 | 0.6 | 49 | (0.6) | 48 | (0.6) | 39 | (0.5) | 55 | (0.7) | 42 | (0.5) |
| Belgium | 86 | 0.8 | 78 | (0.7) | 60 | (0.6) | 60 | (0.6) | 53 | (0.5) | 59 | (0.5) |
| <i>Bulgaria</i> | <i>280</i> | <i>3.7</i> | <i>240</i> | <i>(3.2)</i> | <i>200</i> | <i>(2.7)</i> | <i>200</i> | <i>(2.8)</i> | <i>170</i> | <i>(2.4)</i> | <i>170</i> | <i>(2.4)</i> |
| Croatia | 100 | 2.3 | 100 | (2.4) | 120 | (2.8) | 83 | (1.9) | 66 | (1.5) | 60 | (1.4) |
| Cyprus | 1 | 0.1 | 1 | (0.1) | 0 | (0.0) | 1 | (0.1) | 4 | (0.3) | 5 | (0.4) |
| Czech Republic | 71 | 0.7 | 54 | (0.5) | 52 | (0.5) | 40 | (0.4) | 56 | (0.5) | 30 | (0.3) |
| Denmark | 27 | 0.5 | 17 | (0.3) | 28 | (0.5) | 37 | (0.7) | 17 | (0.3) | 23 | (0.4) |
| <i>Estonia</i> | <i>66</i> | <i>4.9</i> | <i>56</i> | <i>(4.2)</i> | <i>50</i> | <i>(3.7)</i> | <i>42</i> | <i>(3.1)</i> | <i>46</i> | <i>(3.5)</i> | <i>36</i> | <i>(2.7)</i> |
| Finland | 56 | 1.1 | 60 | (1.1) | 54 | (1.0) | 48 | (0.9) | 61 | (1.1) | 49 | (0.9) |
| France | 730 | 1.2 | 700 | (1.1) | 690 | (1.1) | 660 | (1.0) | 650 | (1.0) | 550 | (0.9) |
| Germany | 460 | 0.6 | 370 | (0.5) | 350 | (0.4) | 360 | (0.5) | 350 | (0.4) | 370 | (0.5) |
| Greece | 100 | 0.9 | 86 | (0.8) | 94 | (0.8) | 78 | (0.7) | 75 | (0.7) | 110 | (1.0) |
| Hungary | 220 | 2.2 | 190 | (1.9) | 170 | (1.7) | 150 | (1.6) | 130 | (1.3) | 130 | (1.3) |
| Iceland | 5 | 1.7 | 1 | (0.3) | 7 | (2.2) | 2 | (0.6) | 1 | (0.3) | 1 | (0.3) |
| Ireland | 53 | 1.2 | 32 | (0.7) | 36 | (0.8) | 35 | (0.8) | 29 | (0.6) | 27 | (0.6) |
| Italy | 400 | 0.7 | 400 | (0.7) | 410 | (0.7) | 380 | (0.6) | 390 | (0.7) | 340 | (0.6) |
| <i>Latvia</i> | <i>150</i> | <i>7.0</i> | <i>120</i> | <i>(5.7)</i> | <i>110</i> | <i>(5.2)</i> | <i>91</i> | <i>(4.3)</i> | <i>80</i> | <i>(3.8)</i> | <i>62</i> | <i>(3.0)</i> |
| Liechtenstein | - | - | - | - | - | - | - | - | - | - | - | - |
| <i>Lithuania</i> | <i>360</i> | <i>11.0</i> | <i>350</i> | <i>(11.0)</i> | <i>270</i> | <i>(8.5)</i> | <i>220</i> | <i>(7.2)</i> | <i>220</i> | <i>(7.1)</i> | <i>260</i> | <i>(8.5)</i> |
| Luxembourg | 2 | 0.4 | 0 | (0.0) | 0 | (0.0) | 1 | (0.2) | 2 | (0.4) | 0 | (0.0) |
| Malta | 6 | 1.5 | 1 | (0.2) | 1 | (0.2) | 1 | (0.2) | 3 | (0.7) | 1 | (0.2) |
| Netherlands | 57 | 0.4 | 53 | (0.3) | 66 | (0.4) | 56 | (0.3) | 37 | (0.2) | 35 | (0.2) |
| Norway | 36 | 0.8 | 26 | (0.6) | 28 | (0.6) | 29 | (0.6) | 29 | (0.6) | 22 | (0.4) |
| Poland | 830 | 2.2 | 880 | (2.3) | 810 | (2.1) | 630 | (1.6) | 690 | (1.8) | 680 | (1.8) |
| Portugal | 290 | 2.7 | 260 | (2.5) | 280 | (2.6) | 230 | (2.1) | 230 | (2.2) | 230 | (2.2) |
| <i>Romania</i> | <i>1600</i> | <i>7.7</i> | <i>1600</i> | <i>(7.9)</i> | <i>1500</i> | <i>(7.4)</i> | <i>1500</i> | <i>(7.3)</i> | <i>1300</i> | <i>(6.4)</i> | <i>1300</i> | <i>(6.3)</i> |
| Slovakia | 35 | 0.7 | 43 | (0.8) | 43 | (0.8) | 35 | (0.7) | 26 | (0.5) | 17 | (0.3) |
| Slovenia | 29 | 1.5 | 35 | (1.7) | 25 | (1.2) | 20 | (1.0) | 14 | (0.7) | 11 | (0.5) |
| Spain | 420 | 0.9 | 360 | (0.8) | 410 | (0.9) | 400 | (0.9) | 300 | (0.6) | 330 | (0.7) |
| Sweden | 63 | 0.7 | 64 | (0.7) | 61 | (0.7) | 36 | (0.4) | 47 | (0.5) | 39 | (0.4) |
| United Kingdom | 400 | 0.7 | 440 | (0.7) | 410 | (0.7) | 370 | (0.6) | 330 | (0.5) | 330 | (0.5) |
| Subtotal EU/EEA | 7000 | (1.4) | 6700 | (1.3) | 6400 | (1.3) | 5800 | (1.1) | 5500 | (1.1) | 5300 | (1.0) |
| Non-EU/EEA | | | | | | | | | | | | |
| Albania | 10 | (0.3) | 21 | (0.7) | 6 | (0.2) | 9 | (0.3) | 8 | (0.3) | 8 | (0.3) |
| Andorra | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| <i>Armenia</i> | <i>250</i> | <i>(8.6)</i> | <i>260</i> | <i>(8.8)</i> | <i>220</i> | <i>(7.5)</i> | <i>210</i> | <i>(7.3)</i> | <i>160</i> | <i>(5.5)</i> | <i>180</i> | <i>(6.2)</i> |
| <i>Azerbaijan</i> | <i>340</i> | <i>(3.9)</i> | <i>420</i> | <i>(4.7)</i> | <i>610</i> | <i>(6.8)</i> | <i>730</i> | <i>(8.1)</i> | <i>600</i> | <i>(6.5)</i> | <i>390</i> | <i>(4.2)</i> |
| <i>Belarus</i> | <i>1000</i> | <i>(11.0)</i> | <i>950</i> | <i>(10.0)</i> | <i>860</i> | <i>(9.1)</i> | <i>870</i> | <i>(9.2)</i> | <i>850</i> | <i>(9.0)</i> | <i>770</i> | <i>(8.1)</i> |
| Bosnia and Herzegovina | 200 | (5.2) | 200 | (5.2) | 200 | (5.2) | 190 | (5.2) | 190 | (5.2) | 170 | (4.8) |
| former Yugoslav Republic of Macedonia, the | 60 | (2.9) | 48 | (2.3) | 19 | (0.9) | 34 | (1.7) | 27 | (1.3) | 23 | (1.1) |
| <i>Georgia</i> | <i>220</i> | <i>(5.1)</i> | <i>220</i> | <i>(5.1)</i> | <i>230</i> | <i>(5.4)</i> | <i>230</i> | <i>(5.4)</i> | <i>230</i> | <i>(5.5)</i> | <i>220</i> | <i>(5.4)</i> |
| Israel | 40 | (0.6) | 28 | (0.4) | 24 | (0.3) | 28 | (0.4) | 22 | (0.3) | 22 | (0.3) |
| <i>Kazakhstan</i> | <i>3300</i> | <i>(21.0)</i> | <i>3100</i> | <i>(19.0)</i> | <i>2500</i> | <i>(15.0)</i> | <i>2100</i> | <i>(13.0)</i> | <i>1900</i> | <i>(11.0)</i> | <i>1800</i> | <i>(10.0)</i> |
| <i>Kyrgyzstan</i> | <i>730</i> | <i>(14.0)</i> | <i>640</i> | <i>(12.0)</i> | <i>620</i> | <i>(12.0)</i> | <i>610</i> | <i>(11.0)</i> | <i>680</i> | <i>(12.0)</i> | <i>640</i> | <i>(11.0)</i> |
| <i>Moldova</i> | <i>690</i> | <i>(17.0)</i> | <i>620</i> | <i>(15.0)</i> | <i>630</i> | <i>(15.0)</i> | <i>570</i> | <i>(14.0)</i> | <i>510</i> | <i>(13.0)</i> | <i>490</i> | <i>(12.0)</i> |
| Monaco | 0 | (0.2) | 0 | (0.3) | 0 | (0.3) | 0 | (0.3) | 0 | (0.2) | 0 | (0.1) |
| Montenegro | 8 | (1.3) | 3 | (0.6) | 1 | (0.2) | 1 | (0.2) | 1 | (0.2) | 1 | (0.2) |
| <i>Russia</i> | <i>27000</i> | <i>(19.0)</i> | <i>27000</i> | <i>(19.0)</i> | <i>25000</i> | <i>(18.0)</i> | <i>23000</i> | <i>(16.0)</i> | <i>21000</i> | <i>(15.0)</i> | <i>19000</i> | <i>(13.0)</i> |
| San Marino | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Serbia | 270 | (2.9) | 200 | (2.2) | 190 | (2.1) | 180 | (2.0) | 150 | (1.7) | 160 | (1.8) |
| Switzerland | 29 | (0.4) | 34 | (0.5) | 27 | (0.4) | 28 | (0.4) | 25 | (0.3) | 23 | (0.3) |
| <i>Tajikistan</i> | <i>850</i> | <i>(12.0)</i> | <i>790</i> | <i>(11.0)</i> | <i>740</i> | <i>(9.9)</i> | <i>690</i> | <i>(9.0)</i> | <i>640</i> | <i>(8.2)</i> | <i>600</i> | <i>(7.5)</i> |
| <i>Turkey</i> | <i>760</i> | <i>(1.1)</i> | <i>820</i> | <i>(1.2)</i> | <i>850</i> | <i>(1.2)</i> | <i>740</i> | <i>(1.0)</i> | <i>960</i> | <i>(1.3)</i> | <i>830</i> | <i>(1.1)</i> |
| <i>Turkmenistan</i> | <i>700</i> | <i>(14.0)</i> | <i>630</i> | <i>(13.0)</i> | <i>640</i> | <i>(13.0)</i> | <i>700</i> | <i>(14.0)</i> | <i>600</i> | <i>(12.0)</i> | <i>490</i> | <i>(9.3)</i> |
| <i>Ukraine</i> | <i>11000</i> | <i>(24.0)</i> | <i>11000</i> | <i>(23.0)</i> | <i>8700</i> | <i>(19.0)</i> | <i>8000</i> | <i>(17.0)</i> | <i>7200</i> | <i>(16.0)</i> | <i>7100</i> | <i>(16.0)</i> |
| <i>Uzbekistan</i> | <i>2900</i> | <i>(11.0)</i> | <i>2600</i> | <i>(9.5)</i> | <i>2400</i> | <i>(8.4)</i> | <i>2200</i> | <i>(7.7)</i> | <i>2100</i> | <i>(7.1)</i> | <i>1800</i> | <i>(6.2)</i> |
| Subtotal non-EU/EEA | 50000 | (13.1) | 50000 | (13.0) | 44000 | (11.4) | 41000 | (10.6) | 38000 | (9.7) | 35000 | (8.9) |
| Total European Region | 58000 | (6.5) | 56000 | (6.3) | 51000 | (5.7) | 47000 | (5.2) | 44000 | (4.9) | 40000 | (4.4) |
| Subtotal 18 HPC | 52000 | (13.5) | 51000 | (13.2) | 46000 | (11.9) | 43000 | (11.1) | 39000 | (10.0) | 36000 | (9.2) |

European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

| | 2013 | | 2014 | | 2015 | | 2016 | | Mean annual % change in rate, 2012-2016 | Mean annual % change in rate, 2007-2016 | Country |
|--|--------------|------------------|--------------|------------------|--------------|------------------|--------------|------------------|---|---|--|
| | N | Rate per 100 000 | | | |
| | | | | | | | | | | | EU/EEA |
| | 68 | (0.8) | 71 | (0.8) | 71 | (0.8) | 71 | (0.8) | 13.7% | 4.1% | Austria |
| | 56 | (0.5) | 41 | (0.4) | 42 | (0.4) | 42 | (0.4) | -8.6% | -8.3% | Belgium |
| | 150 | (2.1) | 140 | (2.0) | 130 | (1.9) | 120 | (1.7) | -8.3% | -8.3% | Bulgaria |
| | 54 | (1.3) | 40 | (1.0) | 46 | (1.1) | 27 | (0.6) | -18.1% | -13.4% | Croatia |
| | 1 | (0.1) | 5 | (0.4) | 5 | (0.4) | 5 | (0.4) | -0.6% | 14.9% | Cyprus |
| | 67 | (0.6) | 39 | (0.4) | 57 | (0.5) | 57 | (0.5) | 16.8% | -2.5% | Czech Republic |
| | 17 | (0.3) | 13 | (0.2) | 13 | (0.2) | 13 | (0.2) | -12.5% | -7.6% | Denmark |
| | 26 | (1.9) | 29 | (2.2) | 21 | (1.6) | 16 | (1.2) | -18.4% | -14.5% | Estonia |
| | 31 | (0.6) | 41 | (0.7) | 34 | (0.6) | 31 | (0.6) | -11.4% | -7.2% | Finland |
| | 570 | (0.9) | 490 | (0.8) | 450 | (0.7) | 410 | (0.6) | -7.8% | -6.9% | France |
| | 380 | (0.5) | 320 | (0.4) | 320 | (0.4) | 320 | (0.4) | -3.5% | -3.9% | Germany |
| | 78 | (0.7) | 55 | (0.5) | 55 | (0.5) | 55 | (0.5) | -16.1% | -6.6% | Greece |
| | 98 | (1.0) | 87 | (0.9) | 98 | (1.0) | 72 | (0.7) | -13.1% | -11.4% | Hungary |
| | 0 | (0.0) | 0 | (0.0) | 2 | (0.6) | 2 | (0.6) | 18.4% | -10.8% | Iceland |
| | 23 | (0.5) | 23 | (0.5) | 23 | (0.5) | 23 | (0.5) | -4.1% | -9.5% | Ireland |
| | 340 | (0.6) | 340 | (0.6) | 330 | (0.6) | 330 | (0.6) | 0.0% | -2.1% | Italy |
| | 100 | (5.1) | 67 | (3.3) | 51 | (2.6) | 39 | (2.0) | -9.6% | -13.0% | Latvia |
| | - | - | - | - | - | - | - | - | - | - | Liechtenstein |
| | 210 | (7.1) | 230 | (7.8) | 190 | (6.5) | 190 | (6.4) | -6.8% | -5.8% | Lithuania |
| | 0 | (0.0) | 1 | (0.2) | 1 | (0.2) | 1 | (0.2) | - | -9.2% | Luxembourg |
| | 3 | (0.7) | 1 | (0.2) | 1 | (0.2) | 1 | (0.2) | 0.0% | -18.4% | Malta |
| | 40 | (0.2) | 35 | (0.2) | 37 | (0.2) | 38 | (0.2) | 1.2% | -5.0% | Netherlands |
| | 21 | (0.4) | 13 | (0.3) | 13 | (0.3) | 13 | (0.3) | -13.2% | -11.5% | Norway |
| | 580 | (1.5) | 580 | (1.5) | 520 | (1.4) | 480 | (1.3) | -7.8% | -5.7% | Poland |
| | 230 | (2.2) | 220 | (2.1) | 220 | (2.1) | 210 | (2.0) | -2.4% | -3.3% | Portugal |
| | 1200 | (5.8) | 1100 | (5.7) | 1100 | (5.4) | 1000 | (5.1) | -5.1% | -4.5% | Romania |
| | 20 | (0.4) | 35 | (0.6) | 35 | (0.6) | 35 | (0.6) | 18.9% | -0.3% | Slovakia |
| | 9 | (0.4) | 21 | (1.0) | 11 | (0.5) | 13 | (0.6) | 3.1% | -9.5% | Slovenia |
| | 300 | (0.6) | 290 | (0.6) | 280 | (0.6) | 280 | (0.6) | -3.4% | -4.6% | Spain |
| | 43 | (0.5) | 30 | (0.3) | 25 | (0.3) | 25 | (0.3) | -11.6% | -10.7% | Sweden |
| | 350 | (0.5) | 350 | (0.5) | 350 | (0.5) | 350 | (0.5) | 1.4% | -2.0% | United Kingdom |
| | 5100 | (1.0) | 4700 | (0.9) | 4500 | (0.9) | 4300 | (0.8) | -5.2% | -5.5% | Subtotal EU/EEA |
| | | | | | | | | | | | Non-EU/EEA |
| | 8 | (0.3) | 8 | (0.3) | 8 | (0.3) | 8 | (0.3) | 0.0% | -1.4% | Albania |
| | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - | 0.0% | Andorra |
| | 140 | (4.7) | 100 | (3.6) | 88 | (3.0) | 62 | (2.1) | -23.7% | -14.5% | Armenia |
| | 390 | (4.2) | 390 | (4.1) | 500 | (5.2) | 620 | (6.4) | 11.1% | 5.7% | Azerbaijan |
| | 640 | (6.8) | 510 | (5.3) | 370 | (3.9) | 230 | (2.4) | -26.2% | -15.6% | Belarus |
| | 160 | (4.3) | 140 | (3.9) | 140 | (3.9) | 140 | (3.9) | -5.1% | -3.1% | Bosnia and Herzegovina |
| | 20 | (1.0) | 20 | (1.0) | 20 | (1.0) | 20 | (1.0) | -2.8% | -11.4% | former Yugoslav Republic of Macedonia, the |
| | 210 | (5.1) | 200 | (5.1) | 200 | (5.0) | 190 | (4.8) | -2.9% | -0.7% | Georgia |
| | 15 | (0.2) | 15 | (0.2) | 15 | (0.2) | 15 | (0.2) | -10.0% | -11.7% | Israel |
| | 1200 | (6.7) | 1000 | (5.8) | 800 | (4.5) | 440 | (2.4) | -30.0% | -21.4% | Kazakhstan |
| | 650 | (11.0) | 540 | (9.4) | 480 | (8.3) | 430 | (7.2) | -10.1% | -7.1% | Kyrgyzstan |
| | 360 | (8.7) | 350 | (8.7) | 300 | (7.5) | 260 | (6.3) | -14.9% | -10.4% | Moldova |
| | 0 | (0.1) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | -100.0% | -100.0% | Monaco |
| | 1 | (0.2) | 1 | (0.2) | 1 | (0.2) | 1 | (0.2) | 0.0% | -19.2% | Montenegro |
| | 17000 | (12.0) | 15000 | (11.0) | 14000 | (9.5) | 12000 | (8.2) | -10.9% | -8.9% | Russia |
| | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - | - | San Marino |
| | 150 | (1.6) | 120 | (1.3) | 87 | (1.0) | 84 | (1.0) | -14.5% | -11.6% | Serbia |
| | 20 | (0.2) | 20 | (0.2) | 20 | (0.2) | 20 | (0.2) | -4.6% | -5.0% | Switzerland |
| | 570 | (7.0) | 530 | (6.4) | 520 | (6.0) | 520 | (6.0) | -5.4% | -7.4% | Tajikistan |
| | 760 | (1.0) | 670 | (0.9) | 580 | (0.7) | 480 | (0.6) | -13.7% | -6.3% | Turkey |
| | 450 | (8.4) | 560 | (10.0) | 460 | (8.3) | 430 | (7.6) | -4.9% | -6.6% | Turkmenistan |
| | 6200 | (14.0) | 5400 | (12.0) | 4800 | (11.0) | 4200 | (9.5) | -12.2% | -9.8% | Ukraine |
| | 1800 | (6.0) | 1900 | (6.1) | 1900 | (6.0) | 1900 | (5.9) | -1.2% | -6.7% | Uzbekistan |
| | 31000 | (7.8) | 27000 | (6.8) | 25000 | (6.2) | 22000 | (5.5) | -11.5% | -9.2% | Subtotal non-EU/EEA |
| | 36000 | (4.0) | 33000 | (3.6) | 29000 | (3.2) | 26000 | (2.8) | -10.5% | -8.9% | Total European Region |
| | 32000 | (8.1) | 29000 | (7.3) | 26000 | (6.5) | 23000 | (5.7) | -11.1% | -9.1% | Subtotal ±8 HPC |

Table II: Estimated TB incidence per 100 000 population, European Region, 2007–2016

| Country | 2007 | | 2008 | | 2009 | | 2010 | | 2011 | | 2012 | |
|--|----------------|------------------|----------------|------------------|----------------|------------------|----------------|------------------|----------------|------------------|----------------|------------------|
| | N | Rate per 100 000 |
| EU/EEA | | | | | | | | | | | | |
| Austria | 930 | (11.0) | 870 | (10.0) | 760 | (9.1) | 760 | (9.1) | 770 | (9.1) | 710 | (8.4) |
| Belgium | 1100 | (10.0) | 1100 | (10.0) | 1100 | (9.7) | 1200 | (11.0) | 1100 | (10.0) | 1000 | (9.4) |
| <i>Bulgaria</i> | <i>3 600</i> | <i>(47.0)</i> | <i>3 700</i> | <i>(49.0)</i> | <i>3 300</i> | <i>(45.0)</i> | <i>3 000</i> | <i>(41.0)</i> | <i>2 700</i> | <i>(37.0)</i> | <i>2 600</i> | <i>(36.0)</i> |
| Croatia | 1100 | (25.0) | 1100 | (26.0) | 960 | (22.0) | 790 | (18.0) | 710 | (17.0) | 620 | (14.0) |
| Cyprus | 47 | (4.4) | 55 | (5.1) | 59 | (5.3) | 70 | (6.3) | 59 | (5.2) | 72 | (6.4) |
| Czech Republic | 910 | (8.8) | 930 | (8.9) | 730 | (6.9) | 710 | (6.8) | 650 | (6.2) | 650 | (6.1) |
| Denmark | 410 | (7.5) | 380 | (6.9) | 340 | (6.1) | 380 | (6.9) | 410 | (7.4) | 390 | (7.0) |
| <i>Estonia</i> | <i>480</i> | <i>(36.0)</i> | <i>440</i> | <i>(33.0)</i> | <i>400</i> | <i>(30.0)</i> | <i>370</i> | <i>(28.0)</i> | <i>340</i> | <i>(25.0)</i> | <i>310</i> | <i>(24.0)</i> |
| Finland | 340 | (6.5) | 380 | (7.2) | 460 | (8.7) | 350 | (6.6) | 360 | (6.7) | 300 | (5.5) |
| France | 6300 | (10.0) | 6300 | (10.0) | 5700 | (9.1) | 5600 | (8.8) | 5500 | (8.7) | 5500 | (8.6) |
| Germany | 5400 | (6.6) | 4800 | (5.9) | 4800 | (5.9) | 4700 | (5.8) | 4700 | (5.8) | 4600 | (5.7) |
| Greece | 710 | (6.2) | 670 | (5.9) | 620 | (5.4) | 510 | (4.5) | 520 | (4.6) | 600 | (5.2) |
| Hungary | 1800 | (18.0) | 1600 | (16.0) | 1500 | (15.0) | 1800 | (18.0) | 1500 | (15.0) | 1300 | (14.0) |
| Iceland | 14 | (4.5) | 7 | (2.2) | 10 | (3.3) | 25 | (7.9) | 9 | (2.8) | 12 | (3.5) |
| Ireland | 500 | (11.0) | 490 | (11.0) | 490 | (11.0) | 450 | (9.6) | 450 | (9.6) | 390 | (8.4) |
| Italy | 3200 | (5.3) | 4700 | (8.0) | 4700 | (7.9) | 5200 | (8.7) | 3900 | (6.6) | 3600 | (6.0) |
| <i>Latvia</i> | <i>1400</i> | <i>(62.0)</i> | <i>1200</i> | <i>(57.0)</i> | <i>1100</i> | <i>(53.0)</i> | <i>1100</i> | <i>(51.0)</i> | <i>1000</i> | <i>(50.0)</i> | <i>1000</i> | <i>(50.0)</i> |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Lithuania</i> | <i>2 600</i> | <i>(80.0)</i> | <i>2 500</i> | <i>(78.0)</i> | <i>2 400</i> | <i>(76.0)</i> | <i>2 300</i> | <i>(73.0)</i> | <i>2 200</i> | <i>(70.0)</i> | <i>2 100</i> | <i>(68.0)</i> |
| Luxembourg | 45 | (9.4) | 32 | (6.6) | 31 | (6.3) | 33 | (6.6) | 29 | (5.5) | 52 | (9.7) |
| Malta | 44 | (11.0) | 55 | (13.0) | 48 | (12.0) | 33 | (8.0) | 34 | (8.2) | 48 | (11.0) |
| Netherlands | 1100 | (6.5) | 1100 | (6.7) | 1300 | (7.8) | 1200 | (7.1) | 1100 | (6.7) | 1100 | (6.3) |
| Norway | 330 | (6.9) | 340 | (7.2) | 380 | (7.8) | 340 | (6.9) | 370 | (7.4) | 390 | (7.9) |
| Poland | 9200 | (24.0) | 8500 | (22.0) | 8800 | (23.0) | 8100 | (21.0) | 9100 | (24.0) | 8100 | (21.0) |
| Portugal | 3400 | (32.0) | 3200 | (30.0) | 3100 | (29.0) | 3000 | (28.0) | 2900 | (27.0) | 2900 | (27.0) |
| <i>Romania</i> | <i>26 000</i> | <i>(123.0)</i> | <i>25 000</i> | <i>(120.0)</i> | <i>24 000</i> | <i>(115.0)</i> | <i>21 000</i> | <i>(105.0)</i> | <i>20 000</i> | <i>(97.0)</i> | <i>19 000</i> | <i>(92.0)</i> |
| Slovakia | 720 | (13.0) | 670 | (12.0) | 520 | (9.6) | 470 | (8.7) | 430 | (8.0) | 370 | (6.8) |
| Slovenia | 250 | (12.0) | 240 | (12.0) | 210 | (11.0) | 190 | (9.5) | 210 | (10.0) | 150 | (7.5) |
| Spain | 8400 | (19.0) | 8900 | (19.0) | 8300 | (18.0) | 7900 | (17.0) | 7400 | (16.0) | 6500 | (14.0) |
| Sweden | 530 | (5.8) | 590 | (6.4) | 660 | (7.1) | 710 | (7.5) | 620 | (6.5) | 680 | (7.1) |
| United Kingdom | 9000 | (15.0) | 9300 | (15.0) | 9100 | (15.0) | 8800 | (14.0) | 9500 | (15.0) | 9300 | (14.0) |
| Subtotal EU/EEA | 90 000 | (17.9) | 89 000 | (17.6) | 86 000 | (16.9) | 81 000 | (15.9) | 79 000 | (15.5) | 74 000 | (14.5) |
| Non-EU/EEA | | | | | | | | | | | | |
| Albania | 500 | (17.0) | 490 | (16.0) | 510 | (17.0) | 500 | (17.0) | 490 | (17.0) | 470 | (16.0) |
| Andorra | 6 | (7.0) | 5 | (5.5) | 9 | (11.0) | 8 | (9.5) | 3 | (4.1) | 10 | (13.0) |
| Armenia | 2100 | (72.0) | 2100 | (71.0) | 2000 | (68.0) | 1800 | (61.0) | 1600 | (55.0) | 1500 | (53.0) |
| <i>Azerbaijan</i> | <i>6 900</i> | <i>(79.0)</i> | <i>9 500</i> | <i>(108.0)</i> | <i>12 000</i> | <i>(133.0)</i> | <i>9 400</i> | <i>(104.0)</i> | <i>11 000</i> | <i>(125.0)</i> | <i>8 000</i> | <i>(86.0)</i> |
| <i>Belarus</i> | <i>6 900</i> | <i>(73.0)</i> | <i>6 800</i> | <i>(72.0)</i> | <i>6 700</i> | <i>(70.0)</i> | <i>6 500</i> | <i>(69.0)</i> | <i>6 300</i> | <i>(67.0)</i> | <i>6 100</i> | <i>(64.0)</i> |
| Bosnia and Herzegovina | 3000 | (79.0) | 2100 | (57.0) | 2200 | (58.0) | 1700 | (44.0) | 1700 | (46.0) | 1800 | (48.0) |
| former Yugoslav Republic of Macedonia, the | 660 | (32.0) | 560 | (27.0) | 560 | (27.0) | 480 | (23.0) | 420 | (20.0) | 430 | (21.0) |
| <i>Georgia</i> | <i>6 600</i> | <i>(149.0)</i> | <i>6 100</i> | <i>(140.0)</i> | <i>5 700</i> | <i>(133.0)</i> | <i>5 400</i> | <i>(127.0)</i> | <i>5 100</i> | <i>(122.0)</i> | <i>4 900</i> | <i>(119.0)</i> |
| Israel | 460 | (6.6) | 370 | (5.2) | 400 | (5.5) | 390 | (5.3) | 470 | (6.3) | 580 | (7.6) |
| <i>Kazakhstan</i> | <i>26 000</i> | <i>(163.0)</i> | <i>25 000</i> | <i>(156.0)</i> | <i>24 000</i> | <i>(151.0)</i> | <i>24 000</i> | <i>(145.0)</i> | <i>22 000</i> | <i>(134.0)</i> | <i>21 000</i> | <i>(121.0)</i> |
| <i>Kyrgyzstan</i> | <i>9 300</i> | <i>(179.0)</i> | <i>8 700</i> | <i>(165.0)</i> | <i>8 200</i> | <i>(153.0)</i> | <i>7 800</i> | <i>(145.0)</i> | <i>7 700</i> | <i>(141.0)</i> | <i>7 800</i> | <i>(140.0)</i> |
| <i>Moldova</i> | <i>5 600</i> | <i>(135.0)</i> | <i>5 100</i> | <i>(125.0)</i> | <i>5 100</i> | <i>(126.0)</i> | <i>4 800</i> | <i>(116.0)</i> | <i>4 900</i> | <i>(119.0)</i> | <i>5 100</i> | <i>(124.0)</i> |
| Monaco | 1 | (2.8) | 1 | (3.2) | 1 | (3.3) | 1 | (3.1) | 1 | (2.4) | 1 | (1.5) |
| Montenegro | 170 | (27.0) | 150 | (24.0) | 130 | (21.0) | 130 | (20.0) | 130 | (20.0) | 110 | (18.0) |
| <i>Russia</i> | <i>128 000</i> | <i>(90.0)</i> | <i>130 000</i> | <i>(91.0)</i> | <i>127 000</i> | <i>(89.0)</i> | <i>123 000</i> | <i>(86.0)</i> | <i>116 000</i> | <i>(81.0)</i> | <i>109 000</i> | <i>(76.0)</i> |
| San Marino | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Serbia | 3300 | (36.0) | 3100 | (34.0) | 2900 | (32.0) | 2700 | (30.0) | 2500 | (28.0) | 2200 | (24.0) |
| Switzerland | 480 | (6.4) | 530 | (7.0) | 580 | (7.5) | 580 | (7.5) | 600 | (7.6) | 480 | (6.0) |
| <i>Tajikistan</i> | <i>12 000</i> | <i>(169.0)</i> | <i>11 000</i> | <i>(155.0)</i> | <i>11 000</i> | <i>(141.0)</i> | <i>9 800</i> | <i>(128.0)</i> | <i>9 100</i> | <i>(117.0)</i> | <i>8 600</i> | <i>(108.0)</i> |
| <i>Turkey</i> | <i>22 000</i> | <i>(31.0)</i> | <i>20 000</i> | <i>(29.0)</i> | <i>19 000</i> | <i>(27.0)</i> | <i>18 000</i> | <i>(25.0)</i> | <i>17 000</i> | <i>(24.0)</i> | <i>16 000</i> | <i>(22.0)</i> |
| <i>Turkmenistan</i> | <i>4 300</i> | <i>(88.0)</i> | <i>4 700</i> | <i>(95.0)</i> | <i>3 900</i> | <i>(79.0)</i> | <i>4 000</i> | <i>(79.0)</i> | <i>3 400</i> | <i>(66.0)</i> | <i>3 700</i> | <i>(70.0)</i> |
| <i>Ukraine</i> | <i>57 000</i> | <i>(123.0)</i> | <i>55 000</i> | <i>(119.0)</i> | <i>53 000</i> | <i>(115.0)</i> | <i>50 000</i> | <i>(110.0)</i> | <i>48 000</i> | <i>(105.0)</i> | <i>46 000</i> | <i>(101.0)</i> |
| <i>Uzbekistan</i> | <i>30 000</i> | <i>(110.0)</i> | <i>29 000</i> | <i>(105.0)</i> | <i>29 000</i> | <i>(101.0)</i> | <i>28 000</i> | <i>(97.0)</i> | <i>27 000</i> | <i>(93.0)</i> | <i>26 000</i> | <i>(89.0)</i> |
| Subtotal non-EU/EEA | 325 000 | (85.0) | 320 000 | (83.3) | 314 000 | (81.4) | 299 000 | (77.1) | 285 000 | (73.0) | 270 000 | (68.8) |
| Total European Region | 415 000 | (46.8) | 410 000 | (46.1) | 399 000 | (44.7) | 380 000 | (42.4) | 365 000 | (40.5) | 343 000 | (38.0) |
| Subtotal 18 HPC | 351 000 | (91.3) | 346 000 | (89.7) | 338 000 | (87.3) | 320 000 | (82.4) | 305 000 | (78.1) | 289 000 | (73.7) |

'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

| | 2013 | | 2014 | | 2015 | | 2016 | | Mean annual % change in rate, 2012–2016 | Mean annual % change in rate, 2007–2016 | Country |
|--|---------------|------------------|---------------|------------------|---------------|------------------|---------------|------------------|---|---|--|
| | N | Rate per 100 000 | | | |
| | | | | | | | | | | | EU/EEA |
| | 720 | (8.4) | 650 | (7.5) | 650 | (7.5) | 710 | (8.2) | -0.6% | -3.2% | Austria |
| | 1000 | (9.3) | 1000 | (9.1) | 1100 | (9.5) | 1100 | (10.0) | 1.6% | 0.0% | Belgium |
| | 2400 | (33.0) | 2300 | (32.0) | 2000 | (28.0) | 1900 | (27.0) | -6.9% | -6.0% | Bulgaria |
| | 590 | (14.0) | 570 | (13.0) | 560 | (13.0) | 520 | (12.0) | -3.8% | -7.8% | Croatia |
| | 47 | (4.1) | 45 | (3.9) | 72 | (6.2) | 66 | (5.6) | -3.3% | 2.7% | Cyprus |
| | 540 | (5.1) | 550 | (5.1) | 580 | (5.5) | 530 | (5.0) | -4.8% | -6.1% | Czech Republic |
| | 380 | (6.7) | 340 | (5.9) | 370 | (6.5) | 350 | (6.1) | -3.4% | -2.3% | Denmark |
| | 290 | (22.0) | 270 | (20.0) | 240 | (18.0) | 220 | (16.0) | -9.6% | -8.6% | Estonia |
| | 310 | (5.6) | 290 | (5.3) | 310 | (5.6) | 260 | (4.7) | -3.9% | -3.5% | Finland |
| | 5500 | (8.6) | 5300 | (8.2) | 5200 | (8.1) | 5000 | (7.7) | -2.7% | -2.9% | France |
| | 4800 | (5.9) | 5000 | (6.1) | 6500 | (8.0) | 6600 | (8.1) | 9.2% | 2.3% | Germany |
| | 570 | (5.0) | 560 | (4.9) | 500 | (4.5) | 490 | (4.4) | -4.1% | -3.7% | Greece |
| | 1200 | (12.0) | 920 | (9.4) | 990 | (10.0) | 860 | (8.8) | -11.0% | -7.6% | Hungary |
| | 13 | (3.9) | 9 | (2.8) | 8 | (2.4) | 7 | (2.1) | -12.0% | -8.1% | Iceland |
| | 410 | (8.7) | 340 | (7.3) | 340 | (7.2) | 340 | (7.1) | -4.1% | -4.7% | Ireland |
| | 3500 | (5.8) | 3900 | (6.5) | 4000 | (6.7) | 3700 | (6.1) | 0.4% | 1.6% | Italy |
| | 1000 | (50.0) | 990 | (49.0) | 800 | (40.0) | 740 | (37.0) | -7.3% | -5.6% | Latvia |
| | - | - | - | - | - | - | - | - | - | - | Liechtenstein |
| | 1900 | (65.0) | 1800 | (62.0) | 1600 | (55.0) | 1500 | (53.0) | -6.0% | -4.5% | Lithuania |
| | 44 | (8.0) | 28 | (5.0) | 34 | (6.1) | 33 | (5.8) | -12.1% | -5.2% | Luxembourg |
| | 58 | (14.0) | 52 | (12.0) | 37 | (8.6) | 58 | (13.0) | 4.3% | 1.9% | Malta |
| | 960 | (5.7) | 940 | (5.5) | 980 | (5.8) | 1000 | (5.9) | -1.6% | -1.1% | Netherlands |
| | 420 | (8.2) | 350 | (6.8) | 330 | (6.3) | 320 | (6.1) | -6.3% | -1.4% | Norway |
| | 8100 | (21.0) | 7500 | (20.0) | 7200 | (19.0) | 7100 | (18.0) | -3.8% | -3.1% | Poland |
| | 2700 | (26.0) | 2500 | (24.0) | 2400 | (23.0) | 2100 | (20.0) | -7.2% | -5.1% | Portugal |
| | 18000 | (89.0) | 17000 | (86.0) | 16000 | (82.0) | 15000 | (74.0) | -5.3% | -5.5% | Romania |
| | 460 | (8.4) | 370 | (6.8) | 350 | (6.5) | 320 | (5.9) | -3.5% | -8.4% | Slovakia |
| | 160 | (7.7) | 160 | (7.9) | 150 | (7.2) | 140 | (6.5) | -3.5% | -6.6% | Slovenia |
| | 6000 | (13.0) | 5500 | (12.0) | 4600 | (10.0) | 4700 | (10.0) | -8.1% | -6.9% | Spain |
| | 700 | (7.3) | 730 | (7.5) | 900 | (9.2) | 810 | (8.2) | 3.7% | 3.9% | Sweden |
| | 8300 | (13.0) | 7400 | (11.0) | 6600 | (10.0) | 6500 | (9.9) | -8.3% | -4.5% | United Kingdom |
| | 71000 | (13.9) | 67000 | (13.1) | 65000 | (12.7) | 63000 | (12.3) | -4.1% | -4.1% | Subtotal EU/EEA |
| | | | | | | | | | | | Non-EU/EEA |
| | 550 | (19.0) | 470 | (16.0) | 480 | (16.0) | 480 | (16.0) | 0.0% | -0.7% | Albania |
| | 6 | (7.1) | 7 | (8.7) | 5 | (5.9) | 5 | (6.0) | -17.6% | -1.7% | Andorra |
| | 1700 | (60.0) | 1700 | (57.0) | 1400 | (47.0) | 1300 | (44.0) | -4.5% | -5.3% | Armenia |
| | 7300 | (78.0) | 7200 | (76.0) | 6800 | (71.0) | 6400 | (66.0) | -6.4% | -2.0% | Azerbaijan |
| | 5800 | (61.0) | 5500 | (58.0) | 5200 | (55.0) | 4900 | (52.0) | -5.1% | -3.7% | Belarus |
| | 1600 | (44.0) | 1500 | (42.0) | 1400 | (39.0) | 1100 | (32.0) | -9.6% | -9.6% | Bosnia and Herzegovina |
| | 400 | (19.0) | 350 | (17.0) | 350 | (17.0) | 330 | (16.0) | -6.6% | -7.4% | former Yugoslav Republic of Macedonia, the |
| | 4700 | (116.0) | 4200 | (106.0) | 3900 | (99.0) | 3600 | (92.0) | -6.2% | -5.2% | Georgia |
| | 350 | (4.5) | 420 | (5.2) | 320 | (4.0) | 290 | (3.5) | -17.6% | -6.8% | Israel |
| | 18000 | (107.0) | 16000 | (93.0) | 14000 | (79.0) | 12000 | (67.0) | -13.7% | -9.4% | Kazakhstan |
| | 8000 | (141.0) | 8200 | (142.0) | 8400 | (144.0) | 8700 | (145.0) | 0.9% | -2.3% | Kyrgyzstan |
| | 5200 | (127.0) | 4700 | (115.0) | 4100 | (102.0) | 4100 | (101.0) | -5.0% | -3.2% | Moldova |
| | 0 | (0.6) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - | -100.0% | Monaco |
| | 140 | (22.0) | 130 | (21.0) | 92 | (15.0) | 100 | (16.0) | -2.9% | -5.6% | Montenegro |
| | 104000 | (73.0) | 101000 | (70.0) | 97000 | (68.0) | 94000 | (66.0) | -3.5% | -3.4% | Russia |
| | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | - | - | San Marino |
| | 2400 | (27.0) | 2100 | (24.0) | 1900 | (21.0) | 1700 | (19.0) | -5.7% | -6.9% | Serbia |
| | 540 | (6.6) | 490 | (5.9) | 610 | (7.3) | 660 | (7.8) | 6.8% | 2.2% | Switzerland |
| | 8100 | (100.0) | 7600 | (91.0) | 7400 | (86.0) | 7500 | (85.0) | -5.8% | -7.4% | Tajikistan |
| | 15000 | (20.0) | 15000 | (20.0) | 14000 | (18.0) | 14000 | (18.0) | -4.9% | -5.9% | Turkey |
| | 3800 | (71.0) | 3200 | (59.0) | 3800 | (68.0) | 3400 | (60.0) | -3.8% | -4.2% | Turkmenistan |
| | 44000 | (96.0) | 42000 | (94.0) | 41000 | (91.0) | 39000 | (87.0) | -3.7% | -3.8% | Ukraine |
| | 26000 | (86.0) | 25000 | (82.0) | 25000 | (79.0) | 24000 | (76.0) | -3.9% | -4.0% | Uzbekistan |
| | 258000 | (65.3) | 247000 | (62.1) | 237000 | (59.2) | 228000 | (56.6) | -4.7% | -4.4% | Subtotal non-EU/EEA |
| | 329000 | (36.3) | 315000 | (34.6) | 303000 | (33.2) | 290000 | (31.6) | -4.4% | -4.3% | Total European Region |
| | 275000 | (69.7) | 264000 | (66.5) | 253000 | (63.4) | 242000 | (60.4) | -4.9% | -4.5% | Subtotal 18 HPC |

Table III: Tuberculosis cases in children under 15 years, European Region, 2012–2016^a

| Country | 2012 | | | 2013 | | | 2014 | | | 2015 | | | 2016 | | |
|--|---------------|----------------------|-------------|---------------|----------------------|-------------|---------------|----------------------|-------------|---------------|----------------------|-------------|---------------|----------------------|-------------|
| | N | % among all TB cases | Rate | N | % among all TB cases | Rate | N | % among all TB cases | Rate | N | % among all TB cases | Rate | N | % among all TB cases | Rate |
| EU/EEA | | | | | | | | | | | | | | | |
| Austria | 27 | (4.2) | 2.2 | 23 | (3.5) | 1.9 | 14 | (2.4) | 1.1 | 20 | (3.4) | 1.6 | 31 | (4.9) | 2.5 |
| Belgium | 63 | (6.5) | 3.3 | 58 | (6.0) | 3.1 | 60 | (6.3) | 3.2 | 69 | (7.1) | 3.6 | 59 | (5.6) | 3.1 |
| Bulgaria | 178 | (7.8) | 18.2 | 146 | (7.6) | 14.7 | 145 | (7.7) | 14.6 | 118 | (7.1) | 11.8 | 126 | (7.9) | 12.6 |
| Croatia ^b | 12 | (2.1) | 1.9 | 4 | (0.8) | 0.6 | 2 | (0.4) | 0.3 | 13 | (2.7) | 2.1 | 6 | (1.3) | 1.0 |
| Cyprus | 3 | (4.3) | 2.1 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 |
| Czech Republic | 5 | (0.8) | 0.3 | 5 | (1.0) | 0.3 | 6 | (1.2) | 0.4 | 5 | (1.0) | 0.3 | 10 | (1.9) | 0.6 |
| Denmark | 17 | (4.4) | 1.7 | 22 | (6.2) | 2.3 | 9 | (2.8) | 0.9 | 15 | (4.2) | 1.6 | 18 | (5.5) | 1.9 |
| Estonia | 2 | (0.7) | 1.0 | 1 | (0.3) | 0.5 | 1 | (0.4) | 0.5 | 2 | (0.9) | 1.0 | 4 | (2.1) | 1.9 |
| Finland | 5 | (1.8) | 0.6 | 2 | (0.7) | 0.2 | 10 | (3.8) | 1.1 | 11 | (4.0) | 1.2 | 6 | (2.5) | 0.7 |
| France ^c | 232 | (4.6) | 1.9 | 257 | (5.2) | 2.1 | 257 | (5.3) | 2.1 | 246 | (5.2) | 2.0 | 269 | (5.8) | 2.2 |
| Germany | 173 | (4.1) | 1.6 | 171 | (3.9) | 1.6 | 142 | (3.1) | 1.3 | 196 | (3.3) | 1.8 | 233 | (3.9) | 2.1 |
| Greece | 41 | (7.3) | 2.5 | 30 | (5.6) | 1.9 | 10 | (1.9) | 0.6 | 11 | (2.3) | 0.7 | 22 | (5.0) | 1.4 |
| Hungary | 9 | (0.7) | 0.6 | 8 | (0.8) | 0.6 | 4 | (0.5) | 0.3 | 9 | (1.0) | 0.6 | 6 | (0.8) | 0.4 |
| Iceland | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 |
| Ireland | 10 | (2.8) | 1.0 | 9 | (2.4) | 0.9 | 7 | (2.3) | 0.7 | 14 | (4.9) | 1.4 | 17 | (5.3) | 1.6 |
| Italy | 206 | (4.8) | 2.5 | 205 | (5.2) | 2.5 | 201 | (5.1) | 2.4 | 177 | (4.7) | 2.1 | 158 | (3.9) | 1.9 |
| Latvia | 57 | (5.7) | 19.5 | 45 | (5.0) | 15.4 | 41 | (5.4) | 13.9 | 25 | (3.5) | 8.4 | 23 | (3.5) | 7.7 |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 56 | (3.1) | 12.6 | 37 | (2.2) | 8.5 | 22 | (1.4) | 5.1 | 36 | (2.4) | 8.5 | 47 | (3.3) | 11.1 |
| Luxembourg | 3 | (6.7) | 3.3 | 1 | (2.6) | 1.1 | 0 | (0.0) | 0.0 | 2 | (6.7) | 2.1 | 1 | (3.4) | 1.1 |
| Malta | 2 | (4.8) | 3.2 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 |
| Netherlands | 50 | (5.2) | 1.7 | 33 | (3.9) | 1.1 | 48 | (5.9) | 1.7 | 42 | (4.9) | 1.5 | 49 | (5.5) | 1.8 |
| Norway | 19 | (5.1) | 2.1 | 16 | (4.1) | 1.7 | 14 | (4.3) | 1.5 | 20 | (6.4) | 2.1 | 14 | (4.7) | 1.5 |
| Poland | 95 | (1.3) | 1.6 | 116 | (1.6) | 2.0 | 70 | (1.0) | 1.2 | 81 | (1.3) | 1.4 | 103 | (1.6) | 1.8 |
| Portugal | 75 | (2.9) | 4.8 | 51 | (2.1) | 3.3 | 42 | (1.8) | 2.8 | 34 | (1.6) | 2.3 | 33 | (1.8) | 2.3 |
| Romania | 717 | (3.9) | 22.5 | 695 | (4.2) | 22.1 | 639 | (4.0) | 20.6 | 655 | (4.3) | 21.3 | 596 | (4.4) | 19.4 |
| Slovakia | 19 | (5.5) | 2.3 | 38 | (9.5) | 4.6 | 46 | (13.7) | 5.5 | 67 | (21.1) | 8.1 | 61 | (20.6) | 7.3 |
| Slovenia | 5 | (3.6) | 1.7 | 2 | (1.4) | 0.7 | 3 | (2.1) | 1.0 | 1 | (0.8) | 0.3 | 3 | (2.5) | 1.0 |
| Spain | 388 | (6.4) | 5.5 | 382 | (6.8) | 5.4 | 295 | (6.0) | 4.2 | 365 | (7.3) | 5.2 | 268 | (5.5) | 3.8 |
| Sweden | 25 | (4.0) | 1.6 | 49 | (7.7) | 3.0 | 54 | (8.2) | 3.3 | 47 | (5.8) | 2.8 | 58 | (8.0) | 3.4 |
| United Kingdom | 412 | (4.7) | 3.7 | 315 | (4.0) | 2.8 | 280 | (4.0) | 2.5 | 226 | (3.6) | 2.0 | 226 | (3.7) | 2.0 |
| Subtotal EU/EEA | 2906 | (4.2) | 3.7 | 2721 | (4.1) | 3.4 | 2422 | (4.0) | 3.0 | 2507 | (4.1) | 3.0 | 2447 | (4.1) | 3.0 |
| Non-EU/EEA | | | | | | | | | | | | | | | |
| Albania | 3 | (0.7) | 0.5 | 19 | (4.0) | 3.3 | 21 | (5.1) | 3.8 | 11 | (2.7) | 2.1 | 13 | (3.1) | 2.5 |
| Andorra | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 1 | (25.0) | 9.5 | 0 | (0.0) | 0.0 |
| Armenia | 37 | (3.1) | 6.6 | 42 | (3.0) | 7.4 | 32 | (2.4) | 5.6 | 24 | (2.2) | 4.1 | 21 | (2.0) | 3.6 |
| Azerbaijan | 212 | (3.3) | 10.1 | 215 | (3.7) | 10.1 | 179 | (3.1) | 8.3 | 179 | (3.3) | 8.1 | 175 | (3.4) | 7.8 |
| Belarus | 21 | (0.4) | 1.5 | 14 | (0.3) | 1.0 | 24 | (0.6) | 1.6 | 18 | (0.5) | 1.2 | 13 | (0.4) | 0.8 |
| Bosnia and Herzegovina | 18 | (1.3) | 3.2 | 12 | (1.0) | 2.2 | 15 | (1.3) | 2.9 | 14 | (1.3) | 2.7 | 10 | (1.1) | 2.0 |
| former Yugoslav Republic of Macedonia, the | 29 | (8.4) | 8.1 | 23 | (7.2) | 6.5 | 19 | (6.7) | 5.4 | 14 | (5.0) | 4.0 | 25 | (9.5) | 7.2 |
| Georgia | 215 | (5.5) | 28.7 | 183 | (5.3) | 24.7 | 129 | (4.0) | 17.5 | 139 | (4.4) | 18.8 | 123 | (4.1) | 16.5 |
| Israel | 19 | (3.8) | 0.9 | 15 | (4.9) | 0.7 | 31 | (8.6) | 1.4 | 6 | (2.1) | 0.3 | 13 | (5.2) | 0.6 |
| Kazakhstan | 576 | (3.2) | 13.7 | 511 | (2.7) | 11.6 | 452 | (3.0) | 9.9 | 392 | (2.8) | 8.2 | 326 | (2.6) | 6.6 |
| Kyrgyzstan | 640 | (10.3) | 37.9 | 594 | (8.4) | 34.3 | 438 | (6.9) | 24.7 | 537 | (7.6) | 29.4 | 407 | (5.8) | 21.7 |
| Moldova | 145 | (3.3) | 22.2 | 134 | (3.0) | 20.7 | 114 | (2.8) | 17.7 | 114 | (3.2) | 17.8 | 103 | (2.9) | 16.1 |
| Monaco | – | – | – | – | – | – | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – | – | – |
| Montenegro | 0 | (0.0) | 0.0 | 1 | (0.8) | 0.8 | 0 | (0.0) | 0.0 | 1 | (1.3) | 0.9 | 0 | (0.0) | 0.0 |
| Russia | 3 688 | (3.5) | 16.6 | 3 298 | (3.1) | 14.4 | 3 195 | (3.1) | 13.5 | 3 061 | (3.1) | 12.6 | 2 876 | (3.1) | 11.6 |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | (0.0) | 0.0 |
| Serbia | 20 | (1.1) | 1.3 | 14 | (0.7) | 0.9 | 41 | (2.3) | 2.7 | 29 | (1.8) | 2.0 | 17 | (1.2) | 1.2 |
| Serbia excluding UN Administered Province of Kosovo ^d | 18 | (1.5) | 4.7 | 14 | (1.2) | 0.9 | 21 | (2.1) | 2.0 | 8 | (0.9) | 0.8 | 0 | (0.0) | 0.0 |
| UN Administered Province of Kosovo ^d | 20 | (2.8) | 1.7 | – | – | – | 20 | (2.4) | 4.1 | 21 | (2.7) | 4.3 | 17 | (2.4) | 2.9 |
| Switzerland | 13 | (3.1) | 1.1 | 22 | (4.7) | 1.8 | 11 | (2.6) | 0.9 | 32 | (6.0) | 2.6 | 30 | (5.2) | 2.4 |
| Tajikistan | 360 | (5.5) | 12.7 | 389 | (7.0) | 13.5 | 334 | (5.8) | 11.4 | 328 | (5.6) | 10.9 | 389 | (6.5) | 12.7 |
| Turkey | 672 | (4.8) | 3.4 | 581 | (4.4) | 2.9 | 550 | (4.2) | 2.8 | 633 | (5.0) | 3.2 | 628 | (5.2) | 3.1 |
| Turkmenistan | 44 | (1.5) | 2.8 | – | – | – | – | – | – | – | – | – | 26 | (1.2) | 1.5 |
| Ukraine | 223 | (0.5) | 3.4 | 638 | (1.7) | 9.7 | 532 | (1.7) | 8.0 | 568 | (1.9) | 8.4 | 571 | (2.0) | 8.4 |
| Uzbekistan | 1 561 | (10.5) | 18.5 | 1 960 | (9.4) | 23.1 | 1 913 | (10.4) | 22.3 | 1 795 | (11.0) | 20.7 | 2 010 | (12.5) | 22.8 |
| Subtotal non-EU/EEA | 8 496 | (3.6) | 10.7 | 8 665 | (3.7) | 11.0 | 8 030 | (3.7) | 10.0 | 7 896 | (3.8) | 9.7 | 7 755 | (3.9) | 9.2 |
| Total European Region | 11 402 | (3.9) | 7.2 | 11 386 | (3.9) | 7.2 | 10 452 | (3.9) | 6.5 | 10 403 | (4.0) | 6.5 | 10 275 | (4.2) | 6.3 |
| Subtotal 18 HPC | 9 404 | (3.7) | 12.1 | 9 483 | (3.8) | 12.3 | 8 740 | (3.8) | 11.1 | 8 624 | (3.9) | 10.8 | 8 443 | (4.0) | 10.2 |

^a "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

^b For non-EU countries new and relapse cases under 15 year of age are included, for EU/EEA countries all TB cases under 15 years of age are included.

^c These data are subject to change as the national TB registry was under review when this report was being produced.

^d Provisional data for 2016 including overseas territories reported to WHO Global TB database.

^e In accordance with the UN Security Council Resolution No. 1244 (1999).

| | 2015 | | | | | | | 2016 | | | | | | | Country |
|--|---------------|----------------|----------------|----------------|----------------|----------------|------------------|---------------|----------------|----------------|----------------|----------------|----------------|------------------|--|
| | Foreign | | Native | | Unknown origin | | All TB cases (N) | Foreign | | Native | | Unknown origin | | All TB cases (N) | |
| | N | % among all TB | N | % among all TB | N | % among all TB | | N | % among all TB | N | % among all TB | N | % among all TB | | |
| | | | | | | | | | | | | | | | EU/EEA |
| | 364 | (62.4) | 219 | (37.6) | 0 | (0.0) | 583 | 424 | (66.9) | 210 | (33.1) | 0 | (0.0) | 634 | Austria ^a |
| | 512 | (52.4) | 465 | (47.6) | 0 | (0.0) | 977 | 547 | (52.2) | 500 | (47.8) | 0 | (0.0) | 1047 | Belgium ^a |
| | 10 | (0.6) | 1650 | (99.4) | 0 | (0.0) | 1660 | 4 | (0.2) | 1599 | (99.8) | 0 | (0.0) | 1603 | Bulgaria |
| | 74 | (15.2) | 239 | (49.2) | 173 | (35.6) | 486 | 3 | (0.7) | 161 | (35.0) | 296 | (64.3) | 460 | Croatia ^b |
| | 52 | (82.5) | 11 | (17.5) | 0 | (0.0) | 63 | 56 | (93.3) | 4 | (6.7) | 0 | (0.0) | 60 | Cyprus |
| | 110 | (21.3) | 407 | (78.7) | 0 | (0.0) | 517 | 151 | (29.3) | 365 | (70.7) | 0 | (0.0) | 516 | Czech Republic |
| | 242 | (67.8) | 115 | (32.2) | 0 | (0.0) | 357 | 221 | (67.0) | 109 | (33.0) | 0 | (0.0) | 330 | Denmark |
| | 38 | (17.5) | 179 | (82.5) | 0 | (0.0) | 217 | 42 | (21.9) | 150 | (78.1) | 0 | (0.0) | 192 | Estonia |
| | 115 | (42.3) | 151 | (55.5) | 6 | (2.2) | 272 | 111 | (47.0) | 117 | (49.6) | 8 | (3.4) | 236 | Finland |
| | 2 628 | (55.4) | 1 843 | (38.9) | 270 | (5.7) | 4 741 | 2 758 | (55.6) | 2 200 | (44.4) | 0 | (0.0) | 4 958 | France ^c |
| | 4 066 | (69.5) | 1 560 | (26.7) | 226 | (3.9) | 5 852 | 4 125 | (69.7) | 1 427 | (24.1) | 363 | (6.1) | 5 915 | Germany |
| | 189 | (39.2) | 289 | (60.0) | 4 | (0.8) | 482 | 189 | (42.7) | 254 | (57.3) | 0 | (0.0) | 443 | Greece ^a |
| | 27 | (3.0) | 879 | (97.0) | 0 | (0.0) | 906 | 30 | (3.8) | 756 | (96.2) | 0 | (0.0) | 786 | Hungary ^a |
| | 6 | (85.7) | 1 | (14.3) | 0 | (0.0) | 7 | 4 | (66.7) | 2 | (33.3) | 0 | (0.0) | 6 | Iceland |
| | 126 | (44.5) | 144 | (50.9) | 13 | (4.6) | 283 | 160 | (50.3) | 145 | (45.6) | 13 | (4.1) | 318 | Ireland |
| | 1 764 | (46.8) | 1 227 | (32.6) | 778 | (20.6) | 3 769 | 2 509 | (62.2) | 1 180 | (29.3) | 343 | (8.5) | 4 032 | Italy |
| | 45 | (6.2) | 676 | (93.8) | 0 | (0.0) | 721 | 43 | (6.5) | 617 | (93.5) | 0 | (0.0) | 660 | Latvia |
| | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Liechtenstein |
| | 15 | (1.0) | 1 492 | (99.0) | 0 | (0.0) | 1 507 | 13 | (0.9) | 1 429 | (99.1) | 0 | (0.0) | 1 442 | Lithuania |
| | 20 | (66.7) | 10 | (33.3) | 0 | (0.0) | 30 | 22 | (75.9) | 7 | (24.1) | 0 | (0.0) | 29 | Luxembourg |
| | 24 | (75.0) | 8 | (25.0) | 0 | (0.0) | 32 | 48 | (96.0) | 2 | (4.0) | 0 | (0.0) | 50 | Malta |
| | 624 | (72.4) | 236 | (27.4) | 2 | (0.2) | 862 | 669 | (75.3) | 214 | (24.1) | 6 | (0.7) | 889 | Netherlands |
| | 277 | (88.5) | 36 | (11.5) | 0 | (0.0) | 313 | 265 | (88.6) | 34 | (11.4) | 0 | (0.0) | 299 | Norway |
| | 52 | (0.8) | 6 378 | (99.2) | 0 | (0.0) | 6 430 | 92 | (1.4) | 6 352 | (98.6) | 0 | (0.0) | 6 444 | Poland ^d |
| | 363 | (16.7) | 1 812 | (83.2) | 3 | (0.1) | 2 178 | 336 | (18.3) | 1 500 | (81.7) | 0 | (0.0) | 1 836 | Portugal |
| | 36 | (0.2) | 15 145 | (99.7) | 2 | (0.0) | 15 183 | 24 | (0.2) | 13 593 | (99.8) | 0 | (0.0) | 13 617 | Romania |
| | 11 | (3.5) | 306 | (96.5) | 0 | (0.0) | 317 | 11 | (3.7) | 285 | (96.3) | 0 | (0.0) | 296 | Slovakia |
| | 50 | (38.5) | 80 | (61.5) | 0 | (0.0) | 130 | 43 | (36.4) | 75 | (63.6) | 0 | (0.0) | 118 | Slovenia |
| | 1 546 | (30.9) | 3 278 | (65.6) | 173 | (3.5) | 4 997 | 1 391 | (28.5) | 2 886 | (59.2) | 600 | (12.3) | 4 877 | Spain |
| | 729 | (89.4) | 86 | (10.6) | 0 | (0.0) | 815 | 652 | (89.8) | 74 | (10.2) | 0 | (0.0) | 726 | Sweden |
| | 4 361 | (70.0) | 1 750 | (28.1) | 123 | (2.0) | 6 234 | 4 369 | (70.8) | 1 662 | (26.9) | 144 | (2.3) | 6 175 | United Kingdom |
| | 18 476 | (30.3) | 40 672 | (66.8) | 1 773 | (2.9) | 60 921 | 19 312 | (32.7) | 37 909 | (64.3) | 1 773 | (3.0) | 58 994 | Subtotal EU/EEA |
| | | | | | | | | | | | | | | | Non-EU/EEA |
| | 4 | (1.0) | 411 | (99.0) | - | - | 415 | 0 | (0.0) | 415 | (100.0) | - | - | 415 | Albania |
| | 0 | (0.0) | 4 | (100.0) | - | - | 4 | 0 | (0.0) | 4 | (100.0) | - | - | 4 | Andorra |
| | 1 | (0.1) | 1 103 | (99.9) | - | - | 1 104 | 0 | (0.0) | 1 080 | (100.0) | - | - | 1 080 | Armenia |
| | 15 | (0.2) | 7 486 | (99.8) | - | - | 7 501 | 12 | (0.2) | 6 695 | (99.8) | - | - | 6 707 | Azerbaijan |
| | 0 | (0.0) | 4 177 | (100.0) | - | - | 4 177 | 0 | (0.0) | 3 598 | (100.0) | - | - | 3 598 | Belarus |
| | 0 | (0.0) | 1 095 | (100.0) | - | - | 1 095 | 0 | (0.0) | 907 | (100.0) | - | - | 907 | Bosnia and Herzegovina |
| | 10 | (3.5) | 274 | (96.5) | - | - | 284 | 8 | (3.0) | 259 | (97.0) | - | - | 267 | former Yugoslav Republic of Macedonia, the |
| | 0 | (0.0) | 0 | (0.0) | - | - | 0 | 0 | (0.0) | 0 | (0.0) | - | - | 0 | Georgia |
| | 233 | (83.2) | 47 | (16.8) | - | - | 280 | 202 | (80.8) | 48 | (19.2) | - | - | 250 | Israel |
| | 78 | (0.5) | 14 553 | (99.5) | - | - | 14 631 | 153 | (1.2) | 12 505 | (98.8) | - | - | 12 658 | Kazakhstan |
| | 0 | (0.0) | 0 | (0.0) | - | - | 0 | 0 | (0.0) | 0 | (0.0) | - | - | 7 995 | Kyrgyzstan |
| | 37 | (0.9) | 4 174 | (99.1) | - | - | 4 211 | 39 | (0.9) | 4 095 | (99.1) | - | - | 4 134 | Moldova |
| | 0 | (0.0) | 0 | (0.0) | - | - | - | - | - | - | - | - | - | 0 | Monaco |
| | 3 | (3.8) | 77 | (96.3) | - | - | 80 | 2 | (2.3) | 85 | (97.7) | - | - | 87 | Montenegro |
| | 0 | (0.0) | 130 904 | (100.0) | - | - | 130 904 | 2 797 | (2.3) | 118 249 | (97.7) | - | - | 121 046 | Russia |
| | - | - | - | - | - | - | - | 0 | (0.0) | 0 | (0.0) | - | - | 0 | San Marino |
| | 7 | (0.4) | 1 651 | (99.6) | - | - | 1 658 | 5 | (0.3) | 1 483 | (99.7) | - | - | 1 488 | Serbia |
| | 4 | (0.5) | 884 | (99.5) | - | - | 888 | 1 | (0.1) | 766 | (99.9) | - | - | 767 | Serbia excluding UN Administered Province of Kosovo ^d |
| | 3 | (0.4) | 767 | (99.6) | - | - | 770 | 4 | (0.6) | 717 | (99.4) | - | - | 721 | UN Administered Province of Kosovo ^d |
| | 428 | (75.9) | 136 | (24.1) | - | - | 564 | 486 | (79.8) | 123 | (20.2) | - | - | 609 | Switzerland |
| | 0 | (0.0) | 6 232 | (100.0) | - | - | 6 232 | 0 | (0.0) | 6 241 | (100.0) | - | - | 6 241 | Tajikistan |
| | 872 | (6.8) | 11 900 | (93.2) | - | - | 12 772 | 904 | (7.3) | 11 513 | (92.7) | - | - | 12 417 | Turkey |
| | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Turkmenistan |
| | 10 | (0.0) | 35 294 | (100.0) | - | - | 35 304 | 20 | (0.1) | 34 068 | (99.9) | - | - | 34 088 | Ukraine |
| | 47 | (0.2) | 19 008 | (99.8) | - | - | 19 055 | 0 | (0.0) | 18 441 | (100.0) | - | - | 18 441 | Uzbekistan |
| | 1 745 | (0.7) | 238 526 | (99.3) | 0 | (0.0) | 240 271 | 4 628 | (2.0) | 219 809 | (94.6) | 0 | (0.0) | 232 432 | Subtotal non-EU/EEA |
| | 20 221 | (6.7) | 279 198 | (92.7) | 1 773 | (0.6) | 301 192 | 23 940 | (8.2) | 257 718 | (88.4) | 1 773 | (0.6) | 291 426 | Total European Region |
| | 1 204 | (0.5) | 253 973 | (99.5) | 2 | (0.0) | 255 179 | 4 051 | (1.6) | 233 873 | (95.1) | 0 | (0.0) | 245 919 | Subtotal 18 HPC |

Table V: MDR TB notification among new bacteriologically-confirmed^a pulmonary TB cases with available DST results, European Region, 2012–2016

| Country | 2012 | | | 2013 | | | 2014 | | | 2015 | | | 2016 | | | Mean annual % change in rate, 2012–2016 ^e |
|--|--------------|---------------|------------------|--------------|---------------|------------------|--------------|---------------|------------------|--------------|---------------|------------------|--------------|---------------|------------------|--|
| | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | |
| EU/EEA | | | | | | | | | | | | | | | | |
| Austria | 9 | (4.0) | 0.1 | 7 | (2.5) | 0.1 | 7 | (2.6) | 0.1 | 5 | (1.9) | 0.1 | 6 | (2.2) | 0.1 | -10.4% |
| Belgium ^b | 5 | (1.3) | 0.0 | 7 | (1.8) | 0.1 | 6 | (1.5) | 0.1 | 6 | (1.4) | 0.1 | 6 | (1.4) | 0.1 | 4.1% |
| Bulgaria | 15 | (2.2) | 0.2 | 12 | (1.9) | 0.2 | 17 | (2.7) | 0.2 | 4 | (0.7) | 0.1 | 5 | (0.9) | 0.1 | -23.6% |
| Croatia ^c | 1 | (0.4) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | -100.0% |
| Cyprus | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Czech Republic | 2 | (0.6) | 0.0 | 0 | (0.0) | 0.0 | 3 | (1.0) | 0.0 | 7 | (2.2) | 0.1 | 4 | (1.3) | 0.0 | 18.8% |
| Denmark ^b | 0 | (0.0) | 0.0 | 1 | (0.5) | 0.0 | 1 | (0.5) | 0.0 | 4 | (1.9) | 0.1 | 3 | (1.7) | 0.1 | – |
| Estonia | 38 | (20.4) | 2.9 | 29 | (17.2) | 2.2 | 30 | (19.4) | 2.3 | 18 | (13.5) | 1.4 | 17 | (12.9) | 1.3 | -18.1% |
| Finland | 3 | (2.1) | 0.1 | 2 | (1.2) | 0.0 | 5 | (3.3) | 0.1 | 7 | (4.4) | 0.1 | 2 | (1.6) | 0.0 | -10.0% |
| France ^d | – | – | – | – | – | – | 25 | (1.0) | 0.0 | – | – | – | 33 | (1.4) | 0.0 | – |
| Germany | 12 | (1.6) | 0.0 | 10 | (1.9) | 0.0 | 9 | (3.1) | 0.0 | 4 | (1.4) | 0.0 | 4 | (2.2) | 0.0 | -24.4% |
| Greece | 1 | (0.8) | 0.0 | 7 | (4.0) | 0.1 | 3 | (2.6) | 0.0 | 3 | (1.9) | 0.0 | 2 | (2.0) | 0.0 | 19.7% |
| Hungary | 9 | (2.2) | 0.1 | 6 | (1.8) | 0.1 | 1 | (0.4) | 0.0 | 6 | (1.8) | 0.1 | 12 | (4.1) | 0.1 | 7.7% |
| Iceland | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Ireland ^b | 2 | (1.3) | 0.0 | 2 | (1.4) | 0.0 | 2 | (1.6) | 0.0 | 1 | (1.0) | 0.0 | 4 | (3.1) | 0.1 | 18.0% |
| Italy | 12 | (2.6) | 0.0 | 21 | (3.2) | 0.0 | 24 | (2.0) | 0.0 | 18 | (2.3) | 0.0 | 24 | (3.1) | 0.0 | 18.3% |
| Latvia | 73 | (11.4) | 3.6 | 48 | (8.8) | 2.4 | 38 | (8.2) | 1.9 | 36 | (7.9) | 1.8 | 32 | (7.6) | 1.6 | -17.9% |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 116 | (11.8) | 3.9 | 116 | (11.5) | 3.9 | 128 | (13.6) | 4.3 | 104 | (11.6) | 3.6 | 117 | (13.3) | 4.1 | 1.2% |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | 0 | (0.0) | 0.0 | – |
| Malta | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Netherlands | 5 | (1.3) | 0.0 | 7 | (2.0) | 0.0 | 4 | (1.2) | 0.0 | 6 | (1.6) | 0.0 | 6 | (1.8) | 0.0 | 4.3% |
| Norway ^b | 2 | (1.2) | 0.0 | 4 | (2.2) | 0.1 | 5 | (3.2) | 0.1 | 4 | (2.6) | 0.1 | 7 | (5.1) | 0.1 | 35.3% |
| Poland | 19 | (0.5) | 0.0 | 19 | (0.5) | 0.0 | 17 | (0.4) | 0.0 | 19 | (0.5) | 0.0 | 27 | (0.7) | 0.1 | 9.3% |
| Portugal | 14 | (1.1) | 0.1 | 9 | (0.8) | 0.1 | 17 | (1.6) | 0.2 | 12 | (1.2) | 0.1 | 8 | (1.3) | 0.1 | -12.6% |
| Romania | 153 | (3.1) | 0.8 | 160 | (3.2) | 0.8 | 125 | (2.1) | 0.6 | 129 | (2.0) | 0.6 | 124 | (2.0) | 0.6 | -4.7% |
| Slovakia | 0 | (0.0) | 0.0 | 1 | (0.7) | 0.0 | 1 | (0.8) | 0.0 | 1 | (0.7) | 0.0 | 2 | (2.2) | 0.0 | – |
| Slovenia | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Spain | 26 | (3.2) | 0.1 | 27 | (1.9) | 0.1 | 26 | (1.7) | 0.1 | 30 | (3.9) | 0.1 | 34 | (4.0) | 0.1 | 7.2% |
| Sweden | 6 | (2.1) | 0.1 | 5 | (1.8) | 0.1 | 9 | (3.0) | 0.1 | 14 | (3.3) | 0.1 | 11 | (3.0) | 0.1 | 15.3% |
| United Kingdom ^b | 43 | (1.5) | 0.1 | 35 | (1.4) | 0.1 | 28 | (1.2) | 0.0 | 28 | (1.3) | 0.0 | 34 | (1.6) | 0.1 | -6.4% |
| Subtotal EU/EEA | 566 | (2.7) | 0.1 | 535 | (2.6) | 0.1 | 531 | (2.2) | 0.1 | 432 | (2.2) | 0.1 | 524 | (2.4) | 0.1 | -5.5% |
| Non-EU/EEA | | | | | | | | | | | | | | | | |
| Albania | 1 | (0.6) | 0.0 | 1 | (3.7) | 0.0 | 1 | (4.8) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | -100.0% |
| Andorra | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Armenia | 57 | (13.6) | 2.0 | 43 | (11.6) | 1.5 | 57 | (16.6) | 2.0 | 42 | (14.6) | 1.4 | 55 | (32.7) | 1.7 | -3.1% |
| Azerbaijan | 128 | (13.5) | 1.4 | 187 | (15.2) | 2.0 | 158 | (12.8) | 1.7 | 195 | (15.9) | 2.0 | 161 | (15.4) | 1.7 | 4.6% |
| Belarus | 753 | (34.8) | 7.9 | 755 | (35.2) | 8.0 | 667 | (34.1) | 7.0 | 678 | (35.8) | 7.1 | 654 | (37.1) | 6.9 | -3.5% |
| Bosnia and Herzegovina | 4 | (0.6) | 0.1 | 0 | (0.0) | 0.0 | 2 | (25.0) | 0.1 | 2 | (0.3) | 0.1 | 0 | (0.0) | 0.0 | -100.0% |
| former Yugoslav Republic of Macedonia, the | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 2 | (1.4) | 0.1 | 3 | (1.8) | 0.1 | 2 | (1.5) | 0.1 | – |
| Georgia | 177 | (9.2) | 4.3 | 183 | (11.2) | 4.5 | 172 | (11.6) | 4.3 | 168 | (11.6) | 4.3 | 142 | (10.2) | 3.6 | -4.3% |
| Israel | 15 | (4.7) | 0.2 | 6 | (3.8) | 0.1 | 13 | (6.6) | 0.2 | 10 | (6.8) | 0.1 | 9 | (7.4) | 0.1 | -13.3% |
| Kazakhstan | 1864 | (22.9) | 11.0 | 1997 | (26.3) | 11.6 | 1110 | (23.8) | 6.3 | 1310 | (24.0) | 7.4 | 832 | (25.5) | 4.6 | -19.5% |
| Kyrgyzstan | 433 | (26.1) | 7.7 | 613 | (28.4) | 10.8 | – | – | – | 426 | (25.0) | 7.3 | 398 | (21.9) | 6.7 | -3.6% |
| Moldova | 299 | (23.7) | 7.3 | 343 | (24.5) | 8.4 | 398 | (27.1) | 9.8 | 402 | (31.1) | 9.9 | 304 | (25.6) | 7.5 | 0.5% |
| Monaco | – | – | – | – | – | – | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – | – | – | – |
| Montenegro | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Russia | 6537 | (20.0) | 4.6 | 6726 | (21.2) | 4.7 | 7634 | (24.4) | 5.3 | 8603 | (26.7) | 6.0 | 8463 | (27.3) | 5.9 | – |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | (0.0) | 0.0 | – |
| Serbia | 6 | (0.8) | 0.1 | 6 | (0.9) | 0.1 | 10 | (1.7) | 0.1 | 4 | (0.7) | 0.0 | 3 | (0.8) | 0.0 | -15.6% |
| Serbia excluding UN Administered Province of Kosovo ^e | – | – | – | – | – | – | 9 | (1.7) | 0.1 | 2 | (0.9) | 0.0 | 3 | (0.8) | 0.0 | – |
| UN Administered Province of Kosovo ^e | – | – | – | – | – | – | 1 | (0.6) | 0.1 | 2 | (1.0) | 0.1 | 0 | (0.0) | 0.0 | – |
| Switzerland | 3 | (1.2) | 0.0 | 3 | (1.5) | 0.0 | 5 | (3.1) | 0.1 | 7 | (3.2) | 0.1 | 12 | (4.3) | 0.1 | 39.8% |
| Tajikistan | 286 | (31.1) | 3.6 | 143 | (34.5) | 1.7 | 158 | (8.1) | 1.9 | 484 | (24.2) | 5.7 | 495 | (20.8) | 5.7 | 12.2% |
| Turkey | 151 | (3.2) | 0.2 | 123 | (2.5) | 0.2 | 116 | (2.5) | 0.2 | 122 | (2.6) | 0.2 | 110 | (2.2) | 0.1 | -9.1% |
| Turkmenistan | – | – | – | – | – | – | 32 | (10.3) | 0.6 | – | – | – | – | – | – | – |
| Ukraine | 1614 | (14.4) | 3.6 | 2479 | (19.2) | 5.5 | 2753 | (21.0) | 6.1 | 2856 | (21.3) | 6.4 | 2881 | (22.0) | 6.5 | 16.2% |
| Uzbekistan | 703 | (27.9) | 2.4 | 1535 | (36.3) | 5.1 | 2112 | (66.1) | 6.9 | 211 | (44.6) | 0.7 | 292 | (38.6) | 0.9 | -21.0% |
| Subtotal non-EU/EEA | 13031 | (18.4) | 3.4 | 15143 | (20.8) | 3.9 | 15400 | (23.1) | 3.9 | 15523 | (22.9) | 3.9 | 14813 | (22.8) | 3.7 | 2.6% |
| Total European Region | 13597 | (14.8) | 1.6 | 15678 | (16.8) | 1.9 | 15931 | (17.6) | 1.8 | 15955 | (18.3) | 2.0 | 15337 | (17.7) | 1.7 | 0.8% |
| Subtotal 18 HPC | 13397 | (17.6) | 3.5 | 15492 | (19.9) | 4.0 | 15705 | (21.3) | 4.0 | 15788 | (21.2) | 4.0 | 15082 | (21.2) | 3.8 | 2.5% |

^aEuropean Region^a comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

^b Bacteriologically-confirmed cases – cases with positive identification for *Mycobacterium tuberculosis* complex confirmed by culture and/or line probe assay for non-EU countries, culture-positive and microscopy-positive/nucleic acid amplification test-positive cases for EU/EEA countries.

^c Distribution by previous diagnosis.

^d These data are subject to change as the national TB registry was under review when this report was being produced.

^e Provisional data for 2016 including overseas territories.

^f In accordance with the UN Security Council Resolution No. 1244 (1999).

Table VI: MDR TB notification among previously treated bacteriologically-confirmed^a pulmonary TB cases with available DST results, European Region, 2012–2016

| Country | 2012 | | | 2013 | | | 2014 | | | 2015 | | | 2016 | | | Mean annual % change in rate, 2012–2016 ^e |
|--|--------------|---------------|------------------|--------------|---------------|------------------|--------------|---------------|------------------|--------------|---------------|------------------|--------------|---------------|------------------|--|
| | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | |
| EU/EEA | | | | | | | | | | | | | | | | |
| Austria | 13 | (43.3) | 0.2 | 9 | (37.5) | 0.1 | 7 | (36.8) | 0.1 | 2 | (16.7) | 0.0 | 3 | (17.6) | 0.0 | -31.3% |
| Belgium ^b | 6 | (12.8) | 0.1 | 1 | (2.4) | 0.0 | 2 | (4.2) | 0.0 | 2 | (5.9) | 0.0 | 2 | (5.7) | 0.0 | -24.4% |
| Bulgaria | 33 | (23.4) | 0.5 | 14 | (12.7) | 0.2 | 19 | (19.2) | 0.3 | 19 | (20.7) | 0.3 | 14 | (17.3) | 0.2 | -18.8% |
| Croatia ^c | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 2 | (6.9) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Cyprus | 0 | (0.0) | 0.0 | 1 | (100.0) | 0.1 | 0 | (0.0) | 0.0 | – | – | – | 0 | (0.0) | 0.0 | – |
| Czech Republic | 2 | (9.1) | 0.0 | 0 | (0.0) | 0.0 | 2 | (13.3) | 0.0 | 2 | (8.0) | 0.0 | 2 | (16.7) | 0.0 | -0.1% |
| Denmark ^b | 0 | (0.0) | 0.0 | 1 | (5.0) | 0.0 | 0 | (0.0) | 0.0 | 1 | (4.5) | 0.0 | 0 | (0.0) | 0.0 | – |
| Estonia | 23 | (53.5) | 1.7 | 25 | (52.1) | 1.9 | 19 | (63.3) | 1.4 | 18 | (51.4) | 1.4 | 6 | (46.2) | 0.5 | -28.4% |
| Finland | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 1 | (25.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| France ^d | – | – | – | – | – | – | 30 | (10.4) | 0.0 | – | – | – | 18 | (6.8) | 0.0 | – |
| Germany | 14 | (9.9) | 0.0 | 27 | (16.3) | 0.0 | 22 | (15.9) | 0.0 | 30 | (19.1) | 0.0 | 19 | (14.3) | 0.0 | 7.3% |
| Greece | 0 | (0.0) | 0.0 | 2 | (11.8) | 0.0 | 0 | (0.0) | 0.0 | 5 | (18.5) | 0.0 | 3 | (27.3) | 0.0 | – |
| Hungary | 2 | (6.5) | 0.0 | 4 | (19.0) | 0.0 | 2 | (8.7) | 0.0 | 2 | (5.0) | 0.0 | 6 | (16.2) | 0.1 | – |
| Iceland | – | – | – | – | – | – | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Ireland ^b | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 2 | (18.2) | 0.0 | – |
| Italy | 12 | (8.8) | 0.0 | 7 | (4.2) | 0.0 | 16 | (7.2) | 0.0 | 14 | (12.5) | 0.0 | 9 | (9.3) | 0.0 | -7.4% |
| Latvia | 32 | (33.0) | 1.6 | 27 | (25.7) | 1.3 | 32 | (29.9) | 1.6 | 26 | (29.9) | 1.3 | 21 | (23.3) | 1.1 | -9.1% |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 153 | (44.3) | 5.1 | 135 | (44.1) | 4.5 | 138 | (48.9) | 4.7 | 134 | (46.5) | 4.6 | 125 | (43.0) | 4.3 | -4.0% |
| Luxembourg | 0 | (0.0) | 0.0 | – | – | – | – | – | – | – | – | – | 0 | (0.0) | 0.0 | – |
| Malta | 0 | (0.0) | 0.0 | – | – | – | 0 | (0.0) | 0.0 | – | – | – | 0 | (0.0) | 0.0 | – |
| Netherlands | 1 | (5.0) | 0.0 | 6 | (30.0) | 0.0 | 1 | (12.5) | 0.0 | 2 | (8.7) | 0.0 | 2 | (20.0) | 0.0 | 18.5% |
| Norway ^b | 1 | (7.7) | 0.0 | 1 | (6.3) | 0.0 | 4 | (23.5) | 0.1 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Poland | 11 | (2.1) | 0.0 | 21 | (4.3) | 0.1 | 18 | (4.3) | 0.0 | 13 | (3.0) | 0.0 | 18 | (4.0) | 0.0 | 13.2% |
| Portugal | 6 | (5.2) | 0.1 | 5 | (6.1) | 0.0 | 5 | (5.7) | 0.0 | 6 | (7.1) | 0.1 | 2 | (3.9) | 0.0 | -23.6% |
| Romania | 527 | (20.8) | 2.6 | 410 | (17.6) | 2.0 | 400 | (17.9) | 2.0 | 398 | (17.2) | 2.0 | 334 | (15.6) | 1.7 | -10.4% |
| Slovakia | 1 | (3.8) | 0.0 | 1 | (2.9) | 0.0 | 2 | (7.7) | 0.0 | 1 | (6.3) | 0.0 | 1 | (5.6) | 0.0 | -0.1% |
| Slovenia | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Spain | 11 | (15.9) | 0.0 | 7 | (6.8) | 0.0 | 9 | (8.2) | 0.0 | 10 | (16.4) | 0.0 | 5 | (12.2) | 0.0 | – |
| Sweden | 2 | (13.3) | 0.0 | 2 | (12.5) | 0.0 | 2 | (10.5) | 0.0 | 2 | (11.8) | 0.0 | 3 | (15.8) | 0.0 | 9.6% |
| United Kingdom ^b | 12 | (6.3) | 0.0 | 9 | (4.4) | 0.0 | 5 | (3.0) | 0.0 | 5 | (3.4) | 0.0 | 7 | (4.7) | 0.0 | -13.2% |
| Subtotal EU/EEA | 862 | (18.5) | 0.2 | 715 | (16.4) | 0.2 | 738 | (16.6) | 0.1 | 692 | (17.1) | 0.2 | 602 | (15.0) | 0.1 | -11.9% |
| Non-EU/EEA | | | | | | | | | | | | | | | | |
| Albania | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 1 | (12.5) | 0.0 | 4 | (66.7) | 0.1 | 1 | (50.0) | 0.0 | – |
| Andorra | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Armenia | 35 | (38.5) | 1.2 | 23 | (34.3) | 0.8 | 43 | (86.0) | 1.5 | 47 | (87.0) | 1.6 | 60 | (90.9) | 2.0 | 13.0% |
| Azerbaijan | 468 | (30.0) | 5.1 | 778 | (48.8) | 8.3 | 682 | (35.0) | 7.2 | 711 | (29.7) | 7.4 | 616 | (39.3) | 6.3 | 5.8% |
| Belarus | 811 | (68.6) | 8.6 | 598 | (54.5) | 6.3 | 584 | (69.1) | 6.2 | 597 | (68.4) | 6.3 | 568 | (71.6) | 6.0 | -8.5% |
| Bosnia and Herzegovina | 3 | (4.5) | 0.1 | 1 | (1.6) | 0.0 | 1 | (50.0) | 0.0 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | -100.0% |
| former Yugoslav Republic of Macedonia, the | 4 | (15.4) | 0.2 | 1 | (6.3) | 0.0 | 0 | (0.0) | 0.0 | 1 | (6.7) | 0.0 | 0 | (0.0) | 0.0 | -100.0% |
| Georgia | 169 | (31.2) | 4.1 | 201 | (38.1) | 5.0 | 197 | (39.2) | 4.9 | 186 | (38.8) | 4.7 | 154 | (38.0) | 3.9 | -1.2% |
| Israel | 2 | (33.3) | 0.0 | 1 | (100.0) | 0.0 | 2 | (50.0) | 0.0 | 1 | (16.7) | 0.0 | 0 | (0.0) | 0.0 | -100.0% |
| Kazakhstan | 5744 | (55.0) | 33.9 | 4035 | (57.8) | 23.4 | 1152 | (39.9) | 6.6 | 1411 | (40.0) | 7.9 | 399 | (20.5) | 2.2 | -49.4% |
| Kyrgyzstan | 453 | (54.5) | 8.1 | 547 | (55.1) | 9.6 | – | – | – | 450 | (56.3) | 7.7 | 466 | (56.3) | 7.8 | – |
| Moldova | 581 | (62.3) | 14.3 | 561 | (62.1) | 13.8 | 453 | (65.9) | 11.1 | 501 | (71.9) | 12.3 | 221 | (57.4) | 5.4 | -21.4% |
| Monaco | – | – | – | – | – | – | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – | – | – | – |
| Montenegro | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 2 | (40.0) | 0.3 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Russia | 7075 | (57.4) | 4.9 | 6795 | (56.3) | 4.7 | 7951 | (57.1) | 5.5 | 8529 | (59.1) | 5.9 | 17508 | (65.2) | 12.2 | 25.3% |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | (0.0) | 0.0 | – |
| Serbia | 3 | (3.6) | 0.0 | 4 | (4.7) | 0.0 | 4 | (7.5) | 0.0 | 1 | (2.8) | 0.0 | 5 | (12.5) | 0.1 | 14.1% |
| Serbia excluding UN Administered Province of Kosovo ^e | – | – | – | – | – | – | – | – | – | – | – | – | 3 | (7.5) | 0.0 | – |
| UN Administered Province of Kosovo ^e | – | – | – | – | – | – | – | – | – | – | – | – | 2 | (6.3) | 0.1 | – |
| Switzerland | 4 | (12.9) | 0.0 | 8 | (23.5) | 0.1 | 4 | (14.3) | 0.0 | 4 | (21.1) | 0.0 | 1 | (7.1) | 0.0 | -30.1% |
| Tajikistan | 278 | (56.0) | 3.5 | 16 | (34.8) | 0.2 | 213 | (52.2) | 2.5 | 97 | (48.7) | 1.1 | 151 | (46.3) | 1.7 | -16.0% |
| Turkey | 140 | (21.8) | 0.2 | 105 | (17.8) | 0.1 | 130 | (21.1) | 0.2 | 102 | (17.9) | 0.1 | 80 | (13.7) | 0.1 | -14.4% |
| Turkmenistan | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 32 | (72.7) | 0.6 | – | – | – | – | – | – | – |
| Ukraine | 1908 | (32.2) | 4.2 | 3365 | (40.7) | 7.5 | 3562 | (41.5) | 7.9 | 3169 | (41.5) | 7.1 | 2875 | (40.8) | 6.5 | 11.4% |
| Uzbekistan | 479 | (46.7) | 1.6 | 1495 | (56.1) | 5.0 | 720 | (79.8) | 2.4 | 185 | (56.2) | 0.6 | 311 | (25.3) | 1.0 | -11.6% |
| Subtotal non-EU/EEA | 18157 | (50.1) | 4.7 | 18534 | (51.5) | 4.8 | 15733 | (49.9) | 4.0 | 15996 | (49.8) | 4.1 | 23416 | (55.4) | 5.9 | 5.9% |
| Total European Region | 19019 | (46.5) | 2.3 | 19249 | (47.7) | 2.3 | 16471 | (45.8) | 1.8 | 16688 | (46.3) | 2.1 | 24018 | (51.9) | 2.6 | 3.7% |
| Subtotal 18 HPC | 18909 | (48.3) | 4.9 | 19130 | (49.4) | 4.9 | 16327 | (47.8) | 4.2 | 16580 | (47.7) | 4.2 | 23909 | (53.5) | 6.0 | 5.5% |

^aEuropean Region^a comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

^b Bacteriologically-confirmed cases – cases with positive identification for *Mycobacterium tuberculosis* complex confirmed by culture and/or line probe assay for non-EU countries, culture-positive and microscopy-positive/nucleic acid amplification test-positive cases for EU/EEA countries.

^c Distribution by previous diagnosis.

^d These data are subject to change as the national TB registry was under review when this report was being produced.

^e Provisional data for 2016 including overseas territories.

^f In accordance with the UN Security Council Resolution No. 1244 (1999).

Table VII: MDR TB notification among all bacteriologically confirmed^a TB cases with available DST results, European Region, 2012–2016

| Country | 2012 | | | 2013 | | | 2014 | | | 2015 | | | 2016 | | | Mean annual % change in rate, 2012–2016 |
|--|---------------|---------------|------------------|---------------|---------------|------------------|---------------|---------------|------------------|---------------|---------------|------------------|---------------|---------------|------------------|---|
| | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | N | % | Rate per 100 000 | |
| EU/EEA | | | | | | | | | | | | | | | | |
| Austria | 27 | (6.7) | (0.3) | 16 | (3.5) | (0.2) | 20 | (4.8) | (0.2) | 12 | (2.8) | (0.1) | 16 | (3.4) | (0.2) | -13.0% |
| Belgium | 20 | (2.7) | (0.2) | 13 | (1.8) | (0.1) | 11 | (1.6) | (0.1) | 15 | (2.0) | (0.1) | 10 | (1.3) | (0.1) | -16.4% |
| Bulgaria | 49 | (5.9) | (0.7) | 27 | (3.6) | (0.4) | 37 | (5.0) | (0.5) | 24 | (3.6) | (0.3) | 19 | (2.8) | (0.3) | -20.6% |
| Croatia ^b | 1 | (0.3) | (0.0) | 0 | (0.0) | (0.0) | 2 | (0.5) | (0.0) | 1 | (0.3) | (0.0) | 0 | (0.0) | (0.0) | -100.0% |
| Cyprus | 0 | (0.0) | (0.0) | 1 | (3.3) | (0.1) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 1 | (2.4) | (0.1) | – |
| Czech Republic | 4 | (1.0) | (0.0) | 0 | (0.0) | (0.0) | 5 | (1.5) | (0.0) | 9 | (2.4) | (0.1) | 6 | (1.6) | (0.1) | 10.5% |
| Denmark | 1 | (0.3) | (0.0) | 2 | (0.7) | (0.0) | 2 | (0.7) | (0.0) | 6 | (2.2) | (0.1) | 4 | (1.6) | (0.1) | 40.6% |
| Estonia | 62 | (25.9) | (4.7) | 54 | (24.0) | (4.1) | 50 | (26.0) | (3.8) | 38 | (21.2) | (2.9) | 24 | (15.8) | (1.8) | -21.0% |
| Finland | 3 | (1.4) | (0.1) | 2 | (1.0) | (0.0) | 8 | (3.8) | (0.1) | 8 | (3.8) | (0.1) | 6 | (3.3) | (0.1) | 18.5% |
| France ^{c,d} | – | – | – | 83 | (1.9) | (0.1) | 111 | (2.6) | (0.2) | – | – | – | 71 | (1.7) | (0.1) | – |
| Germany | 62 | (2.1) | (0.1) | 97 | (3.2) | (0.1) | 92 | (3.0) | (0.1) | 117 | (3.0) | (0.1) | 101 | (2.7) | (0.1) | 12.3% |
| Greece | 3 | (1.7) | (0.0) | 10 | (4.3) | (0.1) | 4 | (2.4) | (0.0) | 9 | (4.3) | (0.1) | 5 | (4.0) | (0.0) | 14.4% |
| Hungary | 11 | (2.4) | (0.1) | 10 | (2.8) | (0.1) | 3 | (1.0) | (0.0) | 8 | (2.1) | (0.1) | 18 | (5.3) | (0.2) | 13.4% |
| Iceland | 1 | (20.0) | (0.3) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | -100.0% |
| Ireland | 5 | (1.8) | (0.1) | 4 | (1.5) | (0.1) | 2 | (0.9) | (0.0) | 1 | (0.5) | (0.0) | 6 | (2.6) | (0.1) | 3.9% |
| Italy ^d | 74 | (3.0) | (0.1) | 78 | (3.3) | (0.1) | 78 | (3.1) | (0.1) | 70 | (2.7) | (0.1) | 70 | (2.6) | (0.1) | -1.9% |
| Latvia | 107 | (14.0) | (5.2) | 79 | (11.6) | (3.9) | 70 | (11.9) | (3.5) | 63 | (11.1) | (3.2) | 56 | (10.4) | (2.8) | -14.1% |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 271 | (19.8) | (9.0) | 256 | (18.9) | (8.6) | 271 | (21.5) | (9.2) | 241 | (19.7) | (8.2) | 244 | (20.3) | (8.4) | -1.6% |
| Luxembourg | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 1 | (6.3) | (0.2) | 0 | (0.0) | (0.0) | 1 | (4.0) | (0.2) | – |
| Malta | 0 | (0.0) | (0.0) | 1 | (3.7) | (0.2) | 0 | (0.0) | (0.0) | 1 | (4.5) | (0.2) | 0 | (0.0) | (0.0) | – |
| Netherlands | 11 | (1.7) | (0.1) | 16 | (2.6) | (0.1) | 7 | (1.3) | (0.0) | 9 | (1.6) | (0.1) | 12 | (2.1) | (0.1) | 1.8% |
| Norway | 6 | (2.1) | (0.1) | 6 | (1.9) | (0.1) | 11 | (4.1) | (0.2) | 5 | (2.0) | (0.1) | 11 | (4.8) | (0.2) | 15.1% |
| Poland | 31 | (0.7) | (0.1) | 40 | (0.9) | (0.1) | 35 | (0.8) | (0.1) | 35 | (0.8) | (0.1) | 46 | (1.1) | (0.1) | 10.4% |
| Portugal | 23 | (1.5) | (0.2) | 15 | (1.1) | (0.1) | 25 | (2.0) | (0.2) | 22 | (1.8) | (0.2) | 12 | (1.5) | (0.1) | -14.6% |
| Romania | 684 | (9.0) | (3.4) | 579 | (7.8) | (2.9) | 532 | (6.4) | (2.7) | 535 | (6.0) | (2.7) | 463 | (5.5) | (2.3) | -8.9% |
| Slovakia | 1 | (0.6) | (0.0) | 3 | (1.4) | (0.1) | 3 | (1.9) | (0.1) | 2 | (1.3) | (0.0) | 3 | (2.7) | (0.1) | 31.5% |
| Slovenia | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | – |
| Spain ^d | 37 | (4.2) | (0.1) | 34 | (2.2) | (0.1) | 35 | (2.2) | (0.1) | 40 | (4.8) | (0.1) | 39 | (4.4) | (0.1) | 1.5% |
| Sweden | 14 | (2.8) | (0.1) | 8 | (1.5) | (0.1) | 15 | (2.9) | (0.2) | 22 | (3.2) | (0.2) | 22 | (3.7) | (0.2) | 10.9% |
| United Kingdom | 80 | (1.5) | (0.1) | 74 | (1.6) | (0.1) | 56 | (1.3) | (0.1) | 48 | (1.3) | (0.1) | 56 | (1.5) | (0.1) | -9.2% |
| Subtotal EU/EEA | 1588 | (4.7) | 0.4 | 1508 | (4.1) | 0.3 | 1486 | (4.0) | 0.3 | 1343 | (4.0) | 0.3 | 1322 | (3.7) | 0.3 | -8.0% |
| Non-EU/EEA | | | | | | | | | | | | | | | | |
| Albania | 1 | (0.5) | 0.0 | 1 | (3.2) | 0.0 | 3 | (10.3) | 0.1 | 4 | (30.8) | 0.1 | 4 | (10.0) | 0.1 | 41.3% |
| Andorra | 0 | (0.0) | 0.0 | 1 | (25.0) | 1.2 | 2 | (40.0) | 2.5 | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – |
| Armenia | 92 | (18.0) | 3.2 | 112 | (25.6) | 3.9 | 111 | (18.2) | 3.8 | 101 | (23.2) | 3.5 | 128 | (27.8) | 4.4 | 8.2% |
| Azerbaijan | 599 | (23.9) | 6.5 | 970 | (25.4) | 10.3 | 495 | (8.3) | 5.2 | 1171 | (31.8) | 12.2 | 925 | (31.3) | 9.5 | 10.1% |
| Belarus | 1604 | (47.9) | 16.9 | 1353 | (41.7) | 14.3 | 1251 | (44.6) | 13.2 | 1340 | (47.4) | 14.1 | 1543 | (57.1) | 16.3 | -1.0% |
| Bosnia and Herzegovina | 7 | (0.9) | 0.2 | 1 | (50.0) | 0.0 | 4 | (0.6) | 0.1 | 3 | (0.4) | 0.1 | 0 | (0.0) | 0.0 | -100.0% |
| former Yugoslav Republic of Macedonia, the | 4 | (2.2) | 0.2 | 1 | (0.6) | 0.0 | 3 | (1.7) | 0.1 | 5 | (2.7) | 0.2 | 2 | (1.2) | 0.1 | -16.0% |
| Georgia | 346 | (14.0) | 8.4 | 400 | (17.5) | 9.9 | 441 | (18.9) | 11.0 | 418 | (17.9) | 10.6 | 401 | (17.1) | 10.2 | 4.9% |
| Israel | 17 | (5.2) | 0.2 | 8 | (3.8) | 0.1 | 17 | (6.5) | 0.2 | 15 | (7.7) | 0.2 | 11 | (7.1) | 0.1 | -11.7% |
| Kazakhstan | 7608 | (40.9) | 45.0 | 6032 | (40.5) | 35.1 | 5877 | (36.8) | 33.6 | 6497 | (60.4) | 36.6 | 5817 | (55.4) | 32.3 | -7.9% |
| Kyrgyzstan | 1755 | (70.5) | 31.4 | 1160 | (36.8) | 20.4 | 1267 | – | 21.9 | 1116 | (37.9) | 19.0 | 1236 | (35.4) | 20.8 | -9.8% |
| Moldova | 894 | (40.7) | 21.9 | 1042 | (39.8) | 25.6 | 925 | (35.6) | 22.7 | 1042 | (43.6) | 25.6 | 1031 | (41.4) | 25.4 | 3.7% |
| Monaco | – | – | – | – | – | – | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | – | – | – | – |
| Montenegro | 0 | (0.0) | 0.0 | 0 | (0.0) | 0.0 | 2 | (2.9) | 0.3 | 1 | (1.8) | 0.2 | 0 | (0.0) | 0.0 | – |
| Russia | 13 612 | (30.3) | 9.5 | 12 069 | (27.7) | 8.4 | 15 585 | (34.5) | 10.8 | 17 132 | (36.7) | 11.9 | 27 363 | (47.3) | 19.0 | 19.0% |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | (0.0) | 0 | – |
| Serbia | 9 | (1.1) | 0.1 | 10 | (1.3) | 0.1 | 14 | (2.0) | 0.2 | 5 | (1.1) | 0.1 | 8 | (1.2) | 0.1 | -2.5% |
| Serbia excluding UN Administered Province of Kosovo ^d | – | – | – | – | – | – | – | – | – | – | – | – | 6 | (1.3) | 0.1 | – |
| UN Administered Province of Kosovo ^d | – | – | – | – | – | – | – | – | – | – | – | – | 2 | (0.9) | 0.1 | – |
| Switzerland | 8 | (2.9) | 0.1 | 13 | (3.1) | 0.2 | 17 | (4.2) | 0.2 | 16 | (3.6) | 0.2 | 18 | (3.8) | 0.2 | 21.1% |
| Tajikistan | 954 | (67.4) | 11.9 | 872 | (30.7) | 10.7 | 902 | (27.9) | 10.8 | 675 | (20.9) | 7.9 | 748 | (23.5) | 8.6 | -8.0% |
| Turkey | 291 | (5.4) | 0.4 | 228 | (4.1) | 0.3 | 349 | (6.4) | 0.5 | 304 | (5.4) | 0.4 | 256 | (4.2) | 0.3 | -4.7% |
| Turkmenistan | – | – | – | 81 | – | 1.5 | 210 | – | 3.8 | 270 | – | 4.9 | 557 | – | 9.8 | – |
| Ukraine | 6934 | (40.5) | 15.3 | 9929 | (46.9) | 22.0 | 7735 | (32.9) | 17.2 | 9397 | (39.8) | 21.0 | 8651 | (40.0) | 19.5 | 6.2% |
| Uzbekistan | 2233 | (62.9) | 7.6 | 4366 | (63.3) | 14.5 | 3844 | (21.4) | 12.6 | 2149 | (28.4) | 6.9 | 1956 | (13.4) | 6.2 | -4.8% |
| Subtotal non-EU/EEA | 36 968 | (34.5) | 9.5 | 38 649 | (34.4) | 9.8 | 39 054 | (30.5) | 9.8 | 41 661 | (36.5) | 10.4 | 50 655 | (38.3) | 12.6 | 7.2% |
| Total European Region | 38 556 | (27.4) | 4.6 | 40 157 | (26.9) | 4.4 | 40 540 | (24.5) | 4.5 | 43 004 | (29.2) | 5.1 | 51 977 | (30.9) | 5.7 | 5.3% |
| Subtotal 18 HPC | 38 095 | (33.0) | 9.8 | 39 609 | (32.7) | 10.0 | 39 952 | (29.2) | 10.1 | 42 513 | (34.4) | 10.7 | 51 418 | (36.4) | 12.8 | 6.8% |

EU/EEA countries designated as high-priority countries by WHO are presented in italics.

^a Bacteriologically-confirmed cases – culture-positive and microscopy-positive/nucleic acid amplification test-positive cases for EU/EEA countries.^b These data are subject to change as the national TB registry was under review when this report was being produced.^c Provisional data for 2016 reported to WHO Global TB database.^d Data from France, Italy and Spain reported from NRL may differ from data shown elsewhere in this report.

Table VIII: XDR TB notification among pulmonary MDR TB cases with second-line drug sensitivity test results, European Region, 2012–2016^a

| Country | 2012 | | | 2013 | | | 2014 | | | 2015 | | | 2016 | | |
|--|---------------------------|------------|----------------|---------------------------|------------|----------------|---------------------------|------------|----------------|---------------------------|------------|----------------|---------------------------|-------------|----------------|
| | MDR TB tested for SLD (N) | XDR TB (N) | % among tested | MDR TB tested for SLD (N) | XDR TB (N) | % among tested | MDR TB tested for SLD (N) | XDR TB (N) | % among tested | MDR TB tested for SLD (N) | XDR TB (N) | % among tested | MDR TB tested for SLD (N) | XDR TB (N) | % among tested |
| EU/EEA | | | | | | | | | | | | | | | |
| Austria | 26 | 7 | (26.9) | 16 | 3 | (18.8) | 18 | 2 | (11.1) | 9 | 1 | (11.1) | 14 | 2 | (14.3) |
| Belgium | 16 | 2 | (12.5) | 10 | 0 | (0.0) | 10 | 1 | (10.0) | 11 | 2 | (18.2) | 9 | 0 | (0.0) |
| Bulgaria | 48 | 5 | (10.4) | 26 | 4 | (15.4) | 36 | 3 | (8.3) | 21 | 4 | (19.0) | 19 | 0 | (0.0) |
| Croatia ^b | – | – | – | – | – | – | 2 | 0 | (0.0) | 1 | 0 | (0.0) | 0 | 0 | – |
| Cyprus | 0 | 0 | – | 1 | 1 | (100.0) | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – |
| Czech Republic | 2 | 1 | (50.0) | 0 | 0 | – | 5 | 0 | (0.0) | 8 | 1 | (12.5) | 0 | 0 | – |
| Denmark | 0 | 0 | – | 2 | 1 | (50.0) | 1 | 0 | (0.0) | 5 | 1 | (20.0) | 0 | 0 | – |
| Estonia | 55 | 4 | (7.3) | 53 | 10 | (18.9) | 48 | 8 | (16.7) | 35 | 8 | (22.9) | 23 | 7 | (30.4) |
| Finland | 3 | 1 | (33.3) | 2 | 0 | (0.0) | 6 | 1 | (16.7) | 8 | 1 | (12.5) | 3 | 1 | (33.3) |
| France ^c | – | – | – | 81 | 21 | (25.9) | 70 | 30 | (42.9) | 76 | 8 | (10.5) | 69 | 6 | (8.7) |
| Germany | 18 | 1 | (5.6) | 41 | 3 | (7.3) | 58 | 11 | (19.0) | 72 | 11 | (15.3) | 58 | 5 | (8.6) |
| Greece | 2 | 0 | (0.0) | 10 | 0 | (0.0) | 2 | 1 | (50.0) | 0 | 0 | – | 0 | 0 | – |
| Hungary | 10 | 2 | (20.0) | 9 | 1 | (11.1) | 2 | 0 | (0.0) | 7 | 1 | (14.3) | 0 | 0 | – |
| Iceland | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – |
| Ireland | 1 | 0 | (0.0) | 3 | 1 | (33.3) | 2 | 0 | (0.0) | 0 | 0 | – | 5 | 0 | (0.0) |
| Italy | 50 | 5 | (10.0) | 55 | 7 | (12.7) | 64 | 9 | (14.1) | 31 | 6 | (19.4) | 43 | 5 | (11.6) |
| Latvia | 104 | 17 | (16.3) | 69 | 15 | (21.7) | 70 | 13 | (18.6) | 62 | 16 | (25.8) | 53 | 20 | (37.7) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 210 | 52 | (24.8) | 186 | 46 | (24.7) | 232 | 60 | (25.9) | 238 | 58 | (24.4) | 242 | 58 | (24.0) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | 0 | 0 | – | 1 | 1 | (100.0) | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – |
| Netherlands | – | – | – | 0 | 0 | – | 5 | 0 | (0.0) | 8 | 0 | (0.0) | 8 | 0 | (0.0) |
| Norway | 4 | 0 | (0.0) | 5 | 1 | (20.0) | 9 | 1 | (11.1) | 4 | 0 | (0.0) | 7 | 0 | (0.0) |
| Poland | 4 | 0 | (0.0) | 4 | 1 | (25.0) | 25 | 5 | (20.0) | 23 | 4 | (17.4) | 38 | 8 | (21.1) |
| Portugal | 15 | 3 | (20.0) | 11 | 4 | (36.4) | 13 | 2 | (15.4) | 13 | 5 | (38.5) | 4 | 1 | (25.0) |
| Romania | 369 | 41 | (11.1) | 309 | 56 | (18.1) | 301 | 58 | (19.3) | 315 | 66 | (21.0) | 207 | 62 | (30.0) |
| Slovakia | 1 | 0 | (0.0) | 2 | 0 | (0.0) | 3 | 0 | (0.0) | 2 | 0 | (0.0) | 3 | 0 | (0.0) |
| Slovenia | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 0 | – |
| Spain | 37 | 1 | (2.7) | 34 | 2 | (5.9) | 35 | 2 | (5.7) | 42 | 1 | (2.4) | 39 | 0 | (0.0) |
| Sweden | 9 | 1 | (11.1) | 7 | 2 | (28.6) | 11 | 1 | (9.1) | 16 | 1 | (6.3) | 14 | 4 | (28.6) |
| United Kingdom | 59 | 2 | (3.4) | 43 | 2 | (4.7) | 34 | 2 | (5.9) | 34 | 10 | (29.4) | 39 | 6 | (15.4) |
| Subtotal EU/EEA | 1043 | 145 | (13.9) | 980 | 182 | (18.6) | 1062 | 210 | (19.8) | 1041 | 205 | (19.7) | 897 | 185 | (20.6) |
| Non-EU/EEA | | | | | | | | | | | | | | | |
| Albania | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – |
| Andorra | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – |
| Armenia | 92 | 2 | (2.2) | 66 | 7 | (10.6) | 100 | 8 | (8.0) | 89 | 8 | (9.0) | 53 | 6 | (11.3) |
| Azerbaijan | 319 | 38 | (11.9) | – | – | – | 840 | 100 | (11.9) | 670 | 125 | (18.7) | 535 | 71 | (13.3) |
| Belarus | – | – | – | 1353 | 80 | (5.9) | 1251 | 366 | (29.3) | 1275 | 453 | (35.5) | 1246 | 572 | (45.9) |
| Bosnia and Herzegovina | 5 | 0 | (0.0) | 0 | 0 | – | 3 | 0 | (0.0) | 0 | 0 | – | 0 | 0 | – |
| former Yugoslav Republic of Macedonia, the | 1 | 1 | (100.0) | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – | 0 | 0 | – |
| Georgia | 341 | 30 | (8.8) | 369 | 71 | (19.2) | 357 | 54 | (15.1) | 347 | 62 | (17.9) | 296 | 52 | (17.6) |
| Israel | 17 | 4 | (23.5) | 7 | 1 | (14.3) | 15 | 0 | (0.0) | 11 | 1 | (9.1) | 9 | 2 | (22.2) |
| Kazakhstan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Kyrgyzstan | 511 | 18 | (3.5) | – | – | – | – | – | – | 235 | 44 | (18.7) | 407 | 72 | (17.7) |
| Moldova | 761 | 33 | (4.3) | 782 | 35 | (4.5) | 277 | 11 | (4.0) | – | – | – | 514 | 42 | (8.2) |
| Monaco | – | – | – | – | – | – | 0 | 0 | – | 0 | 0 | – | – | – | – |
| Montenegro | 0 | 0 | – | 0 | 0 | – | 2 | 0 | (0.0) | 0 | 0 | – | 0 | 0 | – |
| Russia | – | – | – | – | – | – | – | – | – | – | – | – | 25258 | 3402 | (13.5) |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 0 | (0.0) |
| Serbia | 9 | 0 | (0.0) | 6 | 0 | (0.0) | 7 | 0 | (0.0) | 0 | 0 | – | 14 | 1 | (7.1) |
| Serbia excluding UN Administered Province of Kosovo ^d | – | – | – | – | – | – | 7 | 0 | (0.0) | – | – | – | 14 | 1 | (7.1) |
| UN Administered Province of Kosovo ^d | – | – | – | – | – | – | 1 | 0 | (0.0) | – | – | – | 0 | 0 | – |
| Switzerland | 8 | 0 | (0.0) | 12 | 1 | (8.3) | 11 | 1 | (9.1) | 11 | 2 | (18.2) | 13 | 0 | (0.0) |
| Tajikistan | 345 | 49 | (14.2) | 159 | 28 | (17.6) | 371 | 54 | (14.6) | 561 | 54 | (9.6) | 697 | 59 | (8.5) |
| Turkey | 104 | 6 | (5.8) | 114 | 3 | (2.6) | 169 | 2 | (1.2) | 133 | 3 | (2.3) | 130 | 9 | (6.9) |
| Turkmenistan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ukraine | – | – | – | – | – | – | – | – | – | – | – | – | 5756 | 247 | (3.3) |
| Uzbekistan | 356 | 31 | (8.7) | 528 | 167 | (31.6) | 927 | 181 | (19.5) | – | – | – | 1802 | 184 | (10.2) |
| Subtotal non-EU/EEA | 2869 | 212 | (7.4) | 3396 | 393 | (11.6) | 4330 | 777 | (17.9) | 3332 | 752 | (22.6) | 36679 | 4719 | (12.9) |
| Total European Region | 3912 | 357 | (9.1) | 4376 | 575 | (13.1) | 5392 | 987 | (18.3) | 4373 | 957 | (21.9) | 37576 | 4904 | (13.1) |
| Subtotal 18 HPC | 3121 | 312 | (10.0) | 4014 | 522 | (13.0) | 4979 | 918 | (18.4) | 3981 | 901 | (22.6) | 37187 | 4863 | (13.1) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

XDR TB – Extensively drug-resistant tuberculosis.

MDR TB – Multidrug-resistant tuberculosis.

SLD – Drug susceptibility testing for second-line TB drugs.

^b Includes only countries reporting second-line anti-TB drug susceptibility testing for at least one fluoroquinolone (ofloxacin, moxifloxacin and ciprofloxacin) and one injectable drug (amikacin, kanamycin and capreomycin).

^c These data are subject to change as the national TB registry was under review when this report was being produced.

^d Provisional data for 2016 including overseas territories.

^e In accordance with the UN Security Council Resolution No. 1244 (1999).

Table IX: Tuberculosis cases with HIV infection, European Region, 2012–2016^a

| Country | 2012 | | | | | 2013 | | | | | 2014 | | | | |
|--|------------------|-----------------------------|---------------|--------------|----------------|------------------|-----------------------------|---------------|--------------|----------------|------------------|-----------------------------|---------------|--------------|----------------|
| | All TB cases (N) | Cases with known HIV status | | HIV positive | | All TB cases (N) | Cases with known HIV status | | HIV positive | | All TB cases (N) | Cases with known HIV status | | HIV positive | |
| | | N | % | N | % ^b | | N | % | N | % ^b | | N | % | N | % ^b |
| EU/EEA | | | | | | | | | | | | | | | |
| Austria | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Belgium | 976 | 550 | (56.4) | 40 | (7.3) | 963 | 482 | (50.1) | 36 | (7.5) | 949 | 494 | (52.1) | 38 | (7.7) |
| Bulgaria | 2280 | 1513 | (66.4) | 3 | (0.2) | 1932 | 1874 | (97.0) | 4 | (0.2) | 1872 | 1377 | (73.6) | 3 | (0.2) |
| Croatia | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Cyprus | – | – | – | – | – | – | – | – | – | – | 41 | 28 | (68.3) | 1 | (3.6) |
| Czech Republic | 597 | 135 | (22.6) | 5 | (3.7) | 497 | 122 | (24.5) | 0 | (0.0) | 511 | 146 | (28.6) | 3 | (2.1) |
| Denmark | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Estonia | 289 | 274 | (94.8) | 45 | (16.4) | 290 | 280 | (96.6) | 37 | (13.2) | 248 | 239 | (96.4) | 24 | (10.0) |
| Finland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Greece | – | – | – | – | – | 540 | 363 | (67.2) | 35 | (9.6) | 519 | 336 | (64.7) | 18 | (5.4) |
| Hungary | – | – | – | – | – | – | – | – | – | – | 851 | 30 | (3.5) | 2 | (6.7) |
| Iceland | 11 | 11 | (100.0) | 0 | (0.0) | 11 | 8 | (72.7) | 0 | (0.0) | 9 | 7 | (77.8) | 0 | (0.0) |
| Ireland | 359 | 102 | (28.4) | 15 | (14.7) | 374 | 124 | (33.2) | 9 | (7.3) | 311 | 119 | (38.3) | 17 | (14.3) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Latvia | 993 | 844 | (85.0) | 114 | (13.5) | 904 | 420 | (46.5) | 95 | (22.6) | 761 | 488 | (64.1) | 95 | (19.5) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 1781 | 1213 | (68.1) | 29 | (2.4) | 1705 | 1144 | (67.1) | 39 | (3.4) | 1607 | 1135 | (70.6) | 36 | (3.2) |
| Luxembourg | 45 | 44 | (97.8) | 1 | (2.3) | 38 | 36 | (94.7) | 1 | (2.8) | 24 | 13 | (54.2) | 1 | (7.7) |
| Malta | 42 | 42 | (100.0) | 4 | (9.5) | 50 | 44 | (88.0) | 0 | (0.0) | 46 | 35 | (76.1) | 6 | (17.1) |
| Netherlands | 956 | 458 | (47.9) | 30 | (6.6) | 845 | 477 | (56.4) | 17 | (3.6) | 814 | 495 | (60.8) | 22 | (4.4) |
| Norway | – | – | – | – | – | 392 | 31 | (7.9) | 8 | (25.8) | 324 | 260 | (80.2) | 17 | (6.5) |
| Poland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Portugal | 2606 | 2277 | (87.4) | 301 | (13.2) | 2410 | 2091 | (86.8) | 252 | (12.1) | 2278 | 1959 | (86.0) | 226 | (11.5) |
| Romania | 18190 | 10402 | (57.2) | 237 | (2.3) | 16689 | 10403 | (62.3) | 271 | (2.6) | 15879 | 11178 | (70.4) | 314 | (2.8) |
| Slovakia | 345 | 322 | (93.3) | 0 | (0.0) | 401 | 368 | (91.8) | 0 | (0.0) | 336 | 282 | (83.9) | 0 | (0.0) |
| Slovenia | 138 | 103 | (74.6) | 0 | (0.0) | 140 | 105 | (75.0) | 1 | (1.0) | 144 | 110 | (76.4) | 0 | (0.0) |
| Spain | 6070 | 4425 | (72.9) | 387 | (8.7) | 5632 | 3609 | (64.1) | 285 | (7.9) | 4914 | 3201 | (65.1) | 228 | (7.1) |
| Sweden | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| United Kingdom | 8711 | 5239 | (60.1) | 268 | (5.1) | 7868 | 5918 | (75.2) | 225 | (3.8) | – | – | – | – | – |
| Subtotal EU/EEA | 44389 | 27954 | (63.0) | 1479 | (5.3) | 41681 | 27899 | (66.9) | 1315 | (4.7) | 32438 | 21932 | (67.6) | 1051 | (4.8) |
| Non-EU/EEA | | | | | | | | | | | | | | | |
| Albania | 420 | 233 | (55.5) | 7 | (3.0) | 474 | 109 | (23.0) | 2 | (1.8) | 408 | 41 | (10.0) | 2 | (4.9) |
| Andorra | 9 | 1 | (11.1) | 0 | (0.0) | 5 | 1 | – | 1 | (100.0) | 6 | 0 | (0.0) | – | – |
| Armenia | 1518 | 1518 | (100.0) | 79 | (5.2) | 1417 | 1417 | (100.0) | 67 | (4.7) | 1342 | 1342 | (100.0) | 84 | (6.3) |
| Azerbaijan | 8140 | 7849 | (96.4) | 129 | (1.6) | 8597 | 8329 | (96.9) | 131 | (1.6) | 7539 | 7004 | (92.9) | 148 | (2.1) |
| Belarus | 5246 | 5246 | (100.0) | 229 | (4.4) | 4859 | 4859 | (100.0) | 250 | (5.1) | 4274 | 4274 | (100.0) | 271 | (6.3) |
| Bosnia and Herzegovina | 1420 | 56 | (3.9) | 0 | (0.0) | 1261 | 74 | (5.9) | 0 | (0.0) | – | – | – | – | – |
| former Yugoslav Republic of Macedonia, the | 355 | 145 | (40.8) | 0 | (0.0) | 323 | 207 | (64.1) | 0 | (0.0) | 285 | 171 | (60.0) | 1 | (0.6) |
| Georgia | 4974 | 1881 | (37.8) | 45 | (2.4) | 4319 | 2739 | (63.4) | 55 | (2.0) | 3850 | 2591 | (67.3) | 57 | (2.2) |
| Israel | 509 | 503 | (98.8) | 16 | (3.2) | 308 | 299 | (97.1) | 14 | (4.7) | 368 | 367 | (99.7) | 25 | (6.8) |
| Kazakhstan | 21523 | 21184 | (98.4) | 441 | (2.1) | 19857 | 18104 | (91.2) | 466 | (2.6) | 15718 | 15435 | (98.2) | 625 | (4.0) |
| Kyrgyzstan | 6916 | 6916 | (100.0) | 151 | (2.2) | – | – | – | – | – | – | – | – | – | – |
| Moldova | 5348 | 5348 | (100.0) | 264 | (4.9) | 5051 | 4085 | (80.9) | 250 | (6.1) | 4636 | 4426 | (95.5) | 338 | (7.6) |
| Monaco | – | – | – | – | – | – | – | – | – | – | 0 | – | – | 0 | – |
| Montenegro | 107 | 82 | (76.6) | 0 | (0.0) | 120 | 98 | (81.7) | 2 | (2.0) | 113 | 94 | (83.2) | 0 | (0.0) |
| Russia | 97542 | 75995 | (77.9) | 4880 | (6.4) | 73361 | 69724 | (95.0) | 4990 | (7.2) | 70854 | 67425 | (95.2) | 5251 | (7.8) |
| San Marino | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Serbia | 1215 | 39 | (3.2) | 6 | (15.4) | 1181 | 132 | (11.2) | 19 | (14.4) | 998 | 127 | (12.7) | 8 | (6.3) |
| Serbia excluding UN Administered Province of Kosovo ^c | 1215 | 39 | (3.2) | 6 | (15.4) | 1181 | 132 | (11.2) | 19 | (14.4) | 998 | 127 | (12.7) | 8 | (6.3) |
| UN Administered Province of Kosovo ^c | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Switzerland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Tajikistan | 6929 | 6375 | (92.0) | 88 | (1.4) | 6495 | 6367 | (98.0) | 135 | (2.1) | 6260 | 5656 | (90.4) | 161 | (2.8) |
| Turkey | 14691 | 8646 | (58.9) | 45 | (0.5) | 13409 | 8787 | (65.5) | 32 | (0.4) | 13378 | 9344 | (69.8) | 45 | (0.5) |
| Turkmenistan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ukraine | 45569 | 34181 | (75.0) | 4726 | (13.8) | 48134 | 42213 | (87.7) | 8290 | (19.6) | 40302 | 39057 | (96.9) | 7640 | (19.6) |
| Uzbekistan | 16810 | 16810 | (100.0) | 820 | (4.9) | 25168 | 24670 | (98.0) | 1097 | (4.4) | 22804 | 22347 | (98.0) | 780 | (3.5) |
| Subtotal non-EU/EEA | 239241 | 193008 | (80.7) | 11926 | (6.2) | 214339 | 192214 | (89.7) | 15801 | (8.2) | 193135 | 179701 | (93.0) | 15436 | (8.6) |
| Total European Region | 283630 | 220962 | (77.9) | 13405 | (6.1) | 256020 | 220113 | (86.0) | 17116 | (7.8) | 225573 | 201633 | (89.4) | 16487 | (8.2) |
| Subtotal 18 HPC | 252332 | 199782 | (79.2) | 12190 | (6.1) | 232495 | 205714 | (88.5) | 16223 | (7.9) | 211692 | 193685 | (91.5) | 15897 | (8.2) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

HIV – Human immunodeficiency virus.

^b HIV prevalence may be underestimated due to incomplete HIV testing and/or reporting of HIV serostatus. Countries were only included in this analysis if total number of cases tested for HIV and test results were provided.

^c Percentages calculated from TB cases with known HIV test results.

^d In accordance with the UN Security Council Resolution No. 1244 (1999).

| | 2015 | | | | | 2016 | | | | | Country |
|--|------------------|-----------------------------|---------------|--------------|----------------|------------------|-----------------------------|---------------|--------------|----------------|--|
| | All TB cases (N) | Cases with known HIV status | | HIV positive | | All TB cases (N) | Cases with known HIV status | | HIV positive | | |
| | | N | % | N | % ^a | | N | % | N | % ^a | |
| | – | – | – | – | – | – | – | – | – | – | EU/EEA |
| | 977 | 432 | (44.2) | 31 | (7.2) | 1047 | 479 | (45.7) | 33 | (6.9) | Austria |
| | 1660 | 1311 | (79.0) | 1 | (0.1) | 1603 | 1260 | (78.6) | 0 | (0.0) | Belgium |
| | – | – | – | – | – | – | – | – | – | – | Bulgaria |
| | 63 | 48 | (76.2) | 2 | (4.2) | 60 | 48 | (80.0) | 0 | (0.0) | Croatia |
| | 517 | 182 | (35.2) | 2 | (1.1) | 516 | 205 | (39.7) | 5 | (2.4) | Cyprus |
| | – | – | – | – | – | 330 | 150 | (45.5) | 9 | (6.0) | Czech Republic |
| | 217 | 210 | (96.8) | 26 | (12.4) | 192 | 184 | (95.8) | 22 | (12.0) | Denmark |
| | – | – | – | – | – | – | – | – | – | – | Estonia |
| | – | – | – | – | – | – | – | – | – | – | Finland |
| | – | – | – | – | – | – | – | – | – | – | France |
| | – | – | – | – | – | – | – | – | – | – | Germany |
| | 482 | 343 | (71.2) | 22 | (6.4) | – | – | – | – | – | Greece |
| | 906 | 20 | (2.2) | 1 | (5.0) | 786 | 19 | (2.4) | 1 | (5.3) | Hungary |
| | 7 | 7 | (100.0) | 0 | (0.0) | 6 | 6 | (100.0) | 0 | (0.0) | Iceland |
| | 283 | 122 | (43.1) | 8 | (6.6) | 318 | 132 | (41.5) | 4 | (3.0) | Ireland |
| | – | – | – | – | – | – | – | – | – | – | Italy |
| | 721 | 449 | (62.3) | 78 | (17.4) | 660 | 507 | (76.8) | 57 | (11.2) | Latvia |
| | – | – | – | – | – | – | – | – | – | – | Liechtenstein |
| | 1507 | 1082 | (71.8) | 39 | (3.6) | 1442 | 1138 | (78.9) | 41 | (3.6) | Lithuania |
| | – | – | – | – | – | 29 | 5 | (17.2) | 2 | (40.0) | Luxembourg |
| | 32 | 26 | (81.3) | 4 | (15.4) | 50 | 46 | (92.0) | 8 | (17.4) | Malta |
| | 862 | 636 | (73.8) | 35 | (5.5) | 889 | 554 | (62.3) | 21 | (3.8) | Netherlands |
| | 313 | 260 | (83.1) | 8 | (3.1) | 299 | 257 | (86.0) | 10 | (3.9) | Norway |
| | – | – | – | – | – | – | – | – | – | – | Poland |
| | 2178 | 1941 | (89.1) | 232 | (12.0) | 1836 | 1212 | (66.0) | 168 | (13.9) | Portugal |
| | 15183 | 11533 | (76.0) | 308 | (2.7) | 13617 | 10634 | (78.1) | 287 | (2.7) | Romania |
| | 317 | 201 | (63.4) | 0 | (0.0) | 296 | 132 | (44.6) | 0 | (0.0) | Slovakia |
| | 130 | 108 | (83.1) | 0 | (0.0) | 118 | 95 | (80.5) | 1 | (1.1) | Slovenia |
| | 4997 | 3129 | (62.6) | 223 | (7.1) | 4877 | 2925 | (60.0) | 226 | (7.7) | Spain |
| | – | – | – | – | – | – | – | – | – | – | Sweden |
| | – | – | – | – | – | – | – | – | – | – | United Kingdom |
| | 31352 | 22040 | (70.3) | 1020 | (4.6) | 28971 | 19988 | (69.0) | 895 | (4.5) | Subtotal EU/EEA |
| | | | | | | | | | | | Non-EU/EEA |
| | 415 | 183 | (44.1) | 6 | (3.3) | 415 | 223 | (53.7) | 6 | (2.7) | Albania |
| | 4 | 0 | (0.0) | 0 | – | 4 | 0 | (0.0) | – | – | Andorra |
| | 1090 | 1090 | (100.0) | 99 | (9.1) | 1027 | 1027 | (100.0) | 57 | (5.6) | Armenia |
| | 6964 | 6964 | (100.0) | 112 | (1.6) | 5159 | 4722 | (91.5) | 99 | (2.1) | Azerbaijan |
| | 3765 | 3740 | (99.3) | 206 | (5.5) | 3211 | 3148 | (98.0) | 275 | (8.7) | Belarus |
| | 1092 | 209 | (19.1) | 0 | (0.0) | 907 | 1 | (0.1) | 1 | (100.0) | Bosnia and Herzegovina |
| | 282 | 185 | (65.6) | 0 | (0.0) | 263 | 207 | (78.7) | 0 | (0.0) | former Yugoslav Republic of Macedonia, the |
| | 3152 | 2809 | (89.1) | 79 | (2.8) | 2983 | 2866 | (96.1) | 61 | (2.1) | Georgia |
| | 280 | 280 | (100.0) | 14 | (5.0) | 250 | 250 | (100.0) | 18 | (7.2) | Israel |
| | 14006 | 13838 | (98.8) | 376 | (2.7) | 12322 | 10616 | (86.2) | 576 | (5.4) | Kazakhstan |
| | 7027 | 6745 | (96.0) | 206 | (3.1) | 7026 | 6254 | (89.0) | 210 | (3.4) | Kyrgyzstan |
| | 3608 | 3439 | (95.3) | 300 | (8.7) | 3571 | 3366 | (94.3) | 293 | (8.7) | Moldova |
| | 0 | 0 | (0.0) | – | – | – | – | – | – | – | Monaco |
| | 80 | 73 | (91.3) | 1 | (1.4) | 87 | 60 | (69.0) | 0 | (0.0) | Montenegro |
| | 68815 | 65585 | (95.3) | 6407 | (9.8) | 92407 | 79935 | (86.5) | 16570 | (20.7) | Russia |
| | – | – | – | – | – | 0 | 0 | – | – | – | San Marino |
| | 1649 | 91 | (5.5) | 4 | (4.4) | 1472 | 84 | (5.7) | 5 | (6.0) | Serbia |
| | 879 | 91 | (10.4) | 4 | (4.4) | 755 | 84 | (11.1) | 5 | (6.0) | Serbia excluding UN Administered Province of Kosovo ^c |
| | 770 | 0 | (0.0) | – | – | 717 | 398 | (55.5) | 0 | (0.0) | UN Administered Province of Kosovo ^c |
| | – | – | – | – | – | – | – | – | – | – | Switzerland |
| | 5894 | 5627 | (95.5) | 152 | (2.7) | 5965 | 5850 | (98.1) | 201 | (3.4) | Tajikistan |
| | 12550 | 8759 | (69.8) | 59 | (0.7) | 12186 | 8549 | (70.2) | 56 | (0.7) | Turkey |
| | – | – | – | – | – | – | – | – | – | – | Turkmenistan |
| | 30151 | 29749 | (98.7) | 6637 | (22.3) | 29052 | 28194 | (97.0) | 5832 | (20.7) | Ukraine |
| | 16315 | 13058 | (80.0) | 841 | (6.4) | 18441 | 18441 | (100.0) | 758 | (4.1) | Uzbekistan |
| | 177139 | 162424 | (91.7) | 15499 | (9.5) | 196748 | 173793 | (88.3) | 25018 | (14.4) | Subtotal non-EU/EEA |
| | 208491 | 184464 | (88.5) | 16519 | (9.0) | 225719 | 193781 | (85.9) | 25913 | (13.4) | Total European Region |
| | 185878 | 169523 | (91.2) | 15734 | (9.3) | 210864 | 186691 | (88.5) | 25395 | (13.6) | Subtotal 18 HPC |

Table X: Treatment success after 12 months of new TB cases and relapses, European Region, 2011–2015^a

| Country | 2011 | | | 2012 | | | 2013 | | | 2014 | | | 2015 | | |
|--|-----------------------------|---------------|---------------|----------------|---------------|---------------|----------------|---------------|---------------|----------------|---------------|---------------|----------------|---------------|---------------|
| | Cases reported ^b | N | (%) | Cases reported | N | (%) |
| EU/EEA | | | | | | | | | | | | | | | |
| Austria | 654 | 472 | (72.2) | 608 | 427 | (70.2) | 621 | 452 | (72.8) | 553 | 410 | (74.1) | 553 | 402 | (72.7) |
| Belgium | 950 | 752 | (79.2) | 880 | 681 | (77.4) | 876 | 690 | (78.8) | 867 | 700 | (80.7) | 905 | 719 | (79.4) |
| Bulgaria | 2263 | 1943 | (85.9) | 2172 | 1886 | (86.8) | 1893 | 1620 | (85.6) | 1789 | 1530 | (85.5) | 1598 | 1350 | (84.5) |
| Croatia ^b | – | – | – | 538 | 51 | (9.5) | 511 | 225 | (44.0) | 496 | 354 | (71.4) | 483 | 50 | (10.4) |
| Cyprus | 51 | 32 | (62.7) | 65 | 28 | (43.1) | 40 | 20 | (50.0) | 39 | 23 | (59.0) | 63 | 35 | (55.6) |
| Czech Republic | 557 | 393 | (70.6) | 554 | 414 | (74.7) | 468 | 321 | (68.6) | 467 | 355 | (76.0) | 499 | 343 | (68.7) |
| Denmark | 356 | 260 | (73.0) | 341 | 230 | (67.4) | 329 | 239 | (72.6) | 291 | 156 | (53.6) | 314 | 157 | (50.0) |
| Estonia | 254 | 186 | (73.2) | 217 | 163 | (75.1) | 222 | 193 | (86.9) | 194 | 162 | (83.5) | 172 | 142 | (82.6) |
| Finland | 313 | 131 | (41.9) | 261 | 116 | (44.4) | 265 | 140 | (52.8) | 250 | 112 | (44.8) | 260 | 94 | (36.2) |
| France | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | 4125 | 2673 | (64.8) | 3981 | 2937 | (73.8) | 4003 | 2681 | (67.0) | 4268 | 2713 | (63.6) | 5543 | 3600 | (64.9) |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 1437 | 1056 | (73.5) | 1169 | 821 | (70.2) | 1029 | 759 | (73.8) | 795 | 577 | (72.6) | 851 | 600 | (70.5) |
| Iceland | 9 | 8 | (88.9) | 10 | 9 | (90.0) | 11 | 10 | (90.9) | 9 | 8 | (88.9) | 7 | 7 | (100.0) |
| Ireland | 385 | 236 | (61.3) | 328 | 203 | (61.9) | 346 | 213 | (61.6) | 288 | 162 | (56.3) | 265 | 151 | (57.0) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Latvia | 775 | 645 | (83.2) | 872 | 758 | (86.9) | 804 | 669 | (83.2) | 675 | 561 | (83.1) | 642 | 540 | (84.1) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 1546 | 1290 | (83.4) | 1447 | 1186 | (82.0) | 1374 | 1111 | (80.9) | 1282 | 1034 | (80.7) | 1219 | 962 | (78.9) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | 32 | 22 | (68.8) | 41 | 10 | (24.4) | 48 | 36 | (75.0) | – | – | – | – | – | – |
| Netherlands | 971 | 841 | (86.6) | 921 | 783 | (85.0) | 814 | 728 | (89.4) | 797 | 708 | (88.8) | 837 | 723 | (86.4) |
| Norway | 316 | 280 | (88.6) | 335 | 293 | (87.5) | 348 | 316 | (90.8) | 293 | 251 | (85.7) | 276 | 243 | (88.0) |
| Poland | 8137 | 5047 | (62.0) | 7253 | 4383 | (60.4) | 7005 | 4161 | (59.4) | 6500 | 3783 | (58.2) | 6196 | 3293 | (53.1) |
| Portugal | 2517 | 1986 | (78.9) | 2535 | 1981 | (78.1) | 2341 | 1748 | (74.7) | 2197 | 1592 | (72.5) | 2114 | 1516 | (71.7) |
| Romania | 17353 | 14691 | (84.7) | 16351 | 13844 | (84.7) | 15115 | 12814 | (84.8) | 14525 | 12304 | (84.7) | 13908 | 11828 | (85.0) |
| Slovakia | 393 | 363 | (92.4) | 343 | 302 | (88.0) | 395 | 370 | (93.7) | 318 | 280 | (88.1) | 305 | 263 | (86.2) |
| Slovenia | 190 | 155 | (81.6) | 138 | 112 | (81.2) | 139 | 107 | (77.0) | 142 | 110 | (77.5) | 129 | 105 | (81.4) |
| Spain | 6410 | 4541 | (70.8) | 5738 | 4087 | (71.2) | 5328 | 4355 | (81.7) | 4686 | 2708 | (57.8) | – | – | – |
| Sweden | 526 | 461 | (87.6) | 578 | 481 | (83.2) | 595 | 537 | (90.3) | 610 | 535 | (87.7) | 754 | 659 | (87.4) |
| United Kingdom | 8300 | 6508 | (78.4) | 8099 | 6511 | (80.4) | 7270 | 6019 | (82.8) | 6534 | 5344 | (81.8) | 5802 | 4594 | (79.2) |
| Subtotal EU/EEA | 58820 | 44972 | (76.5) | 55775 | 42697 | (76.6) | 52190 | 40534 | (77.7) | 48865 | 36472 | (74.6) | 43695 | 32376 | (74.1) |
| Non-EU/EEA^c | | | | | | | | | | | | | | | |
| Albania | 413 | 382 | (92.5) | 407 | 373 | (91.6) | 472 | 416 | (88.1) | 406 | 358 | (88.2) | 409 | 354 | (86.6) |
| Andorra | 3 | 3 | (100.0) | 9 | 9 | (100.0) | 5 | 3 | (60.0) | 6 | 5 | (83.3) | 4 | 4 | (100.0) |
| Armenia | 1200 | 934 | (77.8) | 1350 | 1093 | (81.0) | 1251 | 1008 | (80.6) | 1228 | 959 | (78.1) | 910 | 721 | (79.2) |
| Azerbaijan | 2208 | 1717 | (77.8) | 4616 | 3831 | (83.0) | 4294 | 3504 | (81.6) | 1623 | 1349 | (83.1) | 1475 | 1221 | (82.8) |
| Belarus | 4926 | 3480 | (70.6) | 3425 | 2902 | (84.7) | 3034 | 2626 | (86.6) | 2706 | 2381 | (88.0) | 2525 | 2243 | (88.8) |
| Bosnia and Herzegovina | 1321 | 945 | (71.5) | 1301 | 1096 | (84.2) | 1261 | 1040 | (82.5) | 1196 | 923 | (77.2) | 1092 | 707 | (64.7) |
| former Yugoslav Republic of Macedonia, the | 307 | 272 | (88.6) | 346 | 298 | (86.1) | 317 | 287 | (90.5) | 281 | 244 | (86.8) | 282 | 243 | (86.2) |
| Georgia | 4237 | 3414 | (80.6) | 3638 | 3103 | (85.3) | 3098 | 2465 | (79.6) | 2862 | 2377 | (83.1) | 2841 | 2386 | (84.0) |
| Israel | 514 | 403 | (78.4) | 509 | 412 | (80.9) | 305 | 257 | (84.3) | 322 | 285 | (88.5) | 263 | 218 | (82.9) |
| Kazakhstan | 12400 | 9430 | (76.0) | 16275 | 14068 | (86.4) | 14456 | 12841 | (88.8) | 12473 | 11186 | (89.7) | 14006 | 12691 | (90.6) |
| Kyrgyzstan | 3662 | 3091 | (84.4) | – | – | – | 5658 | 4797 | (84.8) | 5731 | 4837 | (84.4) | 6139 | 5063 | (82.5) |
| Moldova | 3836 | 2815 | (73.4) | 4203 | 3205 | (76.3) | 3889 | 3095 | (79.6) | 3459 | 2724 | (78.8) | 2992 | 2379 | (79.5) |
| Monaco | – | – | – | 0 | – | – | 3 | 3 | (100.0) | 0 | – | – | – | – | – |
| Montenegro | 100 | 86 | (86.0) | 107 | 90 | (84.1) | 119 | 104 | (87.4) | 113 | 101 | (89.4) | 80 | 74 | (92.5) |
| Russia | 88554 | 57801 | (65.3) | 89666 | 61765 | (68.9) | 83301 | 56980 | (68.4) | 77136 | 53266 | (69.1) | 80424 | 57060 | (70.9) |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | – | – |
| Serbia | 1794 | 1537 | (85.7) | 1851 | 1546 | (83.5) | 1427 | 1118 | (78.3) | 1281 | 1042 | (81.3) | 1647 | 1471 | (89.3) |
| Serbia excluding UN Administered Province of Kosovo ^d | – | – | – | 1197 | 968 | (80.9) | 1184 | 928 | (78.4) | 1045 | 828 | (79.2) | 882 | 733 | (83.1) |
| UN Administered Province of Kosovo ^d | – | – | – | 654 | 578 | (88.4) | 243 | 190 | (78.2) | 236 | 214 | (90.7) | 765 | 738 | (96.5) |
| Switzerland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Tajikistan | 5935 | 5145 | (86.7) | 5811 | 4845 | (83.4) | 5263 | 4619 | (87.8) | 5149 | 4606 | (89.5) | 5298 | 4734 | (89.4) |
| Turkey | 14417 | 12915 | (89.6) | 13535 | 11946 | (88.3) | 13170 | 11373 | (86.4) | 12933 | 11245 | (86.9) | 12362 | 10735 | (86.8) |
| Turkmenistan | 2140 | 1852 | (86.5) | 2804 | 2369 | (84.5) | 3046 | 2199 | (72.2) | 2122 | 1797 | (84.7) | 2472 | 2126 | (86.0) |
| Ukraine | 27793 | 18620 | (67.0) | 30928 | 21922 | (70.9) | 29726 | 20959 | (70.5) | 22294 | 16109 | (72.3) | 23892 | 17939 | (75.1) |
| Uzbekistan | 13995 | 11836 | (84.6) | 14132 | 11905 | (84.2) | 17373 | 14457 | (83.2) | 16328 | 14215 | (87.1) | 15220 | 13536 | (88.9) |
| Subtotal non-EU/EEA | 189755 | 136678 | (72.0) | 194913 | 146778 | (75.3) | 191468 | 144151 | (75.3) | 169649 | 130009 | (76.6) | 174333 | 135905 | (78.0) |
| Total European Region | 248575 | 181650 | (73.1) | 250688 | 189475 | (75.6) | 243658 | 184685 | (75.8) | 218514 | 166481 | (76.2) | 218028 | 168281 | (77.2) |
| Subtotal 18 HPC | 207494 | 151805 | (73.2) | 211442 | 160791 | (76.0) | 206967 | 157330 | (76.0) | 184509 | 142642 | (77.3) | 188095 | 147656 | (78.5) |

^a "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

^b Excluding rifampicin-resistant cases.

^c These data are subject to change as the national TB registry was under review when this report was being produced.

^d For non-EU countries data are related to all new and relapse cases except for 2011.

^e In accordance with the UN Security Council Resolution No. 1244 (1999).

Table XI: Treatment success after 12 months of all TB cases, European Region, 2011–2015

| Country | 2011 | | | 2012 | | | 2013 | | | 2014 | | | 2015 | | |
|--|----------------|---------------|---------------|----------------|---------------|---------------|----------------|---------------|---------------|----------------|---------------|---------------|----------------|---------------|---------------|
| | Cases reported | Success | | Cases reported | Success | | Cases reported | Success | | Cases reported | Success | | Cases reported | Success | |
| | | N | (%) |
| EU/EEA | | | | | | | | | | | | | | | |
| Austria | 684 | 476 | (69.6) | 646 | 432 | (66.9) | 653 | 464 | (71.1) | 586 | 423 | (72.2) | 583 | 417 | (71.5) |
| Belgium | 1019 | 788 | (77.3) | 976 | 736 | (75.4) | 963 | 743 | (77.2) | 949 | 752 | (79.2) | 977 | 764 | (78.2) |
| <i>Bulgaria</i> | <i>2406</i> | <i>1991</i> | <i>(82.8)</i> | <i>2280</i> | <i>1917</i> | <i>(84.1)</i> | <i>1932</i> | <i>1626</i> | <i>(84.2)</i> | <i>1872</i> | <i>1565</i> | <i>(83.6)</i> | <i>1660</i> | <i>1385</i> | <i>(83.4)</i> |
| Croatia ^a | – | – | – | 575 | 59 | (10.3) | 517 | 226 | (43.7) | 499 | 354 | (70.9) | 486 | 50 | (10.3) |
| Cyprus | 54 | 34 | (63.0) | 69 | 30 | (43.5) | 41 | 20 | (48.8) | 41 | 24 | (58.5) | 63 | 35 | (55.6) |
| Czech Republic | 600 | 422 | (70.3) | 597 | 444 | (74.4) | 497 | 345 | (69.4) | 511 | 379 | (74.2) | 517 | 350 | (67.7) |
| Denmark | 381 | 276 | (72.4) | 389 | 265 | (68.1) | 356 | 252 | (70.8) | 320 | 174 | (54.4) | 357 | 171 | (47.9) |
| <i>Estonia</i> | <i>339</i> | <i>189</i> | <i>(55.8)</i> | <i>289</i> | <i>168</i> | <i>(58.1)</i> | <i>290</i> | <i>203</i> | <i>(70.0)</i> | <i>248</i> | <i>167</i> | <i>(67.3)</i> | <i>217</i> | <i>149</i> | <i>(68.7)</i> |
| Finland | 324 | 131 | (40.4) | 274 | 122 | (44.5) | 273 | 141 | (51.6) | 263 | 114 | (43.3) | 272 | 95 | (34.9) |
| France ^b | 5000 | 2372 | (47.4) | 5003 | 2277 | (45.5) | 4947 | 2474 | (50.0) | 4888 | 2592 | (53.0) | – | – | – |
| Germany | 4309 | 2752 | (63.9) | 4213 | 3073 | (72.9) | 4340 | 2838 | (65.4) | 4526 | 2826 | (62.4) | 5852 | 3728 | (63.7) |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 1445 | 1059 | (73.3) | 1223 | 847 | (69.3) | 1045 | 765 | (73.2) | 851 | 607 | (71.3) | 906 | 631 | (69.6) |
| Iceland | 9 | 8 | (88.9) | 11 | 9 | (81.8) | 11 | 10 | (90.9) | 9 | 8 | (88.9) | 7 | 7 | (100.0) |
| Ireland | 412 | 250 | (60.7) | 359 | 218 | (60.7) | 374 | 232 | (62.0) | 311 | 173 | (55.6) | 283 | 157 | (55.5) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Latvia | 885 | 655 | (74.0) | 993 | 765 | (77.0) | 904 | 688 | (76.1) | 761 | 593 | (77.9) | 721 | 551 | (76.4) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Lithuania</i> | <i>1904</i> | <i>1326</i> | <i>(69.6)</i> | <i>1781</i> | <i>1222</i> | <i>(68.6)</i> | <i>1705</i> | <i>1132</i> | <i>(66.4)</i> | <i>1607</i> | <i>1058</i> | <i>(65.8)</i> | <i>1507</i> | <i>987</i> | <i>(65.5)</i> |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | 33 | 23 | (69.7) | 42 | 10 | (23.8) | 50 | 37 | (74.0) | – | – | – | – | – | – |
| Netherlands | 1004 | 856 | (85.3) | 956 | 801 | (83.8) | 845 | 737 | (87.2) | 814 | 717 | (88.1) | 862 | 733 | (85.0) |
| Norway | 354 | 308 | (87.0) | 374 | 319 | (85.3) | 392 | 346 | (88.3) | 324 | 268 | (82.7) | 313 | 268 | (85.6) |
| Poland | 8478 | 5191 | (61.2) | 7542 | 4501 | (59.7) | 7250 | 4252 | (58.6) | 6698 | 3865 | (57.7) | 6430 | 3387 | (52.7) |
| Portugal | 2609 | 2024 | (77.6) | 2606 | 2015 | (77.3) | 2410 | 1779 | (73.8) | 2278 | 1625 | (71.3) | 2178 | 1539 | (70.7) |
| <i>Romania</i> | <i>19202</i> | <i>15242</i> | <i>(79.4)</i> | <i>18190</i> | <i>14388</i> | <i>79</i> | <i>16689</i> | <i>13272</i> | <i>(79.5)</i> | <i>15879</i> | <i>12679</i> | <i>(79.8)</i> | <i>15183</i> | <i>12185</i> | <i>(80.3)</i> |
| Slovakia | 399 | 366 | (91.7) | 345 | 303 | (87.8) | 401 | 372 | (92.8) | 336 | 291 | (86.6) | 317 | 271 | (85.5) |
| Slovenia | 192 | 157 | (81.8) | 138 | 112 | (81.2) | 140 | 108 | (77.1) | 144 | 111 | (77.1) | 130 | 106 | (81.5) |
| Spain | 6798 | 4760 | (70.0) | 6070 | 4286 | (70.6) | 5632 | 4582 | (81.4) | 4914 | 2827 | (57.5) | – | – | – |
| Sweden | 580 | 494 | (85.2) | 623 | 504 | (80.9) | 639 | 566 | (88.6) | 659 | 570 | (86.5) | 815 | 688 | (84.4) |
| United Kingdom | 8919 | 6913 | (77.5) | 8711 | 6892 | (79.1) | 7868 | 6411 | (81.5) | 7049 | 5676 | (80.5) | 6234 | 4865 | (78.0) |
| Subtotal EU/EEA | 68339 | 49063 | (71.8) | 65275 | 46715 | (71.6) | 61164 | 44621 | (73.0) | 57337 | 40438 | (70.5) | 46870 | 33519 | (71.5) |
| Non-EU/EEA | | | | | | | | | | | | | | | |
| Albania | 413 | 382 | (92.5) | 413 | 377 | (91.3) | 472 | 416 | (88.1) | 406 | 358 | (88.2) | 409 | 354 | (86.6) |
| Andorra | 3 | 3 | (100.0) | 9 | 9 | (100.0) | 5 | 3 | (60.0) | 6 | 5 | (83.3) | 4 | 4 | (100.0) |
| Armenia | 1200 | 934 | (77.8) | 1365 | 1100 | (80.6) | 1269 | 1022 | (80.5) | 1242 | 966 | (77.8) | 923 | 731 | (79.2) |
| Azerbaijan | 2208 | 1717 | (77.8) | 7495 | 5951 | (79.4) | 6946 | 5436 | (78.3) | 3997 | 3109 | (77.8) | 4213 | 3230 | (76.7) |
| Belarus | 4926 | 3480 | (70.6) | 3613 | 3031 | (83.9) | 3256 | 2784 | (85.5) | 2955 | 2562 | (86.7) | 2788 | 2444 | (87.7) |
| Bosnia and Herzegovina | 1321 | 945 | (71.5) | 1420 | 1188 | (83.7) | 1261 | 1040 | (82.5) | 1196 | 923 | (77.2) | 1095 | 707 | (64.6) |
| former Yugoslav Republic of Macedonia, the | 307 | 272 | (88.6) | 355 | 305 | (85.9) | 322 | 292 | (90.7) | 282 | 245 | (86.9) | 284 | 245 | (86.3) |
| Georgia | 4237 | 3414 | (80.6) | 4524 | 3757 | (83.0) | 3877 | 3006 | (77.5) | 3371 | 2727 | (80.9) | 3144 | 2582 | (82.1) |
| Israel | 514 | 403 | (78.4) | 509 | 412 | (80.9) | 305 | 257 | (84.3) | 322 | 285 | (88.5) | 263 | 218 | (82.9) |
| Kazakhstan | 12400 | 9430 | (76.0) | 19446 | 16556 | (85.1) | 14920 | 13133 | (88.0) | 12803 | 11441 | (89.4) | 14631 | 13172 | (90.0) |
| Kyrgyzstan | 3662 | 3091 | (84.4) | – | – | – | 6788 | 5656 | (83.3) | 6646 | 5563 | (83.7) | 6686 | 5423 | (81.1) |
| Moldova | 3836 | 2815 | (73.4) | 4658 | 3382 | (72.6) | 4246 | 3234 | (76.2) | 3751 | 2861 | (76.3) | 3209 | 2480 | (77.3) |
| Monaco | – | – | – | – | – | – | 3 | 3 | (100.0) | 0 | – | – | – | – | – |
| Montenegro | 100 | 86 | (86.0) | 107 | 90 | (84.1) | 120 | 104 | (86.7) | 113 | 101 | (89.4) | 80 | 74 | (92.5) |
| Russia | 88554 | 57801 | (65.3) | 97627 | 64731 | (66.3) | 90235 | 59691 | (66.2) | 82926 | 55673 | (67.1) | 88718 | 61238 | (69.0) |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | – | – |
| Serbia | 1794 | 1537 | (85.7) | 1888 | 1573 | (83.3) | 1476 | 1152 | (78.0) | 1295 | 1049 | (81.0) | 1669 | 1484 | (88.9) |
| Serbia excluding UN Administered Province of Kosovo ^c | – | – | – | – | – | – | – | – | – | – | – | – | 897 | 739 | (82.4) |
| UN Administered Province of Kosovo ^c | – | – | – | – | – | – | – | – | – | – | – | – | 772 | 745 | (96.5) |
| Switzerland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Tajikistan | 5935 | 5145 | (86.7) | 6929 | 5682 | (82.0) | 6075 | 5282 | (86.9) | 5504 | 4896 | (89.0) | 5584 | 4964 | (88.9) |
| Turkey | 14417 | 12915 | (89.6) | 14691 | 12714 | (86.5) | 13409 | 11465 | (85.5) | 13125 | 11341 | (86.4) | 12520 | 10807 | (86.3) |
| Turkmenistan | 2140 | 1852 | (86.5) | 3422 | 2758 | (80.6) | 3675 | 2364 | (64.3) | 2265 | 1890 | (83.4) | 2753 | 2352 | (85.4) |
| Ukraine | 27793 | 18620 | (67.0) | 36514 | 24790 | (67.9) | 38875 | 26014 | (66.9) | 27563 | 19586 | (71.1) | 27548 | 20034 | (72.7) |
| Uzbekistan | 13995 | 11836 | (84.6) | 16765 | 13799 | (82.3) | 21713 | 17843 | (82.2) | 20275 | 17402 | (85.8) | 17837 | 15694 | (88.0) |
| Subtotal non-EU/EEA | 189755 | 136678 | (72.0) | 221750 | 162205 | (73.1) | 219248 | 160197 | (73.1) | 190043 | 142983 | (75.2) | 194358 | 148237 | (76.3) |
| Total European Region | 258094 | 185741 | (72.0) | 287025 | 208920 | (72.8) | 280412 | 204818 | (73.0) | 247380 | 183421 | (74.1) | 241228 | 181756 | (75.3) |
| Subtotal 18 HPC | 210039 | 152453 | (72.6) | 240582 | 176711 | (73.5) | 236804 | 173851 | (73.4) | 206790 | 156079 | (75.5) | 209842 | 160408 | (76.4) |

^a "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

^b These data are subject to change as the national TB registry was under review when this report was being produced.

^c Data are including overseas territories.

^d In accordance with the UN Security Council Resolution No. 1244 (1999).

Table XII: Treatment success after 24 months of RR/MDR TB cases started on treatment, European Region, 2010–2014

| Country | 2010 | | | 2011 | | | 2012 | | | 2013 | | | 2014 | | |
|--|----------------|--------------|---------------|----------------|--------------|---------------|----------------|--------------|---------------|----------------|--------------|---------------|----------------|--------------|---------------|
| | Cases reported | Success | | Cases reported | Success | | Cases reported | Success | | Cases reported | Success | | Cases reported | Success | |
| | | N | (%) |
| EU/EEA | | | | | | | | | | | | | | | |
| Austria | 16 | 9 | (56.3) | 22 | 15 | (68.2) | 27 | 14 | (51.9) | 16 | 12 | (75.0) | 21 | 13 | (61.9) |
| Belgium | 25 | 14 | (56.0) | 17 | 13 | (76.5) | 25 | 17 | (68.0) | 14 | 11 | (78.6) | 13 | 7 | (53.8) |
| Bulgaria | 70 | 17 | (24.3) | 65 | 37 | (56.9) | 58 | 38 | (65.5) | 37 | 17 | (45.9) | 44 | 22 | (50.0) |
| Croatia ^a | – | – | – | – | – | – | 1 | 0 | (0.0) | – | – | – | 2 | 0 | (0.0) |
| Cyprus | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Czech Republic | 21 | 0 | (0.0) | 13 | 7 | (53.8) | 5 | 2 | (40.0) | 0 | – | – | 7 | 3 | (42.9) |
| Denmark | 2 | 1 | (50.0) | 3 | 0 | (0.0) | 1 | 0 | (0.0) | 2 | 1 | (50.0) | 2 | 1 | (50.0) |
| Estonia | 64 | 34 | (53.1) | 70 | 40 | (57.1) | 57 | 42 | (73.7) | 54 | 34 | (63.0) | 50 | 32 | (64.0) |
| Finland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | 62 | 30 | (48.4) | 65 | 34 | (52.3) | 71 | 35 | (49.3) | 114 | 41 | (36.0) | 104 | 35 | (33.7) |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | 21 | 9 | (42.9) | 8 | 4 | (50.0) | 13 | 6 | (46.2) | 11 | 4 | (36.4) | 4 | 4 | (100.0) |
| Iceland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ireland | 4 | 4 | (100.0) | 3 | 1 | (33.3) | 4 | 4 | (100.0) | 4 | 3 | (75.0) | 2 | 1 | (50.0) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Latvia | 88 | 58 | (65.9) | 96 | 52 | (54.2) | 107 | 66 | (61.7) | 79 | 54 | (68.4) | 71 | 52 | (73.2) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Lithuania | 315 | 94 | (29.8) | 306 | 111 | (36.3) | 285 | 101 | (35.4) | 274 | 90 | (32.8) | 279 | 35 | (12.5) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | 1 | 0 | (0.0) | 0 | – | – | 0 | – | – | 2 | 1 | (0.0) | 0 | – | – |
| Netherlands | 12 | 8 | (66.7) | 17 | 11 | (64.7) | 14 | 10 | (71.4) | 17 | 17 | (100.0) | 7 | 6 | (85.7) |
| Norway | 9 | 5 | (55.6) | 4 | 3 | (75.0) | 7 | 3 | (42.9) | 7 | 5 | (71.4) | 11 | 9 | (81.8) |
| Poland | 38 | 18 | (47.4) | 49 | 16 | (32.7) | 41 | 7 | (17.1) | 47 | 10 | (21.3) | 49 | 9 | (18.4) |
| Portugal | 30 | 11 | (36.7) | 40 | 22 | (55.0) | 27 | 13 | (48.1) | 18 | 10 | (55.6) | 28 | 15 | (53.6) |
| Romania | 639 | 149 | (23.3) | 618 | 184 | (29.8) | 777 | 290 | (37.3) | 657 | 258 | (39.3) | 596 | 245 | (41.1) |
| Slovakia | 1 | 0 | (0.0) | 4 | 2 | (50.0) | 1 | 0 | (0.0) | 2 | 0 | (0.0) | 4 | 2 | (50.0) |
| Slovenia | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Spain | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | 20 | 19 | (95.0) | 18 | 14 | (77.8) | 15 | 13 | (86.7) | 10 | 7 | (70.0) | 17 | 15 | (88.2) |
| United Kingdom | 77 | 38 | (49.4) | 92 | 49 | (53.3) | 85 | 55 | (64.7) | 79 | 51 | (64.6) | 56 | 33 | (58.9) |
| Subtotal EU/EEA | 1515 | 518 | (34.2) | 1510 | 615 | (40.7) | 1621 | 716 | (44.2) | 1444 | 626 | (43.4) | 1367 | 539 | (39.4) |
| Non-EU/EEA | | | | | | | | | | | | | | | |
| Albania | 0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Andorra | 0 | – | – | 0 | – | – | 0 | – | – | 0 | – | – | 0 | – | – |
| Armenia | 132 | 59 | (44.7) | 121 | 61 | (50.4) | 115 | 51 | (44.3) | 104 | 45 | (43.3) | 118 | 68 | (57.6) |
| Azerbaijan | 286 | 156 | (54.5) | 565 | 339 | (60.0) | 373 | 225 | (60.3) | 647 | 382 | (59.0) | 745 | 441 | (59.2) |
| Belarus | 1442 | 452 | (31.3) | 1600 | 807 | (50.4) | 2509 | 1366 | (54.4) | 2136 | 1152 | (53.9) | 1472 | 872 | (59.2) |
| Bosnia and Herzegovina | 7 | 4 | (57.1) | 5 | 1 | (20.0) | 7 | 3 | (42.9) | 1 | 1 | (100.0) | 3 | 2 | (66.7) |
| former Yugoslav Republic of Macedonia, the | 7 | 1 | (14.3) | 1 | 1 | (100.0) | 3 | 2 | (66.7) | 2 | 1 | (50.0) | 3 | 1 | (33.3) |
| Georgia | 504 | 271 | (53.8) | 611 | 305 | (49.9) | 623 | 296 | (47.5) | 411 | 176 | (42.8) | 411 | 201 | (48.9) |
| Israel | 12 | 4 | (33.3) | 11 | 7 | (63.6) | 13 | 12 | (92.3) | 7 | 4 | (57.1) | 16 | 12 | (75.0) |
| Kazakhstan | 5777 | 4197 | (72.7) | 5261 | 3910 | (74.3) | 7213 | 5265 | (73.0) | 6527 | 4730 | (72.5) | 6320 | 4813 | (76.2) |
| Kyrgyzstan | 556 | 236 | (42.4) | 492 | 280 | (56.9) | 775 | 486 | (62.7) | 1064 | 611 | (57.4) | 1157 | 650 | (56.2) |
| Moldova | 791 | 390 | (49.3) | 761 | 413 | (54.3) | 856 | 504 | (58.9) | 943 | 538 | (57.1) | 919 | 457 | (49.7) |
| Monaco | – | – | – | – | – | – | 0 | – | – | 0 | – | – | – | – | – |
| Montenegro | 0 | – | – | 1 | 0 | (0.0) | 1 | 1 | (100.0) | 0 | – | – | 2 | – | – |
| Russia | 4681 | 2035 | (43.5) | 15896 | 5895 | (37.1) | 16021 | 6427 | (40.1) | 18213 | 8802 | (48.3) | 20089 | 10170 | (50.6) |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | – | – |
| Serbia | 10 | 8 | (80.0) | 14 | 9 | (64.3) | 7 | 4 | (57.1) | 19 | 15 | (78.9) | 19 | 12 | (63.2) |
| Serbia excluding UN Administered Province of Kosovo ^b | – | – | – | – | – | – | 6 | 3 | (50.0) | 13 | 10 | (76.9) | 13 | 7 | (53.8) |
| UN Administered Province of Kosovo ^b | – | – | – | – | – | – | 1 | 1 | (100.0) | 6 | 5 | (83.3) | 6 | 5 | (83.3) |
| Switzerland | – | – | – | – | – | – | – | – | – | – | – | – | 12 | 9 | (75.0) |
| Tajikistan | 245 | 151 | (61.6) | 380 | 242 | (63.7) | 535 | 351 | (65.6) | 625 | 375 | (60.0) | 804 | 398 | (49.5) |
| Turkey | 250 | 168 | (67.2) | 275 | 181 | (65.8) | 291 | 193 | (66.3) | 228 | 149 | (65.4) | 257 | 163 | (63.4) |
| Turkmenistan | – | – | – | – | – | – | – | – | – | – | – | – | 213 | 143 | (67.1) |
| Ukraine | 3902 | 1144 | (29.3) | 3810 | 1298 | (34.1) | 5556 | 1909 | (34.4) | 7633 | 2948 | (38.6) | 7174 | 3297 | (46.0) |
| Uzbekistan | 628 | 366 | (58.3) | 855 | 455 | (53.2) | 1491 | 737 | (49.4) | 2647 | 1390 | (52.5) | 3602 | 2216 | (61.5) |
| Subtotal non-EU/EEA | 19230 | 9642 | (50.1) | 30659 | 14204 | (46.3) | 36389 | 17832 | (49.0) | 41207 | 21319 | (51.7) | 43336 | 23925 | (55.2) |
| Total European Region | 20745 | 10160 | (49.0) | 32169 | 14819 | (46.1) | 38010 | 18548 | (48.8) | 42651 | 21945 | (51.5) | 44703 | 24464 | (54.7) |
| Subtotal 18 HPC | 20370 | 9977 | (49.0) | 31782 | 14610 | (46.0) | 37584 | 18347 | (48.8) | 42279 | 21751 | (51.4) | 44321 | 24275 | (54.8) |

^a "European Region" comprises the 53 countries of the WHO European Region and Liechtenstein.

WHO European Region 18 TB high-priority countries presented in italics.

RR/MDR TB – Rifampicin-resistant and multidrug-resistant tuberculosis.

^b These data are subject to change as the national TB registry was under review when this report was being produced.

^c In accordance with the UN Security Council Resolution No. 1244 (1999).

Table XIII: Treatment success after 24 months of XDR TB cases started on treatment, European Region, 2010–2014

| Country | 2010 | | | 2011 | | | 2012 | | | 2013 | | | 2014 | | |
|--|--------------|-----------|---------------|--------------|-----------|---------------|--------------|------------|---------------|--------------|------------|---------------|--------------|-------------|---------------|
| | MDR TB cases | Success | | MDR TB cases | Success | | MDR TB cases | Success | | MDR TB cases | Success | | MDR TB cases | Success | |
| | | N | (%) | | N | (%) | | N | (%) | | N | (%) | | N | (%) |
| EU/EEA | | | | | | | | | | | | | | | |
| Austria | 1 | 1 | (100.0) | 7 | 4 | (57.1) | 7 | 2 | (28.6) | 3 | 2 | (66.7) | 2 | 1 | (50.0) |
| Belgium | 2 | 2 | (100.0) | 3 | 2 | (66.7) | 2 | 2 | (100.0) | 0 | – | – | 1 | 1 | (100.0) |
| Bulgaria | 1 | 1 | (100.0) | – | – | – | 5 | 1 | (20.0) | 4 | 0 | (0.0) | 3 | 0 | (0.0) |
| Croatia | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Cyprus | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Czech Republic | 1 | 1 | (100.0) | 2 | 0 | (0.0) | 1 | 0 | (0.0) | – | – | – | – | – | – |
| Denmark | – | – | – | – | – | – | 0 | – | – | 1 | 1 | (100.0) | – | – | – |
| Estonia | 11 | 3 | (27.3) | 15 | 4 | (26.7) | 3 | 1 | (33.3) | 10 | 3 | (30.0) | 8 | 1 | (12.5) |
| Finland | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Germany | – | – | – | 1 | 1 | (100.0) | 1 | 0 | (0.0) | 3 | 0 | (0.0) | 11 | 2 | (18.2) |
| Greece | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Hungary | 2 | 0 | (0.0) | – | – | – | 2 | 1 | (50.0) | 1 | 0 | (0.0) | – | – | – |
| Iceland | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Ireland | – | – | – | – | – | – | 0 | – | – | 1 | 1 | (100.0) | – | – | – |
| Italy | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Latvia | 13 | 8 | (61.5) | 12 | 5 | (41.7) | 17 | 9 | (52.9) | 15 | 11 | (73.3) | 13 | 10 | (76.9) |
| Liechtenstein | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Lithuania | 50 | 0 | (0.0) | 52 | 0 | (0.0) | 52 | 5 | (9.6) | 47 | 0 | (0.0) | 61 | 0 | (0.0) |
| Luxembourg | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Malta | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Netherlands | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Norway | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | (0.0) |
| Poland | 1 | 1 | (100.0) | 1 | 0 | (0.0) | 0 | – | – | 1 | 0 | (0.0) | 5 | 1 | (20.0) |
| Portugal | 4 | 2 | (50.0) | 9 | 5 | (55.6) | 4 | 2 | (50.0) | 4 | 2 | (50.0) | 3 | 2 | (66.7) |
| Romania | 26 | 2 | (7.7) | 34 | 6 | (17.6) | 41 | 3 | (7.3) | 56 | 9 | (16.1) | 57 | 9 | (15.8) |
| Slovakia | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Slovenia | – | – | – | – | – | – | 0 | – | – | – | – | – | – | – | – |
| Spain | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | – | – | – | – | – | – | 2 | 2 | (100.0) | 2 | 1 | (50.0) | 1 | 0 | (0.0) |
| United Kingdom | 3 | 1 | (33.3) | 6 | 1 | (16.7) | 2 | 0 | (0.0) | 3 | 1 | (33.3) | 3 | 1 | (33.3) |
| Subtotal EU/EEA | 115 | 22 | (19.1) | 142 | 28 | (19.7) | 139 | 28 | (20.1) | 151 | 31 | (20.5) | 168 | 28 | (16.7) |
| Non-EU/EEA | | | | | | | | | | | | | | | |
| Albania | 0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Andorra | 0 | – | – | 0 | – | – | 0 | – | – | 0 | – | – | 0 | – | – |
| Armenia | 3 | 1 | (33.3) | 2 | 1 | (50.0) | 2 | 0 | (0.0) | 10 | 2 | (20.0) | 10 | 4 | (40.0) |
| Azerbaijan | – | – | – | – | – | – | 33 | 12 | (36.4) | 95 | 25 | (26.3) | 69 | 16 | (23.2) |
| Belarus | – | – | – | – | – | – | 0 | – | – | 60 | 23 | (38.3) | 431 | 157 | (36.4) |
| Bosnia and Herzegovina | 0 | – | – | 0 | – | – | – | – | – | 0 | – | – | 0 | – | – |
| former Yugoslav Republic of Macedonia, the | 1 | 0 | (0.0) | 0 | – | – | 1 | 1 | (100.0) | 0 | – | – | 0 | – | – |
| Georgia | 35 | 8 | (22.9) | 19 | 2 | (10.5) | 43 | 12 | (27.9) | 70 | 15 | (21.4) | 56 | 18 | (32.1) |
| Israel | 1 | 0 | (0.0) | 0 | – | – | 4 | 4 | (100.0) | 1 | 0 | (0.0) | 2 | 1 | (50.0) |
| Kazakhstan | – | – | – | 0 | – | – | – | – | – | 360 | 109 | (30.3) | 318 | 98 | (30.8) |
| Kyrgyzstan | 7 | 1 | (14.3) | 14 | 3 | (21.4) | – | – | – | 43 | 12 | (27.9) | 32 | 5 | (15.6) |
| Moldova | – | – | – | – | – | – | – | – | – | – | – | – | 9 | 3 | (33.3) |
| Monaco | – | – | – | – | – | – | – | – | – | 3 | 3 | (100.0) | – | – | – |
| Montenegro | 0 | – | – | 2 | 0 | (0.0) | 0 | – | – | 0 | – | – | 0 | – | – |
| Russia | – | – | – | – | – | – | 1318 | 344 | (26.1) | 1965 | 520 | (26.5) | 2209 | 687 | (31.1) |
| San Marino | – | – | – | – | – | – | – | – | – | – | – | – | 0 | – | – |
| Serbia | 0 | – | – | 3 | 3 | (100.0) | 1 | 1 | (100.0) | 0 | – | – | 0 | – | – |
| Serbia excluding UN Administered Province of Kosovo ^a | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| UN Administered Province of Kosovo ^a | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Switzerland | – | – | – | – | – | – | – | – | – | – | – | – | 1 | 0 | (0.0) |
| Tajikistan | – | – | – | 0 | – | – | 1 | 1 | (100.0) | 4 | 3 | (75.0) | 0 | – | – |
| Turkey | 3 | 2 | (66.7) | 1 | 1 | (100.0) | 6 | 4 | (66.7) | 3 | 1 | (33.3) | 2 | 0 | (0.0) |
| Turkmenistan | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ukraine | – | – | – | – | – | – | – | – | – | – | – | – | 1097 | 278 | (25.3) |
| Uzbekistan | 16 | 0 | (0.0) | 8 | 1 | (12.5) | 21 | 3 | (14.3) | – | – | – | – | – | – |
| Subtotal non-EU/EEA | 66 | 12 | (18.2) | 49 | 11 | (22.4) | 1430 | 382 | (26.7) | 2614 | 713 | (27.3) | 4236 | 1267 | (29.9) |
| Total European Region | 181 | 34 | (18.8) | 191 | 39 | (20.4) | 1569 | 410 | (26.1) | 2765 | 744 | (26.9) | 4404 | 1295 | (29.4) |
| Subtotal 18 HPC | 165 | 26 | (15.8) | 157 | 23 | (14.6) | 1537 | 395 | (25.7) | 2742 | 733 | (26.7) | 4375 | 1286 | (29.4) |

^a 'European Region' comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries presented in italics.

XDR TB – Extensively drug-resistant tuberculosis.

^a In accordance with the UN Security Council Resolution No. 1244 (1999).

Table XIV: Treatment success after 36 months of XDR TB cases notified in European Region, 2009–2013

| Country | 2009 | | | 2010 | | | 2011 | | | 2012 | | | 2013 | | |
|---------------------|--------------|-----------|---------------|--------------|-----------|---------------|--------------|-----------|---------------|--------------|-----------|---------------|--------------|-----------|---------------|
| | XDR TB cases | Success | | XDR TB cases | Success | | XDR TB cases | Success | | XDR TB cases | Success | | XDR TB cases | Success | |
| | | N | (%) |
| EU/EEA | | | | | | | | | | | | | | | |
| Austria | 2 | 1 | (50.0) | 1 | 1 | (100.0) | 7 | 4 | (57.1) | 7 | 2 | (28.6) | 3 | 2 | (66.7) |
| Belgium | 3 | 2 | (66.7) | 2 | 2 | (100.0) | 3 | 3 | (100.0) | 2 | 2 | (100.0) | – | – | – |
| <i>Bulgaria</i> | 1 | 0 | (0.0) | 1 | 1 | (100.0) | – | – | (100.0) | 5 | 1 | (20.0) | 4 | 0 | (0.0) |
| Croatia | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Cyprus | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Czech Republic | 1 | 0 | (0.0) | 1 | 1 | (100.0) | 2 | 0 | (0.0) | 1 | 0 | (0.0) | – | – | – |
| Denmark | – | – | – | – | – | – | – | – | – | – | – | – | 1 | 1 | (100.0) |
| <i>Estonia</i> | 8 | 1 | (12.5) | 11 | 5 | (45.5) | 15 | 6 | (45.5) | 3 | 1 | (25.0) | 10 | 5 | (50.0) |
| Finland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| France | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Germany | – | – | – | – | – | – | 1 | 1 | – | 1 | 0 | (0.0) | 3 | 0 | (0.0) |
| Greece | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Hungary | – | – | – | 2 | 0 | (0.0) | 0 | 0 | (0.0) | 2 | 1 | (50.0) | 1 | 0 | (0.0) |
| Iceland | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Ireland | – | – | – | – | – | – | – | – | – | – | – | – | 1 | 1 | (100.0) |
| Italy | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Latvia</i> | 16 | 9 | (56.3) | 13 | 9 | (69.2) | 12 | 7 | (69.2) | 17 | 9 | (52.9) | 15 | 11 | (73.3) |
| Liechtenstein | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| <i>Lithuania</i> | 4 | 1 | (25.0) | 50 | 3 | (6.0) | 52 | 11 | (6.0) | 52 | 6 | (11.5) | 47 | 11 | (23.4) |
| Luxembourg | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Malta | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Netherlands | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Norway | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Poland | 1 | 0 | (0.0) | 1 | 1 | (100.0) | 1 | 0 | (0.0) | – | – | – | 1 | 0 | (0.0) |
| Portugal | – | – | – | 4 | 3 | – | 9 | 7 | (75.0) | 4 | 4 | (100.0) | 4 | 4 | (100.0) |
| <i>Romania</i> | 26 | 1 | (3.8) | 26 | 2 | (7.7) | 34 | 6 | (7.4) | 41 | 5 | (12.2) | 56 | 11 | (19.6) |
| Slovakia | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Slovenia | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Spain | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sweden | 0 | – | – | – | – | – | 0 | – | – | 2 | 2 | (100.0) | 2 | 2 | (100.0) |
| United Kingdom | 2 | 1 | (50.0) | 3 | 2 | (66.7) | 6 | 3 | (66.7) | 2 | 1 | (50.0) | 3 | 3 | (100.0) |
| Total EU/EEA | 64 | 16 | (25.0) | 115 | 30 | (26.1) | 142 | 48 | (33.8) | 139 | 34 | (24.5) | 151 | 51 | (33.8) |

WHO European Region 5 TB high-priority countries presented in italics.
XDR TB – Extensively drug-resistant tuberculosis.



8. Country profiles



| | | | | | |
|----|------------------------|----|---|----|----------------|
| AD | Andorra | GE | Georgia | PL | Poland |
| AL | Albania | HR | Croatia | PT | Portugal |
| AM | Armenia | HU | Hungary | RO | Romania |
| AT | Austria | IE | Ireland | RS | Serbia |
| AZ | Azerbaijan | IL | Israel | RU | Russia |
| BA | Bosnia and Herzegovina | IS | Iceland | SE | Sweden |
| BE | Belgium | IT | Italy | SI | Slovenia |
| BG | Bulgaria | KG | Kyrgyzstan | SK | Slovakia |
| BY | Belarus | KZ | Kazakhstan | TJ | Tajikistan |
| CH | Switzerland | LT | Lithuania | TM | Turkmenistan |
| CY | Cyprus | LU | Luxembourg | TR | Turkey |
| CZ | Czech Republic | LV | Latvia | UA | Ukraine |
| DE | Germany | MD | Moldova | UK | United Kingdom |
| DK | Denmark | ME | Montenegro | UZ | Uzbekistan |
| EE | Estonia | MK | former Yugoslav Republic of Macedonia, the | | |
| EL | Greece | MT | Malta | | |
| ES | Spain | NL | Netherlands | | |
| FI | Finland | NO | Norway | | |
| FR | France | | | | |

Albania

Population estimate 2016 by UN Statistical Database: 2926348

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 415 |
| Notification rate per 100 000 | 14.2 |
| New* & relapses | 415 |
| New* & relapses notification rate per 100 000 | 14.2 |
| Pulmonary | 301 (72.5%) |
| of which smear positive | - |
| of which laboratory confirmed | 207 (68.8%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 41.6 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 405 (97.6%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 40 (19.3%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 7-1-14 |
| Pulmonary MDR TB cases notified | 1 (2.5%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR | 4 - |
| of which XDR TB cases | 0 - |
| TB cases tested for HIV | 223 (53.7%) |
| HIV-positive TB cases | 6 (3.3%) |
| of these on antiretroviral therapy | 6 (100.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 409 | 0 |
| Success | 354 (86.6%) | - |
| Died | 11 (2.7%) | - |
| Failed | 3 (0.7%) | - |
| Lost to follow-up | 21 (5.1%) | - |
| Not evaluated | 20 (4.9%) | - |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 include new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2007-2016*



* 2007-2011 cohorts include new cases only.

Andorra

Population estimate 2016 by UN Statistical Database: 77 281

Tuberculosis case notifications, 2016

| | |
|---|------------|
| Total number of cases | 4 |
| Notification rate per 100 000 | 5.2 |
| New* & relapses | 4 |
| New* & relapses notification rate per 100 000 | 5.2 |
| Pulmonary | 3 (75.0%) |
| of which smear positive | - |
| of which laboratory confirmed | 2 (66.7%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 42.5 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 4 (100.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-----------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 1 (50.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 0-0-3 |
| Pulmonary MDR TB cases notified | 0 (0.0%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR | 0 - |
| of which XDR TB cases | - - |
| TB cases tested for HIV | 0 (0.0%) |
| HIV-positive TB cases | - - |
| of these on antiretroviral therapy | - - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 4 | 0 |
| Success | 4 (100%) | - - |
| Died | 0 (0.0%) | - - |
| Failed | 0 (0.0%) | - - |
| Lost to follow-up | 0 (0.0%) | - - |
| Not evaluated | 0 (0.0%) | - - |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016



TB-HIV co-infection, 2007-2016



* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016

No MDR cases reported

Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Armenia

Population estimate 2016 by UN Statistical Database: 2924 816

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 1080 |
| Notification rate per 100 000 | 36.9 |
| New* & relapses | 1027 |
| New* & relapses notification rate per 100 000 | 35.1 |
| Pulmonary | 829 (80.7%) |
| of which smear positive | - |
| of which laboratory confirmed | 438 (52.8%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 44.1 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 818 (75.7%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|---------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 457 (100.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 180-160-210 |
| Pulmonary MDR TB cases notified | 115 (25.2%) |
| of which XDR TB cases | 6 (5.2%) |
| Notified MDR | 128 - |
| of which XDR TB cases | 29 - |
| TB cases tested for HIV | 1027 (100.0%) |
| HIV-positive TB cases | 57 (5.6%) |
| of these on antiretroviral therapy | 57 (100.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 910 | 118 |
| Success | 721 (79.2%) | 68 (57.6%) |
| Died | 47 (5.2%) | 8 (6.8%) |
| Failed | 11 (1.2%) | 19 (16.1%) |
| Lost to follow-up | 131 (14.4%) | 23 (19.5%) |
| Not evaluated | 0 (0.0%) | 0 (0.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2006-2011 cohorts include new cases only.

Austria

Total population at 22 September 2017 by EUROSTAT: 8 690 076

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 634 |
| Notification rate per 100 000 | 7.3 |
| New* & relapses | 619 |
| New* & relapses notification rate per 100 000 | 7.1 |
| Pulmonary | 483 (76.1%) |
| of which microscopy-positive | 178 (36.9%) |
| of which laboratory confirmed | 384 (79.5%) |
| Laboratory-confirmed TB cases | 489 (77.0%) |
| Mean age of new native TB cases | 57.3 years |
| Mean age of new foreign TB cases | 33.5 years |
| Foreign origin of all TB cases | 424 (66.8%) |
| New (not previously treated) | 449 (70.7%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | - |
| Case-linked data reporting | Yes |
| Cases with DST results | 473 (96.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 16-6-26 |
| Pulmonary MDR TB cases notified | 14 (3.7%) |
| of which XDR TB cases | 2 (14.3%) |
| Notified MDR TB | 16 (3.4%) |
| of which XDR TB cases | 2 (12.5%) |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 267 | 20 |
| Success | 187 (70.0%) | 13 (65.0%) |
| Died | 17 (6.4%) | 0 (0.0%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 2 (0.7%) | 1 (5.0%) |
| Still on treatment | 27 (10.1%) | 1 (5.0%) |
| Not evaluated | 34 (12.7%) | 5 (25.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016



New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016

Data not available

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Azerbaijan

Population estimate 2016 by UN Statistical Database: 9725376

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 6707 |
| Notification rate per 100 000 | 69.0 |
| New* & relapses | 5159 |
| New* & relapses notification rate per 100 000 | 53.0 |
| Pulmonary | 4122 (79.9%) |
| of which smear positive | - |
| of which laboratory confirmed | 2529 (61.4%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 28.2 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 12 (0.2%) |
| New (not previously treated) | 3793 (56.6%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|----------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 2614 (103.4%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 1500-1400-1600 |
| Pulmonary MDR TB cases notified | 777 (29.7%) |
| of which XDR TB cases | 71 (13.3%) |
| Notified MDR | 925 - |
| of which XDR TB cases | 77 - |
| TB cases tested for HIV | 4722 (91.5%) |
| HIV-positive TB cases | 99 (2.1%) |
| of these on antiretroviral therapy | 78 (78.8%) |


* National coverage 100% or culturing 90%. C+/All TB cases 50%. DST done for C+ 75%. EQA 95%.
** More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | Bacteriologically confirmed new TB cases in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 1475 | 745 |
| Success | 1221 (82.8%) | 441 (59.2%) |
| Died | 49 (3.3%) | 127 (17.0%) |
| Failed | 34 (2.3%) | 135 (18.1%) |
| Lost to follow-up | 132 (8.9%) | 42 (5.6%) |
| Not evaluated | 39 (2.6%) | 0 (0.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.
** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome of new TB cases, 2006-2015



Belarus

Population estimate 2016 by UN Statistical Database: 9480042

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 3598 |
| Notification rate per 100 000 | 38.0 |
| New* & relapses | 3211 |
| New* & relapses notification rate per 100 000 | 33.9 |
| Pulmonary | 2964 (92.3%) |
| of which smear positive | - |
| of which laboratory confirmed | 2350 (79.3%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 44.2 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 2653 (73.7%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|----------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 2555 (108.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 1600-1500-1600 |
| Pulmonary MDR TB cases notified | 1222 (47.8%) |
| of which XDR TB cases | 572 (46.8%) |
| Notified MDR | 1543 - |
| of which XDR TB cases | 572 - |
| TB cases tested for HIV | 3148 (98.0%) |
| HIV-positive TB cases | 275 (8.7%) |
| of these on antiretroviral therapy | 229 (83.3%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | | |
|----------------------------|---|--|---------|
| Geographical coverage | National | | |
| Outcome cohort | New and relapsed TB cases notified in 2014* | All MDR TB cases enrolled into MDR treatment in 2013** | |
| Case-linked data reporting | Yes | | |
| Cases notified | 2525 | 1472 | |
| Success | 2243 (88.8%) | 872 | (59.2%) |
| Died | 76 (3.0%) | 126 | (8.6%) |
| Failed | 72 (2.9%) | 289 | (19.6%) |
| Lost to follow-up | 77 (3.0%) | 181 | (12.3%) |
| Not evaluated | 57 (2.3%) | 4 | (0.3%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases - notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Belgium

Total population at 22 September 2017 by EUROSTAT: 11311117

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 1047 |
| Notification rate per 100 000 | 9.3 |
| New* & relapses | 986 |
| New* & relapses notification rate per 100 000 | 8.7 |
| Pulmonary | 715 (68.3%) |
| of which microscopy-positive | 331 (46.3%) |
| of which laboratory confirmed | 593 (82.9%) |
| Laboratory-confirmed TB cases | 801 (76.5%) |
| Mean age of new native TB cases | 45.2 years |
| Mean age of new foreign TB cases | 35.5 years |
| Foreign origin of all TB cases | 547 (52.2%) |
| New (not previously treated) | 757 (72.3%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 769 (96.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 16-6-26 |
| Pulmonary MDR TB cases notified | 9 (1.6%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR TB | 10 (1.3%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 479 (45.7%) |
| HIV-positive TB cases of these on antiretroviral therapy | 33 (6.9%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 422 | 11 |
| Success | 351 (79.4%) | 6 (54.5%) |
| Died | 34 (7.7%) | 1 (9.1%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 33 (7.5%) | 0 (0.0%) |
| Still on treatment | 12 (2.7%) | 4 (36.4%) |
| Not evaluated | 12 (2.7%) | 0 (0.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Bosnia and Herzegovina

Population estimate 2016 by UN Statistical Database: 3516 816

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 907 |
| Notification rate per 100 000 | 25.8 |
| New* & relapses | 907 |
| New* & relapses notification rate per 100 000 | 25.8 |
| Pulmonary | 792 (87.3%) |
| of which smear positive | - |
| of which laboratory confirmed | 597 (75.4%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 40.0 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 829 (91.4%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 597 (100.0%) |
| Estimated RR-TB among notified pulmonary cases N _i (best-low-high) | 0-0-0 |
| Pulmonary MDR TB cases notified | 0 (0.0%) |
| of which XDR TB cases | 0 |
| Notified MDR | 0 |
| of which XDR TB cases | 0 |
| TB cases tested for HIV | 1 (0.1%) |
| HIV-positive TB cases | 1 (100.0%) |
| of these on antiretroviral therapy | 1 (100.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| Geographical coverage | National | |
|----------------------------|---|--|
| | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Outcome cohort | | |
| Case-linked data reporting | Yes | |
| Cases notified | 1092 | 3 |
| Success | 707 (64.7%) | 2 (66.7%) |
| Died | 84 (7.7%) | 1 (33.3%) |
| Failed | 19 (1.7%) | 0 (0.0%) |
| Lost to follow-up | 2 (0.2%) | 0 (0.0%) |
| Not evaluated | 280 (25.6%) | 0 (0.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007–2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007–2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007–2016




TB-HIV co-infection, 2007–2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new and relapsed TB cases, 2006–2015*



* 2005–2011 cohorts include new cases only.

Bulgaria

Total population at 22 September 2017 by EUROSTAT: 7153784

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 1603 |
| Notification rate per 100 000 | 22.4 |
| New* & relapses | 1525 |
| New* & relapses notification rate per 100 000 | 21.3 |
| Pulmonary | 1186 (74.0%) |
| of which microscopy-positive | 618 (52.1%) |
| of which laboratory confirmed | 745 (62.8%) |
| Laboratory-confirmed TB cases | 764 (47.7%) |
| Mean age of new native TB cases | 46.1 years |
| Mean age of new foreign TB cases | 26.0 years |
| Foreign origin of all TB cases | 4 (0.2%) |
| New (not previously treated) | 1416 (88.3%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 670 (87.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 44-27-61 |
| Pulmonary MDR TB cases notified | 19 (2.9%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR | 19 (2.8%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 1260 (78.6%) |
| HIV-positive TB cases | 0 (0.0%) |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 663 | 37 |
| Success | 574 (86.6%) | 18 (48.6%) |
| Died | 56 (8.4%) | 12 (32.4%) |
| Failed | 10 (1.5%) | 0 (0.0%) |
| Lost to follow-up | 18 (2.7%) | 5 (13.5%) |
| Still on treatment | 2 (0.3%) | 0 (0.0%) |
| Not evaluated | 3 (0.5%) | 2 (5.4%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015*



Croatia

Total population at 22 September 2017 by EUROSTAT: 4 190 669

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 460 |
| Notification rate per 100 000 | 11.0 |
| New* & relapses | 449 |
| New* & relapses notification rate per 100 000 | 10.7 |
| Pulmonary | 307 (66.7%) |
| of which microscopy-positive | 0 (0.0%) |
| of which laboratory confirmed | 193 (62.9%) |
| Laboratory-confirmed TB cases | 262 (57.0%) |
| Mean age of new native TB cases | 52.5 years |
| Mean age of new foreign TB cases | 66.3 years |
| Foreign origin of all TB cases | 3 (0.7%) |
| New (not previously treated) | 293 (63.7%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 262 (100.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 0-0-0 |
| Pulmonary MDR TB cases notified | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| Notified MDR | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| TB cases tested for HIV | - - |
| HIV-positive TB cases | - - |
| of these on antiretroviral therapy | - - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 280 | 2 |
| Success | 35 (12.5%) | 0 (0.0%) |
| Died | 28 (10.0%) | 1 (50.0%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 0 (0.0%) | 0 (0.0%) |
| Still on treatment | 1 (0.4%) | 0 (0.0%) |
| Not evaluated | 216 (77.1%) | 1 (50.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007–2016



New and relapsed TB cases – notification rates by age group, 2007–2016




Tuberculosis cases by geographical origin, 2007–2016




TB-HIV co-infection, 2007–2016

Data not available

MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006–2015



Cyprus

Total population at 22 September 2017 by EUROSTAT: 848 319

Tuberculosis case notifications, 2016

| | |
|---|------------|
| Total number of cases | 60 |
| Notification rate per 100 000 | 7.1 |
| New* & relapses | 57 |
| New* & relapses notification rate per 100 000 | 6.7 |
| Pulmonary | 51 (85.0%) |
| of which microscopy-positive | 23 (45.1%) |
| of which laboratory confirmed | 39 (76.5%) |
| Laboratory-confirmed TB cases | 42 (70.0%) |
| Mean age of new native TB cases | 37.3 years |
| Mean age of new foreign TB cases | 36.9 years |
| Foreign origin of all TB cases | 56 (93.3%) |
| New (not previously treated) | 55 (91.7%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 41 (97.6%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 0-0-0 |
| Pulmonary MDR TB cases notified | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| Notified MDR | 1 (2.4%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 48 (80.0%) |
| HIV-positive TB cases of these on antiretroviral therapy | 0 (0.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 34 | 0 |
| Success | 18 (52.9%) | 0 (0.0%) |
| Died | 3 (8.8%) | 0 (0.0%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 2 (5.9%) | 0 (0.0%) |
| Still on treatment | 2 (5.9%) | 0 (0.0%) |
| Not evaluated | 9 (26.5%) | 0 (0.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Czech Republic

Total population at 22 September 2017 by EUROSTAT: 10538 275

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 516 |
| Notification rate per 100 000 | 4.9 |
| New* & relapses | 511 |
| New* & relapses notification rate per 100 000 | 4.8 |
| Pulmonary | 446 (86.4%) |
| of which microscopy-positive | 212 (47.5%) |
| of which laboratory confirmed | 349 (78.3%) |
| Laboratory-confirmed TB cases | 392 (76.0%) |
| Mean age of new native TB cases | 55.7 years |
| Mean age of new foreign TB cases | 39.7 years |
| Foreign origin of all TB cases | 151 (29.3%) |
| New (not previously treated) | 490 (95.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 367 (93.6%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 13-3-22 |
| Pulmonary MDR TB cases notified | 6 (1.8%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR TB | 6 (1.6%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 205 (39.7%) |
| HIV-positive TB cases of these on antiretroviral therapy | 5 (2.4%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 332 | 5 |
| Success | 222 (66.9%) | 2 (40.0%) |
| Died | 72 (21.7%) | 0 (0.0%) |
| Failed | 2 (0.6%) | 0 (0.0%) |
| Lost to follow-up | 15 (4.5%) | 1 (20.0%) |
| Still on treatment | 12 (3.6%) | 0 (0.0%) |
| Not evaluated | 9 (2.7%) | 2 (40.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Denmark

Total population at 22 September 2017 by EUROSTAT: 5 659 715

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 330 |
| Notification rate per 100 000 | 5.8 |
| New* & relapses | 292 |
| New* & relapses notification rate per 100 000 | 5.2 |
| Pulmonary | 262 (79.4%) |
| of which microscopy-positive | 122 (46.6%) |
| of which laboratory confirmed | 208 (79.4%) |
| Laboratory-confirmed TB cases | 258 (78.2%) |
| Mean age of new native TB cases | 44.7 years |
| Mean age of new foreign TB cases | 38.0 years |
| Foreign origin of all TB cases | 221 (67.0%) |
| New (not previously treated) | 292 (88.5%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 252 (97.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 1-0-4 |
| Pulmonary MDR TB cases notified | 3 (1.5%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR TB | 4 (1.6%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 150 (45.5%) |
| HIV-positive TB cases of these on antiretroviral therapy | 9 (6.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 209 | 2 |
| Success | 100 (47.8%) | 1 (50.0%) |
| Died | 8 (3.8%) | 0 (0.0%) |
| Failed | 6 (2.9%) | 0 (0.0%) |
| Lost to follow-up | 1 (0.5%) | 0 (0.0%) |
| Still on treatment | 8 (3.8%) | 0 (0.0%) |
| Not evaluated | 86 (41.1%) | 1 (50.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Estonia

Total population at 22 September 2017 by EUROSTAT: 1315944

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 192 |
| Notification rate per 100 000 | 14.6 |
| New* & relapses | 188 |
| New* & relapses notification rate per 100 000 | 14.3 |
| Pulmonary | 177 (92.2%) |
| of which microscopy-positive | 90 (50.8%) |
| of which laboratory confirmed | 149 (84.2%) |
| Laboratory-confirmed TB cases | 156 (81.3%) |
| Mean age of new native TB cases | 50.2 years |
| Mean age of new foreign TB cases | 61.2 years |
| Foreign origin of all TB cases | 42 (21.9%) |
| New (not previously treated) | 167 (87.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 152 (97.4%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 34-23-45 |
| Pulmonary MDR TB cases notified | 23 (15.9%) |
| of which XDR TB cases | 7 (30.4%) |
| Notified MDR TB | 24 (15.8%) |
| of which XDR TB cases | 7 (29.2%) |
| TB cases tested for HIV | 184 (95.8%) |
| HIV-positive TB cases | 22 (12.0%) |
| of these on antiretroviral therapy | 20 (90.9%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 133 | 50 |
| Success | 98 (73.7%) | 29 (58.0%) |
| Died | 20 (15.0%) | 10 (20.0%) |
| Failed | 0 (0.0%) | 3 (6.0%) |
| Lost to follow-up | 3 (2.3%) | 3 (6.0%) |
| Still on treatment | 11 (8.3%) | 3 (6.0%) |
| Not evaluated | 1 (0.8%) | 2 (4.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Finland

Total population at 22 September 2017 by EUROSTAT: 5,487,308

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 236 |
| Notification rate per 100 000 | 4.3 |
| New* & relapses | 225 |
| New* & relapses notification rate per 100 000 | 4.1 |
| Pulmonary | 175 (74.2%) |
| of which microscopy-positive | 55 (31.4%) |
| of which laboratory confirmed | 136 (77.7%) |
| Laboratory-confirmed TB cases | 186 (78.8%) |
| Mean age of new native TB cases | 67.4 years |
| Mean age of new foreign TB cases | 33.4 years |
| Foreign origin of all TB cases | 111 (47.0%) |
| New (not previously treated) | 219 (92.8%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | - |
| Case-linked data reporting | Yes |
| Cases with DST results | 183 (98.4%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 3-0-6 |
| Pulmonary MDR TB cases notified | 3 (2.2%) |
| of which XDR TB cases | 1 (33.3%) |
| Notified MDR TB | 6 (3.3%) |
| of which XDR TB cases | 1 (16.7%) |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| Geographical coverage | National | |
|----------------------------|---|-------------------------------------|
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 161 | 8 |
| Success | 86 (53.4%) | 0 (0.0%) |
| Died | 14 (8.7%) | 0 (0.0%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 0 (0.0%) | 0 (0.0%) |
| Still on treatment | 2 (1.2%) | 0 (0.0%) |
| Not evaluated | 59 (36.6%) | 8 (100.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007–2016



New and relapsed TB cases – notification rates by age group, 2007–2016




Tuberculosis cases by geographical origin, 2007–2016




TB-HIV co-infection, 2007–2016

Data not available

MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006–2015



former Yugoslav Republic of Macedonia, the

Population estimate 2016 by UN Statistical Database: 2081206

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 267 |
| Notification rate per 100 000 | 12.8 |
| New* & relapses | 263 |
| New* & relapses notification rate per 100 000 | 12.6 |
| Pulmonary | 211 (80.2%) |
| of which smear positive | - |
| of which laboratory confirmed | 178 (84.4%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 41.3 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 8 (3.0%) |
| New (not previously treated) | 243 (91.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 143 (80.3%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 3-0-6 |
| Pulmonary MDR TB cases notified | 2 (1.4%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR | 2 - |
| of which XDR TB cases | 0 - |
| TB cases tested for HIV | 207 (78.7%) |
| HIV-positive TB cases of these on antiretroviral therapy | 0 (0.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 282 | 3 |
| Success | 243 (86.2%) | 1 (33.3%) |
| Died | 25 (8.9%) | 0 (0.0%) |
| Failed | 3 (1.1%) | 0 (0.0%) |
| Lost to follow-up | 7 (2.5%) | 2 (66.7%) |
| Not evaluated | 4 (1.4%) | 0 (0.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

France

Total population at 22 September 2017 by EUROSTAT: 66 488 186

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 4 958 |
| Notification rate per 100 000 | 7.5 |
| New* & relapses | 4 675 |
| New* & relapses notification rate per 100 000 | 7.0 |
| Pulmonary | 3 319 (66.9%) |
| of which microscopy-positive | - |
| of which laboratory confirmed | 3 120 (94.0%) |
| Laboratory-confirmed TB cases | 4 197 (84.7%) |
| Mean age of new native TB cases | . years |
| Mean age of new foreign TB cases | . years |
| Foreign origin of all TB cases | 2 758 (55.6%) |
| New (not previously treated) | - |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|---------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | - |
| Case-linked data reporting | No |
| Cases with DST results | 4 197 (84.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 63-47-79 |
| Pulmonary MDR TB cases notified | 51 (1.6%) |
| of which XDR TB cases | 6 (11.8%) |
| Notified MDR TB | 69 |
| of which XDR TB cases | 6 (6.3%) |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |


* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

Data not available


Tuberculosis notification rates by treatment history, 2007-2016



New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016

Data not available

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Georgia

Population estimate 2016 by UN Statistical Database: 3925405

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 3330 |
| Notification rate per 100 000 | 84.8 |
| New* & relapses | 2983 |
| New* & relapses notification rate per 100 000 | 76.0 |
| Pulmonary | 2371 (79.5%) |
| of which smear positive | - |
| of which laboratory confirmed | 1998 (84.3%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 42.2 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 2463 (74.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 1791 (89.6%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 460-420-500 |
| Pulmonary MDR TB cases notified | 296 (16.5%) |
| of which XDR TB cases | 52 (17.6%) |
| Notified MDR | 401 - |
| of which XDR TB cases | 56 - |
| TB cases tested for HIV | 2866 (96.1%) |
| HIV-positive TB cases | 61 (2.1%) |
| of these on antiretroviral therapy | 56 (91.8%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | | |
|----------------------------|---|--|---------|
| Geographical coverage | National | | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** | |
| Case-linked data reporting | Yes | | |
| Cases notified | 2841 | 411 | |
| Success | 2386 (84.0%) | 201 | (48.9%) |
| Died | 110 (3.9%) | 32 | (7.8%) |
| Failed | 60 (2.1%) | 27 | (6.6%) |
| Lost to follow-up | 225 (7.9%) | 118 | (28.7%) |
| Not evaluated | 60 (2.1%) | 33 | (8.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New TB cases - notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Germany

Total population at 22 September 2017 by EUROSTAT: 82 175 684

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 5915 |
| Notification rate per 100 000 | 7.2 |
| New* & relapses | 5737 |
| New* & relapses notification rate per 100 000 | 7.0 |
| Pulmonary | 4397 (74.3%) |
| of which microscopy-positive | 1404 (31.9%) |
| of which laboratory confirmed | 3253 (74.0%) |
| Laboratory-confirmed TB cases | 4164 (70.4%) |
| Mean age of new native TB cases | 62.4 years |
| Mean age of new foreign TB cases | 35.7 years |
| Foreign origin of all TB cases | 4125 (69.7%) |
| New (not previously treated) | 5589 (94.5%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | - |
| Case-linked data reporting | Yes |
| Cases with DST results | 3757 (90.2%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 160240 |
| Pulmonary MDR TB cases notified | 90 (3.0%) |
| of which XDR TB cases | 5 (8.6%) |
| Notified MDR TB | 101 (2.7%) |
| of which XDR TB cases | 5 (7.8%) |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| Geographical coverage | National | |
|----------------------------|---|-------------------------------------|
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 312 | 92 |
| Success | 176 (56.4%) | 29 (31.5%) |
| Died | 29 (9.3%) | 9 (9.8%) |
| Failed | 0 (0.0%) | 1 (1.1%) |
| Lost to follow-up | 4 (1.3%) | 3 (3.3%) |
| Still on treatment | 32 (10.3%) | 12 (13.0%) |
| Not evaluated | 71 (22.8%) | 38 (41.3%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007–2016



New and relapsed TB cases – notification rates by age group, 2007–2016




Tuberculosis cases by geographical origin, 2007–2016




TB-HIV co-infection, 2007–2016

Data not available

MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006–2015



Greece

Total population at 22 September 2017 by EUROSTAT: 10783748

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 443 |
| Notification rate per 100 000 | 4.1 |
| New* & relapses | 407 |
| New* & relapses notification rate per 100 000 | 3.8 |
| Pulmonary | 394 (88.9%) |
| of which microscopy-positive | 223 (56.6%) |
| of which laboratory confirmed | 227 (57.6%) |
| Laboratory-confirmed TB cases | 246 (55.5%) |
| Mean age of new native TB cases | 61.1 years |
| Mean age of new foreign TB cases | 35.1 years |
| Foreign origin of all TB cases | 189 (42.7%) |
| New (not previously treated) | 407 (91.9%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | - |
| Case-linked data reporting | Yes |
| Cases with DST results | 124 (50.4%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 10-0-23 |
| Pulmonary MDR TB cases notified | 5 (4.3%) |
| of which XDR TB cases | 0 - |
| Notified MDR TB | 5 (4.0%) |
| of which XDR TB cases | 0 - |
| TB cases tested for HIV | - - |
| HIV-positive TB cases | - - |
| of these on antiretroviral therapy | - - |


* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Data not available


Tuberculosis notification rates by treatment history, 2007–2016




New and relapsed TB cases – notification rates by age group, 2007–2016




Tuberculosis cases by geographical origin, 2007–2016



TB-HIV co-infection, 2007–2016



MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006–2015

Data not available

Hungary

Total population at 22 September 2017 by EUROSTAT: 9855571

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 786 |
| Notification rate per 100 000 | 8.0 |
| New* & relapses | 737 |
| New* & relapses notification rate per 100 000 | 7.5 |
| Pulmonary | 757 (96.3%) |
| of which microscopy-positive | 252 (33.3%) |
| of which laboratory confirmed | 396 (52.3%) |
| Laboratory-confirmed TB cases | 404 (51.4%) |
| Mean age of new native TB cases | 53.7 years |
| Mean age of new foreign TB cases | 36.6 years |
| Foreign origin of all TB cases | 30 (3.8%) |
| New (not previously treated) | 677 (86.1%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 340 (84.2%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 30-17-43 |
| Pulmonary MDR TB cases notified | 18 (5.4%) |
| of which XDR TB cases | 7 (46.7%) |
| Notified MDR TB | 18 (5.3%) |
| of which XDR TB cases | 7 (46.7%) |
| TB cases tested for HIV | 19 (2.4%) |
| HIV-positive TB cases of these on antiretroviral therapy | 1 (5.3%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 366 | 3 |
| Success | 224 (61.2%) | 3 (100.0%) |
| Died | 55 (15.0%) | 0 (0.0%) |
| Failed | 4 (1.1%) | 0 (0.0%) |
| Lost to follow-up | 48 (13.1%) | 0 (0.0%) |
| Still on treatment | 17 (4.6%) | 0 (0.0%) |
| Not evaluated | 18 (4.9%) | 0 (0.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Iceland

Total population at 22 September 2017 by EUROSTAT: 332529

Tuberculosis case notifications, 2016

| | |
|---|------------|
| Total number of cases | 6 |
| Notification rate per 100 000 | 1.8 |
| New* & relapses | 6 |
| New* & relapses notification rate per 100 000 | 1.8 |
| Pulmonary | 6 (100.0%) |
| of which microscopy-positive | 5 (83.3%) |
| of which laboratory confirmed | 5 (83.3%) |
| Laboratory-confirmed TB cases | 5 (83.3%) |
| Mean age of new native TB cases | 69.0 years |
| Mean age of new foreign TB cases | 37.3 years |
| Foreign origin of all TB cases | 4 (66.7%) |
| New (not previously treated) | 6 (100.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 4 (80.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 0-0-4 |
| Pulmonary MDR TB cases notified | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| Notified MDR TB | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| TB cases tested for HIV | 6 (100.0%) |
| HIV-positive TB cases of these on antiretroviral therapy | 0 (0.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 3 | 0 |
| Success | 3 (100.0%) | 0 |
| Died | 0 (0.0%) | 0 |
| Failed | 0 (0.0%) | 0 |
| Lost to follow-up | 0 (0.0%) | 0 |
| Still on treatment | 0 (0.0%) | 0 |
| Not evaluated | 0 (0.0%) | 0 |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



* Not reported any new culture positive pulmonary cases for 2011.

Ireland

Total population at 22 September 2017 by EUROSTAT: 4 724 720

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 318 |
| Notification rate per 100 000 | 6.7 |
| New* & relapses | 293 |
| New* & relapses notification rate per 100 000 | 6.2 |
| Pulmonary | 211 (66.4%) |
| of which microscopy-positive | 85 (40.3%) |
| of which laboratory confirmed | 170 (80.6%) |
| Laboratory-confirmed TB cases | 237 (74.5%) |
| Mean age of new native TB cases | 52.7 years |
| Mean age of new foreign TB cases | 35.4 years |
| Foreign origin of all TB cases | 161 (50.6%) |
| New (not previously treated) | 293 (92.1%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 232 (97.9%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 2-0-6 |
| Pulmonary MDR TB cases notified | 6 (3.6%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR TB | 6 (2.6%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 132 (41.5%) |
| HIV-positive TB cases | 4 (3.0%) |
| of these on antiretroviral therapy | 3 (75.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 99 | 2 |
| Success | 68 (68.7%) | 1 (50.0%) |
| Died | 3 (3.0%) | 0 (0.0%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 0 (0.0%) | 0 (0.0%) |
| Still on treatment | 0 (0.0%) | 0 (0.0%) |
| Not evaluated | 28 (28.3%) | 1 (50.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Israel

Population estimate 2016 by UN Statistical Database: 8191828

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 250 |
| Notification rate per 100 000 | 3.1 |
| New* & relapses | 250 |
| New* & relapses notification rate per 100 000 | 3.1 |
| Pulmonary | 184 (73.6%) |
| of which smear positive | - |
| of which laboratory confirmed | 132 (71.7%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 37.4 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 202 (80.8%) |
| New (not previously treated) | 242 (96.8%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 123 (93.2%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 13-5-22 |
| Pulmonary MDR TB cases notified | 9 (7.3%) |
| of which XDR TB cases | 2 (22.2%) |
| Notified MDR | 11 - |
| of which XDR TB cases | 2 - |
| TB cases tested for HIV | 250 (100.0%) |
| HIV-positive TB cases | 18 (7.2%) |
| of these on antiretroviral therapy | 16 (88.9%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 263 | 16 |
| Success | 218 (82.9%) | 12 (75.0%) |
| Died | 19 (7.2%) | 2 (12.5%) |
| Failed | 1 (0.4%) | 0 (0.0%) |
| Lost to follow-up | 8 (3.0%) | 1 (6.3%) |
| Not evaluated | 17 (6.5%) | 1 (6.3%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



* HIV testing data are available for new TB cases in civilian population only.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Italy

Total population at 22 September 2017 by EUROSTAT: 60 655 551

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 4 032 |
| Notification rate per 100 000 | 6.6 |
| New* & relapses | 3 778 |
| New* & relapses notification rate per 100 000 | 6.2 |
| Pulmonary | 2 820 (69.9%) |
| of which microscopy-positive | 1 515 (53.7%) |
| of which laboratory confirmed | 1 967 (69.8%) |
| Laboratory-confirmed TB cases | 2 666 (66.1%) |
| Mean age of new native TB cases | 51.0 years |
| Mean age of new foreign TB cases | 35.9 years |
| Foreign origin of all TB cases | 2 509 (62.2%) |
| New (not previously treated) | 3 778 (93.7%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|----------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | No |
| Cases with DST results | 2 666 (100.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 110-76-150 |
| Pulmonary MDR TB cases notified | 33 (1.7%) |
| of which XDR TB cases | 5 (11.4%) |
| Notified MDR TB | 70 (2.6%) |
| of which XDR TB cases | 7 (12.7%) |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |


* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

Data not available


Tuberculosis notification rates by treatment history, 2007-2016



New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016



TB-HIV co-infection, 2007-2016

Data not available

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015

Data not available

Kazakhstan

Population estimate 2016 by UN Statistical Database: 17987736

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 12658 |
| Notification rate per 100 000 | 70.4 |
| New* & relapses | 12322 |
| New* & relapses notification rate per 100 000 | 68.5 |
| Pulmonary | 10927 (88.7%) |
| of which smear positive | - |
| of which laboratory confirmed | 9679 (88.6%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 40.3 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 153 (1.2%) |
| New (not previously treated) | 9381 (74.1%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|----------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 5213 (53.9%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 3500-3400-3600 |
| Pulmonary MDR TB cases notified | 1231 (23.6%) |
| of which XDR TB cases | - |
| TB cases tested for HIV | 5817 |
| Notified MDR | 386 |
| of which XDR TB cases | 10616 (86.2%) |
| HIV-positive TB cases | 576 (5.4%) |
| of these on antiretroviral therapy | 478 (83.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| Geographical coverage | National | |
|----------------------------|---|--|
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 14 006 | 6 320 |
| Success | 12 691 (90.6%) | 4 813 (76.2%) |
| Died | 674 (4.8%) | 604 (9.6%) |
| Failed | 440 (3.1%) | 371 (5.9%) |
| Lost to follow-up | 201 (1.4%) | 468 (7.4%) |
| Not evaluated | 0 (0.0%) | 64 (1.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases 2006-2015*



* 2005-2011 cohorts include new cases only.

Kyrgyzstan

Population estimate 2016 by UN Statistical Database: 5955734

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 7995 |
| Notification rate per 100 000 | 134.2 |
| New* & relapses | 7026 |
| New* & relapses notification rate per 100 000 | 118.0 |
| Pulmonary | 5514 (78.5%) |
| of which smear positive | - |
| of which laboratory confirmed | 3183 (57.7%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 38.9 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 5702 (71.3%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|----------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 2642 (83.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 2500-2400-2600 |
| Pulmonary MDR TB cases notified | 864 (32.7%) |
| of which XDR TB cases | 72 (8.3%) |
| Notified MDR | 1236 - |
| of which XDR TB cases | 73 - |
| TB cases tested for HIV | 6254 (89.0%) |
| HIV-positive TB cases | 210 (3.4%) |
| of these on antiretroviral therapy | 144 (68.6%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 6139 | 1157 |
| Success | 5063 (82.5%) | 650 (56.2%) |
| Died | 364 (5.9%) | 142 (12.3%) |
| Failed | 138 (2.2%) | 105 (9.1%) |
| Lost to follow-up | 564 (9.2%) | 260 (22.5%) |
| Not evaluated | 10 (0.2%) | 0 (0.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases - notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome of new TB cases, 2006-2015



* 2005-2011 cohorts include new cases only.

Latvia

Total population at 22 September 2017 by EUROSTAT: 1986957

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 660 |
| Notification rate per 100 000 | 33.5 |
| New* & relapses | 641 |
| New* & relapses notification rate per 100 000 | 32.6 |
| Pulmonary | 619 (93.8%) |
| of which microscopy-positive | 265 (42.8%) |
| of which laboratory confirmed | 535 (86.4%) |
| Laboratory-confirmed TB cases | 559 (84.7%) |
| Mean age of new native TB cases | 44.1 years |
| Mean age of new foreign TB cases | 56.6 years |
| Foreign origin of all TB cases | 43 (6.5%) |
| New (not previously treated) | 560 (84.8%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 536 (95.9%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 62-47-78 |
| Pulmonary MDR TB cases notified | 53 (10.4%) |
| of which XDR TB cases | 20 (37.7%) |
| Notified MDR TB | 56 (10.4%) |
| of which XDR TB cases | 21 (37.5%) |
| TB cases tested for HIV | 507 (76.8%) |
| HIV-positive TB cases of these on antiretroviral therapy | 57 (11.2%) / 34 (59.6%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 477 | 70 |
| Success | 383 (80.3%) | 52 (74.3%) |
| Died | 36 (7.5%) | 5 (7.1%) |
| Failed | 0 (0.0%) | 1 (1.4%) |
| Lost to follow-up | 23 (4.8%) | 11 (15.7%) |
| Still on treatment | 33 (6.9%) | 0 (0.0%) |
| Not evaluated | 2 (0.4%) | 1 (1.4%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007–2016




New and relapsed TB cases – notification rates by age group, 2007–2016




Tuberculosis cases by geographical origin, 2007–2016




TB-HIV co-infection, 2007–2016



MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006–2015



Lithuania

Total population at 22 September 2017 by EUROSTAT: 2888558

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 1442 |
| Notification rate per 100 000 | 49.9 |
| New* & relapses | 1347 |
| New* & relapses notification rate per 100 000 | 46.6 |
| Pulmonary | 1327 (92.0%) |
| of which microscopy-positive | 827 (62.3%) |
| of which laboratory confirmed | 1171 (88.2%) |
| Laboratory-confirmed TB cases | 1201 (83.3%) |
| Mean age of new native TB cases | 46.0 years |
| Mean age of new foreign TB cases | 57.3 years |
| Foreign origin of all TB cases | 13 (0.9%) |
| New (not previously treated) | 1150 (79.8%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|---------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 1201 (100.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 260-240-290 |
| Pulmonary MDR TB cases notified | 242 (20.7%) |
| of which XDR TB cases | 58 (24.0%) |
| Notified MDR TB | 244 (20.3%) |
| of which XDR TB cases | 58 (23.8%) |
| TB cases tested for HIV | 1138 (78.9%) |
| HIV-positive TB cases of these on antiretroviral therapy | 41 (3.6%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 894 | 271 |
| Success | 607 (67.9%) | 32 (11.8%) |
| Died | 111 (12.4%) | 59 (21.8%) |
| Failed | 12 (1.3%) | 7 (2.6%) |
| Lost to follow-up | 66 (7.4%) | 37 (13.7%) |
| Still on treatment | 97 (10.9%) | 131 (48.3%) |
| Not evaluated | 1 (0.1%) | 5 (1.8%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Luxembourg

Total population at 22 September 2017 by EUROSTAT: 576 249

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 29 |
| Notification rate per 100 000 | 5.0 |
| New* & relapses | 29 |
| New* & relapses notification rate per 100 000 | 5.0 |
| Pulmonary | 24 (82.8%) |
| of which microscopy-positive | 10 (41.7%) |
| of which laboratory confirmed | 22 (91.7%) |
| Laboratory-confirmed TB cases | 26 (89.7%) |
| Mean age of new native TB cases | 42.9 years |
| Mean age of new foreign TB cases | 49.0 years |
| Foreign origin of all TB cases | 22 (75.9%) |
| New (not previously treated) | 29 (100.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 25 (96.2%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 0-0-0 |
| Pulmonary MDR TB cases notified | 1 (4.8%) |
| of which XDR TB cases | 0 - |
| Notified MDR TB | 1 (4.0%) |
| of which XDR TB cases | 0 - |
| TB cases tested for HIV | 5 (17.2%) |
| HIV-positive TB cases | 2 (39.7%) |
| of these on antiretroviral therapy | - - |


* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

Data not available


Tuberculosis notification rates by treatment history, 2007–2016




New and relapsed TB cases – notification rates by age group, 2007–2016



Tuberculosis cases by geographical origin, 2007–2016




TB-HIV co-infection, 2007–2016*



* No data available for 2006–2009

MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006–2015

Data not available

Malta

Total population at 22 September 2017 by EUROSTAT: 434 403

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 50 |
| Notification rate per 100 000 | 11.5 |
| New* & relapses | 50 |
| New* & relapses notification rate per 100 000 | 11.5 |
| Pulmonary | 37 (74.0%) |
| of which microscopy-positive | 18 (48.6%) |
| of which laboratory confirmed | 33 (89.2%) |
| Laboratory-confirmed TB cases | 42 (84.0%) |
| Mean age of new native TB cases | 85.0 years |
| Mean age of new foreign TB cases | 30.3 years |
| Foreign origin of all TB cases | 48 (96.0%) |
| New (not previously treated) | 50 (100.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 42 (100.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 0-0-4 |
| Pulmonary MDR TB cases notified | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| Notified MDR TB | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| TB cases tested for HIV | 46 (92.0%) |
| HIV-positive TB cases | 8 (17.4%) |
| of these on antiretroviral therapy | 8 (100.0%) |


* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

Data not available


Tuberculosis notification rates by treatment history, 2007-2016



New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




* By nationality for 2000-2006


TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Moldova

Population estimate 2016 by UN Statistical Database: 4 059 608

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 4 134 |
| Notification rate per 100 000 | 101.8 |
| New* & relapses | 3 571 |
| New* & relapses notification rate per 100 000 | 88.0 |
| Pulmonary | 3 235 (90.6%) |
| of which smear positive | - |
| of which laboratory confirmed | 2 019 (62.4%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new native TB cases | 43.3 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 39 (0.9%) |
| New (not previously treated) | 2 846 (68.8%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 1 574 (78.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 1 400-1 300-1 400 |
| Pulmonary MDR TB cases notified | 525 (33.4%) |
| of which XDR TB cases | 42 (8.0%) |
| Notified MDR | 1 031 - |
| of which XDR TB cases | 72 - |
| TB cases tested for HIV | 3 366 (94.3%) |
| HIV-positive TB cases | 293 (8.7%) |
| of these on antiretroviral therapy | 193 (65.9%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | | |
|----------------------------|---|--|---------|
| Geographical coverage | National | | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** | |
| Case-linked data reporting | Yes | | |
| Cases notified | 2 992 | 919 | |
| Success | 2 379 (79.5%) | 457 | (49.7%) |
| Died | 338 (11.3%) | 129 | (14.0%) |
| Failed | 86 (2.9%) | 142 | (15.5%) |
| Lost to follow-up | 137 (4.6%) | 188 | (20.5%) |
| Not evaluated | 52 (1.7%) | 3 | (0.3%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




** Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Montenegro

Population estimate 2016 by UN Statistical Database: 628615

Tuberculosis case notifications, 2016

| | |
|---|------------|
| Total number of cases | 87 |
| Notification rate per 100 000 | 13.8 |
| New* & relapses | 87 |
| New* & relapses notification rate per 100 000 | 13.8 |
| Pulmonary | 77 (88.5%) |
| of which smear positive | - |
| of which laboratory confirmed | 58 (75.3%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 47.6 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 2 (2.3%) |
| New (not previously treated) | 73 (83.9%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 57 (98.3%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 0-0-0 |
| Pulmonary MDR TB cases notified | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| Notified MDR | 0 - |
| of which XDR TB cases | - - |
| TB cases tested for HIV | 60 (69.0%) |
| HIV-positive TB cases | 0 (0.0%) |
| of these on antiretroviral therapy | 0 - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 80 | 2 |
| Success | 74 (92.5%) | 0 (0.0%) |
| Died | 3 (3.8%) | 1 (50.0%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 3 (3.8%) | 1 (50.0%) |
| Not evaluated | 0 (0.0%) | 0 (0.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016




* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome of new TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Netherlands

Total population at 22 September 2017 by EUROSTAT: 16 979 120

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 889 |
| Notification rate per 100 000 | 5.2 |
| New* & relapses | 877 |
| New* & relapses notification rate per 100 000 | 5.2 |
| Pulmonary | 477 (53.7%) |
| of which microscopy-positive | 185 (38.8%) |
| of which laboratory confirmed | 353 (74.0%) |
| Laboratory-confirmed TB cases | 583 (65.6%) |
| Mean age of new native TB cases | 44.2 years |
| Mean age of new foreign TB cases | 38.2 years |
| Foreign origin of all TB cases | 669 (75.3%) |
| New (not previously treated) | 862 (97.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 583 (100.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 15-6-24 |
| Pulmonary MDR TB cases notified | 8 (2.3%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR TB | 12 (2.1%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 554 (62.3%) |
| HIV-positive TB cases | 21 (3.8%) |
| of these on antiretroviral therapy | 15 (71.4%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 369 | 7 |
| Success | 315 (85.4%) | 5 (71.4%) |
| Died | 22 (6.0%) | 0 (0.0%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 4 (1.1%) | 0 (0.0%) |
| Still on treatment | 6 (1.6%) | 1 (14.3%) |
| Not evaluated | 22 (6.0%) | 1 (14.3%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Norway

Total population at 22 September 2017 by EUROSTAT: 5210721

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 299 |
| Notification rate per 100 000 | 5.7 |
| New* & relapses | 278 |
| New* & relapses notification rate per 100 000 | 5.3 |
| Pulmonary | 186 (62.2%) |
| of which microscopy-positive | 72 (38.7%) |
| of which laboratory confirmed | 158 (84.9%) |
| Laboratory-confirmed TB cases | 230 (76.9%) |
| Mean age of new native TB cases | 47.0 years |
| Mean age of new foreign TB cases | 34.3 years |
| Foreign origin of all TB cases | 264 (88.3%) |
| New (not previously treated) | 278 (93.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 228 (99.1%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 6-1-10 |
| Pulmonary MDR TB cases notified | 7 (4.5%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR TB | 10 (4.4%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 254 (84.9%) |
| HIV-positive TB cases | 10 (3.9%) |
| of these on antiretroviral therapy | 8 (80.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 154 | 11 |
| Success | 127 (82.5%) | 9 (81.8%) |
| Died | 4 (2.6%) | 0 (0.0%) |
| Failed | 2 (1.3%) | 0 (0.0%) |
| Lost to follow-up | 6 (3.9%) | 1 (9.1%) |
| Still on treatment | 6 (3.9%) | 0 (0.0%) |
| Not evaluated | 9 (5.8%) | 1 (9.1%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Poland

Total population at 22 September 2017 by EUROSTAT: 37 967 209

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 6 444 |
| Notification rate per 100 000 | 17.0 |
| New* & relapses | 6 143 |
| New* & relapses notification rate per 100 000 | 16.2 |
| Pulmonary | 6 116 (94.9%) |
| of which microscopy-positive | 2 644 (43.2%) |
| of which laboratory confirmed | 4 475 (73.2%) |
| Laboratory-confirmed TB cases | 4 619 (71.7%) |
| Mean age of new native TB cases | 53.2 years |
| Mean age of new foreign TB cases | 34.6 years |
| Foreign origin of all TB cases | 92 (1.4%) |
| New (not previously treated) | 5 713 (88.7%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|---------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | - |
| Case-linked data reporting | Yes |
| Cases with DST results | 4 189 (90.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 77-56-98 |
| Pulmonary MDR TB cases notified | 45 (1.1%) |
| of which XDR TB cases | 8 (21.1%) |
| Notified MDR TB | 46 (1.1%) |
| of which XDR TB cases | 8 (20.5%) |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 3 978 | 35 |
| Success | 2 085 (52.4%) | 3 (8.6%) |
| Died | 414 (10.4%) | 12 (34.3%) |
| Failed | 3 (0.1%) | 0 (0.0%) |
| Lost to follow-up | 209 (5.3%) | 5 (14.3%) |
| Still on treatment | 8 (0.2%) | 0 (0.0%) |
| Not evaluated | 1 259 (31.6%) | 15 (42.9%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016



New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016

Data not available

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Portugal

Total population at 22 September 2017 by EUROSTAT 10341330

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 1836 |
| Notification rate per 100 000 | 17.8 |
| New* & relapses | 1794 |
| New* & relapses notification rate per 100 000 | 17.3 |
| Pulmonary | 1302 (70.9%) |
| of which microscopy-positive | 760 (58.4%) |
| of which laboratory confirmed | 945 (72.6%) |
| Laboratory-confirmed TB cases | 1123 (61.2%) |
| Mean age of new native TB cases | 52.2 years |
| Mean age of new foreign TB cases | 40.7 years |
| Foreign origin of all TB cases | 336 (18.3%) |
| New (not previously treated) | 1715 (93.4%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 789 (70.3%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 19-10-27 |
| Pulmonary MDR TB cases notified | 10 (1.5%) |
| of which XDR TB cases | 1 (25.0%) |
| Notified MDR TB | 12 (1.5%) |
| of which XDR TB cases | 2 (40.0%) |
| TB cases tested for HIV | 1212 (66.0%) |
| HIV-positive TB cases of these on antiretroviral therapy | 168 (13.9%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 1157 | 25 |
| Success | 835 (72.2%) | 13 (52.0%) |
| Died | 98 (8.5%) | 7 (28.0%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 40 (3.5%) | 0 (0.0%) |
| Still on treatment | 153 (13.2%) | 1 (4.0%) |
| Not evaluated | 31 (2.7%) | 4 (16.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Romania

Total population at 22 September 2017 by EUROSTAT: 19 870 647

Tuberculosis case notifications, 2016

| | |
|---|----------------|
| Total number of cases | 13 617 |
| Notification rate per 100 000 | 68.5 |
| New* & relapses | 12 790 |
| New* & relapses notification rate per 100 000 | 64.4 |
| Pulmonary | 11 523 (84.6%) |
| of which microscopy-positive | 7 454 (64.7%) |
| of which laboratory confirmed | 9 185 (79.7%) |
| Laboratory-confirmed TB cases | 9 517 (69.9%) |
| Mean age of new native TB cases | 42.9 years |
| Mean age of new foreign TB cases | 31.8 years |
| Foreign origin of all TB cases | 24 (0.2%) |
| New (not previously treated) | 10 741 (78.9%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|----------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 8 440 (88.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 730-670-790 |
| Pulmonary MDR TB cases notified | 458 (5.6%) |
| of which XDR TB cases | 62 (29.8%) |
| Notified MDR TB | 463 (5.5%) |
| of which XDR TB cases | 63 (30.0%) |
| TB cases tested for HIV | 10 634 (78.1%) |
| HIV-positive TB cases | 287 (2.7%) |
| of these on antiretroviral therapy | 254 (88.5%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | | |
|----------------------------|---|-------------------------------------|---------|
| Geographical coverage | National | | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** | |
| Case-linked data reporting | Yes | | |
| Cases notified | 7 417 | 532 | |
| Success | 6 282 (84.7%) | 199 | (37.4%) |
| Died | 518 (7.0%) | 93 | (17.5%) |
| Failed | 152 (2.0%) | 156 | (29.3%) |
| Lost to follow-up | 371 (5.0%) | 80 | (15.0%) |
| Still on treatment | 89 (1.2%) | 4 | (0.8%) |
| Not evaluated | 5 (0.1%) | 0 | (0.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Russia

Population estimate 20156 by UN Statistical Database: 143964513

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 121046 |
| Notification rate per 100 000** | 84.1 |
| New* & relapses | 92407 |
| New* & relapses notification rate per 100 000 | 64.2 |
| Pulmonary | 84066 (91.0%) |
| of which smear positive | 26060 (31%) |
| of which laboratory confirmed | 42681 (50.8%) |
| Laboratory-confirmed TB cases*** | 63638 (52.6%) |
| Mean age of new and relapse TB cases | 41.6 years |
| Mean age of new foreign TB cases | 34.6 years |
| Foreign origin of all TB cases | 2797 (2.3%) |
| New (not previously treated) | 78121 (64.5%) |

* Cases with unknown previous treatment included in new cases.
 ** UN Population Division estimates are lower than the population registered by the Federal State Statistics Service of the Russian Federation.
 *** New & relapses before start of treatment.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 57910 (91.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 47000-46000-47000 |
| Pulmonary MDR TB cases notified | 25971 (44.8%) |
| of which XDR TB cases | 3402 (13.1%) |
| Notified MDR | 27363 - |
| of which XDR TB cases | 3402 - |
| TB cases tested for HIV | 79935 (86.5%) |
| HIV-positive TB cases | 16570 (20.7%) |
| of these on antiretroviral therapy | 10549 (63.7%) |


* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.
 ** More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 80424 | 20089 |
| Success | 57060 (70.9%) | 10170 (50.6%) |
| Died | 8035 (10.0%) | 3409 (17.0%) |
| Failed | 5646 (7.0%) | 2655 (13.2%) |
| Lost to follow-up | 4074 (5.1%) | 1830 (9.1%) |
| Not evaluated | 5609 (7.0%) | 2025 (10.1%) |


* Treatment outcome as presented is treatment outcome after 12 months.
 ** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016*




* HIV testing data are available for new TB cases in civilian population only.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Serbia

Population estimate 2016 by UN Statistical Database: 8820083

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 1488 |
| Notification rate per 100 000 | 16.9 |
| New* & relapses | 1472 |
| New* & relapses notification rate per 100 000 | 16.7 |
| Pulmonary | 1206 (81.9%) |
| of which microscopy-positive | - |
| of which laboratory confirmed | 815 (67.6%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new native TB cases | 41.8 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 5 (0.3%) |
| New (not previously treated) | 1348 (90.6%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 398 (48.8%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 19-8-29 |
| Pulmonary MDR TB cases notified | 6 (1.5%) |
| of which XDR TB cases | 1 (16.7%) |
| Notified MDR TB | 8 - |
| of which XDR TB cases | 1 - |
| TB cases tested for HIV | 84 (5.7%) |
| HIV-positive TB cases | 5 (6.0%) |
| of these on antiretroviral therapy | 5 (100.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 1647 | 19 |
| Success | 1471 (89.3%) | 12 (63.2%) |
| Died | 82 (5.0%) | 2 (10.5%) |
| Failed | 12 (0.7%) | 2 (10.5%) |
| Lost to follow-up | 60 (3.6%) | 3 (15.8%) |
| Not evaluated | 22 (1.3%) | 0 (0.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016



TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Slovakia

Total population at 22 September 2017 by EUROSTAT: 5 426 252

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 296 |
| Notification rate per 100 000 | 5.5 |
| New* & relapses | 281 |
| New* & relapses notification rate per 100 000 | 5.2 |
| Pulmonary | 253 (85.5%) |
| of which microscopy-positive | 88 (34.8%) |
| of which laboratory confirmed | 115 (45.5%) |
| Laboratory-confirmed TB cases | 117 (39.5%) |
| Mean age of new native TB cases | 44.4 years |
| Mean age of new foreign TB cases | 30.4 years |
| Foreign origin of all TB cases | 11 (3.7%) |
| New (not previously treated) | 257 (86.8%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 113 (96.6%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 1-0-4 |
| Pulmonary MDR TB cases notified | 3 (2.7%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR TB | 3 (2.7%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 132 (44.6%) |
| HIV-positive TB cases | 0 (0.0%) |
| of these on antiretroviral therapy | 0 (0.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 136 | 3 |
| Success | 119 (87.5%) | 1 (33.3%) |
| Died | 14 (10.3%) | 2 (66.7%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 1 (0.7%) | 0 (0.0%) |
| Still on treatment | 1 (0.7%) | 0 (0.0%) |
| Not evaluated | 1 (0.7%) | 0 (0.0%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016



TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Slovenia

Total population at 22 September 2017 by EUROSTAT: 2 064 188

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 118 |
| Notification rate per 100 000 | 5.7 |
| New* & relapses | 118 |
| New* & relapses notification rate per 100 000 | 5.7 |
| Pulmonary | 103 (87.3%) |
| of which microscopy-positive | 58 (56.3%) |
| of which laboratory confirmed | 96 (93.2%) |
| Laboratory-confirmed TB cases | 109 (92.4%) |
| Mean age of new native TB cases | 60.2 years |
| Mean age of new foreign TB cases | 53.3 years |
| Foreign origin of all TB cases | 43 (36.4%) |
| New (not previously treated) | 113 (95.8%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|--------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 109 (100.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 0-0-0 |
| Pulmonary MDR TB cases notified | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| Notified MDR TB | 0 (0.0%) |
| of which XDR TB cases | 0 - |
| TB cases tested for HIV | 95 (80.5%) |
| HIV-positive TB cases | 1 (1.1%) |
| of these on antiretroviral therapy | 1 (100.0%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 88 | 0 |
| Success | 76 (86.4%) | 0 - |
| Died | 11 (12.5%) | 0 - |
| Failed | 0 (0.0%) | 0 - |
| Lost to follow-up | 0 (0.0%) | 0 - |
| Still on treatment | 1 (1.1%) | 0 - |
| Not evaluated | 0 (0.0%) | 0 - |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007–2016




New and relapsed TB cases – notification rates by age group, 2007–2016




Tuberculosis cases by geographical origin, 2007–2016




TB-HIV co-infection, 2007–2016



MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006–2015



Spain

Total population at 22 September 2017 by EUROSTAT: 46 449 565

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 4 877 |
| Notification rate per 100 000 | 10.5 |
| New* & relapses | 4 734 |
| New* & relapses notification rate per 100 000 | 10.2 |
| Pulmonary | 3 515 (72.1%) |
| of which microscopy-positive | 1 675 (47.7%) |
| of which laboratory confirmed | 2 689 (76.5%) |
| Laboratory-confirmed TB cases | 3 372 (69.1%) |
| Mean age of new native TB cases | 51.8 years |
| Mean age of new foreign TB cases | 38.7 years |
| Foreign origin of all TB cases | 1 391 (28.5%) |
| New (not previously treated) | 4 734 (97.1%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|---------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 896 (26.6%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 25-10-40 |
| Pulmonary MDR TB cases notified | 39 (4.4%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR TB | 39 (4.4%) |
| of which XDR TB cases | 0 (0.0%) |
| TB cases tested for HIV | 2 925 (60.0%) |
| HIV-positive TB cases | 226 (7.7%) |
| of these on antiretroviral therapy | - |


* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Data not available


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Sweden

Total population at 22 September 2017 by EUROSTAT: 9747355

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 726 |
| Notification rate per 100 000 | 7.4 |
| New* & relapses | 702 |
| New* & relapses notification rate per 100 000 | 7.2 |
| Pulmonary | 482 (66.4%) |
| of which microscopy-positive | 123 (25.5%) |
| of which laboratory confirmed | 419 (86.9%) |
| Laboratory-confirmed TB cases | 597 (82.2%) |
| Mean age of new native TB cases | 49.5 years |
| Mean age of new foreign TB cases | 30.3 years |
| Foreign origin of all TB cases | 652 (89.8%) |
| New (not previously treated) | 697 (96.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 595 (99.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 23-13-32 |
| Pulmonary MDR TB cases notified | 14 (3.3%) |
| of which XDR TB cases | 4 (28.6%) |
| Notified MDR TB | 22 (3.7%) |
| of which XDR TB cases | 4 (18.2%) |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 428 | 15 |
| Success | 345 (80.6%) | 13 (86.7%) |
| Died | 15 (3.5%) | 1 (6.7%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 6 (1.4%) | 0 (0.0%) |
| Still on treatment | 24 (5.6%) | 0 (0.0%) |
| Not evaluated | 38 (8.9%) | 1 (6.7%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007–2016



New and relapsed TB cases – notification rates by age group, 2007–2016




Tuberculosis cases by geographical origin, 2007–2016




TB-HIV co-infection, 2007–2016

Data not available

MDR TB cases by previous treatment history, 2007–2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006–2015



Switzerland

Population estimate 2016 by UN Statistical Database: 8 401 739

Tuberculosis case notifications, 2016

| | |
|---|-------------|
| Total number of cases | 609 |
| Notification rate per 100 000 | 7.2 |
| New* & relapses | 573 |
| New* & relapses notification rate per 100 000 | 6.8 |
| Pulmonary | 402 (70.2%) |
| of which smear positive | - |
| of which laboratory confirmed | 362 (90.0%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 34.8 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 486 (79.8%) |
| New (not previously treated) | 573 (94.1%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 296 (81.8%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 22-11-34 |
| Pulmonary MDR TB cases notified | 13 (4.4%) |
| of which XDR TB cases | 0 (0.0%) |
| Notified MDR | 18 |
| of which XDR TB cases | 0 |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| Geographical coverage | National | |
|----------------------------|---|-------------------------------------|
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | - | 12 |
| Success | - | 9 (75.0%) |
| Died | - | 0 (0.0%) |
| Failed | - | 1 (8.3%) |
| Lost to follow-up | - | 0 (0.0%) |
| Not evaluated | - | 2 (16.7%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.


Tuberculosis cases by geographical origin, 2007-2016



TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015

Data not available

Tajikistan

Population estimate 2016 by UN Statistical Database: 8734 951

Tuberculosis case notifications, 2016

| | |
|---|--------------|
| Total number of cases | 6241 |
| Notification rate per 100 000 | 71.4 |
| New* & relapses | 5965 |
| New* & relapses notification rate per 100 000 | 68.3 |
| Pulmonary | 4368 (73.2%) |
| of which smear positive | - |
| of which laboratory confirmed | 3011 (68.9%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 37.1 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 5241 (84.0%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|----------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 2702 (89.7%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 1200-1200-1300 |
| Pulmonary MDR TB cases notified | 646 (23.9%) |
| of which XDR TB cases | 59 (9.1%) |
| Notified MDR | 748 - |
| of which XDR TB cases | 59 - |
| TB cases tested for HIV | 5850 (98.1%) |
| HIV-positive TB cases | 201 (3.4%) |
| of these on antiretroviral therapy | 182 (90.5%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | | |
|----------------------------|---|--|---------|
| Geographical coverage | National | | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** | |
| Case-linked data reporting | Yes | | |
| Cases notified | 5298 | 804 | |
| Success | 4734 (89.4%) | 398 | (49.5%) |
| Died | 237 (4.5%) | 170 | (21.1%) |
| Failed | 111 (2.1%) | 67 | (8.3%) |
| Lost to follow-up | 172 (3.2%) | 159 | (19.8%) |
| Not evaluated | 44 (0.8%) | 10 | (1.2%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Turkey

Population estimate 2016 by UN Statistical Database: 79512426

Tuberculosis case notifications, 2016

| | |
|---|----------------|
| Total number of cases | 12 417 |
| Notification rate per 100 000 | 15.6 |
| New* & relapses | 12 186 |
| New* & relapses notification rate per 100 000 | 15.3 |
| Pulmonary (new and relapse) | 8 044 (66.0%) |
| of which smear positive | - |
| of which laboratory confirmed | 6 334 (78.7%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 41.4 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 904 (7.3%) |
| New (not previously treated) | 11 442 (92.1%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|---------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 5 612 (88.6%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 350-300-390 |
| Pulmonary MDR TB cases notified | 190 (3.4%) |
| of which XDR TB cases | 9 (4.7%) |
| Notified MDR | 256 - |
| of which XDR TB cases | 9 - |
| TB cases tested for HIV | 8 549 (70.2%) |
| HIV-positive TB cases | 56 (0.7%) |
| of these on antiretroviral therapy | 51 (91.1%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 12 362 | 257 |
| Success | 10 735 (86.8%) | 163 (63.4%) |
| Died | 695 (5.6%) | 27 (10.5%) |
| Failed | 30 (0.2%) | 15 (5.8%) |
| Lost to follow-up | 432 (3.5%) | 30 (11.7%) |
| Not evaluated | 470 (3.8%) | 22 (8.6%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Turkmenistan

Population estimate 2016 by UN Statistical Database: 5622544

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 2376 |
| Notification rate per 100 000 | 42.0 |
| New* & relapses | 2104 |
| New* & relapses notification rate per 100 000 | 37.2 |
| Pulmonary | 1616 (76.8%) |
| of which smear positive | - |
| of which laboratory confirmed | 1616 (100.0%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 40.0 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 1952 (82.2%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | No |
| Cases with DST results | - |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 450-390-520 |
| Pulmonary MDR TB cases notified | 557 |
| of which XDR TB cases | - |
| Notified MDR | 557 |
| of which XDR TB cases | - |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 2472 | 213 |
| Success | 2126 (86.0%) | 143 (67.1%) |
| Died | 105 (4.2%) | 24 (11.3%) |
| Failed | 105 (4.2%) | 32 (15.0%) |
| Lost to follow-up | 82 (3.3%) | 9 (6.6%) |
| Not evaluated | 54 (2.2%) | 0 (0.0%) |

* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.


Tuberculosis cases by geographical origin, 2007-2016



TB-HIV co-infection, 2006-2014



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome of new TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

Ukraine

Population estimate 2016 by UN Statistical Database: 44 438 625

Tuberculosis case notifications, 2016

| | |
|---|----------------|
| Total number of cases | 34 088 |
| Notification rate per 100 000 | 76.7 |
| New* & relapses | 29 052 |
| New* & relapses notification rate per 100 000 | 65.4 |
| Pulmonary | 26 357 (90.7%) |
| of which smear positive | - |
| of which laboratory confirmed | 18 125 (68.8%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 41.8 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 20 (0.1%) |
| New (not previously treated) | 23 316 (68.4%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|----------------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 20 147 (111.2%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 10 000-10 000-11 000 |
| Pulmonary MDR TB cases notified | 5 756 (28.6%) |
| of which XDR TB cases | 247 (4.3%) |
| Notified MDR | 8 651 - |
| of which XDR TB cases | 1 195 - |
| TB cases tested for HIV | 28 194 (97.0%) |
| HIV-positive TB cases | 5 832 (20.7%) |
| of these on antiretroviral therapy | 3 945 (67.6%) |


* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.
** More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

| | | |
|----------------------------|---|--|
| Geographical coverage | National | |
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 23 892 | 7 174 |
| Success | 17 939 (75.1%) | 3 297 (46.0%) |
| Died | 2 393 (10.0%) | 1 210 (16.9%) |
| Failed | 1 950 (8.2%) | 1 284 (17.9%) |
| Lost to follow-up | 1 552 (6.5%) | 1 186 (16.5%) |
| Not evaluated | 58 (0.2%) | 197 (2.7%) |


* Treatment outcome as presented is treatment outcome after 12 months.
** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



* Since 2015 data on HIV detection are collected for new TB cases and relapses.

MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.

United Kingdom

Total population at 22 September 2017 by EUROSTAT: 65 382 556

Tuberculosis case notifications, 2016

| | |
|---|---------------|
| Total number of cases | 6 175 |
| Notification rate per 100 000 | 9.4 |
| New* & relapses | 5 793 |
| New* & relapses notification rate per 100 000 | 8.9 |
| Pulmonary | 3 354 (54.3%) |
| of which microscopy-positive | 1 379 (41.1%) |
| of which laboratory confirmed | 2 535 (75.6%) |
| Laboratory-confirmed TB cases | 3 907 (63.3%) |
| Mean age of new native TB cases | 43.7 years |
| Mean age of new foreign TB cases | 41.5 years |
| Foreign origin of all TB cases | 4 369 (70.8%) |
| New (not previously treated) | 5 793 (93.8%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|---------------|
| Completeness of DRS data* | Yes |
| Completeness of HIV data** | No |
| Case-linked data reporting | Yes |
| Cases with DST results | 3 789 (97.0%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 58-39-78 |
| Pulmonary MDR TB cases notified | 43 (1.8%) |
| of which XDR TB cases | 6 (15.4%) |
| Notified MDR TB | 56 (1.5%) |
| of which XDR TB cases | 7 (14.0%) |
| TB cases tested for HIV | - |
| HIV-positive TB cases | - |
| of these on antiretroviral therapy | - |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+ 75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| | | |
|----------------------------|---|-------------------------------------|
| Geographical coverage | National | |
| Outcome cohort | New culture positive pulmonary TB cases notified in 2015* | All MDR TB cases notified in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 2 210 | 56 |
| Success | 1 679 (76.0%) | 29 (51.8%) |
| Died | 158 (7.1%) | 2 (3.6%) |
| Failed | 0 (0.0%) | 0 (0.0%) |
| Lost to follow-up | 112 (5.1%) | 12 (21.4%) |
| Still on treatment | 226 (10.2%) | 10 (17.9%) |
| Not evaluated | 35 (1.6%) | 3 (5.4%) |


* Treatment outcome as presented is treatment outcome after 12 months.

** Treatment outcome as presented is treatment outcome after 24 months.


Tuberculosis notification rates by treatment history, 2007-2016




New and relapsed TB cases – notification rates by age group, 2007-2016




Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new culture-confirmed pulmonary TB cases, 2006-2015



Uzbekistan

Population estimate 2016 by UN Statistical Database: 31446795

Tuberculosis case notifications, 2016

| | |
|---|----------------|
| Total number of cases | 18 441 |
| Notification rate per 100 000 | 58.6 |
| New* & relapses | 16 050 |
| New* & relapses notification rate per 100 000 | 51.0 |
| Pulmonary (new and relapse) | 10 709 (66.7%) |
| of which smear positive | - |
| of which laboratory confirmed | 4 854 (45.3%) |
| Laboratory-confirmed TB cases | - |
| Mean age of new and relapse TB cases | 39.8 years |
| Mean age of new foreign TB cases | - years |
| Foreign origin of all TB cases | 0 (0.0%) |
| New (not previously treated) | 14 436 (78.3%) |

* Cases with unknown previous treatment included in new cases.

Drug resistance surveillance & TB-HIV co-infection, 2016

| | |
|---|-------------------|
| Completeness of DRS data* | No |
| Completeness of HIV data** | Yes |
| Case-linked data reporting | Yes |
| Cases with DST results | 1 986 (40.9%) |
| Estimated RR-TB among notified pulmonary cases N, (best-low-high) | 5 800-4 900-6 600 |
| Pulmonary MDR TB cases notified | 603 (30.4%) |
| of which XDR TB cases | 184 |
| Notified MDR | 1 956 - |
| of which XDR TB cases | 184 - |
| TB cases tested for HIV | 18 441 (114.9%) |
| HIV-positive TB cases | 758 (4.1%) |
| of these on antiretroviral therapy | 496 (65.4%) |

* National coverage 100% or culturing 90%, C+/All TB cases 50%, DST done for C+75%, EQA 95%.

** More than 50% of TB cases with reported HIV status.


Treatment outcome monitoring

| Geographical coverage | National | |
|----------------------------|---|--|
| Outcome cohort | New and relapsed TB cases notified in 2015* | All MDR TB cases enrolled into MDR treatment in 2014** |
| Case-linked data reporting | Yes | |
| Cases notified | 15 220 | 3 602 |
| Success | 13 536 (88.9%) | 2 216 (61.5%) |
| Died | 688 (4.5%) | 587 (16.3%) |
| Failed | 193 (1.3%) | 221 (6.1%) |
| Lost to follow-up | 172 (1.1%) | 220 (6.1%) |
| Not evaluated | 631 (4.1%) | 358 (9.9%) |

* Treatment outcome as presented is treatment outcome after 12 months.


** Treatment outcome as presented is treatment outcome after 24 months.

Tuberculosis notification rates by treatment history, 2007-2016*




* Starting from 2013 onward cases with unknown history are included in new and relapses.

New and relapsed TB cases – notification rates by age group, 2007-2016*




* Data up to 2012 includes new TB cases only.

Tuberculosis cases by geographical origin, 2007-2016




TB-HIV co-infection, 2007-2016



* Since 2015 data on HIV detection are collected for new TB cases and relapses.


MDR TB cases by previous treatment history, 2007-2016



Treatment outcome, new and relapsed TB cases, 2006-2015*



* 2005-2011 cohorts include new cases only.



**European Centre for Disease
Prevention and Control (ECDC)**

Granits väg 8, SE-171 65 Solna, Sweden

Tel. +46 858 60 10 00

Fax +46 858 60 10 01

www.ecdc.europa.eu

Contact us
publications@ecdc.europa.eu

 Follow us on Twitter
[@ECDC_EU](https://twitter.com/ECDC_EU)

 Like our Facebook page
www.facebook.com/ECDC.EU

**World Health Organization
Regional Office for Europe**

UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark

Tel. +45 45 33 70 00

Fax +45 45 33 70 01

www.euro.who.int

Contact us
eucontact@who.int

 Follow us on Twitter
[@WHO_EUROPE](https://twitter.com/WHO_EUROPE)

 Like our Facebook page
www.facebook.com/WHOEuro